

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Multinational Comparison of New Antidepressant Use in Older Adults

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027663
Article Type:	Research
Date Submitted by the Author:	07-Nov-2018
Complete List of Authors:	Tamblyn, Robyn; McGill University, Department of Medicine and Department of Epidemiology and Biostatistics Bates, David ; Brigham and Women's Hospital, Medicine Buckeridge, David; McGill University, Epidemiology, Biostatistics, and Occupational Health; Agence de la Santé et des services Sociaux de Montréal, Direction de santé publique Dixon, Will; University of Manchester, Arthritis Research UK Centre for Epidemiology Forster, Alan; The Ottawa Hospital , Internal Medicine ; The Ottawa Hospital Research Institute, Clinical Epidemiology Program Girard, Nadyne; McGill University, Clinical and Health Informatics Research Group Haas, Jennifer; Brigham and Women's Hospital Habib, Bettina; McGill University, Clinical and Health Informatics Research Group Kurteva, Siyana; McGill University, Epidemiology, Biostatistics, and Occupational Health Li, Jack; Taipei Medical University, Graduate Institute of Biomedical Informatics Sheppard, Therese; University of Manchester
Keywords:	Antidepressants, Multinational comparison, Older adults, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

Multinational Comparison of New Antidepressant Use in Older Adults

Robyn Tamblyn^{1,2,3}, David W. Bates⁴, David L. Buckeridge^{1,3}, William G. Dixon⁵, Alan J. Forster⁶, Nadyne Girard³, Jennifer S. Haas⁴, Bettina Habib³, Siyana Kurteva¹, Jack Li^{7,8}, Therese Sheppard⁵

¹Department of Epidemiology, Biostatistics and Occupational Health, McGill University, 1020 Pine Avenue West, Montreal, QC H3A 1A2, Canada

²Department of Medicine, McGill University Health Center, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada

³Clinical and Health Informatics Research Group, McGill University, 1140 Pine Avenue West, Montreal, QC H3A 1A3, Canada.

⁴Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

⁵Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, 2nd Floor, Stopford Building, Oxford Road, Manchester M13 9PT, UK.

⁶The Ottawa Hospital, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada.

⁷International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan

⁸Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan

Corresponding Author

Robyn Tamblyn, BScN, MSc, PhD, FCAHS, CM

McGill University

1140 Pine Avenue West

Montreal, QC H3A 1A3

Tel. 514-934-1934 ext 32999

robyn.tamblyn@mcgill.ca

Word count: 3,934

ABSTRACT

Objectives: We used an international pharmacosurveillance network to estimate the rate and characteristics of antidepressant use in older adults in countries with more conservative (UK) and liberal depression guidelines (Canada, USA).

Setting: Electronic health records and population-based administrative data from six jurisdictions in four countries (UK, Taiwan, USA, and Canada).

Participants: A historical cohort of older adults (≥ 65) who had a new episode of antidepressant use between 2009-2014.

Outcome Measures: The age-standardized cumulative incidence of new episodes of antidepressant use in older adults was measured. Descriptive statistics were used to compare the proportion of new users by the antidepressant prescribed, therapeutic class, potential treatment indication, and country, as well as the characteristics of the first treatment episode (standardized daily doses, duration and changes).

Results: The incidence of antidepressant use between 2009-2014 varied from 0.7%(UK), to 18.6% (Taiwan). Tricyclic antidepressants (TCAs) were the most commonly used class in the UK (48.8%) and Taiwan (52.4%) compared to selective serotonin reuptake inhibitors (SSRIs) in North American jurisdictions (42.3%-53.3%). Chronic pain was the most common potential treatment indication (41.2%-68.2%). Among users with chronic pain, TCAs were used most frequently in the UK and Taiwan (55.2%-60.4%) whereas SSRIs were used most frequently in North America (33.5%-46.4%). Treatment was longer (252-525 vs 169-437 days), standardized doses were higher (0.7-1.3 vs 0.5-1.0), and treatment was more likely to be changed (31%-46% vs 21%-34%) among patients with depression (9.1%-43%) than those with chronic pain.

Conclusion: Antidepressant use in older adults varied 24-fold by country, being lowest in the UK, which has the most conservative treatment guidelines. Chronic pain was the most common potential treatment indication. Evaluation of real-world risks of TCAs is a priority for future research, given high rates of use, and the potential for increased toxicity in older adults because of potent anti-cholinergic effects.

Summary Boxes

What is already known on this topic

- The use of antidepressants in older adults has been increasing in many countries.
- Antidepressant use in older adults is associated with fall-related injuries, functional decline, and mortality.
- Guidelines on depression management vary between countries, but it is not known how these differences impact the use of antidepressants among older adults.

What this study adds

- Our study shows that antidepressant use among older adults varies between countries and is lowest in England, which has the most conservative guidelines.
- The most common potential treatment indication in all studied countries was chronic pain.
- Antidepressant users with chronic pain in England and Taiwan most frequently used TCAs, whereas those in North America used SSRIs.

Strengths of this study

- Uses an international pharmacosurveillance network to characterize antidepressant use across multiple jurisdictions

Limitations of this study

- Despite data harmonization efforts, measurement and reporting issues may lead to arbitrary differences between regions and countries.
- Treatment indication is unknown for all but one study cohort. Documentation of health problems in medical services billing data and EMRs was used as a proxy for treatment indication for remaining cohorts, which could have resulted in misclassification bias.
- While some cohorts represented total populations or representative samples, others were assembled from practices supported by specific information technology systems.

INTRODUCTION

Depression affects an estimated 300 million people worldwide[1]. In the past decade, many countries have reported a two to three fold increase in the use of antidepressant medications[2]. The primary increase has been in newer antidepressants such as selective serotonin reuptake inhibitors (SSRIs), which are considered to have better efficacy than older drugs, with fewer side effects[3]. Increasing prevalence of use of antidepressants has also been associated with both an increase in the number of people started on therapy as well as its duration, with 40% of antidepressants being prescribed for more than 180 days [4]. Antidepressants now represent one of the most commonly prescribed medications[5 6], especially among older adults, where the increase in use has been the greatest in the US population[5 7].

The increasing use of antidepressants in older adults may be due to a number of factors. There has been long-standing advocacy for better recognition and treatment of depression in older adults[8 9]. In addition, individuals with multiple chronic conditions are more likely to experience depression. In Canada, 12% of persons 65 years and older have two or more major chronic conditions compared to only 3.6% in younger adults; and 4% of adults with at least one major chronic disease have mood or anxiety disorders, which are other approved indications for antidepressant use[10]. While increasing prevalence of depression, anxiety and other mood disorders in older adults may account for increasing use of antidepressants, there is also evidence that antidepressants are prescribed for unapproved indications that may not be supported by scientific evidence of efficacy[11-14]. One recent study found that nearly 50% of antidepressants were prescribed for unapproved indications including chronic pain, tiredness, and sleep disturbance[11], which are also more common in older adults[15].

Taken together, these factors have led to increasing concern about overuse of antidepressants, particularly in older adults[16]. This concern is heightened because of the reported association between antidepressant use and fall-related injuries, motor vehicle accidents, functional decline, and mortality in older adults[17-19]. Clinical practice guidelines for the management of depression vary considerably in their recommendations for first line treatment[20-24], although most acknowledge the need to consider patient preferences (Table 1). The United Kingdom NICE guidelines are the most conservative, recommending first line treatment with psychotherapy such as cognitive behavioral therapy with pharmacotherapy added only if non-pharmacological therapy is unsuccessful[24]. At the other end of the spectrum, the Canadian 2016 guidelines recommend pharmacotherapy as the first line treatment; including selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), mirtazapine, or bupropion for mild or moderate depressive disorder, with the addition of psychotherapy only if there is an inadequate antidepressant response[21]. Of note, Canada ranks as the 3rd highest user of anti-depressants among 23 OECD countries, surpassed only by Australia and Iceland[2].

However, few data are available regarding how national guidelines may contribute to differences in how antidepressants are used for older adults. We took advantage of an international pharmacosurveillance network[25] that uses electronic medical record (EMR) and population-based health administrative data to estimate the rate of antidepressant use in older adults in countries that had more conservative (UK) and lenient guidelines (Canada, USA, Taiwan). We evaluated differences in the choice of antidepressant, dose and duration of treatment, the prevalence of dose changes and switches in treatment of older adults

with new episodes of antidepressant use, as well as differences in treatment approach for patients with a recorded diagnosis of depression, other mental health co-morbidities, and chronic pain.

METHODS

Study Design and Population

To characterize antidepressant use in older adults, a prospective cohort of individuals who were 65 years of age or older and had a new episode of antidepressant use between 2009 and 2014 following two years during which they had no prescription or dispensation of an antidepressant was assembled. Eligible patients were identified from electronic medical record (EMR) or population-based registries in a total of six jurisdictions in four countries (Canada, United States, UK, and Taiwan).

Data Sources

CANADA

Quebec EMR cohort: Data were extracted from the Medical Office of the 21st Century (MOXXI) EMR, which includes a real-time linkage to the Quebec insurance agency, the Régie de l'assurance maladie du Québec (RAMQ) databases. This linkage provides historical and daily updates of patients' received medical services (diagnosis, procedure, date, location, provider), prescriptions dispensed from community pharmacies for persons who are publicly insured (prescriber, pharmacy, drug, dose, dispensing date, duration, refills), and mortality. Approximately 110 primary care physicians in Quebec use MOXXI for approximately 90,000 of their patients, representing approximately 25% of the patients in the practice, and approximately 5% of the Quebec population in primary care practices.

Quebec Administrative Data cohort: Data were retrieved from the Montreal Population Health Record, a population-based 25% random sample of the 4.1 million residents of Montreal, Canada's second largest city, which is dynamically updated each year to account for in and out-migration. Beneficiary characteristics were measured by linking the RAMQ beneficiary database (age, sex, postal code) with Statistics Canada's census file (postal code level measures of socio-economic status), and the Institute of Statistics birth and death registry (date of birth and death). From this population-based dataset, we identified all non-institutionalized persons 65 years of age or older between 2009-2014. All medical services (date, diagnosis, procedure), hospitalizations (admission and discharge date, primary and secondary diagnoses, in-hospital procedures), and medications (prescriber, pharmacy, drug, dose, dispensing date, duration, refills) received by members of the cohort were retrieved from the RAMQ database and those of the Quebec Ministry of Health.

Ontario Administrative Data Cohort: Data were extracted from the Institute for Clinical Evaluative Sciences population-based repository of health records for the 13.6 million Ontario residents. The data is provided by the Ontario Ministry of Health and Long-Term Care, which pays for all essential health services. For the 2 million Ontario non-institutionalized residents who were 65 year or older between 2007 and 2014, we extracted age, sex and date of death from the beneficiary registrants database, all billing claims for medical services provided by Ontario physicians (date of service, diagnosis, procedure code, physician provider), all claims for medications dispensed in the community by Ontario pharmacies (drug, date

1
2
3 dispensed, prescriber, quantity, duration, number of refills), and data from discharge summaries of
4 emergency department visits and hospital stays (date of admission and discharge, primary and secondary
5 diagnoses and procedures).
6

7 8 *UNITED STATES*

9
10 *Boston, Massachusetts EMR cohort:* Data were extracted from the Partners HealthCare Research Patient
11 Data Registry (RPDR), which provides care for approximately 3 million of 5 million residents in Boston and
12 surrounding areas. RPDR includes data from the Longitudinal Medical Record (LMR), an internally
13 developed, web-based, fully functional EMR that was in use during this period for the participating
14 primary care clinics from Brigham and Women's Hospital (BWH) and Massachusetts General Hospital
15 (MGH), the two founding members of Partners Healthcare in Boston, Massachusetts. Data were retrieved
16 from the structured clinical encounter information from RPDR for all outpatient primary care visits. To
17 ensure complete follow-up, patients were eligible if they were seen in one of 37 BWH- or MGH- affiliated
18 primary care or diabetes clinics.
19
20
21

22 *UNITED KINGDOM*

23
24 *EMR cohort:* Data were extracted from the Clinical Practice Research Datalink (CPRD), an anonymised
25 longitudinal medical records database for primary care. The primary care EHR includes information on all
26 primary care interactions, including documented health problems, visit notes, prescriptions, and records
27 of specialty referrals, as well as information on lab results, hospitalizations, and death. The CPRD includes
28 more than 4 million active patients, 76% of whom are in England, representing 6.9% of the 64 million
29 primary care population in the UK, and around 600 primary care practices[26]. Patients were included if
30 their records met minimum quality standards and there were no gaps in registration.
31
32
33

34 *TAIWAN*

35
36 *Administrative Data Cohort:* Data were extracted from the Taiwanese National Health Insurance (NHI)
37 system databases. The NHI provides health coverage to around 99% of Taiwan's population of 23 million,
38 providing comprehensive coverage for all health services, including dental, preventive, Western medicine,
39 and traditional Chinese medicine services. A random sample of 103,400 of the 3.6 million residents that
40 were 65 years or older in Taiwan between 2007 and 2014 was extracted for this study. The NHI's research
41 databases include a registry for beneficiaries (e.g. registrant's age, sex, residence), an outpatient visit
42 database (date and time of visit, ICD-9-CM codes of existing health problems, service provided), an
43 inpatient visit database (date of hospitalization and discharge, ICD-9-CM codes of existing health
44 problems, procedure codes and dates), and a pharmacy database (drug prescribed, date, duration,
45 dosage, prescribing physician, dispensing pharmacy).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Measurement

Patient Characteristics

Age & Sex: Date of birth and sex were retrieved from the administrative data in Canada and Taiwan as these data are verified at the time of enrollment in the health plan. For the US and United Kingdom, these data were retrieved from the EMR.

Depression, Other Mental Health Comorbidities, and Chronic Pain

We measured the existence of potential indications for antidepressant use[11 12] including depression, other mental health conditions, and chronic pain. Depression included mild, moderate, major single or recurrent depressive disorder with or without psychotic symptoms, adjustment reaction, and mixed anxiety and depression. Other mental health conditions included anxiety, alcohol abuse, illicit drug use, attempted suicide, psychosis, schizophrenia, and bipolar disorder. Anxiety included dissociative and somatoform disorders. We used standard diagnostic codes (ICD 9, ICD 10, and Read codes) retrieved from the EMR, and/or medical services claims, and hospitalizations in the two-years prior to the first antidepressant prescription to measure these conditions (Appendix).

To measure chronic pain, we used a previously validated ICD9 and ICD10 code set for non-cancer pain[27]. The concepts and definitions used in the development and validation of this code set were used to map to Read codes (Appendix). Chronic non-cancer pain conditions included lumbar pain, back disorders that are often associated with pain (e.g. degenerative disc disease), neck and back problems (e.g. spondylosis), fibromyalgia, complex regional pain syndromes (e.g. mononeuritis), painful neuropathic disorders (e.g. post herpetic neuralgia), pain disorders with psychosocial dysfunction, and unclassified chronic pain problems.

Characterizing Antidepressant Use

The characteristics of antidepressant use were compared in the population of seniors with a new episode of antidepressant use in each country, overall, and then within subgroups that had a diagnosis of a) depression, b) chronic pain, or c) other mental health problems.

Classification of Starting Therapy: The Anatomic Therapeutic Classification (ATC) system[28] was used to map national drug names and identification numbers to a common nomenclature based on the antidepressants that were prescribed during the study time period. Therapeutic classes included tri-cyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin antagonist and reuptake inhibitors (SARIs), norepinephrine-dopamine reuptake inhibitors (NDRIs), noradrenergic and specific serotonergic antidepressants (NaSSAs), tetracyclic antidepressants (TeCAs), melatonergic agonists (MAs), and norepinephrine reuptake inhibitors (NRIs). Monoamine oxidase inhibitors were excluded as they are rarely used and only for bipolar disorder. Starting therapy was classified by therapeutic class and drug, and by the number of antidepressants prescribed at treatment initiation.

Starting Antidepressant Dose: To enable comparisons in the dose prescribed among antidepressants, we created a standardized dose for each drug by dividing the prescribed dose by the WHO recommended

1
2
3 daily dose for adults. The resulting indicator represents the proportion of the recommended daily adult
4 dose that was prescribed. When more than one antidepressant was prescribed concurrently, we summed
5 the standardized dose for each drug.
6
7

8 9 **Analysis**

10 The cumulative incidence of older adults with new episodes of antidepressant use in the period 2009 to
11 2014 was measured by dividing the number of new users by the total population that was 65 years or
12 older during this time period. Rates were standardized for age using the direct method and the United
13 Kingdom as the reference population. New episodes of use were defined as those who had no prior
14 prescription of an antidepressant in the two years preceding their first prescription. Descriptive statistics
15 were used to compare the proportion of new antidepressants users by the antidepressant prescribed,
16 therapeutic class, country and potential treatment indication, as well as the characteristics of the first
17 treatment episode. As the co-existence of other mental health conditions may modify treatment choices,
18 we used the prevalence ratio to estimate the concurrence of other mental health problems, chronic pain
19 and depression. The prevalence ratio allowed us to compare between countries even if the prevalence of
20 these conditions is different[29].
21
22
23
24

25 **Patient and Public Involvement**

26 Patients and members of the public were not involved in the development of research questions or
27 outcome measures, design, or implementation of this study. There are no plans to involve patients in
28 dissemination of research results.
29
30

31 **RESULTS**

32 The age-standardized cumulative incidence of antidepressant use in persons aged 65 and older in the
33 period 2009-2014 was highest in Taiwan (18.6%) and Ontario, Canada (15.3%), and lowest in England
34 (0.7%) (Table 2). Similarly, the overall prevalence of antidepressant use in the same time period was lowest
35 in England (10.3%), and highest in Ontario, Canada (26.8%) and Taiwan (23.4%) and. The distribution of
36 age was similar in all jurisdictions.
37
38
39
40

41 *Frequency Distribution of the First Antidepressant Prescription by Therapeutic Class*

42 Overall, there were substantial differences between jurisdictions in the choice of starting therapy for new
43 users (Table 3). Tricyclic antidepressants were the most commonly used class of antidepressants in
44 England (48.8%) and Taiwan (52.4%) compared to selective serotonin reuptake inhibitors in North
45 American jurisdictions (42.3%-53.3%). Notably, in the United Kingdom, approximately one-quarter of
46 antidepressant prescriptions were for newer classes of antidepressants: serotonin antagonist & reuptake
47 inhibitors (trazodone), norepinephrine-dopamine reuptake inhibitors (bupropion), and noradrenergic
48 serotonin specific antidepressants (mirtazapine).
49
50
51
52

53 *Co-Existence of Depression, Other Mental Health Problems and Chronic Pain*

54 The prevalence of a depression diagnosis among new antidepressant users was relatively low, varying
55 from 9.1% (Taiwan) to 21.7% (USA). The exception was the EMR cohort in Quebec where the prevalence
56
57

1
2
3 was 43.0% (Table 4). Among new antidepressant users with a diagnosis of depression, there was a 30%
4 (UK Prevalence Ratio: 1.3) to 7-fold (USA Prevalence Ratio: 7.3) increase in the likelihood of also having
5 an alcohol or other substance abuse problem. Anxiety, which varied from being present in 12.1% of new
6 antidepressant users in the UK to 47.8% of new users in Taiwan, was the most common mental health
7 problem, and was also more likely to be present among persons with depression (Prevalence Ratio: 1.3
8 (Ontario, Quebec) to 3.6 (USA)). Although less common in all jurisdictions, both major mental illness and
9 suicide attempt were more likely to be present among antidepressant users with depression compared to
10 those without depression. In contrast, chronic pain was the most prevalent problem among new
11 antidepressant users (41.2% (UK) to 68.2% (Taiwan)), and was as likely to be present among those with
12 or without depression (Prevalence Ratio: 0.9-1.3) (Table 4). For almost one-third of new antidepressant
13 users, there was no documented diagnosis of depression, other mental health problems or chronic pain.
14
15
16
17

18 *Choice of Anti-depressant by Potential Treatment Indication*

19
20 Among new antidepressant users with a diagnosis of depression, selective serotonin reuptake inhibitors
21 were selected as the starting therapy for 55.2% (Ontario) to 71.4% (UK), followed by SNRIs in Canadian
22 jurisdictions, and newer antidepressants in Boston, the UK, and Taiwan (Table 5). For antidepressant users
23 with a diagnosis of chronic pain, starting therapy was predominantly with SSRIs in North American
24 jurisdictions (33.5%-46.1%), and with TCAs in the UK and Taiwan (55.2%-60.4%). Selection of therapy for
25 other mental health problems was a mixture of choices made for persons with a diagnosis of depression
26 and chronic pain.
27
28
29

30 *Characteristics of the First Treatment Episode by Potential Treatment Indication*

31
32 Among patients with a diagnosis of depression who were started on antidepressants, 54% (Ontario) to
33 68% (Taiwan) remained on their initial course of antidepressant treatment (Table 6A). For this group, the
34 mean duration of treatment varied from 104.7 (Taiwan) to 340.9 (Quebec) days, and the mean dose varied
35 from 60% of (0.6) of the recommended adult dose (Taiwan), to the recommended adult dose in the United
36 States site (mean dose: 1.0). Among the 32% (Taiwan) to 46% (Ontario) with a change in treatment, the
37 most common change in all jurisdictions was an increase in dose occurring in 20% (Taiwan) to 33%
38 (Ontario) of patients, followed by a decrease in dose (13% (Taiwan) to 21% (Ontario)), and the addition of
39 a drug from a different therapeutic class (6% (UK) to 18% (Ontario)). Among patients with a change in
40 therapy in their initial treatment episode, the mean duration of treatment was almost double (mean
41 duration 312.6 to 616.9 days) than for patients with no change, and the mean dose during treatment was
42 substantially higher (mean standardized proportion of the adult dose: 0.8 to 1.4).
43
44
45
46

47 The first treatment episode for new antidepressant users with a diagnosis of chronic pain was substantially
48 different than patients with a diagnosis of depression (Table 6B). Overall, 66% (Ontario) to 79% (Taiwan)
49 were kept on the initial treatment regimen, for a much shorter duration than for new users with a
50 diagnosis of depression (mean duration: 83.6 days (Taiwan) to 300.9 days (Quebec)), and at lower mean
51 doses (mean standardized proportion of the adult dose: 0.4 (Taiwan, UK, Montreal) to 0.8 (U.S.)). For the
52 21% to 34% of patients who had a change in treatment, the most common changes in all jurisdictions
53 were an increase in dose (13% to 25%), a decrease in dose (9% to 14%) and the addition of another drug
54 from a different therapeutic class (3% to 11%). For those with a change in treatment, the duration of the
55
56
57
58
59
60

1
2
3 treatment episode was considerably longer in all jurisdictions (264.4 to 590.0 days), and the mean dose
4 during the treatment episode was higher (0.5 to 1.1).
5
6
7

8 **INTERPRETATION**

9
10 This multi-national study is the first to compare the use of antidepressants among comparable cohorts of
11 new users in different countries. We found wide variation in the incidence and prevalence of
12 antidepressant use; the lowest rate was in the UK where guidelines for pharmacotherapy use for
13 depression were the most conservative. Choice of starting therapy also varied widely by country and
14 condition, with the UK and Taiwan more likely to use tricyclic antidepressants for persons with a diagnosis
15 of chronic pain whereas selective serotonin reuptake inhibitors were the most common choice for both
16 depression and pain in North American settings. Overall treatment duration was longer for patients with
17 depression than chronic pain, mean treatment doses were higher, and there were more likely to be
18 changes in therapy.
19
20
21
22

23 Differences in the incidence of antidepressant use in different countries as well as the choice of
24 antidepressant therapy may also be influenced by a variety of system-related factors. For example, direct
25 to consumer advertising of prescription drugs is permitted in the USA but banned in Canada, Europe, and
26 the UK because these ads drive demand for specific treatments[30]. Also, drugs available and covered by
27 public insurance plans in the UK, Taiwan and Canada are influenced by rigorous reviews and guidelines
28 for the use of new drugs and technologies by national agencies such as the National Institute for Health
29 and Care Excellence in the United Kingdom[31-33].
30
31
32

33 A surprisingly large percentage of older adults were prescribed antidepressants for conditions other than
34 depression. We found that chronic pain was the most common problem documented and it appeared to
35 be the most likely reason for antidepressant use. Chronic pain has an estimated prevalence of 11.8%[34]
36 to 43.5%[35] in adults, and increases with age, with an estimated 62% of those 75 years of age or older
37 experiencing this problem[35]. While use of antidepressants for chronic pain has been shown to be
38 effective, particularly tricyclic antidepressants (amitriptyline) and serotonin noradrenalin reuptake
39 inhibitors (duloxetine) for neurogenic pain[36 37], tricyclic antidepressants have been on the lists of
40 potentially contraindicated medications for the elderly for over a decade because of their potent anti-
41 cholinergic effects that can lead to cognitive impairment, and other avoidable morbidity[38 39].
42 Moreover, only one antidepressant, duloxetine has been approved for treatment of chronic pain in North
43 America and Europe[11]. Although the anticholinergic effects of tricyclic antidepressants have been well
44 documented[40-42], the actual “real-world” evidence of harm is limited[43], and should be addressed in
45 future studies given the high rates of use. The variation in approach in the use of antidepressants for
46 depression and chronic pain in different countries creates the natural experiment that could generate
47 unbiased evidence of potential harms and benefits.
48
49
50
51
52
53

54 Notably, in this study of older adults, depression was documented in only two in ten users; the exception
55 being in Quebec City/Montreal where four out of ten patients were prescribed antidepressants for
56
57

1
2
3 depression. There are known problems in under-reporting, diagnosis and documentation of
4 depression[44-46] , which may account for some or all of these differences between sites. The MOXXI
5 system used in the Quebec cohort likely provides an approximate estimate of the extent to which
6 depression is undocumented. In this cohort, physicians are required to document the treatment indication
7 for each drug prescribed[47], data that has been validated in prior studies[48]. Results from this setting
8 suggest that twice as many patients receive antidepressants for depression, whereas a similar proportion
9 of new antidepressant users had a diagnosis of chronic pain as in other sites.
10
11

12
13 Also, of interest, among patients with documented depression, antidepressant use in all countries
14 followed current guidelines for depression management[21 24 49 50]. Choice of first-line therapy was
15 predominantly selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors.
16 Starting doses were lower than the recommended adult doses, mean duration of treatment was 251-525
17 days, and the main changes in treatment were increases in doses and the addition of an antidepressant
18 from a different therapeutic class. Not surprisingly, among patients where there was a change in
19 treatment, both the average antidepressant dose was higher and treatment duration was longer,
20 suggesting a lack of treatment effectiveness. The cohort in Taiwan was different in a number of respects
21 including lower antidepressant doses, shorter treatment duration, and fewer changes in therapy once
22 started. The reason for these differences in approach is not clear. They may represent an innate
23 conservatism in the use of antidepressants in the Taiwanese population where there is an acknowledged
24 absence of evidence to support clinical guidelines[50], or known differences in genetic determinants of
25 drug metabolism that have been established in population-based genomic studies of drug
26 metabolism[51].
27
28
29
30
31

32
33 This study has several limitations to consider in the interpretation of results. Efforts were made to
34 harmonize data from different sources and countries, however both measurement and reporting issues
35 may lead to arbitrary differences between regions and countries. With the exception of the Quebec
36 cohort, treatment indication is unknown. Documentation of health problems in medical services billing
37 data and EMRs was used as a proxy for treatment indication, which based on past studies has a predictive
38 value of 7.8 – 80.3%[52]. The resulting misclassification will attenuate differences observed in treatment
39 approach between conditions. Moreover, diagnoses of health problems tend to be under-reported in
40 administrative data. While the Ontario, Montreal, and Taiwan cohorts represented total populations or
41 representative samples, the UK, Quebec, and USA cohorts were assembled on the basis of practices
42 supported by specific information technology systems. The trends observed in these more selected
43 populations however are similar to those reported for antidepressant use in older adults in these
44 countries[6 53-58].
45
46
47
48

49
50 In conclusion, antidepressant use in older adults varies up to 24-fold by country (cumulative incidence
51 from 0.7% to 17.0%), and chronic pain appears to be the most common treatment indication in all
52 jurisdictions, even more so than depression. Evaluation of real-world risks and benefits of antidepressants
53 by treatment indication should be a priority for future research. The relative contraindication of tricyclic
54 antidepressants in older adults because of their potent anticholinergic effects needs to be assessed given
55 their high rate of use, and proven efficacy in pain management[36-39].
56
57

1
2
3 **Funding:** This project was funded by the Canadian Institutes of Health Research (CIHR) operating grant #
4 MOP-111166.
5

6
7 **Ethical Approval:** This study received ethics approval from the McGill University Institutional Review
8 Board (IRB # A01-B02-02A), the Institute for Clinical Evaluative Sciences, the Partners Human Research
9 Committee IRB (Protocol # 2011P000773/PH), and the Independent Scientific Advisory Committee (ISAC)
10 of CPRD (Protocol # 14_081R).
11

12
13 **Transparency Declaration:** The lead author, Dr. Robyn Tamblyn, affirms that this manuscript is an honest,
14 accurate, and transparent account of the study being reported; that no important aspects of the study
15 have been omitted and that any discrepancies from the study as planned have been explained.
16

17
18 **Competing interests:** None to disclose
19

20
21 **Data sharing:** No additional data available
22

23 **Contributors:** RT, DWB, DLB, WGD, AJF, JSH, and JL contributed to the study concept and design. NG, TS,
24 and BH contributed to the statistical analysis. RT drafted the manuscript. DWB, DLB, WGD, AJF, NG, JSH,
25 BH, SK, JL, and TS critically reviewed the manuscript for intellectual content. All authors read and approved
26 the final manuscript.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference List

1. WHO. Depression. In: Organization WH, ed., 2017.
2. OECD. Health at a Glance 2015: OECD indicators. OECD Indicators, OECD Publishing, Paris. DOI: https://doi.org/10.1787/health_glance-2015-en. Accessed February, 2015:217.
3. Chee KY, Tripathi A, Avasthi A, et al. International study on antidepressant prescription pattern at 40 major psychiatric institutions and hospitals in Asia: A 10-year comparison study. *Asia Pac Psychiatry* 2015;**7**(4):366-74 doi: 10.1111/appy.12176[published Online First: Epub Date]].
4. Burton C, Anderson N, Wilde K, Simpson CR. Factors associated with duration of new antidepressant treatment: analysis of a large primary care database. *Br J Gen Pract* 2012;**62**(595):e104-12 doi: 10.3399/bjgp12X625166[published Online First: Epub Date]].
5. Rotermann M, Sanmartin C, Hennessy D, Arthur M. Prescription medication use by Canadians aged 6 to 79. *Health Rep* 2014;**25**(6):3-9
6. Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005-2008. *NCHS Data Brief* 2011(76):1-8
7. Zhong W, Kremers HM, Yawn BP, et al. Time trends of antidepressant drug prescriptions in men versus women in a geographically defined US population. *Arch Womens Ment Health* 2014;**17**(6):485-92 doi: 10.1007/s00737-014-0450-7[published Online First: Epub Date]].
8. Ivanova JI, Bienfait-Beuzon C, Birnbaum HG, Connolly C, Emani S, Sheehy M. Physicians' decisions to prescribe antidepressant therapy in older patients with depression in a US managed care plan. *Drugs Aging* 2011;**28**(1):51-62 doi: 10.2165/11539900-000000000-00000[published Online First: Epub Date]].
9. Singh R, Mazi-Kotwal N, Thalitaya MD. Recognising and Treating Depression in the Elderly. *Psychiatr Danub* 2015;**27** **Suppl 1**:S231-4
10. PHSA. Chronic disease multi-morbidity. How healthy are Canadians? A Trend analysis of the health of Canadians from a healthy living and chronic disease perspective.: Public Health Agency of Canada, 2014:23-24.
11. Wong J, Motulsky A, Abrahamowicz M, Egale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. *BMJ* 2017;**356**:j603 doi: 10.1136/bmj.j603[published Online First: Epub Date]].
12. Wong J, Motulsky A, Egale T, Buckeridge DL, Abrahamowicz M, Tamblyn R. Treatment indications for antidepressants prescribed in primary care in quebec, canada, 2006-2015. *JAMA* 2016;**315**(20):2230-32 doi: 10.1001/jama.2016.3445[published Online First: Epub Date]].
13. Egale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. *Archives of internal medicine* 2012;**172**(10):781-8 doi: 10.1001/archinternmed.2012.340[published Online First: Epub Date]].
14. Chen H, Reeves JH, Fincham JE, Kennedy WK, Dorfman JH, Martin BC. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia medicaid enrollees in 2001. *The Journal of clinical psychiatry* 2006;**67**(6):972-82
15. Mojtabai R, Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. *Health Aff (Millwood)* 2011;**30**(8):1434-42 doi: 10.1377/hlthaff.2010.1024[published Online First: Epub Date]].
16. Mojtabai R. Diagnosing depression in older adults in primary care. *N Engl J Med* 2014;**370**(13):1180-2 doi: 10.1056/NEJMp1311047[published Online First: Epub Date]].
17. Wang CY, Fu SH, Wang CL, Chen PJ, Wu FL, Hsiao FY. Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study. *Osteoporos Int* 2016;**27**(1):57-63 doi: 10.1007/s00198-015-3213-z[published Online First: Epub Date]].
18. Moura C, Bernatsky S, Abrahamowicz M, et al. Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). *Osteoporos Int* 2014;**25**(5):1473-81 doi: 10.1007/s00198-014-2649-x[published Online First: Epub Date]].

19. Orriols L, Wilchesky M, Lagarde E, Suissa S. Prescription of antidepressants and the risk of road traffic crash in the elderly: a case-crossover study. *Br J Clin Pharmacol* 2013;**76**(5):810-5 doi: 10.1111/bcp.12090[published Online First: Epub Date]].
20. McIntyre RS, Suppes T, Tandon R, Ostacher M. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder. *The Journal of clinical psychiatry* 2017;**78**(6):703-13 doi: 10.4088/JCP.16cs10885[published Online First: Epub Date]].
21. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. *Can J Psychiatry* 2016;**61**(9):540-60 doi: 10.1177/0706743716659417[published Online First: Epub Date]].
22. APA. The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults. Third ed: American Psychiatric Association, 2016:170.
23. Mulsant BH, Blumberger DM, Ismail Z, Rabheru K, Rapoport MJ. A systematic approach to pharmacotherapy for geriatric major depression. *Clin Geriatr Med* 2014;**30**(3):517-34 doi: 10.1016/j.cger.2014.05.002[published Online First: Epub Date]].
24. NICE. Depression in adults: recognition and management. UK: National Institute for Health and Care Excellence, 2009.
25. Tamblyn R, Girard N, Dixon WG, et al. Pharmacosurveillance without borders: electronic health records in different countries can be used to address important methodological issues in estimating the risk of adverse events. *Journal of clinical epidemiology* 2016;**77**:101-11 doi: 10.1016/j.jclinepi.2016.03.033[published Online First: Epub Date]].
26. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). *International Journal of Epidemiology* 2015;**44**(3):827-36 doi: 10.1093/ije/dyv098[published Online First: Epub Date]].
27. Lacasse A, Ware MA, Dorais M, Lanctot H, Choiniere M. Is the Quebec provincial administrative database a valid source for research on chronic non-cancer pain? *Pharmacoepidemiology and drug safety* 2015;**24**(9):980-90 doi: 10.1002/pds.3820[published Online First: Epub Date]].
28. Hohl CM, Zed PJ, Brubacher JR, Abu-Laban RB, Loewen PS, Pursell RA. Do Emergency Physicians Attribute Drug-Related Emergency Department Visits to Medication-Related Problems? *Annals of Emergency Medicine* 2010;**55**(6):493-502.e4 doi: <https://doi.org/10.1016/j.annemergmed.2009.10.008>[published Online First: Epub Date]].
29. Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? *Occupational and environmental medicine* 1998;**55**(4):272-7
30. Magrini N, Font M. Direct to consumer advertising of drugs in Europe. *BMJ* 2007;**335**(7619):526-26 doi: 10.1136/bmj.39310.506308.AD[published Online First: Epub Date]].
31. The development and updating of local formularies, NICE good practice guidance: National Institute for Health and Clinical Excellence (NICE), 2012.
32. Technology appraisal guidance. Secondary Technology appraisal guidance. <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance>.
33. CADTH Common Drug Review (CDR). Secondary CADTH Common Drug Review (CDR). <https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr>.
34. Mansfield KE, Sim J, Jordan JL, Jordan KP. A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. *Pain* 2016;**157**(1):55-64 doi: 10.1097/j.pain.0000000000000314[published Online First: Epub Date]].
35. Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. *BMJ Open* 2016;**6**(6) doi: 10.1136/bmjopen-2015-010364[published Online First: Epub Date]].
36. Fennema J, Petrykiv S, de Jonge L, Arts M. Efficacy and safety of antidepressants as analgesics in chronic pain: A review. *European Psychiatry* 2017;**41**:S234 doi: <https://doi.org/10.1016/j.eurpsy.2017.01.2248>[published Online First: Epub Date]].
37. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *The Lancet Neurology* 2015;**14**(2):162-73 doi: 10.1016/S1474-4422(14)70251-0[published Online First: Epub Date]].

- 1
2 38. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially
3 inappropriate prescribing in older people: version 2. Age and ageing 2015;**44**(2):213-8 doi:
4 10.1093/ageing/afu145[published Online First: Epub Date]].
- 5 39. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.
6 J Am Geriatr Soc 2015;**63**(11):2227-46 doi: 10.1111/jgs.13702[published Online First: Epub Date]].
- 7 40. Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J
8 Am Geriatr Soc 2008;**56**(7):1333-41 doi: 10.1111/j.1532-5415.2008.01737.x[published Online First: Epub Date]].
- 9 41. Pollock BG, Mulsant BH, Nebes R, et al. Serum anticholinergic activity in elderly depressed patients treated with paroxetine
10 or nortriptyline. The American journal of psychiatry 1998;**155**(8):1110-2 doi: 10.1176/ajp.155.8.1110[published
11 Online First: Epub Date]].
- 12 42. Duran CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. European
13 journal of clinical pharmacology 2013;**69**(7):1485-96 doi: 10.1007/s00228-013-1499-3[published Online First: Epub
14 Date]].
- 15 43. Collamati A, Martone AM, Poscia A, et al. Anticholinergic drugs and negative outcomes in the older population: from
16 biological plausibility to clinical evidence. Aging clinical and experimental research 2016;**28**(1):25-35 doi:
17 10.1007/s40520-015-0359-7[published Online First: Epub Date]].
- 18 44. Bharadwaj P, Pai MM, Suziedelyte A. Mental health stigma. Economics Letters 2017;**159**:57-60 doi:
19 <https://doi.org/10.1016/j.econlet.2017.06.028>[published
20 Online First: Epub Date]].
- 21 45. Hunt M, Auriemma J, Cashaw ACA. Self-Report Bias and Underreporting of Depression on the BDI-II. Journal of
22 Personality Assessment 2003;**80**(1):26-30 doi: 10.1207/S15327752JPA8001_10[published Online First: Epub
23 Date]].
- 24 46. Cepoiu M, McCusker J, Cole MG, Sewitch M, Belzile E, Ciampi A. Recognition of Depression by Non-psychiatric
25 Physicians—A Systematic Literature Review and Meta-analysis. Journal of General Internal Medicine
26 2008;**23**(1):25-36 doi: 10.1007/s11606-007-0428-5[published Online First: Epub Date]].
- 27 47. Tamblyn R, Huang A, Kawasumi Y, et al. The Development and Evaluation of an Integrated Electronic Prescribing and
28 Drug Management System for Primary Care. Journal of the American Medical Informatics Association
29 2006;**13**(2):148-59 doi: 10.1197/jamia.M1887[published Online First: Epub Date]].
- 30 48. Eguale T, Winslade N, Hanley JA, Buckeridge DL, Tamblyn R. Enhancing Pharmacosurveillance with Systematic
31 Collection of Treatment Indication in Electronic Prescribing. Drug Safety 2010;**33**(7):559-67 doi:
32 10.2165/11534580-000000000-00000[published Online First: Epub Date]].
- 33 49. Gelenberg AJF, M. P.; Markowitz, J. C.; Rosenbaum, J. F.; Thase, M. E.; Trivedi, M. H.; Van Rhoads, R. S. Practice
34 Guideline for the Treatment of Patients with Major Depressive Disorder: American Psychiatric Association, 2010.
- 35 50. Treuer T, Liu CY, Salazar G, et al. Use of antidepressants in the treatment of depression in Asia: guidelines, clinical
36 evidence, and experience revisited. Asia Pac Psychiatry 2013;**5**(4):219-30 doi: 10.1111/appy.12090[published
37 Online First: Epub Date]].
- 38 51. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of
39 allelic variations to the phenotype of drug response. Molecular Psychiatry 2004;**9**:442 doi:
40 10.1038/sj.mp.4001494[published Online First: Epub Date]].
- 41 52. Jenna W, Michal A, L. BD, Robyn T. Assessing the accuracy of using diagnostic codes from administrative data to infer
42 antidepressant treatment indications: a validation study. Pharmacoepidemiology and drug safety;**0**(0) doi:
43 doi:10.1002/pds.4436[published Online First: Epub Date]].
- 44 53. Gobert M, D'hoore W. Prevalence of psychotropic drug use in nursing homes for the aged in Quebec and in the
45 French-speaking area of Switzerland. International Journal of Geriatric Psychiatry 2005;**20**(8):712-21 doi:
46 doi:10.1002/gps.1349[published Online First: Epub Date]].
- 47 54. Beck CA, Williams JV, Wang JL, et al. Psychotropic Medication Use in Canada. The Canadian Journal of Psychiatry
48 2005;**50**(10):605-13 doi: 10.1177/070674370505001006[published Online First: Epub Date]].
- 49 55. Beck CA, Patten SB, Williams JVA, et al. Antidepressant utilization in Canada. Social Psychiatry and Psychiatric
50 Epidemiology 2005;**40**(10):799 doi: 10.1007/s00127-005-0968-0[published Online First: Epub Date]].
- 51
52
53
54
55
56
57
58
59
60

- 1
2 56. Lewer D, O'Reilly C, Mojtabai R, Evans-Lacko S. Antidepressant use in 27 European countries: Associations with
3 sociodemographic, cultural and economic factors. *British Journal of Psychiatry* 2018;**207**(3):221-26 doi:
4 10.1192/bjp.bp.114.156786[published Online First: Epub Date]].
- 5 57. Petty DR, House A, Knapp P, Raynor T, Zermansky A. Prevalence, duration and indications for prescribing of
6 antidepressants in primary care. *Age and ageing* 2006;**35**(5):523-26 doi: 10.1093/ageing/af023[published Online
7 First: Epub Date]].
- 8 58. Mark TL, Joish VN, Hay JW, Sheehan DV, Johnston SS, Cao Z. Antidepressant Use in Geriatric Populations: The Burden
9 of Side Effects and Interactions and Their Impact on Adherence and Costs. *The American Journal of Geriatric
10 Psychiatry* 2011;**19**(3):211-21 doi: <https://doi.org/10.1097/JGP.0b013e3181f1803d>[published
11 Online First: Epub
12 Date]].
- 13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Summary of Depression Guidelines

	US – APA guidelines (2010)	UK – NICE guidelines (2009)	Canada – CANMAT (2016)	Taiwan - Taiwan Association Against Depression (2012)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	<p>First line treatment</p> <p>Antidepressant medications for patients with mild, moderate, or severe MDD, especially patients with a history of prior positive response, moderate to severe symptoms, significant sleep or appetite disturbances, agitation, patient preference, etc.</p> <p><u>Psychotherapy</u> for patients with mild/moderate MDD, especially in the presence of significant psychosocial stressors, intrapsychic conflict, interpersonal difficulties, a co-occurring Axis II disorder, treatment availability, or patient preference.</p> <p>The <u>combination of psychotherapy and antidepressant medication</u> for patients with moderate to severe MDD, as well as in milder cases for patients with psychosocial or interpersonal problems, intrapsychic conflict, or co-occurring Axis II disorder.</p>	<p>For patients with persistent subthreshold depressive symptoms or mild to moderate depression, first-line treatment is <u>low-intensity psychosocial interventions</u>. Antidepressants should only be considered for patients with a past history of moderate or severe depression, initial presentation of symptoms that have been present for a long period (at least 2 years), or subthreshold depressive symptoms or mild depression that persists after other interventions.</p> <p>For patients with persistent subthreshold depressive symptoms or mild to moderate depression with inadequate response to initial interventions, an <u>antidepressant or a high-intensity psychological intervention</u> should be considered.</p> <p>For patients with moderate or severe depression, a <u>combination of antidepressant medication and a high-intensity psychological intervention</u> should be provided.</p>	<p>Second-generation antidepressants are first line treatments for patients with a major depressive episode of moderate or greater severity.</p> <p>First line treatments for individuals with depression of mild severity include <u>psychoeducation, self-management, and psychological treatment</u>. Pharmacological treatments can be considered for mild depression in some situations, including patient preference, previous response to antidepressants, or lack of response to nonpharmacological interventions.</p> <p><u>Psychotherapy</u> should be considered for patients with inadequate antidepressant response to initial treatment.</p>	<p><u>Pharmacotherapy (preferred) or psychotherapy</u></p>
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	<p>Pharmacotherapy first-line treatment</p> <p>Antidepressant selection should be based on the tolerability, safety, and cost of the medication, as well as patient preference and history of prior medication treatment.</p> <p>SSRIs, SNRIs, mirtazapine, and bupropion are optimal for most patients.</p> <p>MAOIs are limited to patients who do not respond to other treatments.</p>	<p>Prescribed antidepressant should normally be an SSRI in a generic form.</p> <p>When prescribing drugs other than SSRIs, the following should be considered:</p> <ul style="list-style-type: none"> • The increased likelihood of the person stopping treatment because of side effects (and the consequent need to increase the dose gradually) with venlafaxine, duloxetine and TCAs. • The specific cautions, contraindications, and monitoring requirements for some drugs • Non-reversible MAOIs, such as phenelzine, should normally be prescribed only by specialist mental health professionals. • Dosulepin should not be prescribed 	<p>Choice of antidepressant should be based on patient factors (clinical features, patient preference, etc.) and medication factors (drug-drug interactions, cost, availability, efficacy and tolerability, etc.)</p> <p>First-line treatments include SSRIs, SNRIs, agomelatine, bupropion, mirtazapine, mianserin and vortioxetine.</p> <p>Second-line treatments include TCAs, quetiapine and trazodone, moclobemide and selegiline, levomilnacipran, and vilazodone.</p> <p>Third-line treatments include MAOIs and reboxetine.</p>	<p>SSRIs, SNRIs, or any one of the newer antidepressive agents except MAOIs.</p>

Table 2 Comparisons in the Cumulative Incidence and Prevalence of Episodes of Antidepressant Use in Adults 65 Years of Age or Older Between Regions and Countries

Elderly Population	Canada			United States	United Kingdom	Taiwan
	Ontario Sample (Admin. Data) ¹	Montreal Sample (Admin. Data) ¹	Quebec City & Mtl (EMR Data) ²	Boston (EMR Data) ²	CPRD (EMR Data) ²	NHIRDB (Admin. Data) ¹
Total Population Elderly	2,053,588	120,777	28,273	83,394	2,436,180	103,400
New Episodes of Antidepressant Use³						
Number of New Users	306,197	13,303	1,308	10,131	15,868	17,580
Incidence in Elderly (%)	14.9%	11.0%	4.6%	12.2%	0.7%	17.0%
Age Standardized Incidence (%)	15.3%	12.1%	4.7%	12.3%	0.7% (reference)	18.6%
All Users of Antidepressants⁴						
Number of Users	549,444	23,422	4,450	17,359	251,543	24,239
Prevalence in Elderly (%)	26.8%	19.4%	15.74%	20.8%	10.3%	23.4%
Demographics						
Between 65 – 74 years old	162,895 (53.2%)	5,713 (42.9%)	699 (53.4%)	5,826 (57.5%)	7,129 (44.9%)	8,811 (50.1%)
75 years or older	143,302 (46.8%)	7,590 (57.1%)	609 (46.6%)	4,305 (42.5%)	8,739 (55.1%)	8,769 (49.9%)
% Female	187,037 (61.1%)	8,986 (67.5%)	853 (65.2%)	6,136 (60.6%)	10,045 (63.3%)	9,539 (54.3%)

¹Administrative data is retrieved from population-based health insurance claims for medical visits, and prescriptions.

²EMR data are extracted from primary care clinic electronic health records in the USA (Partners Inc.), Quebec (MOXXI), and the United Kingdom (Clinical Practice Research Database)

³New Episodes of Use of Antidepressants were defined as no prescription or dispensing of an antidepressant in the two years prior to the first antidepressant in the period 2009-2014

⁴All users include persons with an active prescription or dispensed supply of antidepressants between 2007-2008 as well as all new users between the period 2009-2014

Table 3 Frequency Distribution of the First Antidepressant Prescribed for New Antidepressant Users by Therapeutic Class by Country and Jurisdiction

Antidepressant	Canada			United States	United Kingdom	Taiwan
	Ontario Sample	Montreal Sample	Quebec City & Mtl	Boston	CPRD	NHIRDB
	(N=60,366 patients N=61,696 Rx)	(N=13,303 patients N=14,217 Rx)	(N=1,308 patients N=1,324 Rx)	(N=10,131 patients N=10,586 Rx)	(N=15,868 patients N=15,970 Rx)	(N=17,580 patients N=17,790 Rx)
	N Rx (%)	N Rx (%)	N Rx (%)	N Rx (%)	N Rx (%)	N Rx (%)
Selective Serotonin Reuptake Inhibitors						
Citalopram	8,760 (14.2%)	4,708 (33.1%)	410 (30.9%)	2,117 (19.9%)	4,232 (26.4%)	335 (1.8%)
Escitalopram	9,000 (14.6%)	1 (0.0%)	73 (5.5%)	438 (4.1%)	145 (0.9%)	825 (4.6%)
Fluoxetine	697 (1.1%)	114 (0.8%)	8 (0.6%)	1,156 (10.9%)	876 (5.4%)	773 (4.3%)
Fluvoxamine	172 (0.3%)	44 (0.3%)	6 (0.4%)	29 (0.2%)	1 (0.0%)	101 (0.5%)
Paroxetine	1,924 (3.1%)	515 (3.6%)	23 (1.7%)	432 (4.0%)	92 (0.5%)	435 (2.4%)
Sertraline	2,561 (4.2%)	640 (4.5%)	132 (20.2%)	1,481 (13.9%)	990 (6.1%)	1,174 (32.2%)
Subtotal	23,114 (37.4%)	6,022 (42.3%)	652 (49.2%)	5,653 (53.3%)	6,336 (39.6%)	3,643 (20.4%)
Selective Noradrenaline Reuptake Inhibitors						
Desvenlafaxine	0 (0.0%)	1 (0.0%)	4 (0.3%)	28 (0.2%)	-	-
Duloxetine	3,190 (5.2%)	161 (1.1%)	57 (4.3%)	267 (2.5%)	156 (0.9%)	241 (1.3%)
Milnacipran	0 (0.0%)	-	-	2 (0.0%)	-	18 (0.1%)
Venlafaxine	3,323 (5.4%)	1,514 (10.6%)	105 (7.9%)	434 (4.0%)	144 (0.8%)	206 (1.1%)
Subtotal	6,513 (10.5%)	1,676 (11.7%)	166 (12.5%)	731 (6.9%)	290 (1.8%)	465 (2.6%)
Tricyclic Antidepressants						
Amitriptyline	10,448 (16.9%)	2,629 (18.4%)	120 (9.0%)	796 (7.5%)	7,255 (45.4%)	1,181 (6.6%)
Dosulepin	-	-	-	-	177 (1.1%)	25 (0.2%)
Imipramine	-	-	-	32 (0.3%)	54 (0.3%)	7,340 (41.2%)
Nortriptyline	3,158 (5.1%)	95 (0.6%)	18 (1.3%)	566 (5.3%)	208 (1.3%)	-
Other TCAs	1,860 (12.0%)	263 (1.8%)	24 (1.8%)	117 (1.1%)	113 (0.7%)	778 (4.4%)
Subtotal	15,466 (25.0%)	2,987 (21.0%)	162 (12.2%)	1,511 (14.2%)	7,807 (48.8%)	9,324 (52.4%)
Serotonin Antagonist & Reuptake Inhibitors						
Trazodone	12,373 (20.1%)	2,362 (16.6%)	192 (14.5%)	1,279 (12.0%)	360 (2.2%)	3,574 (20.0%)
Norepinephrine-Dopamine Reuptake Inhibitors						
Bupropion	1,406 (2.3%)	278 (1.9%)	49 (3.7%)	1,056 (9.9%)	34 (0.2%)	215 (1.2%)
Noradrenergic Serotonin Specific Antidepressants						
Mirtazapine	2,819 (4.6%)	892 (6.2%)	103 (7.7%)	354 (3.3%)	1,141 (7.1%)	535 (3.0%)
Subtotal	16,598 (26.9%)	3,532 (24.8%)	344 (26.0%)	2,689 (25.4%)	1,535 (9.6%)	4,324 (24.3%)
Other Antidepressants	5 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.0%)	2 (0.0%)	34 (0.2%)

1. Other tricyclic antidepressants include Amoxapine, Clomipramine, Desipramine, Doxepin, Lofepramine, and Trimipramine

2. Other antidepressants include Nefazodone, Maprotiline, Agomelatine, and Roboxetine

Table 4 The Prevalence of Potential Therapeutic Indications; Depression, Other Mental Health Problems, and Chronic Pain Among New Antidepressant Users, and the Proportion of Persons with Depression who had Other Concurrent Mental Health Problems or Pain by Jurisdiction

	Canada			USA	United Kingdom	Taiwan
	Ontario Sample (N=60,366 patients)	Montreal Sample (N=13,303 patients)	Quebec City & Mtl (N=1,308 patients)	Boston (N=10,131 patients)	CPRD (N=15,868 patients)	NHIRDB (N=17,580 patients)
Depression						
Prevalence, N (%)	7,484 (12.4%)	2333 (17.5%)	563 (43.0%)	2203 (21.7%)	2478 (15.6%)	1603 (9.1%)
Alcohol/Drug Abuse						
Prevalence, N (%)	1989 (3.3%)	326 (2.5%)	23 (1.8%)	290 (2.9%)	4188 (26.4%)	224 (1.3%)
Abuse in Depressed, N (%)	450 (6.0%)	97 (4.2%)	12 (2.1%)	194 (8.8%)	795 (32.1%)	25 (1.6%)
Prevalence Ratio	2.1	2.0	1.4	7.3	1.3	1.3
Anxiety						
Prevalence, N (%)	23374 (38.7%)	3641 (27.4%)	465 (35.6%)	1798 (17.7%)	1914 (12.1%)	6277 (35.7%)
Anxiety in Depressed, N (%)	3684 (49.2%)	807 (34.6%)	218 (38.7%)	905 (41.1%)	588 (23.7%)	767 (47.8%)
Prevalence Ratio	1.3	1.3	1.2	3.6	2.4	1.4
Major Mental Illness						
Prevalence, N (%)	2627 (4.4%)	692 (5.2%)	50 (3.8%)	502 (5.0%)	253 (1.6%)	570 (3.2%)
Mental Ill. In Depressed, N (%)	1473 (19.7%)	225 (9.6%)	23 (4.1%)	323 (14.7%)	79 (3.2%)	95 (5.9%)
Prevalence Ratio	9.0	2.3	1.1	6.5	2.5	2.0
Suicide Attempt						
Prevalence, N (%)	101 (0.2%)	30 (0.2%)	-	72 (0.7%)	129 (0.8%)	6 (0.0%)
Suicide Att. in Depressed, N (%)	80 (1.1%)	8 (0.3%)	-	67 (3.0%)	67 (2.7%)	2 (0.1%)
Prevalence Ratio	26.9	1.7	-	48.2	5.8	5.0
Chronic Pain						
Prevalence, N (%)	28687 (47.5%)	6379 (48.0%)	571 (43.7%)	5200 (51.3%)	6539 (41.2%)	11994 (68.2%)
Pain in Depressed, N (%)	3591 (48.0%)	1105 (47.4%)	235 (41.7%)	1365 (62.0%)	1021 (41.2%)	994 (62.0%)
Prevalence Ratio	1.0	1.0	0.9	1.3	1.0	0.9

Table 5 Starting Therapy for New Users of Antidepressants by Potential Therapeutic Indication by Therapeutic Class and Country

Therapeutic Class	Canada			United States	United Kingdom	Taiwan
	Ontario Sample (N=60,366 patients)	Montreal Sample (N=13,303 patients)	Quebec City & Mtl (N=1,308 patients)	Boston (N=10,131 patients)	CPRD (N=15,868 patients)	NHIRDB (N=17,580 patients)
	N Rx (%)	N Rx (%)	N Rx (%)	N Rx (%)	N Rx (%)	N Rx (%)
Starting Therapy for Persons with a Diagnosis of Depression						
Selective Serotonin Re. Inh.	4,357 (55.2%)	1,548 (59.5%)	386 (67.5%)	1,388 (59.0%)	1,797 (71.4%)	930 (55.8%)
Selective Noradrenaline Re. Inh.	1,039 (13.2%)	408 (15.7%)	72 (12.6%)	162 (6.9%)	67 (2.7%)	104 (6.2%)
Tricyclic Antidepressants	647 (8.2%)	129 (5.0%)	20 (3.5%)	179 (7.6%)	319 (12.7%)	138 (8.3%)
Serotonin Antagonist & Re. Inh.	940 (11.9%)	212 (8.2%)	32 (5.6%)	269 (11.4%)	56 (2.2%)	263 (15.8%)
Norepinephrine-Dopam Re. Inh.	321 (4.1%)	81 (3.1%)	30 (5.2%)	233 (9.9%)	1 (0.0%)	43 (2.6%)
Noradrenergic serotonin specific	590 (7.5%)	224 (8.6%)	32 (5.6%)	120 (5.1%)	277 (11.0%)	184 (11.0%)
Other	1 (0.0%)	-	-	1 (0.0%)	-	4 (0.2%)
Starting Therapy for Persons with a Diagnosis of Chronic Pain						
Selective Serotonin Re. Inh.	9,823 (33.5%)	2,643 (39.0%)	268 (46.4%)	2,481 (46.1%)	2,085 (31.8%)	2,291 (18.9%)
Selective Noradrenaline Re. Inh.	3,516 (12.0%)	762 (11.2%)	83 (14.4%)	395 (7.3%)	95 (1.5%)	315 (2.6%)
Tricyclic Antidepressants	8,771 (29.9%)	1,863 (27.5%)	100 (17.3%)	1,176 (21.8%)	3,963 (60.4%)	6,703 (55.2%)
Serotonin Antagonist & Re. Inh.	5,410 (18.5%)	1,020 (15.0%)	65 (11.3%)	703 (13.0%)	89 (1.4%)	2,353 (19.4%)
Norepinephrine-Dopam Re. Inh.	551 (1.9%)	108 (1.6%)	24 (4.2%)	424 (7.9%)	17 (0.3%)	126 (1.0%)
Noradrenergic serotonin specific	1,221 (4.2%)	386 (5.7%)	38 (6.6%)	211 (3.9%)	315 (4.8%)	330 (2.7%)
Other	3 (0.0%)	-	-	2 (0.0%)	1 (0.02%)	27 (0.2%)
Starting Therapy for Persons with a Diagnosis of Other Mental Health Problems						
Selective Serotonin Re. Inh.	13,018 (49.5%)	2,459 (53.3%)	309 (61.1%)	1,384 (61.4%)	2,565 (45.1%)	2,212 (32.3%)
Selective Noradrenaline Re. Inh.	3,099 (11.8%)	550 (11.9%)	61 (12.1%)	147 (6.5%)	105 (1.9%)	254 (3.7%)
Tricyclic Antidepressants	3,823 (14.5%)	563 (12.2%)	28 (5.5%)	186 (8.2%)	2,518 (44.3%)	2,250 (32.8%)
Serotonin Antagonist & Re. Inh.	4,107 (15.6%)	591 (12.8%)	53 (10.5%)	280 (12.4%)	102 (1.8%)	1,684 (24.6%)
Norepinephrine-Dopam Re. Inh.	773 (2.9%)	98 (2.1%)	18 (3.6%)	163 (7.2%)	20 (0.4%)	126 (1.8%)
Noradrenergic serotonin specific	1,480 (5.6%)	357 (7.7%)	37 (7.3%)	94 (4.2%)	374 (6.6%)	318 (4.6%)
Other	3 (0.0%)	-	-	2 (0.1%)	1 (0.0%)	15 (0.2%)

Table 6A Characteristics of the First Antidepressant Treatment Episode Among Persons with a Diagnosis of Depression

Characteristics	Canada				United States		United Kingdom		Taiwan			
	Ontario		Montreal Sample		Quebec City & Mtl		Boston		CPRD		NHIRDB	
	N	%	N	%	N	%	N	%	N	%	N	%
All patients	4,407	100%	1,221	100%	324	100%	1,259	100%	2,152	100%	835	100%
No treatment change	2,383	54%	680	56%	220	68%	757	60%	1,317	61%	566	68%
Treatment change	2,024	46%	541	44%	104	32%	502	40%	835	39%	269	32%
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
All patients												
Dose*	1.3	1.0	0.9	0.6	0.9	0.5	1.3	0.8	1.0	0.5	0.7	0.4
Duration (days)	519.5	285.1	462.5	298.9	467.7	255.0	395.6	266.2	356.2	278.7	217.0	248.0
No treatment change**												
Dose	0.9	0.7	0.7	0.4	0.8	0.4	1.0	0.9	0.8	0.4	0.6	0.4
Duration (days)	289.1	309.6	246.3	290.4	340.9	243.2	225.7	212.3	192.8	239.9	104.7	179.7
Treatment change**												
Dose	1.5	1.0	1.0	0.6	1.1	0.6	1.4	0.8	1.2	0.6	0.8	0.4
Duration (days)	616.9	209.8	569.0	240.8	574.7	213.9	507.7	239.4	469.5	247.6	312.6	260.2
	N	%	N	%	N	%	N	%	N	%	N	%
Type of changes***												
Added molecule (different class)	796	18%	139	11%	31	10%	125	10%	125	6%	72	9%
Added molecule (same class)	174	4%	22	2%	6	2%	42	3%	54	3%	26	3%
Dose decrease	921	21%	246	20%	38	12%	151	12%	407	19%	105	13%
Dose increase	1,464	33%	387	32%	64	20%	348	28%	611	28%	171	20%
Removed molecule (different class)	710	16%	132	11%	26	8%	34	3%	19	1%	75	9%
Removed molecule (same class)	178	4%	23	2%	5	2%	6	0%	6	0%	28	3%
Switch class	10	0%	48	4%	-	-	56	4%	70	3%	1	0%
Switch molecule (same class)	5	0%	11	1%	-	-	19	2%	24	1%	-	-

*Dose is the proportion of the WHO recommended daily dose (dose prescribed/recommended daily dose)

**Treatment change in the first antidepressant episode, defined as continuous therapy with gaps of no greater than 90 days

***Patients can have >1 type of change in the episode of antidepressant use.

Table 6B. Characteristics of the First Antidepressant Treatment Episode Among Persons with a Diagnosis of Chronic Pain

Characteristics	Canada				United States		United Kingdom		Taiwan			
	Ontario		Montreal Sample		Quebec City & Mtl		Boston		CPRD		NHIRDB	
	N	%	N	%	N	%	N	%	N	%	N	%
All patients, all changes	16045	100%	3276	100%	349	100%	2657	100%	5360	100%	6029	100%
No treatment change	10650	66%	2220	68%	261	75%	1793	67%	4017	75%	4761	79%
Treatment change	5395	34%	1056	32%	88	25%	864	33%	1343	25%	1268	21%
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
All patients, all changes												
Dose*	0.9	0.7	0.7	0.5	0.8	0.6	1.0	0.8	0.6	0.5	0.5	0.4
Duration (days)	416.3	312.8	407.8	313.7	437.0	263.6	384.6	261.7	257.6	270.8	168.9	227.3
No treatment change**												
Dose	0.6	0.5	0.4	0.3	0.6	0.5	0.8	0.7	0.40	0.4	0.4	0.3
Duration (days)	198.7	271.4	202.1	270.2	300.9	238.6	247.4	223.3	122.3	192	83.6	154.6
Treatment change**												
Dose	1	0.7	0.8	0.5	1.0	0.6	1.1	0.7	0.7	0.5	0.5	0.4
Duration (days)	534.6	260.5	534.7	265.1	590.0	201.5	482.2	239.6	398.0	266.9	264.4	252.8
	N	%	N	%	N	%	N	%	N	%	N	%
Type of changes***												
Added molecule (different class)	1776	11%	267	8%	30	9%	189	7%	159	3%	245	4%
Added molecule (same class)	375	2%	31	1%	5	1%	69	3%	68	1%	90	1%
Dose decrease	2291	14%	455	14%	32	9%	243	9%	629	12%	569	9%
Dose increase	3980	25%	818	25%	58	17%	611	23%	1032	19%	809	13%
Removed molecule (different class)	1547	10%	245	7%	26	7%	47	2%	14	0%	262	4%
Removed molecule (same class)	372	2%	32	1%	4	1%	6	0%	7	0%	95	2%
Switch class	30	0%	120	4%	-	-	92	3%	77	1%	15	0%
Switch molecule (same class)	22	0%	30	1%	-	-	27	1%	29	1%	4	0%

*Dose is the proportion of the WHO recommended daily dose (dose prescribed/recommended daily dose)

**Treatment change in the first antidepressant episode, defined as continuous therapy with gaps of no greater than 90 days

***Patients can have >1 type of change in the episode of antidepressant use.

APPENDIX**DEPRESSION****At least one ICD-9 in:**

- 311 Depressive disorder, not elsewhere classified
- 296.2 Major depressive disorder, single episode
- 296.3 Major depressive disorder, recurrent episode
- 309 Adjustment reaction
 - 309.0 Adjustment disorder with depressed mood
 - 309.1 Prolonged depressive reaction
 - 309.2 With predominant disturbance of other emotions
 - 309.3 Adjustment disorder with disturbance of conduct
 - 309.4 Adjustment disorder with mixed disturbance of emotions and conduct
 - 309.8 Other specified adjustment reactions
 - 309.9 Unspecified adjustment reaction

OR

At least one ICD-10 in:

- F32 Depressive episode
 - F32.0 Mild depressive episode
 - F32.1 Moderate depressive episode
 - F32.2 Severe depressive episode without psychotic symptoms
 - F32.3 Severe depressive episode with psychotic symptoms
 - F32.8 Other depressive episodes
 - F32.9 Depressive episode, unspecified
- F33 Recurrent depressive disorder
 - F33.0 Recurrent depressive disorder, current episode mild
 - F33.1 Recurrent depressive disorder, current episode moderate
 - F33.2 Recurrent depressive disorder, current episode severe without psychotic symptoms
 - F33.3 Recurrent depressive disorder, current episode severe with psychotic symptoms
 - F33.4 Recurrent depressive disorder, currently in remission
 - F33.8 Other recurrent depressive disorders
 - F33.9 Recurrent depressive disorder, unspecified
- F41.2 Mixed anxiety and depressive disorder

OR

At least one READ code in:†:

E2B..00	Depressive disorder NEC	Eu32311	[X]Single episode of major depression and psychotic symptoms
Eu32z11	[X]Depression NOS	E113400	Recurrent major depressive episodes, severe, with

1	E112.14	Endogenous depression	E113z00	psychosis Recurrent major depressive episode NOS
2	E200300	Anxiety with depression	E113300	Recurrent major depressive episodes, severe, no psychosis
3				
4	E135.00	Agitated depression	E11y200	Atypical depressive disorder
5	E204.00	Neurotic depression reactive type	E001300	Presenile dementia with depression
6	E290.00	Brief depressive reaction	Eu02z16	[X] Senile dementia, depressed or paranoid type
7	2257.00	O/E - depressed	Eu32z13	[X]Prolonged single episode of reactive depression
8	1B17.00	Depressed	Eu33.14	[X]Seasonal depressive disorder
9	E11..12	Depressive psychoses	Eu32314	[X]Single episode of reactive depressive psychosis
10	E204.11	Postnatal depression	E113100	Recurrent major depressive episodes, mild
11	1465.00	H/O: depression	Eu33100	[X]Recurrent depressive disorder, current episode moderate
12				
13				
14	62T1.00	Puerperal depression	R007z13	[D]Postoperative depression
15	Eu32z00	[X]Depressive episode, unspecified	Eu33000	[X]Recurrent depressive disorder, current episode mild
16				
17	E2B0.00	Postviral depression	Eu33314	[X]Recurr severe episodes/psychogenic depressive psychosis
18				
19	Eu32z12	[X]Depressive disorder NOS	E112400	Single major depressive episode, severe, with psychosis
20				
21	Eu33.00	[X]Recurrent depressive disorder	Eu92000	[X]Depressive conduct disorder
22	E2B1.00	Chronic depression	Eu33313	[X]Recurr severe episodes/major depression+psychotic symptom
23				
24	Eu32.00	[X]Depressive episode	Eu33200	[X]Recurr depress disorder cur epi severe without psyc sympt
25				
26	1B17.11	C/O - feeling depressed	E112000	Single major depressive episode, unspecified
27	Eu53012	[X]Postpartum depression NOS	E113000	Recurrent major depressive episodes, unspecified
28	E112.11	Agitated depression	E290z00	Brief depressive reaction NOS
29	Eu32z14	[X] Reactive depression NOS	Eu33z11	[X]Monopolar depression NOS
30	E113700	Recurrent depression	Eu33316	[X]Recurrent severe episodes/reactive depressive psychosis
31				
32	E112.12	Endogenous depression first episode	E002z00	Senile dementia with depressive or paranoid features NOS
33				
34	Eu32y00	[X]Other depressive episodes	Eu32211	[X]Single episode agitated depressn w/out psychotic symptoms
35				
36	E113.11	Endogenous depression - recurrent	E004300	Arteriosclerotic dementia with depression
37	E112.13	Endogenous depression first episode	E112500	Single major depressive episode, partial or unspec remission
38				
39	E112z00	Single major depressive episode NOS	Eu33z00	[X]Recurrent depressive disorder, unspecified
40	Eu32.13	[X]Single episode of reactive depression	E002.00	Senile dementia with depressive or paranoid features
41				
42	Eu34113	[X]Neurotic depression	E02y300	Drug-induced depressive state
43	Eu41211	[X]Mild anxiety depression	Eu33300	[X]Recurrent depress disorder cur epi severe with psyc symp
44				
45	Eu34100	[X]Dysthymia	Eu33y00	[X]Other recurrent depressive disorders
46	Eu34111	[X]Depressive neurosis	Eu32312	[X]Single episode of psychogenic depressive psychosis
47				
48	Eu33.15	[X]SAD - Seasonal affective disorder	E113600	Recurrent major depressive episodes, in full remission
49				
50	Eu33.11	[X]Recurrent episodes of depressive reaction	E113500	Recurrent major depressive episodes,partial/unspec remission
51				
52	Eu33.13	[X]Recurrent episodes of reactive depression	Eu32y12	[X]Single episode of masked depression NOS
53				
54				
55				
56				
57				
58				
59				
60				

1	Eu32.11 [X]Single episode of depressive reaction	E112600 Single major depressive episode, in full remission
2	E11z200 Masked depression	Eu32213 [X]Single episode vital depression w/out psychotic symptoms
3		
4	Eu32100 [X]Moderate depressive episode	Eu33214 [X]Vital depression, recurrent without psychotic symptoms
5		
6	Eu32200 [X]Severe depressive episode without psychotic symptoms	Eu32600 [X]Major depression, moderately severe
7		
8	1B1U.00 Symptoms of depression	Eu32500 [X]Major depression, mild
9	1BT..00 Depressed mood	Eu32700 [X]Major depression, severe without psychotic symptoms
10		
11	1B1U.11 Depressive symptoms	Eu32800 [X]Major depression, severe with psychotic symptoms
12		
13	E112.00 Single major depressive episode	Eu32900 [X]Single major depr ep, severe with psych, psych in remiss
14		
15	Eu32400 [X]Mild depression	Eu32A00 [X]Recurr major depr ep, severe with psych, psych in remiss
16		
17		
18	Eu32y11 [X]Atypical depression	Eu32B00 [X]Antenatal depression
19	E118.00 Seasonal affective disorder	Eu34114 [X]Persistant anxiety depression
20	Eu33212 [X]Major depression, recurrent without psychotic symptoms	E112100 Single major depressive episode, mild
21		
22	Eu33211 [X]Endogenous depression without psychotic symptoms	E291.00 Prolonged depressive reaction
23		
24	Eu32000 [X]Mild depressive episode	Eu33315 [X]Recurrent severe episodes of psychotic depression
25		
26		
27	Eu41200 [X]Mixed anxiety and depressive disorder	Eu32.12 [X]Single episode of psychogenic depression
28		
29	Eu32300 [X]Severe depressive episode with psychotic symptoms	Eu3y111 [X]Recurrent brief depressive episodes
30		
31	Eu53011 [X]Postnatal depression NOS	Eu33.12 [X]Recurrent episodes of psychogenic depression
32	E113200 Recurrent major depressive episodes, moderate	Eu20400 [X]Post-schizophrenic depression
33		
34	E113.00 Recurrent major depressive episode	E002100 Senile dementia with depression
35	E112200 Single major depressive episode, moderate	Eu33400 [X]Recurrent depressive disorder, currently in remission
36		
37	E112300 Single major depressive episode, severe, without psychosis	Eu32212 [X]Single episode major depression w/out psychotic symptoms
38		
39	Eu32313 [X]Single episode of psychotic depression	Eu33311 [X]Endogenous depression with psychotic symptoms
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

ANXIETY**At least one ICD-9 in:**

300 Anxiety, dissociative and somatoform disorders

OR

At least one ICD-10 in:

F40 Phobic anxiety disorders
 F41 Other anxiety disorders (except F41.2)
 F42 Obsessive-compulsive disorder
 F43 Reaction to severe stress, and adjustment disorders
 F44 Dissociative and conversion disorders
 F45 Somatoform disorders
 F48 Other nonpsychotic mental disorders

OR

At least one READ code in:

1B13.00	Anxiousness	Eu42.11	[X]Anankastic neurosis
E28..00	Acute reaction to stress	Eu45213	[X]Hypochondriacal neurosis
E200111	Panic attack	Eu93100	[X]Phobic anxiety disorder of childhood
E200.00	Anxiety states	Eu45000	[X]Somatization disorder
E200300	Anxiety with depression	E201C00	Phantom pregnancy
E20z.11	Nervous breakdown	E201z12	Ataxia - hysterical
Eu41111	[X]Anxiety neurosis	E283100	Acute posttrauma stress state
E202B00	Cancer phobia	Eu41z11	[X]Anxiety NOS
E205.11	Nervous exhaustion	E28z.00	Acute stress reaction NOS
E202800	Claustrophobia	Z4I7211	Reducing anxiety
E200400	Chronic anxiety	E29y400	Adjustment reaction due to hospitalisation
E202.00	Phobic disorders	Eu44.13	[X]Hysteria
E203100	Obsessional neurosis	Eu44600	[X]Dissociative anaesthesia and sensory loss
E201.00	Hysteria	Eu40y00	[X]Other phobic anxiety disorders
E202000	Phobia unspecified	E28z.13	Stage fright
E202C00	Dental phobia	Eu46.00	[X]Other neurotic disorders
Eu40000	[X]Agoraphobia	E202600	Acrophobia
E29..00	Adjustment reaction	E28z.11	Examination fear
E264200	Cyclical vomiting - psychogenic	Eu41y11	[X]Anxiety hysteria
E202100	Agoraphobia with panic attacks	E292312	Specific work inhibition
E203.00	Obsessive-compulsive disorders	Z4I7200	Alleviating anxiety
E205.00	Neurasthenia - nervous debility	E202700	Animal phobia
1466.00	H/O: anxiety state	E201B00	Compensation neurosis
E201100	Hysterical blindness	Eu45413	[X]Psychogenic headache
E20y100	Writer's cramp neurosis	E262.00	Psychogenic cardiovascular symptoms
E264400	Psychogenic dyspepsia	E263.00	Psychogenic skin symptoms
E200100	Panic disorder	E283z00	Other acute stress reaction NOS
Eu41012	[X]Panic state	Eu93200	[X]Social anxiety disorder of childhood

1	E201z11	Aphonia - hysterical	Eu45400	[X]Persistent somatoform pain disorder
2	E201612	Globus hystericus	Eu45212	[X]Dysmorphophobia nondelusional
3	E202A0	Fear of flying	E262300	Psychogenic cardiovascular disorder
4	0			
5	Eu43100	[X]Post - traumatic stress disorder	E264.00	Psychogenic gastrointestinal tract symptoms
6	E26..00	Physiological malfunction arising from mental factors	Eu43z00	[X]Reaction to severe stress, unspecified
7				
8	E201700	Hysterical amnesia	E2D0.00	Disturbance of anxiety and fearfulness childhood/adolescent
9				
10	E200z00	Anxiety state NOS	E202900	Fear of crowds
11	E200500	Recurrent anxiety	E202400	Social phobia, fear of public speaking
12	E200200	Generalised anxiety disorder	E261000	Psychogenic air hunger
13	E201800	Hysterical fugue	Eu43111	[X]Traumatic neurosis
14	E264000	Psychogenic aerophagy	E29y100	Other post-traumatic stress disorder
15	E26z.00	Psychosomatic disorder NOS	Eu45312	[X]Da Costa's syndrome
16	E20..00	Neurotic disorders	E201511	Fit - hysterical
17	Eu42.00	[X]Obsessive - compulsive disorder	Eu40z00	[X]Phobic anxiety disorder, unspecified
18	E206.00	Depersonalisation syndrome	E261z00	Psychogenic respiratory symptom NOS
19	Eu41.00	[X]Other anxiety disorders	E201400	Hysterical paralysis
20	E203000	Compulsive neurosis	Eu45111	[X]Undifferentiated psychosomatic disorder
21	1B13.11	Anxiousness - symptom	Eu44400	[X]Dissociative motor disorders
22	E202E00	Fear of pregnancy	Eu44.11	[X]Conversion hysteria
23	E293000	Adjustment reaction with aggression	E2D0z00	Disturbance anxiety and fearfulness childhood/adolescent NOS
24				
25	E292000	Separation anxiety disorder	E2D0000	Childhood and adolescent overanxiousness disturbance
26				
27				
28	Eu41011	[X]Panic attack	E29y200	Adjustment reaction with physical symptoms
29	E200000	Anxiety state unspecified	Eu41112	[X]Anxiety reaction
30	Eu40z11	[X]Phobia NOS	E293100	Adjustment reaction with antisocial behaviour
31	Eu45200	[X]Hypochondriacal disorder	Eu45y14	[X]Psychogenic torticollis
32	E29y300	Elective mutism due to an adjustment reaction	Eu45414	[X]Somatoform pain disorder
33				
34				
35	Eu41211	[X]Mild anxiety depression	Eu43211	[X]Culture shock
36	Eu43015	[X]Psychic shock	Eu43011	[X]Acute crisis reaction
37	Eu41000	[X]Panic disorder [episodic paroxysmal anxiety]	E29z.00	Adjustment reaction NOS
38				
39	Eu46100	[X]Depersonalization - derealization syndrome	E264.11	Globus abdominalis
40				
41	Eu40.00	[X]Phobic anxiety disorders	E261.00	Psychogenic respiratory symptoms
42	Eu46011	[X]Fatigue syndrome	Eu45412	[X]Psychogenic backache
43	Eu40200	[X]Specific (isolated) phobias	E283.00	Other acute stress reactions
44	E202.12	Phobic anxiety	Eu42y00	[X]Other obsessive-compulsive disorders
45	Eu41100	[X]Generalized anxiety disorder	E20y200	Other occupational neurosis
46	E202D0	Fear of death	Eu44300	[X]Trance and possession disorders
47	0			
48				
49	Eu43012	[X]Acute reaction to stress	Eu44100	[X]Dissociative fugue
50	Eu43.00	[X]Reaction to severe stress, and adjustment disorders	Eu44y12	[X]Multiple personality
51				
52	Eu40213	[X]Claustrophobia	E201z13	Ganser's syndrome - hysterical
53	Eu43200	[X]Adjustment disorders	E278.00	Psychalgia
54	Eu46y13	[X]Occupational neurosis, including writer's cramp	Eu44000	[X]Dissociative amnesia
55				
56				
57	Eu44511	[X]Pseudoseizures	Eu45300	[X]Somatoform autonomic dysfunction
58	Eu40100	[X]Social phobias	Eu43213	[X]Hospitalism in children
59				
60				

1	Eu43000	[X]Acute stress reaction	E29y.00	Other adjustment reactions
2	146G.00	H/O: agoraphobia	E201000	Hysteria unspecified
3	1B1V.00	C/O - panic attack	E261500	Psychogenic aphonia
4	Eu41200	[X]Mixed anxiety and depressive disorder	E20y.00	Other neurotic disorders
5	E280.00	Acute panic state due to acute stress reaction	E2z..00	Neuroses or other mental disorder NOS
6				
7	Eu44411	[X]Psychogenic aphonia	E281.00	Acute fugue state due to acute stress reaction
8	Eu45500	[X]Globus pharyngeus	Eu40112	[X]Social neurosis
9	Eu40300	[X]Needle phobia	E20yz00	Other neurotic disorder NOS
10	Eu40214	[X]Simple phobia	E201900	Multiple personality
11	Eu45316	[X]Psychogenic cough	Eu45317	[X]Psychogenic diarrhoea
12	Eu45322	[X]Psychogenic hyperventilat	E28..11	Combat fatigue
13	E202200	Agoraphobia without mention of panic attacks	E260.00	Psychogenic musculoskeletal symptoms
14				
15	2258.00	O/E - anxious	Eu45311	[X]Cardiac neurosis
16	E202z00	Phobic disorder NOS	Eu41300	[X]Other mixed anxiety disorders
17	E20z.00	Neurotic disorder NOS	Eu46y00	[X]Other specified neurotic disorders
18	Eu40012	[X]Panic disorder with agoraphobia	E265200	Psychogenic dysmenorrhea
19	E262z00	Psychogenic cardiovascular symptom NOS	Eu46y16	[X]Psychogenic syncope
20	E260z00	Psychogenic musculoskeletal symptoms NOS	E201200	Hysterical deafness
21	Eu34114	[X]Persistant anxiety depression	E278200	Psychogenic backache
22	E263z00	Psychogenic skin symptoms NOS	E294.00	Adjustment reaction with disturbance emotion and conduct
23				
24	E262200	Neurocirculatory asthenia	E201611	Astasia - abasia, hysterical
25	E262000	Cardiac neurosis	Eu44y11	[X]Ganser's syndrome
26	E20y000	Somatization disorder	Eu45y11	[X]Psychogenic dysmenorrhoea
27	E264300	Psychogenic diarrhoea	E203.11	Anancastic neurosis
28	E201600	Other conversion disorder	Eu46y12	[X]Dhat syndrome
29	E261100	Psychogenic cough	Eu45320	[X]Psychogenic flatulence
30	E282.00	Acute stupor state due to acute stress reaction	E261200	Psychogenic hiccough
31				
32	E203z00	Obsessive-compulsive disorder NOS	E260000	Psychogenic paralysis
33	E292z00	Adjustment reaction with disturbance of other emotion NOS	E292y00	Adjustment reaction with mixed disturbance of emotion
34				
35	E264500	Psychogenic constipation	Eu45z00	[X]Somatoform disorder, unspecified
36	E263000	Psychogenic pruritus	Eu44z00	[X]Dissociative [conversion] disorder, unspecified
37				
38	E202300	Social phobia, fear of eating in public	Eu46z00	[X]Neurotic disorder, unspecified
39	E293.00	Adjustment reaction with predominant disturbance of conduct	E2y..00	Other specified neuroses or other mental disorders
40				
41	E201500	Hysterical seizures	Eu44611	[X]Psychogenic deafness
42	Eu45324	[X]Psychogenic IBS	Eu41113	[X]Anxiety state
43	Eu46000	[X]Neurasthenia	Eu45314	[X]Neurocirculatory asthenia
44	E202.11	Social phobic disorders	Eu44.12	[X]Conversion reaction
45	Eu45y13	[X]Psychogenic pruritis	Eu45319	[X]Psychogenic dysuria
46	Eu45318	[X]Psychogenic dyspepsia	E29y000	Concentration camp syndrome
47	Eu40011	[X]Agoraphobia without history of panic disorder	Eu45321	[X]Psychogenic hiccough
48				
49	Eu44y13	[X]Psychogenic confusion	E278000	Psychogenic pain unspecified
50	Eu45323	[X]Psychogenic freq micturit	E278z00	Psychalgia NOS
51	Eu51511	[X]Dream anxiety disorder	Eu45411	[X]Psychalgia
52	Eu93000	[X]Separation anxiety disorder of childhood	E292200	Early adult emancipation disorder
53	Eu45.00	[X]Somatoform disorders	E265300	Psychogenic dysuria
54	Eu40212	[X]Animal phobias	Eu44200	[X]Dissociative stupor
55				
56				
57				
58				
59				
60				

1	Eu42200	[X]Mixed obsessional thoughts and acts	E260100	Psychogenic torticollis
2	E202500	Social phobia, fear of public washing	E292400	Adjustment reaction with anxious mood
3	Eu44412	[X]Psychogenic dysphonia	E20y011	Briquet's disorder
4	225J.00	O/E - panic attack	Eu44500	[X]Dissociative convulsions
5	Eu45z11	[X]Psychosomatic disorder NOS	Eu45100	[X]Undifferentiated somatoform disorder
6	E29y500	Other adjustment reaction with withdrawal	E292500	Culture shock
7	E261300	Psychogenic hyperventilation	Eu45012	[X]Briquet's syndrome
8	E265100	Psychogenic vaginismus	Eu93y12	[X]Childhood overanxious disorder
9	E283000	Acute situational disturbance	Eu46y14	[X]Psychasthenia
10	Eu42000	[X]Predominantly obsessional thoughts or ruminations	Eu45y00	[X]Other somatoform disorders
11				
12	Eu05400	[X]Organic anxiety disorder	E292300	Specific academic or work inhibition
13	E28z.12	Flying phobia	E26y.00	Other psychogenic malfunction
14	Eu45y12	[X]Globus hystericus	Z4I7100	Recognising anxiety
15	Eu46z11	[X]Neurosis NOS	Eu45313	[X]Gastric neurosis
16	Eu43014	[X]Crisis state	Eu44y00	[X]Other dissociative [conversion] disorders
17	Eu43y00	[X]Other reactions to severe stress	E293200	Adjustment reaction with destructiveness
18	Eu42.12	[X]Obsessive-compulsive neurosis	Eu45215	[X]Nosophobia
19	Eu42100	[X]Predominantly compulsive acts [obsessional rituals]	E292311	Specific academic or work inhibition
20				
21	Eu44.00	[X]Dissociative [conversion] disorders	Eu40z12	[X]Phobic state NOS
22	Z4I7.00	Acknowledging anxiety	Eu40211	[X]Acrophobia
23	Eu42z00	[X]Obsessive-compulsive disorder, unspecified	Eu44y14	[X]Psychogenic twilight state
24				
25	E292100	Adolescent emancipation disorder	E265.00	Psychogenic genitourinary tract symptoms
26	E201z00	Hysteria NOS	Eu43013	[X]Combat fatigue
27	E261400	Psychogenic yawning	E264z00	Psychogenic gastrointestinal tract symptom NOS
28				
29	E29yz00	Other adjustment reactions NOS	E20y300	Psychasthenic neurosis
30	E201A0	Dissociative reaction unspecified	E265z00	Psychogenic genitourinary tract symptom NOS
31	0			
32	E201300	Hysterical tremor	Eu44700	[X]Mixed dissociative [conversion] disorders
33	Eu45011	[X]Multiple psychosomatic disorder	E267.00	Psychogenic symptom of special sense organ
34	Eu4..00	[X]Neurotic, stress - related and somoform disorders	Eu46y15	[X]Psychasthenia neurosis
35				
36	Eu41z00	[X]Anxiety disorder, unspecified	Eu45325	[X]Psychogenic pylorospasm
37	E284.00	Stress reaction causing mixed disturbance of emotion/conduct	1B13.12	Anxious
38				
39	Eu41y00	[X]Other specified anxiety disorders	E26yz00	Other psychogenic malfunction NOS
40	E292.00	Adjustment reaction, predominant disturbance other emotions	Eu45511	[X]Globus hystericus
41				
42	E293z00	Adjustment reaction with predominant disturbance conduct NOS	Eu46y11	[X]Briquet's disorder
43	Eu45013	[X]Briquet's disorder	Eu43400	[X]Chron post-traumatic stress disorder follow military comb
44			Eu43300	[X]Acute post-traumatic stress disorder follow military comb
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

MENTAL DISORDERS**At least one ICD-9 in:**

295	Schizophrenic disorders
296	Episodic mood disorders (except 296.2 & 296.3)
297	Delusional disorders
298	Other nonorganic psychoses
299	Pervasive developmental disorders
301	Personality disorders

OR

At least one ICD-10 in:

F20	Schizophrenia
F21	Schizotypal disorder
F22	Delusional disorders
F23	Brief psychotic disorder
F24	Shared psychotic disorder
F25	Schizoaffective disorders
F28	Other psychotic disorder not due to a substance or known physiological condition
F29	Unspecified psychosis not due to a substance or known physiological condition
F30	Manic episode
F31	Bipolar disorder
F34	Persistent mood [affective] disorders
F39	Unspecified mood [affective] disorder

OR

At least one READ code in:

E104.00	Acute schizophrenic episode	Eu6y100	[X]Intent product/feign of symptom/disab eith physical/psych
Eu2z.11	[X]Psychosis NOS	Eu50400	[X]Overeating associated with other psychological disturbncs
E21z.11	Psychopathic personality	Eu60711	[X]Asthenic personality disorder
E10..00	Schizophrenic disorders	E04z.00	Chronic organic psychosis NOS
E2F3z00	Speech or language developmental disorder NOS	Eu34z00	[X]Persistent mood affective disorder, unspecified
E214100	Obsessional personality	Eu6z.00	[X]Unspecified disorder of adult personality and behaviour
E21y500	Immature personality disorder	Eu10600	[X]Mental and behav dis due to use alcohol: amnesic syndrome
E103.00	Paranoid schizophrenia	E214.11	Anancastic personality
Eu31.11	[X]Manic-depressive illness	Eu60800	[X]Addictive personality
E2A1200	Change in personality	Eu53000	[X]Mild mental/behav disorder assoc with the puerperium NEC
1B1E.00	Hallucinations	Eu21.15	[X]Prodromal schizophrenia
1BH..00	Delusions	Eu53100	[X]Severe mental and behav disorder assoc wth puerperium NEC
ZV40.13	[V]Psychological problems	Eu22y11	[X]Delusional dysmorphophobia

1	E21..00	Personality disorders	Eu25112	[X]Schizophreniform psychosis, depressive type
2	Eu22011	[X]Paranoid psychosis	E141100	Residual disintegrative psychoses
3	E03y300	Unspecified puerperal psychosis	Eu13.00	[X]Mental and behavioural dis due use sedatives/hypnotics
4	E107.00	Schizo-affective schizophrenia	Eu05y00	[X]Oth sp mental disord brain damag/dysfunction/physcal disd
5			E11z.00	Other and unspecified affective psychoses
6	R001.00	[D]Hallucinations	1S04.00	C/O - illusions seen
7	E11..12	Depressive psychoses	E2z..00	Neuroses or other mental disorder NOS
8	E21y711	Neurotic personality	Eu11000	[X]Mental & behav dis due to use opioids: acute intoxication
9	Eu30000	[X]Hypomania	Eu60z00	[X]Personality disorder, unspecified
10			Eu34.00	[X]Persistent mood affective disorders
11	E00z.00	Senile or presenile psychoses NOS	E110300	Single manic episode, severe without mention of psychosis
12	Eu63300	[X]Trichotillomania	Eu15.00	[X]Mental & behav disorder due other stimulants inc caffein
13	E212.00	Schizoid personality disorder	E14..00	Psychoses with origin in childhood
14			Eu20100	[X]Hebephrenic schizophrenia
15	E11z100	Rebound mood swings	1BH0.00	Delusion of persecution
16	E2F3.00	Speech or language developmental disorder	Eu60400	[X]Histrionic personality disorder
17	E...00	Mental disorders	E107200	Chronic schizo-affective schizophrenia
18	E13z.11	Psychotic episode NOS	E215000	Unspecified histrionic personality disorder
19	E114.00	Bipolar affective disorder, currently manic	Eu10000	[X]Mental & behav dis due to use alcohol: acute intoxication
20	E215200	Emotionally unstable personality	Eu23300	[X]Other acute predominantly delusional psychotic disorders
21	E121.00	Chronic paranoid psychosis	Eu84z00	[X]Pervasive developmental disorder, unspecified
22	E100200	Chronic schizophrenic	Eu13200	[X]Mental and behav dis due to seds/hypntcs: dependence synd
23			Eu81y00	[X]Other developmental disorders of scholastic skills
24			E100400	Acute exacerbation of chronic schizophrenia
25	E12..00	Paranoid states	Eu23y00	[X]Other acute and transient psychotic disorders
26			Eu30z00	[X]Manic episode, unspecified
27	285..11	Psychotic condition, insight present	Eu8y.00	[X]Other disorders of psychological development
28	E011000	Korsakov's alcoholic psychosis	Eu31600	[X]Bipolar affective disorder, current episode mixed
29			Eu60215	[X]Sociopathic personality disorder
30	E216.00	Inadequate personality disorder	Eu19200	[X]Mental and behav dis mlti/oth psych sbs: dependence syndr
31	E115.00	Bipolar affective disorder, currently depressed	ZV40z00	[V]Unspecified mental or behavioural problem
32	Eu30z11	[X]Mania NOS	Eu0z.00	[X]Unspecified organic or symptomatic mental disorder
33	Eu31500	[X]Bipolar affect dis cur epi severe depres with psyc symp	Eu80y00	[X]Other developmental disorders of speech and language
34			E111z00	Recurrent manic episode NOS
35	E215.11	Hysterical personality disorders	E111100	Recurrent manic episodes, mild
36	Eu22015	[X]Paranoia	E114200	Bipolar affective disorder, currently manic, moderate
37	Eu10.00	[X]Mental and behavioural disorders due to use of alcohol	Eu6y200	[X]Munchausen's by proxy
38	E210.00	Paranoid personality disorder		
39			L184.00	Mental disorders in pregnancy, childbirth and the puerperium
40	Eu3..00	[X]Mood - affective disorders	Eu33300	[X]Recurrent depress disorder cur epi severe with psyc symp
41	146..00	H/O: psychiatric disorder	Eu24.12	[X] Induced paranoid disorder
42			Eu11.00	[X]Mental and behavioural disorders due to use of opioids
43	Eu80.00	[X]Specific developmental disorders of speech and language	Eu02z12	[X] Presenile psychosis NOS
44	1464.00	H/O: schizophrenia	Eu14100	[X]Mental and behav dis due to use of cocaine:
45	E213.11	Aggressive personality		
46	Eu83.00	[X]Mixed specific developmental disorders		
47	Eu80z00	[X]Developmental disorder of speech and language unspecified		
48	Eu81z00	[X]Developmental disorder of scholastic skills, unspecified		
49	Eu05y11	[X]Epileptic psychosis NOS		
50				
51	Eu31.12	[X]Manic-depressive psychosis		
52	Eu31.00	[X]Bipolar affective disorder		
53				
54	Eu84.00	[X]Pervasive developmental disorders		
55	Eu0..00	Organic psychotic conditions		

1	Eu82.00	[X]Specific developmental disorder of motor function	Eu22013	harmful use [X]Paraphrenia - late
2				
3	E132.00	Reactive confusion	Eu84y00	[X]Other pervasive developmental disorders
4	Eu60300	[X]Emotionally unstable personality disorder	E101z00	Hebephrenic schizophrenia NOS
5	E10z.00	Schizophrenia NOS	Eu62000	[X]Enduring personality change after catastrophic experience
6				
7	Eu60600	[X]Anxious [avoidant] personality disorder	1S40.00	Dysphoric mood
8	E130.00	Reactive depressive psychosis	Eu06013	[X]Limbic epilepsy personality
9	E11..11	Bipolar psychoses	Eu30212	[X]Mania with mood-incongruent psychotic symptoms
10	Eu0z.12	[X]Symptomatic psychosis NOS	Eu60014	[X]Sensitive paranoid personality disorder
11	E103z00	Paranoid schizophrenia NOS	E216.11	Asthenic personality
12	Eu25.00	[X]Schizoaffective disorders	Eu66z00	[X]Psychosexual development disorder, unspecified
13	Eu30.11	[X]Bipolar disorder, single manic episode	Eu22z00	[X]Persistent delusional disorder, unspecified
14	E2...00	Neurotic, personality and other nonpsychotic disorders	Eu20y00	[X]Other schizophrenia
15				
16	Eu...00	[X]Mental and behavioural disorders	E2A..00	Nonpsychotic mental disorders following organic brain damage
17				
18	Eu34112	[X]Depressive personality disorder	Eu14500	[X]Mental & behav dis due to use cocaine: psychotic disorder
19				
20	E211200	Depressive personality disorder	Eu14000	[X]Mental & behav dis due to use cocaine: acute intoxication
21				
22	E03y000	Organic delusional syndrome	Eu60y00	[X]Other specific personality disorders
23	E107z00	Schizo-affective schizophrenia NOS	Eu60z12	[X]Pathological personality NOS
24	Eu12.00	[X]Mental and behavioural disorders due to use cannabinoids	E10yz00	Other schizophrenia NOS
25				
26	Eu19.00	[X]Men & behav disorder multiple drug use/psychoactive subst	E117000	Unspecified bipolar affective disorder, unspecified
27				
28	Ez...00	Mental disorders NOS	Eu60y13	[X]Immature personality disorder
29	Eu25100	[X]Schizoaffective disorder, depressive type	Eu21.16	[X]Pseudoneurotic schizophrenia
30	E011100	Korsakov's alcoholic psychosis with peripheral neuritis	Eu15500	[X]Mental/behav dis oth stims inc caffeine: psychotic dis
31				
32	Eu22012	[X]Paranoid state	Eu23011	[X]Bouffee delirante
33	Eu2z.00	[X]Unspecified nonorganic psychosis	Eu20011	[X]Paraphrenic schizophrenia
34	146D.00	H/O: manic depressive disorder	Eu05z00	[X]Unspec mental disorder brain damag/dysfunction/physcal dr
35				
36	E11y000	Unspecified manic-depressive psychoses	E2y..00	Other specified neuroses or other mental disorders
37	Eu10611	[X]Korsakov's psychosis, alcohol induced	Eu18000	[X]Mental & behav dis due vol solvents: acute intoxication
38				
39	Eu23200	[X]Acute schizophrenia-like psychotic disorder	Eu60.00	[X]Specific personality disorders
40	Eu24.13	[X]Induced psychotic disorder	E110400	Single manic episode, severe, with psychosis
41	R001400	[D]Visual hallucinations	Eu34y00	[X]Other persistent mood affective disorders
42	Eu32300	[X]Severe depressive episode with psychotic symptoms	Eu22y12	[X]Involutional paranoid state
43				
44	R001000	[D]Hallucinations, auditory	Eu16.00	[X]Mental and behavioural disorders due to use hallucinogens
45				
46	Eu30.00	[X]Manic episode	Eu14200	[X]Mental and behav dis due to use cocaine: dependence syndr
47				
48	E211100	Hypomanic personality disorder	Eu52800	[X]Erotomania
49	Eu10500	[X]Mental & behav dis due to use alcohol: psychotic disorder	Eu12100	[X]Mental and behav dis due to use cannabinoids: harmful use
50				
51	225E.00	O/E - paranoid delusions	Eu60y16	[X]Psychoneurotic personality disorder
52	Eu45211	[X]Body dysmorphic disorder	E123.11	Folie a deux
53	E211300	Cyclothymic personality disorder	Eu11500	[X]Mental & behav dis due to use opioids: psychotic disorder
54				
55	E12z.00	Paranoid psychosis NOS	Eu3y000	[X]Other single mood affective disorders
56	146H.00	H/O: psychosis	Eu31y12	[X]Recurrent manic episodes
57	E115.11	Manic-depressive - now depressed	E02y.00	Other drug psychoses
58	Eu30100	[X]Mania without psychotic symptoms	Eu19300	[X]Mental and behav dis mlti/oth psychoa sbs:
59				

1	E11..00	Affective psychoses			withdrwl state
2	E110100	Single manic episode, mild		Eu24.00	[X]Induced delusional disorder
3				E103300	Acute exacerbation of subchronic paranoid schizophrenia
4	E120.00	Simple paranoid state		Eu84511	[X]Autistic psychopathy
5	E212z00	Schizoid personality disorder NOS		E00y.11	Presbyophrenic psychosis
6	E117.00	Unspecified bipolar affective disorder		E211z00	Affective personality disorder NOS
7	E13z.00	Nonorganic psychosis NOS		Eu25012	[X]Schizophreniform psychosis, manic type
8	E122.00	Paraphrenia		Eu60500	[X]Anankastic personality disorder
9	E211.00	Affective personality disorder		225F.00	O/E - delusion of persecution
10	E133.00	Acute paranoid reaction		Eu32312	[X]Single episode of psychogenic depressive psychosis
11	F481K00	Visual hallucinations		Eu18200	[X]Mental and behav dis due to vol solvents: dependence synd
12				E14z.00	Child psychosis NOS
13	E21z.00	Personality disorder NOS		Eu06y00	[X]Oth organ personality behav disorders brain dis dam dysf
14	E00y.00	Other senile and presenile organic psychoses		E22y500	Nymphomania
15				E103400	Acute exacerbation of chronic paranoid schizophrenia
16	E100000	Unspecified schizophrenia		Eu60y14	[X]Narcissistic personality disorder
17	E115000	Bipolar affective disorder, currently depressed, unspecified		Eu62013	[X]Personality change aft prolong captiv+possib/being killed
18	E1...00	Non-organic psychoses		E100z00	Simple schizophrenia NOS
19	E21yz00	Other personality disorder NOS		Ryu5300	[X]Other hallucinations
20				Eu31y00	[X]Other bipolar affective disorders
21	E211000	Unspecified affective personality disorder		Eu84314	[X]Symbiotic psychosis
22	E01..00	Alcoholic psychoses		Eu20111	[X]Disorganised schizophrenia
23	E02..00	Drug psychoses		R001100	[D]Hallucinations, gustatory
24	E13y.00	Other reactive psychoses		E116400	Mixed bipolar affective disorder, severe, with psychosis
25	E13y.00	Other reactive psychoses		Eu21.12	[X]Borderline schizophrenia
26	E114300	Bipolar affect disord, currently manic, severe, no psychosis		E11z000	Unspecified affective psychoses NOS
27	E1y..00	Other specified non-organic psychoses		Eu34012	[X]Cycloid personality
28				Eu16500	[X]Mental & behav dis due to hallucinogens: psychotic disord
29	Eu31300	[X]Bipolar affect disorder cur epi mild or moderate depressn		E116600	Mixed bipolar affective disorder, in full remission
30	Eu20000	[X]Paranoid schizophrenia		E03..00	Transient organic psychoses
31	Eu31000	[X]Bipolar affective disorder, current episode hypomanic		Eu22111	[X]Capgras syndrome
32	Eu33315	[X]Recurrent severe episodes of psychotic depression		Eu22y13	[X]Paranoia querulans
33	Eu25011	[X]Schizoaffective psychosis, manic type		1BH2.00	Ideas of reference
34	Eu2..00	[X]Schizophrenia, schizotypal and delusional disorders		ZV40y00	[V]Other specified mental or behavioural problem
35	E114.11	Manic-depressive - now manic		E114400	Bipolar affect disord, currently manic,severe with psychosis
36	Eu60513	[X]Obsessive-compulsive personality disorder		Eu60y11	[X]Eccentric personality disorder
37	Eu10514	[X]Alcoholic psychosis NOS		E141.00	Disintegrative psychosis
38	Eu53111	[X]Puerperal psychosis NOS		Eu17100	[X]Mental and behav dis due to use of tobacco: harmful use
39	E130.11	Psychotic reactive depression		Eu16300	[X]Mental and behav dis due hallucinogens: withdrawal state
40	1BH..11	Delusion		Eu62.00	[X]Enduring personality change not attrib to brain damag/dis
41	Eu20y13	[X]Schizophrenifrm psychos NOS		E107500	Schizo-affective schizophrenia in remission
42	E21y200	Borderline personality disorder		Eu60213	[X]Asocial personality disorder
43				Eu12200	[X]Mental and behav dis due to cannabinoids: dependence synd
44	E110.11	Hypomanic psychoses			
45	212T.00	Psychosis, schizophrenia + bipolar affective disord resolved			
46	1B1b.00	Transient hallucinations			
47	R001z00	[D]Hallucinations NOS			
48	E215100	Munchausen's syndrome			

1	E216.13	Labile personality	Eu19700	[X]Men/beh dis mlt drg use/oth subs: resid/late psychot dis
2	E111000	Recurrent manic episodes, unspecified	Eu8z.00	[X]Unspecified disorder of psychological development
3	E2C3200	Kleptomania	Z57C611	Schizophrenic language
4	E21yz11	Manipulative personality	Eu62011	[X]Personality change after concentration camp experiences
5			E115600	Bipolar affective disorder, now depressed, in full remission
6	E110000	Single manic episode, unspecified	Eu12700	[X]Mnt/bh dis due cannabinds: resid & late-onset psychot dis
7	E13..11	Reactive psychoses	E114z00	Bipolar affective disorder, currently manic, NOS
8			E03z.00	Transient organic psychoses NOS
9	E2C3300	Pyromania	E100300	Acute exacerbation of subchronic schizophrenia
10	Eu10300	[X]Mental and behav dis due to use alcohol: withdrawal state	Eu03.11	[X]Korsakov's psychosis, nonalcoholic
11	Eu20211	[X]Catatonic stupor	Eu25y00	[X]Other schizoaffective disorders
12	Eu20400	[X]Post-schizophrenic depression	E100500	Schizophrenia in remission
13	Eu60311	[X]Aggressive personality disorder	Eu60313	[X]Explosive personality disorder
14	E214.00	Compulsive personality disorders	E102000	Unspecified catatonic schizophrenia
15	Eu6..00	[X]Disorders of adult personality and behaviour	E107000	Unspecified schizo-affective schizophrenia
16	Eu30200	[X]Mania with psychotic symptoms	E111500	Recurrent manic episodes, partial or unspecified remission
17	E21y700	Psychoneurotic personality disorder	E107300	Acute exacerbation subchronic schizo-affective schizophrenia
18	Eu81.00	[X]Specific developmental disorders of scholastic skills	Eu60714	[X]Self defeating personality disorder
19	Eu60000	[X]Paranoid personality disorder	Eu18100	[X]Mental and behav dis due volatile solvents: harmful use
20	Eu23012	[X]Cycloid psychosis	E114500	Bipolar affect disord,currently manic, part/unspec remission
21	Eu34000	[X]Cyclothymia	Eu23211	[X]Brief schizophreniform disorder
22	Eu23100	[X]Acute polymorphic psychot disord with symp of schizophren	Eu15700	[X]Mnt/bh dis oth stm inc caffne resid/late-onset psycht dis
23	E216.12	Dependent personality	E03yz00	Other transient organic psychoses NOS
24	Eu60214	[X]Psychopathic personality disorder	Eu84512	[X]Schizoid disorder of childhood
25	Eu10100	[X]Mental and behav dis due to use of alcohol: harmful use	Eu06000	[X]Organic personality disorder
26	Eu0z.11	[X]Organic psychosis NOS	Eu20300	[X]Undifferentiated schizophrenia
27	Eu05200	[X]Organic delusional [schizophrenia-like] disorder	E11y.00	Other and unspecified manic-depressive psychoses
28	Eu04.15	[X]Acute / subacute psycho-organic reaction	E2Az.00	Nonpsychotic mental disorder post-organic brain damage NOS
29	ZV11112	[V]Personal history of manic-depressive psychosis	E215z00	Histrionic personality disorder NOS
30	E02y400	Drug-induced personality disorder	Eu19000	[X]Mental/behav dis multi drg use/psychoac subs: acute intox
31	ZV11000	[V]Personal history of schizophrenia	E107100	Subchronic schizo-affective schizophrenia
32	E13y000	Psychogenic stupor	Eu84013	[X]Infantile psychosis
33	E1z..00	Non-organic psychosis NOS	Eu13300	[X]Mental and behav dis due sed/s/hypntcs: withdrawal state
34	Eu60512	[X]Obsessional personality disorder	Eu20200	[X]Catatonic schizophrenia
35	Euz..11	[X]Mental illness NOS	Eu17.00	[X]Mental and behavioural disorder due to use of tobacco
36	1BH3.00	Paranoid ideation	E212200	Schizotypal personality
37	286..11	Poor insight into psychotic condition	Eu10700	[X]Men & behav dis due alcoh: resid & late-onset psychot dis
38	1S42.00	Manic mood	E04..00	Other chronic organic psychoses
39	Eu0..00	[X]Organic, including symptomatic, mental disorders	Eu84312	[X]Disintegrative psychosis
40	E13y100	Brief reactive psychosis	Eu22100	[X]Delusional misidentification syndrome
41	E213.00	Explosive personality disorder	Eu21.14	[X]Prepsychotic schizophrenia
42	E100100	Subchronic schizophrenia		
43	Eu53z00	[X]Puerperal mental disorder, unspecified		

E04y.00	Other specified chronic organic psychoses	E123.00	Shared paranoid disorder
Eu06.00	[X]Personality and behav disorder brain dis dam and dysfunct	E2Ay.00	Other specific mental disorder post-organic brain damage
Eu31400	[X]Bipol aff disord, curr epis sev depress, no psychot symp	Eu19100	[X]Mental and behav dis mlti drg/oth psychoa sbs: harmfl use
Eu33311	[X]Endogenous depression with psychotic symptoms	E116200	Mixed bipolar affective disorder, moderate
E040.11	Korsakoff's non-alcoholic psychosis	E116300	Mixed bipolar affective disorder, severe, without psychosis
Eu34013	[X]Cyclothymic personality	E107400	Acute exacerbation of chronic schizo-affective schizophrenia
ZV11111	[V]Personal history of manic-depressive psychosis	E116z00	Mixed bipolar affective disorder, NOS
E217.00	Antisocial or sociopathic personality disorder	E116500	Mixed bipolar affective disorder, partial/unspec remission
Eu05300	[X]Organic mood [affective] disorders	E117100	Unspecified bipolar affective disorder, mild
Eu84111	[X]Atypical childhood psychosis	E115400	Bipolar affect disord, now depressed, severe with psychosis
Eu20511	[X]Chronic undifferentiated schizophrenia	E114600	Bipolar affective disorder, currently manic, full remission
Eu32313	[X]Single episode of psychotic depression	ZV40200	[V]Other mental problems
Eu32311	[X]Single episode of major depression and psychotic symptoms	E2A1z00	Organic personality syndrome NOS
E113400	Recurrent major depressive episodes, severe, with psychosis	E102z00	Catatonic schizophrenia NOS
E117600	Unspecified bipolar affective disorder, in full remission	Eu06z00	[X]Unspec organ personality behav disorder brain dam dysfunc
E14y000	Atypical childhood psychoses	R001300	[D]Hallucinations, tactile
E134.00	Psychogenic paranoid psychosis	Eu13000	[X]Mental & behav dis due seds/hypntcs: acute intoxication
Eu04.13	[X]Acute / subacute infective psychosis	Eu20500	[X]Residual schizophrenia
146Z.00	H/O: psychiatric disorder NOS	Eu20212	[X]Schizophrenic catalepsy
Eu19500	[X]Ment/behav dis mlti drug use/oth psyc sbs: psychotc dis	Eu6y.00	[X]Other disorders of adult personality and behaviour
E110200	Single manic episode, moderate	Eu21.13	[X]Latent schizophrenia
E116100	Mixed bipolar affective disorder, mild	Eu22014	[X]Sensitiver Beziehungswahn
Eu53.00	[X]Mental and behav disorders assoc with the puerperium NEC	Eu12300	[X]Mental and behav dis due cannabinoids: withdrawal state
Eu23.00	[X]Acute and transient psychotic disorders	Eu62012	[X]Personality change after disasters
Eu04.00	[X]Delirium, not induced by alcohol+other psychoactive subs	E111300	Recurrent manic episodes, severe without mention psychosis
E2A1.00	Organic personality syndrome	Eu16200	[X]Mental and behav dis due to hallucinogens: dependence syn
ZV40.00	[V]Mental and behavioural problems	Eu22y00	[X]Other persistent delusional disorders
E21y.00	Other personality disorders	Eu31.13	[X]Manic-depressive reaction
Eu8..00	[X]Disorders of psychological development	Eu16000	[X]Mental & behav dis due hallucinogens: acute intoxicatn
R001200	[D]Hallucinations, olfactory	E105.00	Latent schizophrenia
E102.00	Catatonic schizophrenia	E101000	Unspecified hebephrenic schizophrenia
Eu54.00	[X]Psychological/behav factor assoc with disorder or dis EC	E0y..00	Other specified organic psychoses
E02z.00	Drug psychosis NOS	E14yz00	Other childhood psychoses NOS
E13yz00	Other reactive psychoses NOS	E12y000	Paranoia querulans
Eu23112	[X]Cycloid psychosis with symptoms of schizophrenia	E212000	Unspecified schizoid personality disorder
E11..13	Manic psychoses	Eu16100	[X]Mental and behav dis due to use hallucinogens: harmfl use
E111.00	Recurrent manic episodes	Eu14300	[X]Mental and behav dis due to use cocaine: withdrawal state

1	Eu31100	[X]Bipolar affect disorder cur epi manic wout psychotic symp	E215300	Psychoinfantile personality
2	Eu34011	[X]Affective personality disorder	E01z.00	Alcoholic psychosis NOS
3	Eu21.18	[X]Schizotypal personality disorder	E101500	Hebephrenic schizophrenia in remission
4	E215.00	Histrionic personality disorders	E217.11	Amoral personality
5	Eu31700	[X]Bipolar affective disorder, currently in remission	E133.11	Bouffe delirante
6				
7	Eu11700	[X]Men & beh dis due opioids: resid & late-onset psychot dis	E01yz00	Other alcoholic psychosis NOS
8				
9	Eu66.00	[X]Psychol and behav disorder assoc with sex dev and orienta	E03y.00	Other transient organic psychoses
10				
11	Ey...00	Other specified mental disorders	E117400	Unspecified bipolar affective disorder,severe with psychosis
12				
13	E111200	Recurrent manic episodes, moderate	E117200	Unspecified bipolar affective disorder, moderate
14	Eu02z16	[X] Senile dementia, depressed or paranoid type	Eu60013	[X]Querulant personality disorder
15				
16	Eu23312	[X]Psychogenic paranoid psychosis	Eu13500	[X]Mental & behav dis due to seds/hypntcs: psychotic disordr
17				
18	E21y400	Eccentric personality disorder	E14y100	Borderline psychosis of childhood
19	E115200	Bipolar affective disorder, currently depressed, moderate	Eu60412	[X]Psychoinfantile personality disorder
20				
21	Eu02z15	[X] Senile psychosis NOS	E110600	Single manic episode in full remission
22	Eu60411	[X]Hysterical personality disorder	E11y300	Other mixed manic-depressive psychoses
23	Eu05.00	[X]Oth mental disorder brain damag/dysfunction/physical disr	E117500	Unspecified bipolar affect disord, partial/unspec remission
24				
25	E117z00	Unspecified bipolar affective disorder, NOS	Eu23212	[X]Brief schizophrenifrm psych
26	Eu3y.00	[X]Other mood affective disorders	E21y600	Masochistic personality disorder
27	Eu44.14	[X]Hysterical psychosis	E11y100	Atypical manic disorder
28	E21..11	Neurotic personality disorder	Eu21.17	[X]Pseudopsychopathic schizophrenia
29	Eu31200	[X]Bipolar affect disorder cur epi manic with psychotic symp	Eu60y12	[X]Haltlose type personality disorder
30				
31	Eu22.00	[X]Persistent delusional disorders	E14y.00	Other childhood psychoses
32	Eu33312	[X]Manic-depress psychosis,depressed type+psychotic symptoms	E115500	Bipolar affect disord, now depressed, part/unspec remission
33				
34	E02yz00	Other drug psychoses NOS	E100.11	Schizophrenia simplex
35	Eu32314	[X]Single episode of reactive depressive psychosis	E117300	Unspecified bipolar affective disorder, severe, no psychosis
36				
37	Eu33213	[X]Manic-depress psychosis,depressd,no psychotic symptoms	ZVu6K00	[X]Personal history/other mental and behavioural disorders
38				
39	Eu3yy00	[X]Other specified mood affective disorders	Eu31y11	[X]Bipolar II disorder
40	Eu23z12	[X]Reactive psychosis	ZV11z00	[V]Personal history of unspecified mental disorder
41	Eu3y100	[X]Other recurrent mood affective disorders	212V.00	Bipolar affective disorder resolved
42	E131.00	Acute hysterical psychosis	1B1e.00	Hypnopompic hallucination
43	Eu1..00	[X]Mental and behavioural disorders due to psychoactive subs	212X.00	Psychosis resolved
44				
45	ZV11.00	[V]Personal history of mental disorder	Eu1A100	[X]Mental behav disorders due use crack cocaine: harmful use
46				
47	ZRby100	Profile of mood states, bipolar	1B1d.00	Hypnagogic hallucination
48	E214000	Anankastic personality	Eu62z00	[X]Enduring personality change, unspecified
49	Eu66y00	[X]Other psychosexual development disorders	212W.00	Schizophrenia resolved
50	Eu61.00	[X]Mixed and other personality disorders	Eu21.11	[X]Latent schizophrenic reaction
51	E101.00	Hebephrenic schizophrenia	Eu20311	[X]Atypical schizophrenia
52	Eu3y011	[X]Mixed affective episode	E10y.11	Cenesthopathic schizophrenia
53	Eu2y.00	[X]Other nonorganic psychotic disorders	Eu13100	[X]Mental and behav dis due to use seds/hypntcs: harmful use
54				
55	ZV71000	[V]Observation for mental disorder	ZV11y00	[V]Personal history of other specified mental disorder
56	Eu6y111	[X] Munchausens syndrome	Eu06011	[X]Organic pseudopsychopathic personality
57	E116.00	Mixed bipolar affective disorder	Eu20y12	[X]Schizophreniform disord NOS
58				
59				
60				

1	E103200	Chronic paranoid schizophrenia	E105200	Chronic latent schizophrenia
2	E12yz00	Other paranoid states NOS	Eu23214	[X]Schizophrenic reaction
3	Eu20214	[X]Schizophrenic flexibilatis cerea	E105500	Latent schizophrenia in remission
4	E116000	Mixed bipolar affective disorder, unspecified	Eu12600	[X]Mental and behav dis due to use cannabinoids: amnesic syn
5	E12y.00	Other paranoid states	Eu05z12	[X]Organic mental disorder NOS
6	Eu60200	[X]Dissocial personality disorder	E101400	Acute exacerbation of chronic hebephrenic schizophrenia
7			Eu32800	[X]Major depression, severe with psychotic symptoms
8	Eu3z.11	[X]Affective psychosis NOS	Eu18500	[X]Mental & behav dis due to vol solvents: psychotic disordr
9	ZV40.12	[V]Mental problems	Eu22200	[X]Cotard syndrome
10			E107.11	Cyclic schizophrenia
11	Eu23z11	[X]Brief reactive psychosis NOS	E10y100	Coenesthopathic schizophrenia
12	Eu18.00	[X]Mental & behav disorders due to use of volatile solvents	E102100	Subchronic catatonic schizophrenia
13			Eu94211	[X]Affectionless psychopathy
14	Eu2y.11	[X]Chronic hallucinatory psychosis	Eu3y200	[X]Premenstrual dysphoric disorder
15	Eu33314	[X]Recurr severe episodes/psychogenic depressive psychosis	14g..00	History of developmental disorder
16			L184400	Mental disorder in puerperium - baby previously delivered
17	Eu60312	[X]Borderline personality disorder	Eu32900	[X]Single major depr ep, severe with psych, psych in remiss
18	Eu62015	[X]Personality change after torture	Eu32A00	[X]Recurr major depr ep, severe with psych, psych in remiss
19	Eu60700	[X]Dependent personality disorder	Eu17300	[X]Mental and behav dis due to use tobacco: withdrawal state
20	Eu05212	[X]Schizophrenia-like psychosis in epilepsy	Eu22300	[X]Paranoid state in remission
21			Eu1A300	[X]Mental behav disord due crack cocaine: withdrawal state
22	E13..00	Other nonorganic psychoses	Eu26.00	[X]Nonorganic psychosis in remission
23			E105000	Unspecified latent schizophrenia
24	Eu14.00	[X]Mental and behavioural disorders due to use of cocaine	E102500	Catatonic schizophrenia in remission
25			E105z00	Latent schizophrenia NOS
26	Eu30y00	[X]Other manic episodes	Eu1A500	[X]Mental behav disord due crack cocaine: psychotic disorder
27			Eu1A200	[X]Mental behav disorders due use crack cocaine: depend synd
28	E112400	Single major depressive episode, severe, with psychosis	Eu14700	[X]Men & beh dis due cocaine: resid & late-onset psychot dis
29	E100.00	Simple schizophrenia	L184200	Mental disorder in the puerperium - baby delivered
30			Eu31900	[X]Bipolar affective disorder type II
31	E111400	Recurrent manic episodes, severe, with psychosis	Eu11600	[X]Mental and behav dis due to use opioids: amnesic syndrome
32	Eu1A.00	[X]Mental and behavioural disorders due use of crack cocaine	Eu31911	[X]Bipolar II disorder
33			Eu31800	[X]Bipolar affective disorder type I
34	Eu60212	[X]Antisocial personality disorder	E103100	Subchronic paranoid schizophrenia
35	1BH1.00	Grandiose delusions	Eu25211	[X]Cyclic schizophrenia
36	Eu33313	[X]Recurr severe episodes/major depression+psychotic symptom	Eu60211	[X]Amoral personality disorder
37	E10y000	Atypical schizophrenia	Eu16700	[X]Mnt/bh dis due hallucngns: resid & late-onset psychot dis
38			Eu24.11	[X]Folie a deux
39	E103000	Unspecified paranoid schizophrenia	Eu19600	[X]Mental/behav dis multi drg use/oth psy sbs:
40				
41	Eu25z11	[X]Schizoaffective psychosis NOS		
42	E11zz00	Other affective psychosis NOS		
43	E11yz00	Other and unspecified manic-depressive psychoses NOS		
44	Eu15200	[X]Mental and behav dis oth stim inc caffein: dependnce synd		
45	E01y.00	Other alcoholic psychosis		
46	Eu25200	[X]Schizoaffective disorder, mixed type		
47	E00..00	Senile and presenile organic psychotic conditions		
48	Eu60713	[X]Passive personality disorder		
49	Eu31z00	[X]Bipolar affective disorder, unspecified		
50				
51	E2Fz.00	Developmental disorder NOS		
52	Eu25000	[X]Schizoaffective disorder, manic type		
53				
54				
55				
56				
57				
58				
59				

1	Eu23z00	[X]Acute and transient psychotic disorder, unspecified	amnesic syndr	E102400	Acute exacerbation of chronic catatonic schizophrenia
2					
3	Eu20.00	[X]Schizophrenia	Eu8z.11	[X]Psychological developmental disorder NOS	
4	Eu11200	[X]Mental and behav dis due to use opioids: dependence syndr	Eu17200	[X]Mental and behav dis due to use tobacco: dependence syndr	
5					
6	Eu22000	[X]Delusional disorder	E21y000	Narcissistic personality disorder	
7	E214z00	Compulsive personality disorder NOS	E115z00	Bipolar affective disorder, currently depressed, NOS	
8	Eu62y11	[X]Chronic pain personality syndrome	Eu12000	[X]Mental & behav dis due cannabinoids: acute intoxication	
9					
10	Eu6yy00	[X]Other specified disorders of adult personality/behaviour	E14z.11	Childhood schizophrenia NOS	
11					
12	Eu20z00	[X]Schizophrenia, unspecified	Eu62100	[X]Enduring personality change after psychiatric illness	
13	Eu2..00	[X]Mental disorder, not otherwise specified	Eu11100	[X]Mental and behav dis due to use of opioids: harmful use	
14					
15	Eu62y00	[X]Other enduring personality changes	Eu25212	[X]Mixed schizophrenic and affective psychosis	
16	Eu25111	[X]Schizoaffective psychosis, depressive type	Eu6y000	[X]Elaboration of physical symptoms for psychological reason	
17					
18	E115300	Bipolar affect disord, now depressed, severe, no psychosis	Eu25z00	[X]Schizoaffective disorder, unspecified	
19					
20	E21y100	Avoidant personality disorder	Eu33316	[X]Recurrent severe episodes/reactive depressive psychosis	
21					
22	E115100	Bipolar affective disorder, currently depressed, mild	Eu60712	[X]Inadequate personality disorder	
23					
24	E114000	Bipolar affective disorder, currently manic, unspecified	E106.00	Residual schizophrenia	
25					
26	E21y300	Passive-aggressive personality disorder	Eu60511	[X]Compulsive personality disorder	
27	Eu20600	[X]Simple schizophrenia	Eu60100	[X]Schizoid personality disorder	
28	Eu20213	[X]Schizophrenic catatonia	Eu12500	[X]Mental & behav dis due to cannabinoids: psychotic disordr	
29					
30	E213.12	Quarrelsome personality	E212100	Introverted personality	
31					
32	E114100	Bipolar affective disorder, currently manic, mild	E10y.00	Other schizophrenia	
33					
34	E103500	Paranoid schizophrenia in remission	ZS34.00	Developmental disorder of scholastic skill	
35	Eu11300	[X]Mental and behav dis due to use opioids: withdrawal state	Eu21.00	[X]Schizotypal disorder	
36					
37	E110z00	Manic disorder, single episode NOS	Eu10200	[X]Mental and behav dis due to use alcohol: dependence syndr	
38					
39	Eu23000	[X]Acute polymorphic psychot disord without symp of schizop	Eu3z.00	[X]Unspecified mood affective disorder	
40					
41	E0z..00	Organic psychoses NOS	Eu30211	[X]Mania with mood-congruent psychotic symptoms	
42	E110.00	Manic disorder, single episode	E111600	Recurrent manic episodes, in full remission	
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

ALCOHOL AND DRUG DEPENDENCE**At least one ICD-9 in:**

- 303 Alcohol dependance syndrome
- 305.00 Non dependent alcohol abuse
- 305.00 Alcohol abuse, unspecified
- 305.01 Alcohol abuse, continuous
- 305.03** Alcohol abuse, episodic
- 305.03 Alcohol abuse, in remission
- 304 Drug dependence
- 304.0 Opioid type dependence
- 304.1 Sedative, hypnotic or anxiolytic dependence
- 304.2 Cocaine dependence
- 304.3 Cannabis dependence
- 304.4 Amphetamine and other psychostimulant dependence
- 304.5 Hallucinogen dependence
- 304.6 Other specified drug dependence
- 304.7 Combinations of opioid type drug with any other drug dependence
- 304.8 Combinations of drug dependence excluding opioid type drug
- 304.9 Unspecified drug dependence

OR

At least one ICD-10 in:

- F10 Alcohol related disorders
- F10.0 acute intoxication
- F10.1 harmful use
- F10.2 dependence syndrome
- F10.3 withdrawal state
- F10.4 withdrawal state with delirium
- F10.5 psychotic disorder
- F10.6 amnesic syndrome
- F10.7 Residual and late-onset psychotic disorder
- F10.8 other mental and behavioural disorder
- F10.9 unspecified mental and behavioural disorder
- F11 Opioids related disorders
- F12 Cannabis related disorders
- F13 Sedative, hypnotic, or anxiolytic related disorders
- F14 Cocaine related disorders
- F15 Other stimulant related disorders
- F16 Hallucinogen related disorders
- F17 Nicotine dependence
- F18 Inhalant related disorders
- F19 Other psychoactive substance related disorders

OR

At least one READ code in:

136..00	Alcohol consumption	E245z00	Hallucinogen dependence NOS
136K.00	Alcohol intake above recommended sensible limits	E246.00	Glue sniffing dependence
136S.00	Hazardous alcohol use	E246000	Glue sniffing dependence, unspecified
136T.00	Harmful alcohol use	E246100	Glue sniffing dependence, continuous
136W.00	Alcohol misuse	E246200	Glue sniffing dependence, episodic
136Z.00	Alcohol consumption NOS	E246300	Glue sniffing dependence in remission
13c..00	Drug user	E246z00	Glue sniffing dependence NOS
13c0.00	Injecting drug user	E247.00	Other specified drug dependence
13c1.00	Intravenous drug user	E247.11	Absinthe addiction
13c2.00	Never injecting drug user	E247000	Other specified drug dependence, unspecified
13c3.00	Intramuscular drug user	E247100	Other specified drug dependence, continuous
13c4.00	Intranasal drug user	E247200	Other specified drug dependence, episodic
13c7.00	Current drug user	E247300	Other specified drug dependence in remission
13c9.00	Subcutaneous drug user	E247z00	Other specified drug dependence NOS
13cA.00	Smokes drugs	E248.00	Combined opioid with other drug dependence
13cB.00	Misuses drugs orally	E248000	Combined opioid with other drug dependence, unspecified
13cC.00	Continuous use of drugs	E248100	Combined opioid with other drug dependence, continuous
13cD.00	Episodic use of drugs	E248200	Combined opioid with other drug dependence, episodic
13cE.00	Prolonged high dose use of cannabis	E248300	Combined opioid with other drug dependence in remission
13cH.00	Persistent substance misuse	E248z00	Combined opioid with other drug dependence NOS
13cJ.00	Previously injecting drug user	E249.00	Combined drug dependence, excluding opioids
13cK.00	Current non recreational drug user	E249000	Combined drug dependence, excluding opioid, unspecified
1462.00	H/O: alcoholism	E249100	Combined drug dependence, excluding opioid, continuous
1463.00	H/O: drug dependency	E249200	Combined drug dependence, excluding opioid, episodic
146E.00	H/O: recreational drug use	E249300	Combined drug dependence, excluding opioid, in remission
146F.00	H/O: drug abuse	E249z00	Combined drug dependence, excluding opioid, NOS
1B1c.00	Alcohol induced hallucinations	E24A.00	Ecstasy type drug dependence
1P30.00	Compulsive uncontrollable drug taking	E24z.00	Drug dependence NOS
1P31.00	Compulsive drug taking	E250.11	Drunkenness NOS
1P6..00	Craving for drugs	E250.12	Hangover (alcohol)
1P62.00	Abnormal craving for drugs	E250.13	Inebriety NOS
1T...00	History of substance misuse	E250.14	Intoxication - alcohol
1T0..00	H/O heroin misuse	E254.11	Barbiturate abuse
1T00.00	H/O daily heroin misuse	E254.12	Hypnotic or anxiolytic abuse
1T01.00	H/O weekly heroin misuse	E254.13	Sedative abuse
1T02.00	Previous history of heroin misuse	E254.14	Tranquilliser abuse
1T03.00	H/O infrequent heroin misuse	E257.11	Psychostimulant abuse
1T1..00	H/O methadone misuse	E257.12	Stimulant abuse
1T10.00	H/O daily methadone misuse	E259400	Misuse of prescription only drugs
1T11.00	H/O weekly methadone misuse	E25y.11	Analgesic abuse
1T12.00	H/O infrequent methadone misuse	E25y.12	Laxative abuse
1T13.00	Previous history of methadone misuse	E25y.13	Steroid abuse

1T2..00	H/O ecstasy misuse	E25z.00	Misuse of drugs NOS
1T20.00	H/O daily ecstasy misuse	Eu1..00	[X]Mental and behavioural disorders due to psychoactive subs
1T21.00	H/O weekly ecstasy misuse	Eu10.00	[X]Mental and behavioural disorders due to use of alcohol
1T22.00	H/O infrequent ecstasy misuse	Eu10000	[X]Mental & behav dis due to use alcohol: acute intoxication
1T23.00	Previous history of ecstasy misuse	Eu10011	[X]Acute alcoholic drunkenness
1T3..00	H/O benzodiazepine misuse	Eu10100	[X]Mental and behav dis due to use of alcohol: harmful use
1T30.00	H/O daily benzodiazepine misuse	Eu10200	[X]Mental and behav dis due to use alcohol: dependence syndr
1T31.00	H/O weekly benzodiazepine misuse	Eu10211	[X]Alcohol addiction
1T32.00	H/O infrequent benzodiazepine misuse	Eu10212	[X]Chronic alcoholism
1T33.00	Previous history of benzodiazepine misuse	Eu10213	[X]Dipsomania
1T4..00	H/O amphetamine misuse	Eu10300	[X]Mental and behav dis due to use alcohol: withdrawal state
1T40.00	H/O daily amphetamine misuse	Eu10400	[X]Men & behav dis due alcohol: withdrawal state with delirium
1T41.00	H/O weekly amphetamine misuse	Eu10411	[X]Delirium tremens, alcohol induced
1T42.00	H/O infrequent amphetamine misuse	Eu10500	[X]Mental & behav dis due to use alcohol: psychotic disorder
1T43.00	Previous history of amphetamine misuse	Eu10511	[X]Alcoholic hallucinosis
1T5..00	H/O cocaine misuse	Eu10512	[X]Alcoholic jealousy
1T50.00	H/O daily cocaine misuse	Eu10513	[X]Alcoholic paranoia
1T51.00	H/O weekly cocaine misuse	Eu10514	[X]Alcoholic psychosis NOS
1T52.00	H/O infrequent cocaine misuse	Eu10600	[X]Mental and behav dis due to use alcohol: amnesic syndrome
1T53.00	Previous history of cocaine misuse	Eu10611	[X]Korsakov's psychosis, alcohol induced
1T6..00	H/O crack cocaine misuse	Eu10700	[X]Men & behav dis due alcohol: resid & late-onset psychot dis
1T60.00	H/O daily crack cocaine misuse	Eu10711	[X]Alcoholic dementia NOS
1T61.00	H/O weekly crack cocaine misuse	Eu10712	[X]Chronic alcoholic brain syndrome
1T62.00	H/O infrequent crack cocaine misuse	Eu10800	[X]Alcohol withdrawal-induced seizure
1T63.00	Previous history of crack cocaine misuse	Eu10y00	[X]Men & behav dis due to use alcohol: oth men & behav dis
1T7..00	H/O hallucinogen misuse	Eu10z00	[X]Ment & behav dis due use alcohol: unsp ment & behav dis
1T73.00	Previous history of hallucinogen misuse	Eu11.00	[X]Mental and behavioural disorders due to use of opioids
1T8..00	H/O cannabis misuse	Eu11000	[X]Mental & behav dis due to use opioids: acute intoxication
1T80.00	H/O daily cannabis misuse	Eu11100	[X]Mental and behav dis due to use of opioids: harmful use
1T81.00	H/O weekly cannabis misuse	Eu11200	[X]Mental and behav dis due to use opioids: dependence syndr
1T82.00	H/O infrequent cannabis misuse	Eu11211	[X]Drug addiction - opioids
1T83.00	Previous history of cannabis misuse	Eu11212	[X]Heroin addiction
1T9..00	H/O solvent misuse	Eu11300	[X]Mental and behav dis due to use opioids: withdrawal state
1T90.00	H/O daily solvent misuse	Eu11311	[X]Cold turkey, opiate withdrawal
1T91.00	H/O weekly solvent misuse	Eu11400	[X]Men & behav dis due opioid: withdrawal state with delirium
1T93.00	Previous history of solvent misuse	Eu11500	[X]Mental & behav dis due to use opioids: psychotic disorder
1TA..00	H/O barbiturate misuse	Eu11600	[X]Mental and behav dis due to use opioids: amnesic syndrome
1TB..00	H/O major tranquilliser misuse	Eu11700	[X]Men & beh dis due opioids: resid & late-onset psychot dis

1	1TB0.00	H/O daily major tranquilliser misuse	Eu11y00	[X]Men & behav dis due to use opioids: oth men & behav dis
2	1TC..00	H/O anti-depressant misuse	Eu11z00	[X]Ment & behav dis due use opioids: unsp ment & behav dis
3				
4	1TC0.00	H/O daily anti-depressant misuse	Eu12.00	[X]Mental and behavioural disorders due to use cannabinoids
5				
6	1TC3.00	Previous history of anti-depressant misuse	Eu12000	[X]Mental & behav dis due cannabinoids: acute intoxication
7				
8	1TD..00	H/O opiate misuse	Eu12100	[X]Mental and behav dis due to use cannabinoids: harmful use
9				
10	1TD0.00	H/O daily opiate misuse	Eu12200	[X]Mental and behav dis due to cannabinoids: dependence synd
11				
12	1TD1.00	H/O weekly opiate misuse	Eu12211	[X]Drug addiction - cannabis
13	1TD2.00	H/O infrequent opiate misuse	Eu12300	[X]Mental and behav dis due cannabinoids: withdrawal state
14				
15	1TD3.00	Previous history of opiate misuse	Eu12500	[X]Mental & behav dis due to cannabinoids: psychotic disordr
16				
17	1TE..00	Uses heroin on top of substitution therapy	Eu12600	[X]Mental and behav dis due to use cannabinoids: amnesic syn
18				
19	1V...00	Drug misuse behaviour	Eu12700	[X]Mnt/bh dis due cannabinds: resid & late-onset psychot dis
20				
21	1V0..00	Misuses drugs	Eu12y00	[X]Men/behav dis due to use cannabinoids: oth men/behav disd
22				
23	1V01.00	Long-term drug misuser	Eu12z00	[X]Ment/behav dis due use cannabinoids: unsp ment/behav disd
24				
25	1V02.00	Poly-drug misuser	Eu13.00	[X]Mental and behavioural dis due use sedatives/hypnotics
26				
27	1V08.00	Smokes drugs in cigarette form	Eu13000	[X]Mental & behav dis due seds/hypntcs: acute intoxication
28				
29	1V09.00	Smokes drugs through a pipe	Eu13100	[X]Mental and behav dis due to use seds/hypntcs: harmful use
30				
31	1V0A.00	Chases the dragon	Eu13200	[X]Mental and behav dis due to seds/hypntcs: dependence synd
32				
33	1V0B.00	Sniffs drugs	Eu13211	[X]Drug addiction- sedative / hypnotics
34	1V0C.00	Drug addict	Eu13300	[X]Mental and behav dis due seds/hypntcs: withdrawal state
35				
36	1V0E.00	Health problem secondary to drug misuse	Eu13400	[X]Men & beh dis due seds/hypns: withdrwl state wth delirium
37				
38	1V26.00	Misused drugs in past	Eu13500	[X]Mental & behav dis due to seds/hypntcs: psychotic disordr
39				
40	1V3..00	Drug injection behaviour	Eu14.00	[X]Mental and behavioural disorders due to use of cocaine
41				
42	1V4..00	Priority of drug-related activities	Eu14000	[X]Mental & behav dis due to use cocaine: acute intoxication
43				
44	1V5..00	Routine of drug-related activities	Eu14100	[X]Mental and behav dis due to use of cocaine: harmful use
45				
46	1V6..00	Drug-related offending behaviour	Eu14200	[X]Mental and behav dis due to use cocaine: dependence syndr
47				
48	1V64.00	Illicit drug use	Eu14211	[X]Drug addiction - cocaine
49	1V65.00	Heroin misuse	Eu14300	[X]Mental and behav dis due to use cocaine: withdrawal state
50				
51	1V66.00	Ecstasy misuse	Eu14500	[X]Mental & behav dis due to use cocaine: psychotic disorder
52				
53	222N.00	O/E - signs of drug withdrawal	Eu14700	[X]Men & beh dis due cocaine: resid & late-onset psychot dis
54				
55	C150500	Alcohol-induced pseudo-Cushing's syndrome	Eu15.00	[X]Mental & behav disorder due other stimulants inc caffein
56				
57	E01..00	Alcoholic psychoses	Eu15000	[X]Mnt/beh dis due oth stim inc caffein: acute intoxication
58				
59	E010.00	Alcohol withdrawal delirium	Eu15100	[X]Ment/behav dis due to use oth stims inc caff: harmful use

1	E010.11	DTs - delirium tremens	Eu15200	[X]Mental and behav dis oth stim inc caffein: dependnce synd
2	E010.12	Delirium tremens	Eu15211	[X]Drug addiction-other stimul
3	E011.00	Alcohol amnestic syndrome	Eu15300	[X]Mnt/behav dis other stimInts inc caffeine: withdrwl state
4				
5	E011000	Korsakov's alcoholic psychosis	Eu15500	[X]Mental/behav dis oth stims inc caffeine: psychotic dis
6				
7	E011100	Korsakov's alcoholic psychosis with peripheral neuritis	Eu15700	[X]Mnt/bh dis oth stm inc caffne resid/late-onset psycht dis
8				
9	E011z00	Alcohol amnestic syndrome NOS	Eu15z00	[X]Ment/beh dis oth stims inc caffeine: unsp ment/behav disd
10				
11	E012.00	Other alcoholic dementia	Eu16.00	[X]Mental and behavioural disorders due to use hallucinogens
12				
13	E012.11	Alcoholic dementia NOS	Eu16000	[X]Mental & behav dis due hallucinogens: acute intoxicatn
14				
15	E012000	Chronic alcoholic brain syndrome	Eu16100	[X]Mental and behav dis due to use hallucinogens: harmfl use
16				
17	E013.00	Alcohol withdrawal hallucinosis	Eu16200	[X]Mental and behav dis due to hallucinogens: dependence syn
18				
19	E014.00	Pathological alcohol intoxication	Eu16211	[X]Drug addiction - hallucinogen
20	E015.00	Alcoholic paranoia	Eu16300	[X]Mental and behav dis due hallucinogens: withdrawal state
21				
22	E01y.00	Other alcoholic psychosis	Eu16500	[X]Mental & behav dis due to hallucinogens: psychotic disord
23				
24	E01y000	Alcohol withdrawal syndrome	Eu16700	[X]Mnt/bh dis due hallucngns: resid & late-onset psychot dis
25				
26	E01yz00	Other alcoholic psychosis NOS	Eu16711	[X]Post hallucinogen perception disorder
27	E01z.00	Alcoholic psychosis NOS	Eu16z00	[X]Ment/behav dis due use hallucinogens: unsp ment/behav dis
28				
29	E02..00	Drug psychoses	Eu18.00	[X]Mental & behav disorders due to use of volatile solvents
30				
31	E020.00	Drug withdrawal syndrome	Eu18000	[X]Mental & behav dis due vol solvents: acute intoxication
32				
33	E021.00	Drug-induced paranoia or hallucinatory states	Eu18100	[X]Mental and behav dis due volatile solvents: harmful use
34				
35	E021000	Drug-induced paranoid state	Eu18200	[X]Mental and behav dis due to vol solvents: dependence synd
36				
37	E021100	Drug-induced hallucinosis	Eu18211	[X]Drug addiction - solvent
38	E021z00	Drug-induced paranoia or hallucinatory state NOS	Eu18400	[X]Men & beh dis vol solvents: withdrawal state wth delirium
39				
40	E022.00	Pathological drug intoxication	Eu18500	[X]Mental & behav dis due to vol solvents: psychotic disordr
41				
42	E023.00	Nicotine withdrawal	Eu18z00	[X]Ment/behav dis due use vol solvents: unsp ment/behav dis
43				
44	E02y.00	Other drug psychoses	Eu19.00	[X]Men & behav disorder multiple drug use/psychoactive subst
45				
46	E02y000	Drug-induced delirium	Eu19000	[X]Mental/behav dis multi drg use/psychoac subs: acute intox
47				
48	E02y100	Drug-induced dementia	Eu19100	[X]Mental and behav dis mlti drg/oth psychoa sbs: harmfl use
49				
50	E02y300	Drug-induced depressive state	Eu19200	[X]Mental and behav dis mlti/oth psych sbs: dependence syndr
51				
52	E02y400	Drug-induced personality disorder	Eu19211	[X]Drug addiction NOS
53	E02yz00	Other drug psychoses NOS	Eu19300	[X]Mental and behav dis mlti/oth psychoa sbs: withdrwl state
54				
55	E02z.00	Drug psychosis NOS	Eu19400	[X]Mnt/bh dis mlti drg use/oth psy sbs: wthdr state + dlrium
56				
57	E040.11	Korsakoff's non-alcoholic psychosis	Eu19500	[X]Ment/behav dis mlti drug use/oth psyc sbs: psychotc dis
58				
59	E23..00	Alcohol dependence syndrome	Eu19600	[X]Mental/behav dis multi drg use/oth psy sbs:

1	E23..11	Alcoholism	Eu19700	amnesic syndr [X]Men/beh dis mlt drg use/oth subs: resid/late psychot dis
2				
3	E23..12	Alcohol problem drinking	Eu19y00	[X]Men/beh dis mlt drg use/oth psy sbs: oth men & behav dis
4				
5	E230.00	Acute alcoholic intoxication in alcoholism	Eu19z00	[X]Ment/beh dis multi drug use/oth psy sbs unsp mnt/beh dis
6				
7	E230.11	Alcohol dependence with acute alcoholic intoxication	Eu1A.00	[X]Mental and behavioural disorders due use of crack cocaine
8				
9	E230000	Acute alcoholic intoxication, unspecified, in alcoholism	Eu1A000	[X]Ment behav dis due use crack cocaine: acute intoxication
10				
11	E230100	Continuous acute alcoholic intoxication in alcoholism	Eu1A100	[X]Mental behav disorders due use crack cocaine: harmful use
12				
13	E230200	Episodic acute alcoholic intoxication in alcoholism	Eu1A200	[X]Mental behav disorders due use crack cocaine: depend synd
14				
15	E230300	Acute alcoholic intoxication in remission, in alcoholism	Eu1A300	[X]Mental behav disord due crack cocaine: withdrawal state
16				
17	E230z00	Acute alcoholic intoxication in alcoholism NOS	Eu1A500	[X]Mental behav disord due crack cocaine: psychotic disorder
18				
19	E231.00	Chronic alcoholism	Eu1Az00	[X]Ment behav dis due crack cocaine: unsp ment and behav dis
20				
21				
22	E231.11	Dipsomania	F11x000	Cerebral degeneration due to alcoholism
23	E231000	Unspecified chronic alcoholism	F11x011	Alcoholic encephalopathy
24	E231100	Continuous chronic alcoholism	F144000	Cerebellar ataxia due to alcoholism
25	E231200	Episodic chronic alcoholism	F25B.00	Alcohol-induced epilepsy
26	E231300	Chronic alcoholism in remission	F375.00	Alcoholic polyneuropathy
27	E231z00	Chronic alcoholism NOS	F394000	Drug-induced myopathy
28				
29	E23z.00	Alcohol dependence syndrome NOS	F394100	Alcoholic myopathy
30	E24..00	Drug dependence	G555.00	Alcoholic cardiomyopathy
31	E24..11	Drug addiction	G852300	Oesophageal varices in alcoholic cirrhosis of the liver
32				
33	E240.00	Opioid type drug dependence	J153.00	Alcoholic gastritis
34	E240.11	Heroin dependence	J610.00	Alcoholic fatty liver
35	E240.12	Methadone dependence	J611.00	Acute alcoholic hepatitis
36	E240.13	Morphine dependence	J612.00	Alcoholic cirrhosis of liver
37	E240.14	Opium dependence	J612000	Alcoholic fibrosis and sclerosis of liver
38	E240000	Unspecified opioid dependence	J613.00	Alcoholic liver damage unspecified
39	E240100	Continuous opioid dependence	J613000	Alcoholic hepatic failure
40	E240200	Episodic opioid dependence	J617.00	Alcoholic hepatitis
41	E240300	Opioid dependence in remission	J617000	Chronic alcoholic hepatitis
42	E240z00	Opioid drug dependence NOS	J61y.00	Other non-alcoholic chronic liver disease
43	E241.00	Hypnotic or anxiolytic dependence	J670800	Alcohol-induced acute pancreatitis
44	E241.11	Anxiolytic dependence	J671000	Alcohol-induced chronic pancreatitis
45	E241.12	Barbiturate dependence	L183.00	Drug dependence in pregnancy, childbirth and the puerperium
46				
47				
48	E241.13	Benzodiazepine dependence	L183.11	Pregnancy and drug dependence
49	E241.14	Diazepam dependence	L183100	Drug dependence during pregnancy - baby delivered
50				
51	E241.15	Librium dependence	L183300	Drug dependence during pregnancy - baby not yet delivered
52				
53	E241.16	Sedative dependence	L183z00	Drug dependence during pregnancy/childbirth/puerperium NOS
54				
55	E241.17	Valium dependence	L255300	Maternal care for (suspected) damage to fetus from alcohol
56				
57	E241000	Hypnotic or anxiolytic dependence, unspecified	SM0..00	Alcohol causing toxic effect
58				
59				

1	E241100 Hypnotic or anxiolytic dependence, continuous	SM00.00 Ethyl alcohol causing toxic effect
2	E241200 Hypnotic or anxiolytic dependence, episodic	SM00000 Ethanol causing toxic effect
3		
4	E241300 Hypnotic or anxiolytic dependence in remission	SM00100 Denatured alcohol causing toxic effect
5		
6	E241z00 Hypnotic or anxiolytic dependence NOS	SM00z00 Ethyl alcohol causing toxic effect NOS
7	E242.00 Cocaine type drug dependence	SM01.00 Methyl alcohol causing toxic effect
8	E242000 Cocaine dependence, unspecified	SM01000 Methanol causing toxic effect
9	E242100 Cocaine dependence, continuous	SM01100 Wood alcohol causing toxic effect
10	E242200 Cocaine dependence, episodic	SM02.00 Isopropyl alcohol causing toxic effect
11	E242300 Cocaine dependence in remission	SM03000 Amyl alcohol causing toxic effect
12	E242z00 Cocaine drug dependence NOS	SM03100 Butyl alcohol causing toxic effect
13	E243.00 Cannabis type drug dependence	SM0y.00 Other alcohol causing toxic effect
14	E243.11 Hashish dependence	SM0z.00 Alcohol causing toxic effect NOS
15	E243.12 Hemp dependence	SyuG000 [X]Toxic effect of other alcohols
16	E243.13 Marihuana dependence	Z1Q6200 Methadone maintenance
17	E243000 Cannabis dependence, unspecified	Z1Q6214 Heroin maintenance
18	E243100 Cannabis dependence, continuous	ZV11300 [V]Personal history of alcoholism
19	E243200 Cannabis dependence, episodic	ZV11311 [V]Problems related to lifestyle alcohol use
20	E243300 Cannabis dependence in remission	ZV11400 [V]Personal history of psychoactive substance abuse
21		
22	E243z00 Cannabis drug dependence NOS	ZV11500 [V]Personal history of drug abuse by injection
23	E244.00 Amphetamine or other psychostimulant dependence	ZV4K100 [V]Drug use
24		
25	E244.11 Psychostimulant dependence	ZV4KC00 [V] Alcohol use
26	E244.12 Stimulant dependence	E245.11 LSD dependence
27	E244000 Amphetamine or psychostimulant dependence, unspecified	E245.12 Lysergic acid diethylamide dependence
28	E244100 Amphetamine or psychostimulant dependence, continuous	E245000 Hallucinogen dependence, unspecified
29	E244200 Amphetamine or psychostimulant dependence, episodic	E245100 Hallucinogen dependence, continuous
30	E244300 Amphetamine or psychostimulant dependence in remission	E245200 Hallucinogen dependence, episodic
31	E244z00 Amphetamine or psychostimulant dependence NOS	E245300 Hallucinogen dependence in remission
32	E244z11 Amphetamine or psychostimulant dependence NOS	E245.00 Hallucinogen dependence
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

ATTEMPTED SUICIDE**At least one ICD-9 in:**

- E950 Self-inflicted poisoning
- E950.0 Self-inflicted poisoning by analgesics antipyretics and antirheumatics
 - E950.1 Self-inflicted poisoning by barbiturates
 - E950.2 Self-inflicted poisoning by other sedatives and hypnotics
 - E950.3 Self-inflicted poisoning by tranquilizers and other psychotropic agents
 - E950.4 Self-inflicted poisoning by other specified drugs and medicinal substances
 - E950.5 Self-inflicted poisoning by unspecified drug or medicinal substance
 - E950.6 Self-inflicted poisoning by agricultural and horticultural chemical and pharmaceutical preparations other than plant foods and fertilizers
 - E950.7 Self-inflicted poisoning by corrosive and caustic substances
 - E950.8 Self-inflicted poisoning by arsenic and its compounds
 - E950.9 Self-inflicted poisoning by other and unspecified solid and liquid substances
- E951 Self-inflicted poisoning
- E951.0 Self-inflicted poisoning by gas distributed by pipeline
 - E951.1 Self-inflicted poisoning by liquefied petroleum gas distributed in mobile containers
 - E951.8 Self-inflicted poisoning by other utility gas
- E952 Self-inflicted poisoning
- E952.0 Self-inflicted poisoning by motor vehicle exhaust gas
 - E952.1 Self-inflicted poisoning by other carbon monoxide
 - E952.8 Self-inflicted poisoning by other specified gases and vapors
 - E952.9 Self-inflicted poisoning by un specified gases and vapors
- E953 Self-inflicted injury by hanging, strangulation and suffocation
- E953.0 Self-inflicted injury by hanging
 - E953.1 Self-inflicted injury by suffocation by plastic bag
 - E953.8 Self-inflicted injury by other specified means
 - E953.9 Self-inflicted injury by other unspecified means
- E954 Self-inflicted injury by drowning
- E955 Self-inflicted injury by firearms and explosives
- E955.0 Self-inflicted injury by handgun
 - E955.1 Self-inflicted injury by shotgun
 - E955.2 Self-inflicted injury by hunting rifle
 - E955.3 Self-inflicted injury by military firearms
 - E955.4 Self-inflicted injury by other and unspecified firearm
 - E955.5 Self-inflicted injury by explosives
 - E955.6 Self-inflicted injury by air gun
 - E955.7 Self-inflicted injury by paintball gun
 - E955.9 Self-inflicted injury by firearms and explosives unspecified
- E956 Self-inflicted injury by cutting and piercing instrument
- E957 Self-inflicted injury by jumping from high places
- E957.0 Self-inflicted injury by jumping from residential premises
 - E957.1 Self-inflicted injuries by jumping from other man-made structures
 - E957.2 Self-inflicted injuries by jumping from natural sites
 - E957.9 Self-inflicted injuries by jumping from unspecified site
- E958 Self-inflicted injury
- E958.0 Self-inflicted injury by jumping or lying before a moving object
 - E958.1-E958.2 Self-inflicted injury by smoke, fire, flames, steam, hot vapours and

hot objects

E958.3, E958.4, E958.6-E958.9 Self-inflicted injury by other and unspecified means

E958.5 Self-inflicted injury by crashing of motor vehicle

E959 Late effects of self-inflicted injury

OR

At least one ICD-10 in:

X60-84 Intentional self-harm

X60 Intentional self-poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics

X61 Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified

X62 Intentional self-poisoning by and exposure to narcotics and psychodysleptics [hallucinogens], not elsewhere classified

X63 Intentional self-poisoning by and exposure to other drugs acting on the autonomic nervous system

X64 Intentional self-poisoning by and exposure to other and unspecified drugs, medicaments and biological substances

X65 Intentional self-poisoning by and exposure to alcohol

X66 Intentional self-poisoning by and exposure to organic solvents and halogenated hydrocarbons and their vapours

X67 Intentional self-poisoning by and exposure to other gases and vapours

X68 Intentional self-poisoning by and exposure to pesticides

X69 Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances

X70 Intentional self-harm by hanging, strangulation and suffocation

X71 Intentional self-harm by drowning and submersion

X72 Intentional self-harm by handgun discharge

X73 Intentional self-harm by rifle, shotgun and larger firearm discharge

X74 Intentional self-harm by other and unspecified firearm discharge

X75 Intentional self-harm by explosive material

X76 Intentional self-harm by smoke, fire and flames

X77 Intentional self-harm by steam, hot vapours and hot objects

X78 Intentional self-harm by sharp object

X79 Intentional self-harm by blunt object

X80 Intentional self-harm by jumping from a high place

X81 Intentional self-harm by jumping or lying before moving object

X82 Intentional self-harm by crashing of motor vehicle

X83 Intentional self-harm by other specified means

X84 Intentional self-harm by unspecified means

Y87.0 Late effects of intentional self-harm

OR

At least one READ code in:

SL...15	Overdose of drug	U1A4.11	[X]Accidental poisoning with antidepressant
T8...00	Accidental poisoning by drugs, medicines and biologicals	T952.00	Accidental poisoning from other fish
T91z.00	Accidental poisoning by household agents NOS	ZX1C.00	Nipping self
U20...11	[X]Deliberate drug overdose / other poisoning	ZX17.00	Head-banging
T8...11	Cause of overdose - accidental	T938000	Accidental poisoning by cyanides
1BD1.00	Suicidal ideation	U20A000	[X]Intent self pois organ solvent,halogen hydrocarb, home
T803000	Accidental poisoning by aspirin	TK7z.00	Suicide+selfinflicted injury-jump from high place NOS
TK05.00	Suicide + selfinflicted poisoning by drug or medicine NOS	T964200	Accidental poisoning by cadmium and its compounds
T921300	Accidental poisoning by kerosene	ZX1B200	Jumping from bridge
TK...15	Attempted suicide	T953z00	Accidental poisoning from berries or seeds NOS
T930.00	Accidental poisoning by organochlorine insecticides	T80y.00	Accidental poisoning by oth analgesics,antipyretic,antirheum
U1A..12	[X]Accidental drug overdose / other poisoning	TKx0000	Suicide + selfinflicted injury-jumping before moving object
TK...17	Para-suicide	U209z00	[X]Intent self poison alcohol unspecif place
TK...12	Injury - self-inflicted	T930500	Accidental poisoning by toxaphene
U2...13	[X]Suicide	ZX11400	Biting own arm
1BD3.00	Suicidal plans	T954.00	Accidental poisoning from other plants
T924z00	Accidental poisoning by other solvents NOS	T820.00	Accidental poisoning by chloral hydrate
T81..00	Accidental poisoning by barbiturates	U221.00	[X]Intent self harm by drowning/submersn occ resid instit'n
T804100	Accidental poisoning by paracetamol	T935200	Accidental poisoning by chlorates
U2E..00	[X]Self mutilation	T930100	Accidental poisoning by chlordane
1BD4.00	Suicide risk	U1A0z00	[X]Accid poison/expos to nonopioid analgesic unspecif place
TK3y.00	Suicide + selfinflicted inj oth mean hang/strangle/suffocate	U204.13	[X]Overdose - SSRI
TK...11	Cause of overdose - deliberate	T951.00	Accidental poisoning from shellfish
146B.00	H/O: deliberate self harm	U2A1.00	[X]Intent self harm by blunt object occ resident instit'n
U2...15	[X]Para-suicide	T903300	Accidental poisoning by secondary propyl alcohol
1B19.11	Suicidal - symptom	TK3z.00	Suicide + selfinflicted inj by hang/strangle/suffocate NOS
TK60111	Slashed wrists self inflicted	T854.00	Accidental poisoning by anticholinergics
ZX1..13	Deliberate self-harm	TK72.00	Suicide+selfinflicted injury-jump from natural sites
U209.00	[X]Intent self poison/exposure to alcohol	U2zz.00	[X]Intent self harm by unspecif means occ at unspecif place
ZX...00	Self-harm	U1A9z00	[X]Accid poison/expos to alcohol unspecif place
T99y000	Accidental poisoning by chlorine	U409z00	[X]Pois/expos ?intent to alcohol unspecif place
TK...13	Poisoning - self-inflicted	T83yz00	Accidental poisoning by other tranquillisers NOS
U2...11	[X]Self inflicted injury	T842100	Accidental poisoning by caffeine
146A.00	H/O: attempted suicide	T806300	Accidental poisoning by ibuprofen
TK60100	Self inflicted lacerations to wrist	U408z00	[X]Pois/expos ?intent to oth/unsp drug/medic unspecif place

ZX17100	Banging own head against object	U20y200	[X]Int self poison unspecif chemical school/pub admin area
SL...14	Overdose of biological substance	U1A2.00	[X]Accident poisoning/exposure to sedative hypnotic
1BDC.00	Intent of deliberate self harm with detailed plans	TK70.00	Suicide+selfinflicted injury-jump from residential premises
ZX16211	Poking own eyes	TK2..00	Suicide + selfinflicted poisoning by other gases and vapours
ZX13.00	Cutting self	T840200	Accidental poisoning by monoamine oxidase inhibitors
1BDA.00	Thoughts of deliberate self harm	T93z.00	Accidental poisoning agricultural chemical preparations NOS
ZX14200	Pulling out sutures	T832z00	Accidental poisoning- benzodiazepine-based tranquilliser NOS
TK30.00	Suicide and selfinflicted injury by hanging	T932.00	Accidental poisoning by carbamates
14K0.00	H/O: repeated overdose	TN04.00	Injury ?accidental, poisoning by other spec drug/medicament
T967.00	Accidental poisoning by cosmetics	ZX1K.00	Self-incineration
TK00.00	Suicide + selfinflicted poisoning by analgesic/antipyretic	U40y400	[X]Pois/expos ?intent unspecif chemical in street/highway
TK60.00	Suicide and selfinflicted injury by cutting	U40B400	[X]Pois/expos ?intent other gas/vapour in street/highway
1B19.00	Suicidal	T993000	Accidental poisoning by bromobenzyl cyanide
T901.00	Accidental poisoning by other ethyl alcohol and its products	T832100	Accidental poisoning by diazepam
T9...00	Accidental poisoning by other non-drug substances	U405.00	[X]Poisoning/exposure, ? intent, to narcotic drug
TK01.00	Suicide + selfinflicted poisoning by barbiturates	U208000	[X]Int self poison/exposure to oth/unsp drug/medicam home
14K..00	H/O: poisoning	T840.00	Accidental poisoning by antidepressants
U30..11	[X]Deliberate drug poisoning	U1Ayy00	[X]Accid pois/expos to unspecif chemical other spec place
U2...00	[X]Intentional self-harm	T971.00	Accidental poisoning by coal gas NOS
U2...14	[X]Attempted suicide	T99yz00	Accidental poisoning by other gases and vapours NOS
T955.00	Accidental poisoning from mushrooms and other fungi	U2A..00	[X]Intentional self harm by blunt object
T80..00	Accidental poisoning by analgesics,antipyretic,antirheumatic	T840000	Accidental poisoning by amitriptyline
T88..00	Accidental poisoning by other drugs	T805.00	Accidental poisoning by pyrazole derivatives
T8z..00	Accidental poisoning by drugs NOS	U2C4.00	[X]Int self harm jump/lying befr mov obje occ street/highway
T840z00	Accidental poisoning by antidepressants NOS	U274.00	[X]Intent self harm by smoke fire/flame occ street/highway
U1AB.11	[X]Accidental carbon monoxide poisoning	U400.00	[X]Poisoning/exposure, ? intent, to nonopioid analgesic
T90..00	Accidental poisoning by alcohol, NEC	U1ADz00	[X]Acc poison by and exposure to amphetamine - unspec places
U200.11	[X]Overdose - paracetamol	T825.00	Accidental poisoning by mixed sedatives NEC
1BD8.00	At risk of DSH - deliberate self harm	U1A9000	[X]Accident poison/exposure to alcohol at home
ZX13100	Cutting own wrists	T832500	Accidental poisoning by nitrazepam
ZX1P.00	Swallowing substances	U1A2.13	[X]Accidental poisoning with temazepam
ZX1I.00	Self-scalding	T83y.00	Accidental poisoning by other tranquillisers
T91..00	Accidental poisoning by household agents	U4A5.00	[X]Contct wth blunt obj undet intent occ trade/service area

1	T921200	Accidental poisoning by petrol	TN0..00	Injury ?accidental, poisoning by solid/liquid substances
2	U2...12	[X]Injury - self-inflicted	T912.00	Accidental poisoning by polishes
3	U200z00	[X]Intent self poison nonopioid analgesic unspecif place	T916z00	Accidental poisoning by paint or varnish NOS
4				
5	U1A..11	[X]Accidental drug / other poisoning	U1A9400	[X]Accid poison/expos alcohol in street/highway
6				
7	TK...14	Suicide and self harm	TN07.00	Injury ?accidental, poisoning by agricultural chemicals
8				
9	TK...00	Suicide and selfinflicted injury	T980100	Accidental poisoning by butane
10	U200.00	[X]Intent self poison/exposure to nonopioid analgesic	ZX1L600	Self-mutilation of ears
11				
12	T910.00	Accidental poisoning by synthetic detergents and shampoos	ZX1L500	Enucleation of own eyes
13				
14	ZV1B200	[V]Personal history of self-harm	ZX1K.11	Setting fire to self
15	TK04.00	Suicide + selfinflicted poisoning by other drugs/medicines	T964000	Accidental poisoning by beryllium and its compounds
16				
17	ZX11.00	Biting self	ZX1E.00	Pinching self
18	U1Ay.00	[X]Accident poisoning/exposure to unspecif chemical	U20Bz00	[X]Intent self poison other gas/vapour unspecif place
19				
20	TK3..00	Suicide + selfinflicted injury by hang/strangulate/suffocate	T920z00	Accidental poisoning by petrol solvents NOS
21				
22	T935.00	Accidental poisoning by herbicides	U211.00	[X]Intent self harm by hangng strangult/suffoct resid instit
23				
24	T913z00	Accidental poisoning by other cleaning agents NOS	T965100	Accidental poisoning by fertilisers
25				
26	T884.00	Accidental poisoning by gastrointestinal system drugs	U1A3.00	[X]Accident poisoning/exposure to antiparkinson drug
27				
28	T96y.00	Accidental poisoning by other solid and liquid substances OS	T983z00	Accidental poisoning by carbon monoxide - domestic fuel NOS
29				
30	TK7..00	Suicide and selfinflicted injury by jumping from high place	TKx5.00	Suicide and selfinflicted injury by crashing motor vehicle
31				
32	U40..00	[X]Poisoning/expos to noxious substance,undetermined intent	T822000	Accidental poisoning by bromides
33				
34	U20A.11	[X]Self poisoning from glue solvent	T930300	Accidental poisoning by dieldrin
35	T970.00	Accidental poisoning by carbon monoxide from piped gas	T938.00	Accidental poisoning by fumigants
36				
37	U27..00	[X]Intentional self harm by smoke, fire and flames	U1A6.00	[X]Accident poisoning/exposure to hallucinogen
38				
39	U20B.11	[X]Self carbon monoxide poisoning	U40A300	[X]Pois/exp ?intent org solvent,halogen hydrocarb,sport area
40				
41	T95..00	Accidental poisoning from foodstuffs and poisonous plants	ZX1L811	Snapping own bones
42				
43	U1A..00	[X]Accidental poisoning by + exposure to noxious substances	TK54.00	Suicide and selfinflicted injury by other firearm
44				
45	ZX11200	Biting own fingers	T961000	Accidental poisoning by mercury, unspecified
46	ZX11500	Biting own tongue	TK6z.00	Suicide and selfinflicted injury by cutting and stabbing NOS
47				
48	TN...11	Poisoning undetermined - accidentally or purposely inflicted	U4C..00	[X]Falling lying running befor/into moving obj undet intent
49				
50	ZX19.00	Hitting self	T843100	Accidental poisoning by opiate antagonists
51	ZX1G.00	Scratches self	TN21.00	Injury ?accidental, poisoning by other carbon monoxide
52				
53	1BD7.00	Low suicide risk	T921z00	Accidental poisoning by petrol fuel or cleaner NOS
54				
55	T911.00	Accidental poisoning by soap products	U1AD000	[X]Accident poisoning by and exposure to
56				
57				
58				
59				
60				

1	U29..00	[X]Intentional self harm by sharp object	U1A5000	amphetamine - home [X]Accident poison/exposure to narcotic drug at home
2				
3	TK61.00	Suicide and selfinflicted injury by stabbing	U201.00	[X]Intent self poison/exposure to antiepileptic
4	TK03.00	Suicide + selfinflicted poisoning	TKxy.00	Suicide and selfinflicted injury by other
5		tranquilliser/psychotropic		specified means
6	T842000	Accidental poisoning by amphetamine	TK01000	Suicide and self inflicted injury by
7				Amylobarbitone
8	U20..00	[X]Intentional self poisoning/exposure to noxious substances	U201z00	[X]Intent self poison antiepileptic unspecif place
9				
10	U40y.00	[X]Poisoning/exposure, ? intent, to unspecif chemical	U204z00	[X]Intent self poison psychotropic drug unspecif place
11				
12	T953000	Accidental poisoning from berries	T936000	Accidental poisoning by organic mercurials
13	TK07.00	Suicide + selfinflicted poisoning by corrosive/caustic subst	U1A7z00	[X]Accid poison/expos to oth autonomic drug unspecif place
14				
15	T913.00	Accidental poisoning by other cleaning agents	TK0z.00	Suicide + selfinflicted poisoning by solid/liquid subst NOS
16				
17	TK51.00	Suicide and selfinflicted injury by shotgun	U207z00	[X]Intent self poison oth autonomic drug unspecif place
18				
19	U45..00	[X]Other+unspecified firearm discharge undetermined intent	T83z.00	Accidental poisoning by tranquilisers NOS
20				
21	ZX1LD00	[X]Self mutilation	U402.00	[X]Poisoning/exposure, ? intent, to sedative hypnotic
22				
23	ZX1..14	Self-abusive behaviour	T84z.00	Accidental poisoning by psychotropic agents NOS
24				
25	ZX18.00	Hanging self	T96..00	Accidental poisoning by other solid and liquid substances
26				
27	U205.11	[X]Overdose - heroin	U1AA000	[X]Accid poison/expos organ solvent,halogen hydrocarb, home
28				
29	T938200	Accidental poisoning by phosphine	U40B.00	[X]Poisoning/exposure, ? intent, to other gas/vapour
30				
31	U200.13	[X]Overdose - aspirin	U1AC.12	[X]Accidental poisoning with paraquat
32	U409.00	[X]Poisoning/exposure, ? intent, to alcohol	U1Ay600	[X]Acc pois/expos unspecif chemical indust/construct area
33				
34	T955000	Accidental poisoning from mushrooms	TK5..00	Suicide and selfinflicted injury by firearms and explosives
35				
36	U290.00	[X]Intentional self harm by sharp object occurrence at home	TN20.00	Injury ?accidental, poisoning by motor vehicle exhaust gas
37				
38	TK0..00	Suicide + selfinflicted poisoning by solid/liquid substances	T921.00	Accidental poisoning by petrol fuels and cleaners
39				
40	U21..00	[X]Intent self harm by hanging strangulation / suffocation	U4A3.00	[X]Contct wth blunt obj undet intent occ sport/athletic area
41				
42	ZX1H100	Self-strangulation	T831000	Accidental poisoning by haloperidol
43	T916200	Accidental poisoning by non-lead paints	U280.00	[X]Intent self harm by steam hot vapour/hot obj occ at home
44				
45	U1A9.00	[X]Accident poisoning/exposure to alcohol	U2y0.00	[X]Intentionl self harm by oth specif means occurrn at home
46				
47	T935500	Accidental poisoning by paraquat	T935z00	Accidental poisoning by herbicides NOS
48	TN1..00	Injury ?accidental, poisoning by gases in domestic use	T80yz00	Accidental poisoning-oth analgesic,antipyretic,antirheum NOS
49				
50	TK4..00	Suicide and selfinflicted injury by drowning	U241.00	[X]Int self harm rifl s'gun/lrg frarm disch occ resid instit
51				
52	ZX1L.00	Self-mutilation	T955z00	Accidental poisoning from mushrooms and fungi NOS
53				
54	ZX19300	Head-hitting	U406y00	[X]Pois/exp ?intent to hallucinogen other spec place
55				
56				
57				
58				
59				
60				

1	ZX1..11	Self-destructive behaviour	T935400	Accidental poisoning by mixtures herbicides+plant food etc
2	T92..00	Accidental poisoning by petrol products	U4D3.00	[X]Crash of motor vehicle undeterm intent sport/athlet area
3				
4	TK02.00	Suicide + selfinflicted poisoning by oth sedatives/hypnotics	T82y.00	Accidental poisoning by other sedatives and hypnotics OS
5				
6	T914.00	Accidental poisoning by disinfectants	U20C.12	[X]Self poisoning with paraquat
7	T88yz00	Accidental poisoning by other drugs NOS	T940.00	Accidental poisoning by corrosive aromatics
8	T961.00	Accidental poisoning by mercury and its compounds and fumes	TN05.00	Injury ?accidental, poisoning by drug or medicament NOS
9				
10				
11	T9z..00	Accidental poisoning NOS	T802.00	Accidental poisoning by other opiates
12	T85..00	Accidental poisoning by other drugs acting on nervous system	T841.00	Accidental poisoning by hallucinogens
13				
14	T883.00	Accidental poisoning by cardiovascular system drugs	U1A2.12	[X]Accidental poisoning with diazepam
15				
16	U2z..00	[X]Intentional self harm by unspecified means	U2A0.00	[X]Intentional self harm by blunt object occurrence at home
17				
18	U1AA.11	[X]Accidental poisoning from glue solvent	U208z00	[X]Intent self poison oth/unsp drug/medic unspecif place
19				
20	T886.00	Accidental poisoning by muscle + respiratory system drugs	T991.00	Accidental poisoning by sulphur dioxide
21				
22	U204.12	[X]Overdose - amitriptyline	U409000	[X]Poison/exposure ?intent, to alcohol at home
23				
24	T923000	Accidental poisoning by paraffin wax	T99..00	Accidental poisoning by other gases and vapours
25				
26	T902000	Accidental poisoning by methanol	T850.00	Accidental poisoning by anticonvulsant + anti-parkinson drug
27				
28	ZX10.00	Swallowing objects	T850.11	Accidental poisoning by anticonvulsant
29	ZX1L100	Self-mutilation of hands	U205z00	[X]Intent self poison narcotic drug unspecif place
30				
31	ZX1..00	Self-injurious behaviour	U202z00	[X]Intent self poison sedative hypnotic unspecif place
32				
33				
34	1BD5.00	High suicide risk	U207.00	[X]Intent self poison/exposure to oth autonomic drug
35				
36	ZX1LA00	Removing own nails	U20C.00	[X]Intent self poison/exposure to pesticide
37	ZX11100	Biting own hand	T964700	Accidental poisoning by thallium compounds
38	ZX11300	Biting own toes	U40y600	[X]Poison/expos ?intent unspec chemic indust/construct area
39				
40	U4D0.00	[X]Crashng of motor vehicle undetermined intent occ at home	T95y.00	Accidental poisoning by other foods
41				
42	T800.11	Accidental poisoning by diamorphine	T88y000	Accidental poisoning by central appetite depressants
43				
44	U2D4.00	[X]Intent self harm by crash motor vehicl occ street/highway	T961z00	Accidental poisoning by mercury, NOS
45				
46	U208.00	[X]Int self poison/exposure to other/unspec drug/medicament	U1A8y00	[X]Accid pois/expos to oth/unsp drug/medic other spec place
47				
48	T887000	Accidental poisoning by skin drugs	ZX1K.12	Setting self alight
49	TKx2.00	Suicide and selfinflicted injury by scald	U720.00	[X]Sequelae of intentional self-harm
50	U4B..00	[X]Falling jumping/pushed from high place undeterm intent	U2yz.00	[X]Intent self harm by oth specif means occ unspecif place
51				
52	TK6..00	Suicide and selfinflicted injury by cutting and stabbing	U202y00	[X]Int self poison sedative hypnotic other spec place
53				
54	T86..00	Accidental poisoning by antibiotics	U404300	[X]Pois/exp ?intent psychotropic drug in sport/athletic area
55				
56				
57	T98..00	Accidental poisoning by other utility gas + carbon monoxide	T802z00	Accidental poisoning by other opiates NOS
58				
59				

1	U204.00	[X]Intent self poison/exposure to psychotropic drug	U409200	[X]Pois/exp ?intent alcohol school/pub admin area
2	ZX13.11	Cuts self	U1Ayz00	[X]Accid poison/expos to unspecif chemical unspecif place
3			T950.00	Accidental poisoning from meat
4	T966000	Accidental poisoning by glues	U1A1.00	[X]Accident poisoning/exposure to antiepileptic
5	ZX14100	Reopening scars	T913000	Accidental poisoning by scouring agents
6			TK10.00	Suicide + selfinflicted poisoning by gas via pipeline
7	T901100	Accidental poisoning by methylated spirit	TN08.00	Injury ?accidental, poisoning by arsenic or its compounds
8	T935300	Accidental poisoning by diquat	T966y00	Accidental poisoning by other adhesives
9			U205y00	[X]Int self poison narcotic drug other spec place
10	T902.00	Accidental poisoning by methyl alcohol	TK1..00	Suicide + selfinflicted poisoning by gases in domestic use
11			U20A400	[X]Int self poison org solvent,halogen hydrocarb,in highway
12	1BD6.00	Moderate suicide risk	T803z00	Accidental poisoning by salicylates NOS
13	T83..00	Accidental poisoning by tranquilisers	U1A2000	[X]Accident poison/exposure to sedative hypnotic at home
14			T931300	Accidental poisoning by malathion
15	U1AB.00	[X]Accident poisoning/exposure to other gas/vapour	TKx0.00	Suicide + selfinflicted injury-jump/lie before moving object
16	T942z00	Accidental poisoning by caustic alkalis NOS	TN1z.00	Injury ?accidental, poisoning by gas in domestic use NOS
17			T85z.00	Accidental poisoning by drugs acting on nervous system NOS
18	T841000	Accidental poisoning by cannabis derivatives	TKx4.00	Suicide and selfinflicted injury by electrocution
19	ZX12.00	Burning self	T807.00	Accidental poisoning by other non-narcotic analgesics
20			TK11.00	Suicide + selfinflicted poisoning by liquified petrol gas
21	U27z.00	[X]Intent self harm by smoke fire/flames occ unspecif place	TN0z.00	Injury ?accidental, poisoning by solid or liquid subst NOS
22	T901300	Accidental poisoning by ethanol, NOS	ZX...11	Self-damage
23			TKxz.00	Suicide and selfinflicted injury by other means NOS
24	T88z.00	Accidental poisoning by unspecified drugs	T806.00	Accidental poisoning by antirheumatics
25	ZX11600	Biting sides of own cheeks	T964600	Accidental poisoning by nickel compounds
26			T813.00	Accidental poisoning by pentobarbitone
27	T88y.00	Accidental poisoning by other drugs OS	T806z00	Accidental poisoning by antirheumatics NOS
28	T937300	Accidental poisoning by warfarin	ZX19100	Punching self
29			U2B0.00	[X]Intent self harm by jumping from high place occ at home
30	U20B200	[X]Int self poison other gas/vapour school/pub admin area	U270.00	[X]Intention self harm by smoke fire/flames occurrn at home
31	U2y..00	[X]Intentional self harm by other specified means	U206400	[X]Intent self pois hallucinogen in street/highway
32			C110100	Self-induced hyperinsulinism
33	T973.00	Accidental poisoning by piped natural gas	T916000	Accidental poisoning by lacquers
34	T93..00	Accidental poisoning by agricultural chemical preparations	T850z00	Accidental poisoning by anticonvulsant/anti-
35	ZX13200	Cutting own throat		
36	T806100	Accidental poisoning by indomethacin		
37	ZX1A.00	Inserting foreign bodies into own orifices		
38	T924.00	Accidental poisoning by other solvents		
39	T97..00	Accidental poisoning by gas distributed by pipeline		
40	ZX14300	Poking fingers into wound		
41				
42	ZX11111	Hand biting		
43				
44	T802200	Accidental poisoning by morphine		
45				
46	T881.00	Accidental poisoning by primarily systemic agents		
47	U41..00	[X]Hanging strangulation + suffocation undetermined intent		
48				
49	T900.00	Accidental poisoning by alcoholic beverages		
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				

1	ZV15600	[V]Personal history of poisoning	T854000	parkin drug NOS
2	T98z.00	Accidental poisoning by carbon monoxide NOS	T830200	Accidental poisoning by atropine
3	TKz..00	Suicide and selfinflicted injury NOS	T931z00	Accidental poisoning by prochlorperazine
4				Accidental poisoning by organophosphorus insecticides NOS
5	ZX1B.00	Jumping from height	T964.00	Accidental poisoning by other metals + compounds and fumes
6			U29y.00	[X]Intention self harm by sharp object occ oth specif place
7	U22..00	[X]Intentional self harm by drowning and submersion	T81z.00	Accidental poisoning by barbiturates NOS
8	U209000	[X]Int self poison/exposure to alcohol at home	U28z.00	[X]Intent self harm by steam hot vapour/obj occ unspec place
9	U1AB600	[X]Acc pois/expos other gas/vapour indust/construct area	TK2z.00	Suicide + selfinflicted poisoning by gases and vapours NOS
10	U1ABz00	[X]Accid poison/expos to other gas/vapour unspecif place	U26..00	[X]Intentional self harm by explosive material
11	T916.00	Accidental poisoning by other paints and varnishes	U1A8100	[X]Accid poison/expos to oth/unsp drug/medicam res institut
12	U20yz00	[X]Intent self poison unspecif chemical unspecif place	T95z.00	Accidental poisoning by foodstuffs and poisonous plants NOS
13	U2C..00	[X]Intent self harm by jumping / lying before moving object	U207000	[X]Int self poison/exposure to oth autonomic drug at home
14	U2z0.00	[X]Intentional self harm by unspecif means occurrn at home	T936.00	Accidental poisoning by fungicides
15	T981z00	Accidental poisoning by utility gas NOS	U1A8z00	[X]Accid poison/expos to oth/unsp drug/medic unspecif place
16	U20A.00	[X]Intentional self poison organ solvent,halogen hydrocarb	U2Cy.00	[X]Int self harm jump/lying bef mov obje occ oth specif plice
17	TKy..00	Late effects of selfinflicted injury	T963100	Accidental poisoning by arsenic compounds
18	U21z.00	[X]Intent self harm by hangng strangul/suffoct unspecif plce	T903100	Accidental poisoning by isopropanol
19	U1AD.00	[X]Accidental poisoning by and exposure to amfetamine	T855100	Accidental poisoning by noradrenalin
20	T931.00	Accidental poisoning by organophosphorus insecticides	T932200	Accidental poisoning by propoxur
21	U1A0000	[X]Accident poison/exposure to nonopioid analgesic at home	T932100	Accidental poisoning by carbaryl
22	T98yz00	Accidental poisoning by carbon monoxide from oth source NOS	T963.00	Accidental poisoning by arsenic and its compounds and fumes
23	T92z.00	Accidental poisoning by solvent NOS	T853.00	Accidental poisoning by cholinergics
24	TK71.00	Suicide+selfinflicted injury-jump from oth manmade structure	U2y1.00	[X]Intent self harm by oth specif means occ resid instit'n
25	T84..00	Accidental poisoning by other psychotropic agents	T98y200	Accidental poisoning by CO - fuels in industrial use
26	U40C.00	[X]Poisoning/exposure, ? intent, to pesticide	ZX1Q.11	Jumping under train
27	T915.00	Accidental poisoning by lead paints	U20C.11	[X]Self poisoning with weedkiller
28	U1AC.11	[X]Accidental poisoning with weedkiller	T961200	Accidental poisoning by mercury fumes
29	U4A..00	[X]Contact with blunt object, undetermined intent	ZX1H200	Self-suffocation
30	T937z00	Accidental poisoning by rodenticides NOS	T916300	Accidental poisoning by white washes
31	U204000	[X]Int self poison/exposure to psychotropic drug at home	ZX1L900	Pulling own teeth out
32	U202000	[X]Int self poison/exposure to sedative hypnotic at home	U294.00	[X]Intention self harm by sharp object occ street/highway
33	T96z.00	Accidental poisoning by solid and liquid substances NOS		

T934.00	Accidental poisoning by other insecticides	ZX1L300	Self-mutilation of penis
T953100	Accidental poisoning from seeds	U21y.00	[X]Intent self harm by hangng strangul/suffocat oth spec plce
U47..00	[X]Exposure to smoke, fire and flames, undetermined intent	T815.00	Accidental poisoning by quinalbarbitone
T832.00	Accidental poisoning by benzodiazepine-based tranquillisers	U4D7.00	[X]Crashng of motor vehicle undetermined intent occ on farm
T82..00	Accidental poisoning by other sedatives and hypnotics	ZX1R.00	Throwing self in front of vehicle
U200.12	[X]Overdose - ibuprofen	U1Ay200	[X]Acc poison/expos unspecif chemical school/pub admin area
T920.00	Accidental poisoning by petroleum solvents	U1A3500	[X]Accid poison/expos antiparkinson drug trade/service area
ZX1B100	Jumping from building	U1A9500	[X]Accid poison/expos alcohol trade/service area
U2D0.00	[X]Intent self harm by crash of motor vehicl occurrn at home	T832400	Accidental poisoning by medazepam
ZX1F.00	Rubbing own skin	TN2..00	Injury ?accidental, poisoning by other gases
T887300	Accidental poisoning by otorhinolaryngological drugs	U410.00	[X]Hanging strangulat+suffocat undet intent occurrn at home
T880.00	Accidental poisoning by hormones and synthetic substitutes	T920200	Accidental poisoning by petroleum naphtha
U1Ay000	[X]Accident poison/exposure to unspecif chemical at home	T887z00	Accidental poisoning by skin, eye, ENT and dental drug NOS
T885.00	Accidental poisoning by water,mineral,uric acid metab drugs	U2C1.00	[X]Int self harm jump/lying befr mov obje occ resid instit'n
U25..00	[X]Intent self harm by other/unspecified firearm discharge	T921.12	Accidental poisoning by petroleum fuels
U205.00	[X]Intent self poison/exposure to narcotic drug	T940011	Accidental poisoning by phenol
U202.12	[X]Overdose - diazepam	U1AC000	[X]Accident poison/exposure to pesticide at home
U72..00	[X]Sequel intentn self-harm assault+event of undeterm intent	TN11.00	Injury ?accidental, poisoning by liquid petrol gas
ZX1LB00	Eating own flesh	U2Bz.00	[X]Int self harm by jump from high place occ unspecif place
ZX17200	Banging own head against own body parts	TK1z.00	Suicide + selfinflicted poisoning by domestic gases NOS
T983100	Accidental poisoning by CO- coke in domestic stove/fireplace	T98y000	Accidental poisoning by CO - blast furnace gas
U49..00	[X]Contact with sharp object, undetermined intent	TK01400	Suicide and self inflicted injury by Phenobarbitone
ZX15.00	Drowning self	T85y.00	Accid. poisoning by other drugs acting on nervous system OS
U204.11	[X]Overdose - antidepressant	U22y.00	[X]Intent self harm by drown/submersn occ oth specif place
T814.00	Accidental poisoning by phenobarbitone	U20Cy00	[X]Int self poison pesticide other spec place
U1A2.11	[X]Accidental poisoning with sleeping tablets	U206.00	[X]Intent self poison/exposure to hallucinogen
TKx1.00	Suicide and selfinflicted injury by burns or fire	U202.18	[X]Overdose - amobarbital
U2B..00	[X]Intentional self harm by jumping from a high place	T830000	Accidental poisoning by chlorpromazine
T470.00	Accidental poisoning by gases or fumes on ship	ZX16.00	Gouging own body parts
ZX1LC00	Stripping own skin	T807z00	Accidental poisoning by non-narcotic analgesics NOS
ZRLfC12	HoNOS item 2 - non-accidental self injury	T887400	Accidental poisoning by dental drugs
ZX1L911	Extracting own teeth	U1Ay500	[X]Accid poison/expos unspecif chemical trade/service area

1	1BDB.00	Plans for deliberate self harm without intent	T966.00	Accidental poisoning by glues and adhesives
2	ZX11.11	Bites self	ZX1B300	Jumping from cliff
3	U1A2.15	[X]Accidental poisoning with nitrazepam	U2B6.00	[X]Int self harm by jump from high place indust/constr area
4	TKx..00	Suicide and selfinflicted injury by other means	U250.00	[X]Intent self harm oth/unspecif firearm disch occ at home
5	TH02.00	Late effects of accidental poisoning	ZX1L700	Self-inducing a prolapse
6	ZX1..12	SIB - Self-injurious behaviour	T852100	Accidental poisoning by lignocaine
7	T937200	Accidental poisoning by thallium	U1A5z00	[X]Accid poison/expos to narcotic drug unspecif place
8	T981400	Accidental poisoning by cooking gas NOS	U409400	[X]Pois/expos ?intent alcohol in street/highway
9	T921100	Accidental poisoning by gas oils	U2zy.00	[X]Intent self harm by unspecif means occ oth specif place
10	T965000	Accidental poisoning by plant food	ZX1L800	Breaking own bones
11	U202.16	[X]Overdose - benzodiazepine	TKx7.00	Suicide and selfinflicted injury caustic subst, excl poison
12	ZX1N.00	Stabbing self	U200y00	[X]Int self poison nonopioid analgesic other spec place
13	T803.00	Accidental poisoning by salicylates	U204y00	[X]Int self poison psychotropic drug other spec place
14	TK20.00	Suicide + selfinflicted poisoning by motor veh exhaust gas	T852.00	Accidental poisoning by local anaesthetic
15	T99y.00	Accidental poisoning by other gases and vapours OS	U408000	[X]Poison/exposure ?intent, to oth/unsp drug/medicam home
16	U200000	[X]Int self poison/exposure to nonopioid analgesic at home	U202400	[X]Intent self pois sedative hypnotic in street/highway
17	U1A5.00	[X]Accident poisoning/exposure to narcotic drug	U1ABy00	[X]Accid pois/expos to other gas/vapour other spec place
18	TK1y.00	Suicide and selfinflicted poisoning by other utility gas	U200500	[X]Intent self pois nonopioid analgesic trade/service area
19	T953.00	Accidental poisoning from berries and seeds	U208400	[X]Intent self pois oth/unsp drug/medic in street/highway
20	U202.17	[X]Overdose - barbiturate	U200100	[X]Intent self poison nonopioid analgesic at res institut
21	U1A0.11	[X]Accidental poisoning with paracetamol	U20C000	[X]Int self poison/exposure to pesticide at home
22	T955y00	Accidental poisoning from other fungi	U402z00	[X]Pois/expos ?intent to sedative hypnotic unspecif place
23	T852000	Accidental poisoning by cocaine	U208y00	[X]Int self poison oth/unsp drug/medic other spec place
24	T942000	Accidental poisoning by sodium hydroxide	U209y00	[X]Int self poison alcohol other spec place
25	U1A0.00	[X]Accident poisoning/exposure to nonopioid analgesic	U2z2.00	[X]Intent self harm by unsp mean occ sch/ins/pub adm area
26	T941000	Accidental poisoning by hydrochloric acid	ZX16100	Gouging own flesh
27	ZX1J.00	Self-electrocution	T841z00	Accidental poisoning by hallucinogen NOS
28	T854200	Accidental poisoning by hyoscine	T982z00	Accidental poisoning by exhaust gas from motor vehicle NOS
29	TN00.00	Injury ?accidental, poisoning by analgesic or anti- pyretic	T964500	Accidental poisoning by manganese and its compounds
30	T80z.00	Accidental poisoning by analgesics,antipyretic,antirheum NOS	U404.00	[X]Poisoning/exposure, ? intent, to psychotropic drug
31	ZX19200	Slapping self	U22z.00	[X]Intent self harm by drown/submersn occ unspecified place
32	U1A7.00	[X]Accident poisoning/exposure to oth autonomic drug	T94y.00	Accidental poisoning by other corrosives and caustics

1	U1A0.12	[X]Accidental poisoning with ibuprofen	U20Az00	[X]Int self pois org solv,halogen hydrocarb, unspec place
2	U408.00	[X]Poison/exposure, ?intent, to other/unspec drug/medicament	ZV71600	[V]Observation following other inflicted injury
3	U48..00	[X]Contact with steam hot vapours+objects undetermn intent	T830z00	Accidental poisoning- phenothiazine-based tranquilisers NOS
4	T982100	Accidental poisoning by exhaust gas from gas engine	T924000	Accidental poisoning by benzene
5	ZX15.00	Throwing self onto floor	ZVu0600	[X]Examination & observat following other inflicted injury
6	U24..00	[X]Intent self harm by rifle shotgun/larger firearm disch	TKx3.00	Suicide and selfinflicted injury by extremes of cold
7	T942.00	Accidental poisoning by caustic alkalis	T964100	Accidental poisoning by brass fumes
8	U202.00	[X]Intent self poison/exposure to sedative hypnotic	T960000	Accidental poisoning by lead, unspecified
9	U20B.00	[X]Intent self poison/exposure to other gas/vapour	U40yz00	[X]Pois/expos ?intent to unspecif chemical unspecif place
10	TK21.00	Suicide and selfinflicted poisoning by other carbon monoxide	T980200	Accidental poisoning by propane
11	U1A5.11	[X]Accidental poisoning with heroin	T983.00	Accidental poisoning by carbon monoxide- other domestic fuel
12	U20y000	[X]Int self poison/exposure to unspecif chemical at home	U204100	[X]Intent self poison psychotropic drug at res institut
13	ZC15100	Repeated self-induced vomiting	T964z00	Accidental poisoning by metals + compounds and fumes NOS
14	U202.13	[X]Overdose - temazepam	U1AA100	[X]Acc poison/expos org solvent,halogen hydrocarb,res instit
15	T802000	Accidental poisoning by codeine	ZX1Q.00	Throwing self in front of train
16	T82z.00	Accidental poisoning by sedatives and hypnotics NOS	T851.00	Accidental poisoning by oth central nervous syst depressants
17	T94..00	Accidental poisoning by corrosives and caustics NEC	T806200	Accidental poisoning by naproxen
18	TK31.00	Suicide + selfinflicted injury by suffocation by plastic bag	TK01100	Suicide and self inflicted injury by Barbitone
19	U1A4.13	[X]Accidental poisoning with SSRI	T990.00	Accidental poisoning by nitrogen oxides
20	T960.00	Accidental poisoning by lead and its compounds and fumes	T963000	Accidental poisoning by arsenic, unspecified
21	U1AB700	[X]Accident poison/exposure to other gas/vapour on farm	14K1.00	Intentional overdose of prescription only medication
22	T941.00	Accidental poisoning by acids	U212.00	[X]Inten slf harm hang strang/suffc sch oth ins/pub adm area
23	TN06.00	Injury ?accidental, poisoning by corrosive/caustic substance	T802300	Accidental poisoning by opium
24	U470.00	[X]Exposure to smoke fire+flame undeterm intent occ at home	U1AD200	[X]Acc pois/expo to amphet - sch, other inst+pub admin area
25	T981.00	Accidental poisoning by other utility gas	T98y.00	Accidental poisoning by carbon monoxide from other sources
26	U4D..00	[X]Crashing of motor vehicle, undetermined intent	T802100	Accidental poisoning by pethidine
27	U49z.00	[X]Contact with sharp obj undeterm intent occ unspecif place	T983300	Accidental poisoning by CO- kerosene in domestic stove/fire
28	U42..00	[X]Drowning and submersion, undetermined intent	U4Bz.00	[X]Fall jump/push frm high plce undt intnt occ unspecif plce
29	TK06.00	Suicide + selfinflicted poisoning by agricultural chemical	T850.12	Accidental poisoning by anti-parkinsonism drug
30	U40A.00	[X]Pois/exposure,?intent,to organ	T98y100	Accidental poisoning by CO - kiln vapour

1	U205000	solvent,halogen hydrocarb [X]Int self poison/exposure to narcotic drug at home	T830.00	Accidental poisoning by phenothiazine-based tranquillisers
2				
3	U1AB000	[X]Accident poison/exposure to other gas/vapour at home	U2By.00	[X]Int self harm by jump from high place oth specif plce
4				
5	U29z.00	[X]Intentional self harm by sharp object occ unspecif place	T941z00	Accidental poisoning by acids NOS
6				
7	U1A4100	[X]Accid poison/expos to psychotropic drug at res institut	U1A2.16	[X]Accidental poisoning with benzodiazepine
8				
9	T832000	Accidental poisoning by chlordiazepoxide	T936z00	Accidental poisoning by fungicides NOS
10	U291.00	[X]Intent self harm by sharp object occ resident instit'n	TK5z.00	Suicide and selfinflicted injury by firearms/explosives NOS
11				
12	U202.15	[X]Overdose - nitrazepam	T930200	Accidental poisoning by DDT
13	U1A8000	[X]Accident poison/exposure to oth/unsp drug/medicam home	U1A1000	[X]Accident poison/exposure to antiepileptic at home
14				
15	U20B000	[X]Int self poison/exposure to other gas/vapour at home	T811.00	Accidental poisoning by barbitone
16				
17	U1AC.00	[X]Accident poisoning/exposure to pesticide	T901z00	Accidental poisoning by ethyl alcohol NOS
18	T882.00	Accidental poisoning by drugs affecting blood constituents	U200400	[X]Intent self pois nonopioid analgesic in street/highway
19				
20	T90y.00	Accidental poisoning by other alcohols	T923.00	Accidental poisoning by petroleum solids
21	U201000	[X]Int self poison/exposure to antiepileptic at home	TKx6.00	Suicide and selfinflicted injury by crashing of aircraft
22				
23	ZX14.00	Damaging own wounds	U2D6.00	[X]Intent self harm crash motor vehic occ indust/constr area
24				
25	U2A3.00	[X]Intent self harm by blunt object occ sports/athlet area	U4Az.00	[X]Contact with blunt obj undeterm intent occ unspecif place
26				
27	T941200	Accidental poisoning by sulphuric acid	U40C000	[X]Poison/exposure ?intent, to pesticide at home
28				
29	T937400	Accidental poisoning by zinc phosphide	T923z00	Accidental poisoning by petrol solids NOS
30	U1A0.13	[X]Accidental poisoning with aspirin	U4B6.00	[X]Fall jump/push frm high plce undt intr indust/constr area
31				
32	U1AA.00	[X]Accid poison/exposure to organ solvent,halogen hydrocarb	U206000	[X]Int self poison/exposure to hallucinogen at home
33				
34	T960z00	Accidental poisoning by lead, NOS	U40y000	[X]Poison/exposure ?intent, to unspecif chemical at home
35				
36	U210.00	[X]Intent self harm by hanging strangulat/suffocat occ home	U220.00	[X]Intent self harm by drowning/submersion occurrn at home
37				
38	T800.00	Accidental poisoning by heroin	U1Ay700	[X]Accident poison/exposure to unspecif chemical on farm
39				
40	T94z.00	Accidental poisoning by corrosives and caustics NOS	U40yy00	[X]Pois/exp ?intent to unspecif chemical other spec place
41				
42	U1A8.00	[X]Accident poison/exposure to other/unspec drug/medicament	T941100	Accidental poisoning by nitric acid
43				
44	U20By00	[X]Int self poison other gas/vapour other spec place	U1A9200	[X]Acc poison/expos alcohol school/pub admin area
45				
46	T938100	Accidental poisoning by methyl bromide	ZX16300	Gouging own rectum
47	U1A4.12	[X]Accidental poisoning with amitriptyline	T830300	Accidental poisoning by promazine
48	ZX1M.00	Shooting self	U216.00	[X]Intent self harm by hang strangl/suffc indust/constr area
49				
50	U44..00	[X]Rifle shotgun+larger firearm discharge undeterm intent	T887200	Accidental poisoning by ophthalmological drugs
51				
52	T922.00	Accidental poisoning by lubricating oils	1BDE.00	Suicide risk increased from previous level
53	T964400	Accidental poisoning by iron compounds	ZX1R.11	Jumping in front of vehicle
54	T964300	Accidental poisoning by copper salts	U1A9300	[X]Accid pois/expos alcohol in sport/athletic area
55				
56				
57				
58				
59				

1	T887100	Accidental poisoning by mucous membrane drugs	U1A9y00	[X]Accid pois/expos to alcohol other spec place
2	U202.11	[X]Overdose - sleeping tabs	TN02.00	Injury ?accidental, poisoning by other
3				sedative/hypnotic
4	T90z.00	Accidental poisoning by alcohol NOS	T806000	Accidental poisoning by gold salts
5	T981300	Accidental poisoning by heating gas NOS	T937100	Accidental poisoning by squill and derivatives
6	T801.00	Accidental poisoning by methadone	T965z00	Accidental poisoning by plant foods and
7				fertilisers NOS
8	T841100	Accidental poisoning by lysergide, LSD	T823.00	Accidental poisoning by methaqualone
9				compounds
10	T840100	Accidental poisoning by imipramine	U1A8600	[X]Acc pois/expos oth/unsp drug/medic
11				indust/construct area
12	U2B4.00	[X]Intent self harm by jump from high place occ	T966z00	Accidental poisoning by glues and adhesives
13		street/h'way		NOS
14	TN2y.00	Injury ?accidental, poisoning by other spec gas or	TK2y.00	Suicide + selfinflicted poisoning by other gases
15		vapour		and vapours
16	U4A0.00	[X]Contact wth blunt object undetermined intent	T832300	Accidental poisoning by lorazepam
17		occ at home		
18	TK52.00	Suicide and selfinflicted injury by hunting rifle	T822.00	Accidental poisoning by bromine compounds
19	U242.00	[X]Int slf hrm rifl s'gun/lrg frarm dis sch/ins/pub	T804.00	Accidental poisoning by aromatic analgesics
20		adm area		NEC
21	U28..00	[X]Intentional self harm by steam hot vapours /	T80y000	Accidental poisoning by pentazocine
22		hot objects		
23	U2D..00	[X]Intentional self harm by crashing of motor	U4A6.00	[X]Contct wth blunt obj undet intent occ
24		vehicle		industr/constr area
25	ZX1H.00	Self-asphyxiation	U2y6.00	[X]Intent self harm oth specif means occ
26				industr/constr area
27	T983000	Accidental poisoning by CO- coal in domestic	U200600	[X]Int self pois nonopioid analgesic
28		stove/fireplace		indust/construct area
29	T87..00	Accidental poisoning by anti-infectives	TN01300	Injury ?accidental poisoning by Pentobarbitone
30	T77z.00	Accident/poisoning occurred in residential	U1A2z00	[X]Accid poison/expos to sedative hypnotic
31		institution NOS		unspecif place
32	U20y.00	[X]Intent self poison/exposure to unspecif	TK01z00	Suicide and self inflicted injury by barbiturates
33		chemical		
34	T937.00	Accidental poisoning by rodenticides	TKx0z00	Suicide + selfinflicted inj-jump/lie before
35				moving obj NOS
36	T934z00	Accidental poisoning by insecticides NOS	T805100	Accidental poisoning by phenylbutazone
37	U1A4.00	[X]Accident poisoning/exposure to psychotropic	U1A4200	[X]Acc poison/expos psychotropic drug
38		drug		school/pub admin area
39	U1A4000	[X]Accident poison/exposure to psychotropic	U2Dz.00	[X]Intent self harm by crash motor vehic occ
40		drug at home		unspecif place
41	ZX1L200	Self-mutilation of genitalia	T804200	Accidental poisoning by phenacetin
42	T855000	Accidental poisoning by adrenalin	1BDF.00	Suicide risk unchanged from previous level
43	T99z.00	Accidental poisoning by gases and vapours NOS	U40By00	[X]Pois/exp ?intent to other gas/vapour other
44				spec place
45	T982.00	Accidental poisoning by motor vehicle exhaust	T993.00	Accidental poisoning by tear gas
46		gas		
47	ZX16200	Gouging own eyes	U1Ay100	[X]Accid poison/expos to unspecif chemical at
48				res institut
49	T940000	Accidental poisoning by carbolic acid	U2yy.00	[X]Intent self harm oth specif means occ oth
50				specif place

PAIN**At least one ICD-9 in:**

Lumbar pain	724
Back disorders	721, 722, 723, 723, 737
Neck and back problems	721.0, 721.1, 721.2, 721.3, 721.4, 721.5, 721.6, 721.7, 721.8, 721.9, 722.0, 722.1, 722.2, 722.3, 722.4, 722.5, 722.6, 722.7, 722.8, 722.9, 723.0, 723.1, 723.2, 723.3, 723.4, 723.5, 723.7, 723.8, 723.9, 724.0, 724.1, 724.2, 724.3, 724.4, 724.5, 724.6, 724.8, 724.9, 737.1, 737.2, 738.2, 738.4, 738.5, 739.1, 739.2, 739.3, 739.4, 756.1, 846.0, 846.1, 846.2, 846.3, 846.8, 846.9, 847.0, 847.1, 847.2, 847.3, 847.9
Complex regional pain syndrome	337.2, 354.4, 355.7, 355.9
Fibromyalgia	729.1
Painful neuropathic disorders	250.6, 357.2, 053.1, 722.1, 722.2, 722.7, 724.0, 724.3, 724.4, 721.1, 722.0, 723.0, 723.4, 337.2, 353.2, 353.3, 353.4, 354.4, 355.7, 355.9, 729.2, 353.6, 350.1, 350.2, 352.1, 353.0, 353.1, 353.8, 353.9, 354.0, 354.1, 354.2, 354.3, 354.5, 354.8, 354.9, 355.0, 355.1, 355.2, 355.3, 355.4, 355.5, 355.6, 355.8,
Pain	338
Chronic pain	338.2
Chronic pain associated with significant psychosocial dysfunction	338.4
Pain disorders related to psychological factors	307.8
Migraine and headache	346, 784, 339
Osteoarthritis/Rheumatoid Arthritis	714, 715
Irritable bowel syndrome	564.1
Lupus	710.0

OR

At least one READ code in:

N131.00	cervicalgia - pain in neck	N05..00	osteoarthritis and allied disorders
1B1G.00	headache	N217700	calcaneal spur
1BA5.00	frontal headache	N23y400	spasm of muscle
F26..00	migraine	F260.00	classical migraine
E278100	tension headache	N224.00	ganglion and cyst of synovium, tendon and bursa
N143.00	sciatica	N081000	loose body in joint, unspecified joint
N216500	prepatellar bursitis	PG17.00	spina bifida occulta
J521.11	irritable bowel syndrome	1BA8.00	temporal headache
N090.00	effusion of joint	N140.11	spinal stenosis
N213300	olecranon bursitis	N235.00	hypermobility syndrome
N145.00	backache, unspecified	N37..00	curvature of spine
N12..00	intervertebral disc disorders	N225100	rupture of popliteal space synovial cyst
N217900	plantar fasciitis	F26y000	hemiplegic migraine
F340.00	carpal tunnel syndrome	1B1G000	sinus headache
N040.00	rheumatoid arthritis	N066.00	unspecified monoarthritis
J521.00	irritable colon - irritable bowel syndrome	7H48211	release of trigger finger
N224A00	synovial cyst of popliteal space	N01w.00	reactive arthropathy, unspecified
N371.00	acquired kyphosis	F330.00	brachial plexus lesions
N21z300	exostosis of unspecified site	N224000	synovial cyst unspecified
N221.00	bunion	N043.00	juvenile rheumatoid arthritis - still's

1	R040.00	[d]headache	SC20z12	disease
2	N220.00	synovitis and tenosynovitis	F355.00	headache - post traumatic
3	N20..00	polymyalgia rheumatica	N224200	tarsal tunnel syndrome
4	F301.00	other specified trigeminal neuralgia	N083.00	ganglion of tendon sheath
5	N142.14	lumbago	N245.00	recurrent dislocation of joint
6	1BA6.00	occipital headache	N21..00	pain in limb
7				peripheral enthesopathies and allied syndromes
8	N372.00	acquired lordosis	PG16.00	klippel-feil syndrome
9	PG12.00	congenital spondylolisthesis	N213200	lateral epicondylitis of the elbow
10	N11..00	spondylosis and allied disorders	N221000	infected bunion
11	N244.00	fasciitis unspecified	N141.00	pain in thoracic spine
12	N220300	trigger finger - acquired	1BB4.00	morning headache
13	F261.00	common migraine	F262200	abdominal migraine
14	F262000	cluster headache	N110.00	cervical spondylosis without myelopathy
15	N370.00	adolescent postural kyphosis	N384.00	acquired spondylolisthesis
16	N07..00	internal derangement of knee	7K51111	unionectomy
17	N234.00	laxity of ligament		

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	4-5
Methods			
Study design	4	Present key elements of study design early in the paper	5-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5-6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	N/A
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	N/A
		(e) <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	N/A

Results			Page No
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	N/A
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	N/A
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	8-9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	9-10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-11
Generalisability	21	Discuss the generalisability (external validity) of the study results	N/A
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Multinational Comparison of New Antidepressant Use in Older Adults: A Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027663.R1
Article Type:	Research
Date Submitted by the Author:	13-Mar-2019
Complete List of Authors:	Tamblyn, Robyn; McGill University, Department of Medicine and Department of Epidemiology and Biostatistics Bates, David ; Brigham and Women's Hospital, Medicine Buckeridge, David; McGill University, Epidemiology, Biostatistics, and Occupational Health; Agence de la Santé et des services Sociaux de Montréal, Direction de santé publique Dixon, Will; University of Manchester, Arthritis Research UK Centre for Epidemiology Forster, Alan; The Ottawa Hospital , Internal Medicine ; The Ottawa Hospital Research Institute, Clinical Epidemiology Program Girard, Nadyne; McGill University, Clinical and Health Informatics Research Group Haas, Jennifer; Brigham and Women's Hospital Habib, Bettina; McGill University, Clinical and Health Informatics Research Group Kurteva, Siyana; McGill University, Epidemiology, Biostatistics, and Occupational Health Li, Jack; Taipei Medical University, Graduate Institute of Biomedical Informatics Sheppard, Therese; University of Manchester
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Mental health
Keywords:	Antidepressants, Multinational comparison, Older adults, EPIDEMIOLOGY, pharmacosurveillance

SCHOLARONE™
Manuscripts

Multinational Comparison of New Antidepressant Use in Older Adults: A Cohort Study

Robyn Tamblyn^{1,2,3}, David W. Bates⁴, David L. Buckeridge^{1,3}, William G. Dixon⁵, Alan J. Forster⁶, Nadyne Girard³, Jennifer S. Haas⁴, Bettina Habib³, Siyana Kurteva¹, Jack Li^{7,8}, Therese Sheppard⁵

¹Department of Epidemiology, Biostatistics and Occupational Health, McGill University, 1020 Pine Avenue West, Montreal, QC H3A 1A2, Canada

²Department of Medicine, McGill University Health Center, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada

³Clinical and Health Informatics Research Group, McGill University, 1140 Pine Avenue West, Montreal, QC H3A 1A3, Canada.

⁴Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

⁵Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, 2nd Floor, Stopford Building, Oxford Road, Manchester M13 9PT, UK.

⁶The Ottawa Hospital, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada.

⁷International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan

⁸Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan

Corresponding Author

Robyn Tamblyn, BScN, MSc, PhD, FCAHS, CM

McGill University

1140 Pine Avenue West

Montreal, QC H3A 1A3

Tel. 514-934-1934 ext 32999

robyn.tamblyn@mcgill.ca

Word count: 3,934

ABSTRACT

Objectives: We used an international pharmacosurveillance network to estimate the rate and characteristics of antidepressant use in older adults in countries with more conservative (UK) and liberal depression guidelines (Canada, USA).

Setting: Electronic health records and population-based administrative data from six jurisdictions in four countries (UK, Taiwan, USA, and Canada).

Participants: A historical cohort of older adults (≥ 65) who had a new episode of antidepressant use between 2009-2014.

Outcome Measures: The age and sex-standardized cumulative incidence of new episodes of antidepressant use in older adults was measured. Descriptive statistics were used to compare the proportion of new users by the antidepressant prescribed, therapeutic class, potential treatment indication, and country, as well as the characteristics of the first treatment episode (standardized daily doses, duration and changes).

Results: The incidence of antidepressant use between 2009-2014 varied from 0.7%(UK), to 18.6% (Taiwan). Tricyclic antidepressants (TCAs) were the most commonly used class in the UK (48.8%) and Taiwan (52.4%) compared to selective serotonin reuptake inhibitors (SSRIs) in North American jurisdictions (42.3%-53.3%). Chronic pain was the most common potential treatment indication (41.2%-68.2%). Among users with chronic pain, TCAs were used most frequently in the UK and Taiwan (55.2%-60.4%) whereas SSRIs were used most frequently in North America (33.5%-46.4%). Treatment was longer (252-525 vs 169-437 days), standardized doses were higher (0.7-1.3 vs 0.5-1.0), and treatment was more likely to be changed (31%-46% vs 21%-34%) among patients with depression (9.1%-43%) than those with chronic pain.

Conclusion: Antidepressant use in older adults varied 24-fold by country, being lowest in the UK, which has the most conservative treatment guidelines. Chronic pain was the most common potential treatment indication. Evaluation of real-world risks of TCAs is a priority for future research, given high rates of use, and the potential for increased toxicity in older adults because of potent anti-cholinergic effects.

Article Summary

Strengths and Limitations of this Study

- Uses an international pharmacosurveillance network to characterize antidepressant use across multiple jurisdictions
- Despite data harmonization efforts, measurement and reporting issues may lead to arbitrary differences between regions and countries.
- Treatment indication is unknown for all but one study cohort. Documentation of health problems in medical services billing data and EMRs was used as a proxy for treatment indication for remaining cohorts, which could have resulted in misclassification bias.
- While some cohorts represented total populations or representative samples, others were assembled from practices supported by specific information technology systems.

INTRODUCTION

Depression affects an estimated 300 million people worldwide[1]. In the past decade, many countries have reported a two to three fold increase in the use of antidepressant medications[2]. The primary increase has been in newer antidepressants such as selective serotonin reuptake inhibitors (SSRIs), which are considered to have better efficacy than older drugs, with fewer side effects[3]. Increasing prevalence of use of antidepressants has also been associated with both an increase in the number of people started on therapy as well as its duration, with 40% of antidepressants being prescribed for more than 180 days [4]. Antidepressants now represent one of the most commonly prescribed medications[5 6], especially among older adults, where the increase in use has been the greatest in the US population[5 7].

The increasing use of antidepressants in older adults may be due to a number of factors. There has been long-standing advocacy for better recognition and treatment of depression in older adults[8 9]. In addition, individuals with multiple chronic conditions are more likely to experience depression. In Canada, 12% of persons 65 years and older have two or more major chronic conditions compared to only 3.6% in younger adults; and 4% of adults with at least one major chronic disease have mood or anxiety disorders, which are other approved indications for antidepressant use[10]. While increasing prevalence of depression, anxiety and other mood disorders in older adults may account for increasing use of antidepressants, there is also evidence that antidepressants are prescribed for unapproved indications that may not be supported by scientific evidence of efficacy[11-14]. One recent study found that nearly 50% of antidepressants were prescribed for unapproved indications including chronic pain, tiredness, and sleep disturbance[11], which are also more common in older adults[15].

Taken together, these factors have led to increasing concern about overuse of antidepressants, particularly in older adults[16]. This concern is heightened because of the reported association between antidepressant use and fall-related injuries, motor vehicle accidents, functional decline, and mortality in older adults[17-19]. Clinical practice guidelines for the management of depression vary considerably in their recommendations for first line treatment[20-24], although most acknowledge the need to consider patient preferences (Table 1). The United Kingdom NICE guidelines are the most conservative, recommending first line treatment with psychotherapy such as cognitive behavioral therapy with pharmacotherapy added only if non-pharmacological therapy is unsuccessful[24]. At the other end of the spectrum, the Canadian 2009 guidelines list pharmacotherapy as a first-line treatment for major depressive disorder, including selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), mirtazapine, or bupropion[25-27]. Of note, Canada ranks as the 3rd highest user of anti-depressants among 23 OECD countries, surpassed only by Australia and Iceland[2].

However, few data are available regarding how national guidelines may contribute to differences in how antidepressants are used for older adults. We took advantage of an international pharmacosurveillance network[28] that uses electronic medical record (EMR) and population-based health administrative data to estimate the rate of antidepressant use in older adults in countries that had more conservative (UK) and lenient guidelines (Canada, USA, Taiwan). We evaluated differences in the choice of antidepressant, dose and duration of treatment, the prevalence of dose changes and switches in treatment of older adults

with new episodes of antidepressant use, as well as differences in treatment approach for patients with a recorded diagnosis of depression, other mental health co-morbidities, and chronic pain.

METHODS

Study Design and Population

To characterize antidepressant use in older adults, a cohort of individuals who were 65 years of age or older and had a new episode of antidepressant use between January 1, 2009 and December 31, 2014 following two years during which they had no prescription or dispensation of an antidepressant was assembled. Eligible patients were identified from electronic medical record (EMR) or population-based registries in a total of six jurisdictions in four countries (Canada, United States, UK, and Taiwan).

Data Sources

CANADA

Quebec EMR cohort: Data were extracted from the Medical Office of the 21st Century (MOXXI) EMR, which includes a real-time linkage to the Quebec insurance agency, the Régie de l'assurance maladie du Québec (RAMQ) databases. This linkage provides historical and daily updates of patients' received medical services (diagnosis, procedure, date, location, provider), prescriptions dispensed from community pharmacies for persons who are publicly insured (prescriber, pharmacy, drug, dose, dispensing date, duration, refills), and mortality. Approximately 110 primary care physicians in Quebec use MOXXI for approximately 90,000 of their patients, representing approximately 25% of the patients in the practice, and approximately 5% of the Quebec population in primary care practices.

Quebec Administrative Data cohort: Data were retrieved from the Montreal Population Health Record, a population-based 25% random sample of the 4.1 million residents of Montreal, Canada's second largest city, which is dynamically updated each year to account for in and out-migration. Beneficiary characteristics were measured by linking the RAMQ beneficiary database (age, sex, postal code) with Statistics Canada's census file (postal code level measures of socio-economic status), and the Institute of Statistics birth and death registry (date of birth and death). From this population-based dataset, we identified all non-institutionalized persons 65 years of age or older between 2009-2014. All medical services (date, diagnosis, procedure), hospitalizations (admission and discharge date, primary and secondary diagnoses, in-hospital procedures), and medications (prescriber, pharmacy, drug, dose, dispensing date, duration, refills) received by members of the cohort were retrieved from the RAMQ database and those of the Quebec Ministry of Health.

Ontario Administrative Data Cohort: Data were extracted from the Institute for Clinical Evaluative Sciences population-based repository of health records for the 13.6 million Ontario residents. The data is provided by the Ontario Ministry of Health and Long-Term Care, which pays for all essential health services. For the 2,053,588 Ontario non-institutionalized residents who were 65 year or older between 2007 and 2014, we randomly sampled 20% and extracted age, sex and date of death from the beneficiary registrants database, all billing claims for medical services provided by Ontario physicians (date of service, diagnosis, procedure code, physician provider), all claims for medications dispensed in the community by Ontario

1
2
3 pharmacies (drug, date dispensed, prescriber, quantity, duration, number of refills), and data from
4 discharge summaries of emergency department visits and hospital stays (date of admission and discharge,
5 primary and secondary diagnoses and procedures).
6

8 *UNITED STATES*

9
10 *Boston, Massachusetts EMR cohort:* Data were extracted from the Partners HealthCare Research Patient
11 Data Registry (RPDR), which provides care for approximately 3 million of 5 million residents in Boston and
12 surrounding areas. RPDR includes data from the Longitudinal Medical Record (LMR), an internally
13 developed, web-based, fully functional EMR that was in use during this period for the participating
14 primary care clinics from Brigham and Women's Hospital (BWH) and Massachusetts General Hospital
15 (MGH), the two founding members of Partners Healthcare in Boston, Massachusetts. Data were retrieved
16 from the structured clinical encounter information from RPDR for all outpatient primary care visits. To
17 ensure complete follow-up, patients were eligible if they were seen in one of 37 BWH- or MGH- affiliated
18 primary care or diabetes clinics.
19
20
21

22 *UNITED KINGDOM*

23
24 *EMR cohort:* Data were extracted from the Clinical Practice Research Datalink (CPRD), an anonymised
25 longitudinal medical records database for primary care. The primary care EHR includes information on all
26 primary care interactions, including documented health problems, visit notes, prescriptions, and records
27 of specialty referrals, as well as information on lab results, hospitalizations, and death. The CPRD includes
28 more than 4 million active patients, 76% of whom are in England, representing 6.9% of the 64 million
29 primary care population in the UK, and around 600 primary care practices[29]. Patients were included if
30 their records met minimum quality standards and there were no gaps in registration. A 10% random
31 sample of the 2,436,180 elderly patients in the database were extracted.
32
33
34

35 *TAIWAN*

36
37 *Administrative Data Cohort:* Data were extracted from the Taiwanese National Health Insurance (NHI)
38 system databases. The NHI provides health coverage to around 99% of Taiwan's population of 23 million,
39 providing comprehensive coverage for all health services, including dental, preventive, Western medicine,
40 and traditional Chinese medicine services. A random sample of 103,400 of the 3.6 million residents that
41 were 65 years or older in Taiwan between 2007 and 2014 was extracted for this study. The NHI's research
42 databases include a registry for beneficiaries (e.g. registrant's age, sex, residence), an outpatient visit
43 database (date and time of visit, ICD-9-CM codes of existing health problems, service provided), an
44 inpatient visit database (date of hospitalization and discharge, ICD-9-CM codes of existing health
45 problems, procedure codes and dates), and a pharmacy database (drug prescribed, date, duration,
46 dosage, prescribing physician, dispensing pharmacy).
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Measurement

Patient Characteristics

Age & Sex: Date of birth and sex were retrieved from the administrative data in Canada and Taiwan as these data are verified at the time of enrollment in the health plan. For the US and United Kingdom, these data were retrieved from the EMR.

Depression, Other Mental Health Comorbidities, and Chronic Pain

We measured the existence of potential indications for antidepressant use^[11 12] including depression, other mental health conditions, and chronic pain. Depression included mild, moderate, major single or recurrent depressive disorder with or without psychotic symptoms, adjustment reaction, and mixed anxiety and depression. Other mental health conditions included anxiety, alcohol abuse, illicit drug use, attempted suicide, psychosis, schizophrenia, and bipolar disorder. Anxiety included dissociative and somatoform disorders. We used standard diagnostic codes (ICD 9, ICD 10, and Read codes) retrieved from the EMR, and/or medical services claims, and hospitalizations in the two-years prior to the first antidepressant prescription to measure these conditions (Appendix).

To measure chronic pain, we used a previously validated ICD9 and ICD10 code set for non-cancer pain^[30]. The concepts and definitions used in the development and validation of this code set were used to map to Read codes (Appendix available upon request). Chronic non-cancer pain conditions included lumbar pain, back disorders that are often associated with pain (e.g. degenerative disc disease), neck and back problems (e.g. spondylosis), fibromyalgia, complex regional pain syndromes (e.g. mononeuritis), painful neuropathic disorders (e.g. post herpetic neuralgia), pain disorders with psychosocial dysfunction, and unclassified chronic pain problems.

Characterizing Antidepressant Use

The characteristics of antidepressant use were compared in the population of seniors with a new episode of antidepressant use in each country, overall, and then within subgroups that had a diagnosis of a) depression, b) chronic pain, or c) other mental health problems.

Classification of Starting Therapy: The Anatomic Therapeutic Classification (ATC) system^[31] was used to map national drug names and identification numbers to a common nomenclature based on the antidepressants that were prescribed during the study time period. Therapeutic classes included tri-cyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin antagonist and reuptake inhibitors (SARIs), norepinephrine-dopamine reuptake inhibitors (NDRIs), noradrenergic and specific serotonergic antidepressants (NaSSAs), tetracyclic antidepressants (TeCAs), melatonergic agonists (MAs), and norepinephrine reuptake inhibitors (NRIs). Monoamine oxidase inhibitors were excluded as they are rarely used and only for bipolar disorder. Starting therapy was classified by therapeutic class and drug, and by the number of antidepressants prescribed at treatment initiation.

1
2
3 *Starting Antidepressant Dose:* To enable comparisons in the dose prescribed among antidepressants, we
4 created a standardized dose for each drug by dividing the prescribed dose by the WHO recommended
5 daily dose for adults. The resulting indicator represents the proportion of the recommended daily adult
6 dose that was prescribed. When more than one antidepressant was prescribed concurrently, we summed
7 the standardized dose for each drug.
8
9

10 11 12 **Analysis**

13 The cumulative incidence of older adults with new episodes of antidepressant use in the period 2009 to
14 2014 was measured by dividing the number of new users by the total population that was 65 years or
15 older during this time period. Rates were standardized for age and sex using the direct method and the
16 United Kingdom as the reference population. New episodes of use were defined as those who had no
17 prior prescription of an antidepressant in the two years preceding their first prescription. Descriptive
18 statistics were used to compare the proportion of new antidepressant users by the antidepressant
19 prescribed, therapeutic class, country and potential treatment indication, as well as the characteristics of
20 the first treatment episode. As the co-existence of other mental health conditions may modify treatment
21 choices, we used the prevalence ratio to estimate the concurrence of other mental health problems,
22 chronic pain and depression. The prevalence ratio allowed us to compare between countries even if the
23 prevalence of these conditions is different[32] It was calculated as the prevalence of the health problem
24 of interest among individuals with depression, divided by the prevalence of the health problem among
25 individuals without depression.
26
27
28
29

30 31 **Patient and Public Involvement**

32 Patients and members of the public were not involved in the development of research questions or
33 outcome measures, design, or implementation of this study. There are no plans to involve patients in
34 dissemination of research results.
35
36

37 **RESULTS**

38 The age-standardized cumulative incidence of antidepressant use in persons aged 65 and older in the
39 period 2009-2014 was highest in Taiwan (18.6%) and Ontario, Canada (15.3%), and lowest in Quebec-
40 Montreal (4.7%) and England (6.6%) (Table 2). Similarly, the overall prevalence of antidepressant use in
41 the same time period was lowest in England (10.3%), and highest in Ontario, Canada (26.8%) and Taiwan
42 (23.4%). The distribution of age was similar in all jurisdictions.
43
44
45
46

47 *Frequency Distribution of the First Antidepressant Prescription by Therapeutic Class*

48 Overall, there were substantial differences between jurisdictions in the choice of starting therapy for new
49 users (Table 3). Tricyclic antidepressants were the most commonly used class of antidepressants in
50 England (48.8%) and Taiwan (52.4%) compared to selective serotonin reuptake inhibitors in North
51 American jurisdictions (42.3%-53.3%). Notably, in the United Kingdom, approximately one-quarter of
52 antidepressant prescriptions were for newer classes of antidepressants: serotonin antagonist & reuptake
53 inhibitors (trazodone), norepinephrine-dopamine reuptake inhibitors (bupropion), and noradrenergic
54 serotonin specific antidepressants (mirtazapine).
55
56
57

Co-Existence of Depression, Other Mental Health Problems and Chronic Pain

The prevalence of a depression diagnosis among new antidepressant users was relatively low, varying from 9.1% (Taiwan) to 21.7% (USA). The exception was the EMR cohort in Quebec where the prevalence was 43.0% (Table 4). Among new antidepressant users with a diagnosis of depression, there was a 30% (UK Prevalence Ratio: 1.3) to 7-fold (USA Prevalence Ratio: 7.3) increase in the likelihood of also having an alcohol or other substance abuse problem. Anxiety, which varied from being present in 12.1% of new antidepressant users in the UK to 47.8% of new users in Taiwan, was the most common mental health problem, and was also more likely to be present among persons with depression (Prevalence Ratio: 1.3 (Ontario, Quebec) to 3.6 (USA)). Although less common in all jurisdictions, both major mental illness and suicide attempt were more likely to be present among antidepressant users with depression compared to those without depression. In contrast, chronic pain was the most prevalent problem among new antidepressant users (41.2% (UK) to 68.2% (Taiwan)), and was as likely to be present among those with or without depression (Prevalence Ratio: 0.9-1.3) (Table 4). For almost one-third of new antidepressant users, there was no documented diagnosis of depression, other mental health problems or chronic pain.

Choice of Anti-depressant by Potential Treatment Indication

Among new antidepressant users with a diagnosis of depression, selective serotonin reuptake inhibitors were selected as the starting therapy for 55.2% (Ontario) to 71.4% (UK), followed by SNRIs in Canadian jurisdictions, and newer antidepressants in Boston, the UK, and Taiwan (Table 5). For antidepressant users with a diagnosis of chronic pain, starting therapy was predominantly with SSRIs in North American jurisdictions (33.5%-46.1%), and with TCAs in the UK and Taiwan (55.2%-60.4%). Selection of therapy for other mental health problems was a mixture of choices made for persons with a diagnosis of depression and chronic pain.

Characteristics of the First Treatment Episode by Potential Treatment Indication

Among patients with a diagnosis of depression who were started on antidepressants, 54% (Ontario) to 68% (Taiwan) remained on their initial course of antidepressant treatment (Table 6A). For this group, the mean duration of treatment varied from 104.7 (Taiwan) to 340.9 (Quebec) days, and the mean dose varied from 0.6 of the recommended adult dose (Taiwan), to the recommended adult dose in the United States site (mean dose: 1.0). Among the 32% (Taiwan) to 46% (Ontario) with a change in treatment, the most common change in all jurisdictions was an increase in dose occurring in 20% (Taiwan) to 33% (Ontario) of patients, followed by a decrease in dose (13% (Taiwan) to 21% (Ontario)), and the addition of a drug from a different therapeutic class (6% (UK) to 18% (Ontario)). Among patients with a change in therapy in their initial treatment episode, the mean duration of treatment was almost double (mean duration 312.6 to 616.9 days) than for patients with no change, and the mean dose during treatment was substantially higher (mean standardized proportion of the adult dose: 0.8 to 1.4).

The first treatment episode for new antidepressant users with a diagnosis of chronic pain was substantially different than patients with a diagnosis of depression (Table 6B). Overall, 66% (Ontario) to 79% (Taiwan) were kept on the initial treatment regimen, for a much shorter duration than for new users with a diagnosis of depression (mean duration: 83.6 days (Taiwan) to 300.9 days (Quebec)), and at lower mean

1
2
3 doses (mean standardized proportion of the adult dose: 0.4 (Taiwan, UK, Montreal) to 0.8 (U.S.)). For the
4 21% to 34% of patients who had a change in treatment, the most common changes in all jurisdictions
5 were an increase in dose (13% to 25%), a decrease in dose (9% to 14%) and the addition of another drug
6 from a different therapeutic class (3% to 11%). For those with a change in treatment, the duration of the
7 treatment episode was considerably longer in all jurisdictions (264.4 to 590.0 days), and the mean dose
8 during the treatment episode was higher (0.5 to 1.1).
9
10

11 **INTERPRETATION**

12
13
14 This multi-national study is the first to compare the use of antidepressants among comparable cohorts of
15 new users in different countries. We found wide variation in the incidence and prevalence of
16 antidepressant use; the lowest rate was in the UK where guidelines for pharmacotherapy use for
17 depression were the most conservative. Choice of starting therapy also varied widely by country and
18 condition, with the UK and Taiwan more likely to use tricyclic antidepressants for persons with a diagnosis
19 of chronic pain whereas selective serotonin reuptake inhibitors were the most common choice for both
20 depression and pain in North American settings. Overall treatment duration was longer for patients with
21 depression than chronic pain, mean treatment doses were higher, and there were more likely to be
22 changes in therapy.
23
24
25
26
27

28
29 Differences in the incidence of antidepressant use in different countries as well as the choice of
30 antidepressant therapy may also be influenced by a variety of system-related factors. For example, direct
31 to consumer advertising of prescription drugs is permitted in the USA but banned in Canada, Europe, and
32 the UK because these ads drive demand for specific treatments[33]. Also, drugs available and covered by
33 public insurance plans in the UK, Taiwan and Canada are influenced by rigorous reviews and guidelines
34 for the use of new drugs and technologies by national agencies such as the National Institute for Health
35 and Care Excellence in the United Kingdom[34-36].
36
37
38

39 A surprisingly large percentage of older adults were prescribed antidepressants for conditions other than
40 depression. We found that chronic pain was the most common problem documented and it appeared to
41 be the most likely reason for antidepressant use. Chronic pain has an estimated prevalence of 11.8%[37]
42 to 43.5%[38] in adults, and increases with age, with an estimated 62% of those 75 years of age or older
43 experiencing this problem[38]. While use of antidepressants for chronic pain has been shown to be
44 effective, particularly tricyclic antidepressants (amitriptyline) and serotonin noradrenalin reuptake
45 inhibitors (duloxetine) for neurogenic pain[39 40], tricyclic antidepressants have been on the lists of
46 potentially contraindicated medications for the elderly for over a decade because of their potent anti-
47 cholinergic effects that can lead to cognitive impairment, and other avoidable morbidity[41 42].
48 Moreover, only one antidepressant, duloxetine has been approved for treatment of chronic pain in North
49 America and Europe[11]. Although the anticholinergic effects of tricyclic antidepressants have been well
50 documented[43-45], the actual “real-world” evidence of harm is limited[46], and should be addressed in
51 future studies given the high rates of use.
52
53
54
55
56
57
58
59
60

1
2
3 Notably, in this study of older adults, depression was documented in only two in ten users; the exception
4 being in Quebec City/Montreal where four out of ten patients were prescribed antidepressants for
5 depression. There are known problems in under-reporting, diagnosis and documentation of
6 depression[47-49], which may account for some or all of these differences between sites. The MOXXI
7 system used in the Quebec cohort likely provides an approximate estimate of the extent to which
8 depression is undocumented. In this cohort, physicians are required to document the treatment indication
9 for each drug prescribed[50], data that has been validated in prior studies[51]. Results from this setting
10 suggest that twice as many patients receive antidepressants for depression, whereas a similar proportion
11 of new antidepressant users had a diagnosis of chronic pain as in other sites.
12
13
14
15

16 Also, of interest, among patients with documented depression, antidepressant use in all countries
17 followed current guidelines for depression management[21 24 52 53]. Choice of first-line therapy was
18 predominantly selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors.
19 Starting doses were lower than the recommended adult doses, mean duration of treatment was 251-525
20 days, and the main changes in treatment were increases in doses and the addition of an antidepressant
21 from a different therapeutic class. Not surprisingly, among patients where there was a change in
22 treatment, both the average antidepressant dose was higher and treatment duration was longer,
23 suggesting a lack of treatment effectiveness. The cohort in Taiwan was different in a number of respects
24 including lower antidepressant doses, shorter treatment duration, and fewer changes in therapy once
25 started. The reason for these differences in approach is not clear. They may represent an innate
26 conservatism in the use of antidepressants in the Taiwanese population where there is an acknowledged
27 absence of evidence to support clinical guidelines[53], or known differences in genetic determinants of
28 drug metabolism that have been established in population-based genomic studies of drug
29 metabolism[54].
30
31
32
33
34

35 This study has several limitations to consider in the interpretation of results. Efforts were made to
36 harmonize data from different sources and countries, however both measurement and reporting issues
37 may lead to arbitrary differences between regions and countries. With the exception of the Quebec
38 cohort, treatment indication is unknown. Documentation of health problems in medical services billing
39 data and EMRs was used as a proxy for treatment indication, which based on past studies has a predictive
40 value of 7.8 – 80.3%[55]. The resulting misclassification will attenuate differences observed in treatment
41 approach between conditions. Moreover, diagnoses of health problems tend to be under-reported in
42 administrative data. Prescription data was used in the three jurisdictions and may overestimate the
43 incidence and prevalence of anti-depressant use as approximately 37% of antidepressant prescriptions
44 are not filled[56]. The Ontario, Montreal, and Taiwan cohorts represented total populations or
45 representative samples, the UK, Quebec, and USA cohorts were assembled on the basis of practices
46 supported by specific information technology systems. The trends observed in these more selected
47 populations however are similar to those reported for antidepressant use in older adults in these
48 countries[6 57-62].
49
50
51
52
53

54 In conclusion, antidepressant use in older adults varies up to 24-fold by country (cumulative incidence
55 from 0.7% to 17.0%), and chronic pain appears to be the most common treatment indication in all
56
57

1
2
3 jurisdictions, even more so than depression. Evaluation of real-world risks and benefits of antidepressants
4 by treatment indication should be a priority for future research. The relative contraindication of tricyclic
5 antidepressants in older adults because of their potent anticholinergic effects needs to be assessed given
6 their high rate of use, and proven efficacy in pain management[39-42].
7
8

9
10 **Funding:** This project was funded by the Canadian Institutes of Health Research (CIHR) operating grant #
11 MOP-111166.
12

13 **Ethical Approval:** This study received ethics approval from the McGill University Institutional Review
14 Board (IRB # A01-B02-02A), the Institute for Clinical Evaluative Sciences, the Partners Human Research
15 Committee IRB (Protocol # 2011P000773/PH), and the Independent Scientific Advisory Committee (ISAC)
16 of CPRD (Protocol # 14_081R).
17
18

19 **Transparency Declaration:** The lead author, Dr. Robyn Tamblyn, affirms that this manuscript is an honest,
20 accurate, and transparent account of the study being reported; that no important aspects of the study
21 have been omitted and that any discrepancies from the study as planned have been explained.
22
23

24 **Competing interests:** None to disclose
25
26

27 **Data sharing:** No additional data available
28

29 **Contributors:** RT, DWB, DLB, WGD, AJF, JSH, and JL contributed to the study concept and design. NG, TS,
30 and BH contributed to the statistical analysis. RT drafted the manuscript. DWB, DLB, WGD, AJF, NG, JSH,
31 BH, SK, JL, and TS critically reviewed the manuscript for intellectual content. All authors read and approved
32 the final manuscript.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference List

1. WHO. Depression. In: Organization WH, ed., 2017.
2. OECD. Health at a Glance 2015: OECD indicators. OECD Indicators, OECD Publishing, Paris. DOI: https://doi.org/10.1787/health_glance-2015-en. Accessed February, 2015:217.
3. Chee KY, Tripathi A, Avasthi A, et al. International study on antidepressant prescription pattern at 40 major psychiatric institutions and hospitals in Asia: A 10-year comparison study. *Asia Pac Psychiatry* 2015;**7**(4):366-74 doi: 10.1111/appy.12176[published Online First: Epub Date]].
4. Burton C, Anderson N, Wilde K, Simpson CR. Factors associated with duration of new antidepressant treatment: analysis of a large primary care database. *Br J Gen Pract* 2012;**62**(595):e104-12 doi: 10.3399/bjgp12X625166[published Online First: Epub Date]].
5. Rotermann M, Sanmartin C, Hennessy D, Arthur M. Prescription medication use by Canadians aged 6 to 79. *Health Rep* 2014;**25**(6):3-9
6. Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005-2008. *NCHS Data Brief* 2011(76):1-8
7. Zhong W, Kremers HM, Yawn BP, et al. Time trends of antidepressant drug prescriptions in men versus women in a geographically defined US population. *Arch Womens Ment Health* 2014;**17**(6):485-92 doi: 10.1007/s00737-014-0450-7[published Online First: Epub Date]].
8. Ivanova JI, Bienfait-Beuzon C, Birnbaum HG, Connolly C, Emani S, Sheehy M. Physicians' decisions to prescribe antidepressant therapy in older patients with depression in a US managed care plan. *Drugs Aging* 2011;**28**(1):51-62 doi: 10.2165/11539900-000000000-00000[published Online First: Epub Date]].
9. Singh R, Mazi-Kotwal N, Thalitaya MD. Recognising and Treating Depression in the Elderly. *Psychiatr Danub* 2015;**27** **Suppl 1**:S231-4
10. PHSA. Chronic disease multi-morbidity. How healthy are Canadians? A Trend analysis of the health of Canadians from a healthy living and chronic disease perspective.: Public Health Agency of Canada, 2014:23-24.
11. Wong J, Motulsky A, Abrahamowicz M, Egale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. *BMJ* 2017;**356**:j603 doi: 10.1136/bmj.j603[published Online First: Epub Date]].
12. Wong J, Motulsky A, Egale T, Buckeridge DL, Abrahamowicz M, Tamblyn R. Treatment indications for antidepressants prescribed in primary care in quebec, canada, 2006-2015. *JAMA* 2016;**315**(20):2230-32 doi: 10.1001/jama.2016.3445[published Online First: Epub Date]].
13. Egale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. *Archives of internal medicine* 2012;**172**(10):781-8 doi: 10.1001/archinternmed.2012.340[published Online First: Epub Date]].
14. Chen H, Reeves JH, Fincham JE, Kennedy WK, Dorfman JH, Martin BC. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia medicaid enrollees in 2001. *The Journal of clinical psychiatry* 2006;**67**(6):972-82
15. Mojtabai R, Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. *Health Aff (Millwood)* 2011;**30**(8):1434-42 doi: 10.1377/hlthaff.2010.1024[published Online First: Epub Date]].
16. Mojtabai R. Diagnosing depression in older adults in primary care. *N Engl J Med* 2014;**370**(13):1180-2 doi: 10.1056/NEJMp1311047[published Online First: Epub Date]].
17. Wang CY, Fu SH, Wang CL, Chen PJ, Wu FL, Hsiao FY. Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study. *Osteoporos Int* 2016;**27**(1):57-63 doi: 10.1007/s00198-015-3213-z[published Online First: Epub Date]].
18. Moura C, Bernatsky S, Abrahamowicz M, et al. Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). *Osteoporos Int* 2014;**25**(5):1473-81 doi: 10.1007/s00198-014-2649-x[published Online First: Epub Date]].

19. Orriols L, Wilchesky M, Lagarde E, Suissa S. Prescription of antidepressants and the risk of road traffic crash in the elderly: a case-crossover study. *Br J Clin Pharmacol* 2013;**76**(5):810-5 doi: 10.1111/bcp.12090[published Online First: Epub Date]].
20. McIntyre RS, Suppes T, Tandon R, Ostacher M. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder. *The Journal of clinical psychiatry* 2017;**78**(6):703-13 doi: 10.4088/JCP.16cs10885[published Online First: Epub Date]].
21. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. *Can J Psychiatry* 2016;**61**(9):540-60 doi: 10.1177/0706743716659417[published Online First: Epub Date]].
22. APA. The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults. Third ed: American Psychiatric Association, 2016:170.
23. Mulsant BH, Blumberger DM, Ismail Z, Rabheru K, Rapoport MJ. A systematic approach to pharmacotherapy for geriatric major depression. *Clin Geriatr Med* 2014;**30**(3):517-34 doi: 10.1016/j.cger.2014.05.002[published Online First: Epub Date]].
24. NICE. Depression in adults: recognition and management. UK: National Institute for Health and Care Excellence, 2009.
25. Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. *Journal of affective disorders* 2009;**117** Suppl 1:S1-2 doi: 10.1016/j.jad.2009.06.043[published Online First: Epub Date]].
26. Parikh SV, Segal ZV, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. *Journal of affective disorders* 2009;**117** Suppl 1:S15-25 doi: 10.1016/j.jad.2009.06.042[published Online First: Epub Date]].
27. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. *Journal of affective disorders* 2009;**117** Suppl 1:S26-43 doi: 10.1016/j.jad.2009.06.041[published Online First: Epub Date]].
28. Tamblyn R, Girard N, Dixon WG, et al. Pharmacosurveillance without borders: electronic health records in different countries can be used to address important methodological issues in estimating the risk of adverse events. *Journal of clinical epidemiology* 2016;**77**:101-11 doi: 10.1016/j.jclinepi.2016.03.033[published Online First: Epub Date]].
29. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). *International Journal of Epidemiology* 2015;**44**(3):827-36 doi: 10.1093/ije/dyv098[published Online First: Epub Date]].
30. Lacasse A, Ware MA, Dorais M, Lanctot H, Choiniere M. Is the Quebec provincial administrative database a valid source for research on chronic non-cancer pain? *Pharmacoepidemiology and drug safety* 2015;**24**(9):980-90 doi: 10.1002/pds.3820[published Online First: Epub Date]].
31. ATC: Structure and Principles. Secondary ATC: Structure and Principles 2018-02-05. https://www.whocc.no/atc/structure_and_principles/.
32. Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? *Occupational and environmental medicine* 1998;**55**(4):272-7
33. Magrini N, Font M. Direct to consumer advertising of drugs in Europe. *BMJ* 2007;**335**(7619):526-26 doi: 10.1136/bmj.39310.506308.AD[published Online First: Epub Date]].
34. The development and updating of local formularies, NICE good practice guidance: National Institute for Health and Clinical Excellence (NICE), 2012.
35. Technology appraisal guidance. Secondary Technology appraisal guidance. <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance>.
36. CADTH Common Drug Review (CDR). Secondary CADTH Common Drug Review (CDR). <https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr>.
37. Mansfield KE, Sim J, Jordan JL, Jordan KP. A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. *Pain* 2016;**157**(1):55-64 doi: 10.1097/j.pain.0000000000000314[published Online First: Epub Date]].

- 1
- 2 38. Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and
3 meta-analysis of population studies. *BMJ Open* 2016;**6**(6) doi: 10.1136/bmjopen-2015-010364[published Online
4 First: Epub Date]].
- 5 39. Fennema J, Petrykiv S, de Jonge L, Arts M. Efficacy and safety of antidepressants as analgesics in chronic pain: A
6 review. *European Psychiatry* 2017;**41**:S234 doi: <https://doi.org/10.1016/j.eurpsy.2017.01.2248>[published
7 Online
8 First: Epub Date]].
- 9 40. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and
10 meta-analysis. *The Lancet Neurology* 2015;**14**(2):162-73 doi: 10.1016/S1474-4422(14)70251-0[published Online
11 First: Epub Date]].
- 12 41. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially
13 inappropriate prescribing in older people: version 2. *Age and ageing* 2015;**44**(2):213-8 doi:
14 10.1093/ageing/afu145[published Online First: Epub Date]].
- 15 42. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.
16 *J Am Geriatr Soc* 2015;**63**(11):2227-46 doi: 10.1111/jgs.13702[published Online First: Epub Date]].
- 17 43. Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. *J*
18 *Am Geriatr Soc* 2008;**56**(7):1333-41 doi: 10.1111/j.1532-5415.2008.01737.x[published Online First: Epub Date]].
- 19 44. Pollock BG, Mulsant BH, Nebes R, et al. Serum anticholinergic activity in elderly depressed patients treated with paroxetine
20 or nortriptyline. *The American journal of psychiatry* 1998;**155**(8):1110-2 doi: 10.1176/ajp.155.8.1110[published
21 Online First: Epub Date]].
- 22 45. Duran CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. *European*
23 *journal of clinical pharmacology* 2013;**69**(7):1485-96 doi: 10.1007/s00228-013-1499-3[published Online First: Epub
24 Date]].
- 25 46. Collamati A, Martone AM, Poscia A, et al. Anticholinergic drugs and negative outcomes in the older population: from
26 biological plausibility to clinical evidence. *Aging clinical and experimental research* 2016;**28**(1):25-35 doi:
27 10.1007/s40520-015-0359-7[published Online First: Epub Date]].
- 28 47. Bharadwaj P, Pai MM, Suziedelyte A. Mental health stigma. *Economics Letters* 2017;**159**:57-60 doi:
29 <https://doi.org/10.1016/j.econlet.2017.06.028>[published
30 Online First: Epub Date]].
- 31 48. Hunt M, Auriemma J, Cashaw ACA. Self-Report Bias and Underreporting of Depression on the BDI-II. *Journal of*
32 *Personality Assessment* 2003;**80**(1):26-30 doi: 10.1207/S15327752JPA8001_10[published Online First: Epub
33 Date]].
- 34 49. Cepoiu M, McCusker J, Cole MG, Sewitch M, Belzile E, Ciampi A. Recognition of Depression by Non-psychiatric
35 Physicians—A Systematic Literature Review and Meta-analysis. *Journal of General Internal Medicine*
36 2008;**23**(1):25-36 doi: 10.1007/s11606-007-0428-5[published Online First: Epub Date]].
- 37 50. Tamblyn R, Huang A, Kawasumi Y, et al. The Development and Evaluation of an Integrated Electronic Prescribing and
38 Drug Management System for Primary Care. *Journal of the American Medical Informatics Association*
39 2006;**13**(2):148-59 doi: 10.1197/jamia.M1887[published Online First: Epub Date]].
- 40 51. Eguale T, Winslade N, Hanley JA, Buckeridge DL, Tamblyn R. Enhancing Pharmacosurveillance with Systematic
41 Collection of Treatment Indication in Electronic Prescribing. *Drug Safety* 2010;**33**(7):559-67 doi:
42 10.2165/11534580-000000000-00000[published Online First: Epub Date]].
- 43 52. Gelenberg AJF, M. P.; Markowitz, J. C.; Rosenbaum, J. F.; Thase, M. E.; Trivedi, M. H.; Van Rhoads, R. S. Practice
44 Guideline for the Treatment of Patients with Major Depressive Disorder: American Psychiatric Association, 2010.
- 45 53. Treuer T, Liu CY, Salazar G, et al. Use of antidepressants in the treatment of depression in Asia: guidelines, clinical
46 evidence, and experience revisited. *Asia Pac Psychiatry* 2013;**5**(4):219-30 doi: 10.1111/appy.12090[published
47 Online First: Epub Date]].
- 48 54. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of
49 allelic variations to the phenotype of drug response. *Molecular Psychiatry* 2004;**9**:442 doi:
50 10.1038/sj.mp.4001494[published Online First: Epub Date]].
- 51 55. Jenna W, Michal A, L. BD, Robyn T. Assessing the accuracy of using diagnostic codes from administrative data to infer
52 antidepressant treatment indications: a validation study. *Pharmacoepidemiology and drug safety*; **0**(0) doi:
53 doi:10.1002/pds.4436[published Online First: Epub Date]].
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2 56. Tamblyn R, Egualé T, Huang A, Winslade N, Doran P. The Incidence and Determinants of Primary Nonadherence With
3 Prescribed Medication in Primary Care: A Cohort Study Primary Nonadherence With Prescribed Medication in
4 Primary Care. *Annals of Internal Medicine* 2014;**160**(7):441-50 doi: 10.7326/M13-1705 %J *Annals of Internal*
5 *Medicine*[published Online First: Epub Date]].
- 6 57. Gobert M, D'hoore W. Prevalence of psychotropic drug use in nursing homes for the aged in Quebec and in the
7 French-speaking area of Switzerland. *International Journal of Geriatric Psychiatry* 2005;**20**(8):712-21 doi:
8 doi:10.1002/gps.1349[published Online First: Epub Date]].
- 9 58. Beck CA, Williams JV, Wang JL, et al. Psychotropic Medication Use in Canada. *The Canadian Journal of Psychiatry*
10 2005;**50**(10):605-13 doi: 10.1177/070674370505001006[published Online First: Epub Date]].
- 11 59. Beck CA, Patten SB, Williams JVA, et al. Antidepressant utilization in Canada. *Social Psychiatry and Psychiatric*
12 *Epidemiology* 2005;**40**(10):799 doi: 10.1007/s00127-005-0968-0[published Online First: Epub Date]].
- 13 60. Lewer D, O'Reilly C, Mojtabai R, Evans-Lacko S. Antidepressant use in 27 European countries: Associations with
14 sociodemographic, cultural and economic factors. *British Journal of Psychiatry* 2018;**207**(3):221-26 doi:
15 10.1192/bjp.bp.114.156786[published Online First: Epub Date]].
- 16 61. Petty DR, House A, Knapp P, Raynor T, Zermansky A. Prevalence, duration and indications for prescribing of
17 antidepressants in primary care. *Age and ageing* 2006;**35**(5):523-26 doi: 10.1093/ageing/af023[published Online
18 First: Epub Date]].
- 19 62. Mark TL, Joish VN, Hay JW, Sheehan DV, Johnston SS, Cao Z. Antidepressant Use in Geriatric Populations: The Burden
20 of Side Effects and Interactions and Their Impact on Adherence and Costs. *The American Journal of Geriatric*
21 *Psychiatry* 2011;**19**(3):211-21 doi: <https://doi.org/10.1097/JGP.0b013e3181f1803d>[published
22 Online First: Epub
23 Date]].
- 24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Summary of Depression Guidelines

	US – APA guidelines (2010)	UK – NICE guidelines (2009)	Canada – CANMAT (2009)	Taiwan - Taiwan Association Against Depression (2012)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	<p>First line treatment</p> <p>Antidepressant medications for patients with mild, moderate, or severe MDD, especially patients with a history of prior positive response, moderate to severe symptoms, significant sleep or appetite disturbances, agitation, patient preference, etc.</p> <p><u>Psychotherapy</u> for patients with mild/moderate MDD, especially in the presence of significant psychosocial stressors, intrapsychic conflict, interpersonal difficulties, a co-occurring Axis II disorder, treatment availability, or patient preference.</p> <p>The <u>combination of psychotherapy and antidepressant medication</u> for patients with moderate to severe MDD, as well as in milder cases for patients with psychosocial or interpersonal problems, intrapsychic conflict, or co-occurring Axis II disorder.</p>	<p>For patients with persistent subthreshold depressive symptoms or mild to moderate depression, first-line treatment is <u>low-intensity psychosocial interventions</u>. Antidepressants should only be considered for patients with a past history of moderate or severe depression, initial presentation of symptoms that have been present for a long period (at least 2 years), or subthreshold depressive symptoms or mild depression that persists after other interventions.</p> <p>For patients with persistent subthreshold depressive symptoms or mild to moderate depression with inadequate response to initial interventions, an <u>antidepressant or a high-intensity psychological intervention</u> should be considered.</p> <p>For patients with moderate or severe depression, a <u>combination of antidepressant medication and a high-intensity psychological intervention</u> should be provided.</p>	<p>Second-generation antidepressants are first line treatments for patients with a major depressive episode of moderate or greater severity.</p> <p>First line treatments for individuals with depression of mild severity include <u>cognitive behavioral therapy (CBT) and interpersonal therapy (IPT)</u>.</p> <p><u>Psychotherapy</u> should be considered for patients with treatment-resistant depression.</p>	<p><u>Pharmacotherapy (preferred) or psychotherapy</u></p>
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	<p>Pharmacotherapy first-line treatment</p> <p>Antidepressant selection should be based on the tolerability, safety, and cost of the medication, as well as patient preference and history of prior medication treatment.</p> <p>SSRIs, SNRIs, mirtazapine, and bupropion are optimal for most patients.</p> <p>MAOIs are limited to patients who do not respond to other treatments.</p>	<p>Prescribed antidepressant should normally be an SSRI in a generic form.</p> <p>When prescribing drugs other than SSRIs, the following should be considered:</p> <ul style="list-style-type: none"> • The increased likelihood of the person stopping treatment because of side effects (and the consequent need to increase the dose gradually) with venlafaxine, duloxetine and TCAs. • The specific cautions, contraindications, and monitoring requirements for some drugs • Non-reversible MAOIs, such as phenelzine, should normally be prescribed only by specialist mental health professionals. • Dosulepin should not be prescribed 	<p>Choice of antidepressant should be based on patient factors (clinical features, patient preference, etc.) and medication factors (drug-drug interactions, cost, availability, efficacy and tolerability, etc.)</p> <p>First-line treatments include SSRIs, SNRIs, agomelatine, bupropion, mirtazapine, mianserin and vortioxetine.</p> <p>Second-line treatments include TCAs, quetiapine and trazodone, moclobemide and selegiline, levomilnacipran, and vilazodone.</p> <p>Third-line treatments include MAOIs and reboxetine.</p>	<p>SSRIs, SNRIs, or any one of the newer antidepressive agents except MAOIs.</p>

Table 2 Comparisons in the Cumulative Incidence and Prevalence of Episodes of Antidepressant Use in Adults 65 Years of Age or Older Between Regions and Countries

Elderly Population	Canada			United States	United Kingdom	Taiwan
	Ontario Sample (Admin. Data) ^{1,3}	Montreal Sample (Admin. Data) ^{1,3}	Quebec City & Mtl (EMR Data) ²	Boston (EMR Data) ²	CPRD Sample (EMR Data) ^{2,3}	NHIRDB (Admin. Data) ¹
Total Population Elderly	405,141	120,777	28,273	83,394	241,339	103,400
All Users of Antidepressants⁵						
Number of Users	108,577	23,422	4,450	17,359	24,858	24,239
Prevalence in Elderly (%)	26.8%	19.4%	15.7%	20.8%	10.3%	23.4%
New Episodes of Antidepressant Use⁴						
Number of New Users	60,366	13,303	1,308	10,131	15,868	17,580
Incidence in Elderly (%)	14.9%	11.0%	4.6%	12.2%	6.6%	17.0%
Age Standardized Incidence (%)	15.3%	12.1%	4.7%	12.3%	6.6% (reference)	18.6%
Sex Standardized Incidence (%)	14.9%	11.0%	4.6%	12.1%	6.6% (reference)	17.0%
Demographics						
Between 65 – 74 years old	32,115 (53.2%)	5,713 (42.9%)	699 (53.4%)	5,826 (57.5%)	7,129 (44.9%)	8,811 (50.1%)
75 years or older	28,251 (46.8%)	7,590 (57.1%)	609 (46.6%)	4,305 (42.5%)	8,739 (55.1%)	8,769 (49.9%)
% Female	36,884 (61.1%)	8,986 (67.5%)	853 (65.2%)	6,136 (60.6%)	10,045 (63.3%)	9,539 (54.3%)

¹Administrative data is retrieved from population-based health insurance claims for medical visits, and prescriptions.

²EMR data are extracted from primary care clinic electronic health records in the USA (Partners Inc.), Quebec (MOXXI), and the United Kingdom (Clinical Practice Research Database)

³Ontario represents a 20% random sample of elderly, Montreal represents a 25% annual random sample of Montreal residents, and the United Kingdom is a 10% random sample of elderly in the CPRD

⁴New Episodes of Use of Antidepressants were defined as no prescription or dispensing of an antidepressant in the two years prior to the first antidepressant in the period 2009-2014

⁵All users include persons with an active prescription or dispensed supply of antidepressants between 2007-2008 as well as all new users between the period 2009-2014

Table 3 Frequency Distribution of the First Antidepressant Prescribed for New Antidepressant Users by Therapeutic Class by Country and Jurisdiction

Antidepressant	Canada			United States	United Kingdom	Taiwan
	Ontario Sample	Montreal Sample	Quebec City & Mtl	Boston	CPRD	NHIRDB
	(N=60,366 patients N=61,696 Rx)	(N=13,303 patients N=14,217 Rx)	(N=1,308 patients N=1,324 Rx)	(N=10,131 patients N=10,586 Rx)	(N=15,868 patients N=15,970 Rx)	(N=17,580 patients N=17,790 Rx)
	N Rx (%)	N Rx (%)	N Rx (%)	N Rx (%)	N Rx (%)	N Rx (%)
Selective Serotonin Reuptake Inhibitors						
Citalopram	8,760 (14.2%)	4,708 (33.1%)	410 (30.9%)	2,117 (19.9%)	4,232 (26.4%)	335 (1.8%)
Escitalopram	9,000 (14.6%)	1 (0.0%)	73 (5.5%)	438 (4.1%)	145 (0.9%)	825 (4.6%)
Fluoxetine	697 (1.1%)	114 (0.8%)	8 (0.6%)	1,156 (10.9%)	876 (5.4%)	773 (4.3%)
Fluvoxamine	172 (0.3%)	44 (0.3%)	6 (0.4%)	29 (0.2%)	1 (0.0%)	101 (0.5%)
Paroxetine	1,924 (3.1%)	515 (3.6%)	23 (1.7%)	432 (4.0%)	92 (0.5%)	435 (2.4%)
Sertraline	2,561 (4.2%)	640 (4.5%)	132 (20.2%)	1,481 (13.9%)	990 (6.1%)	1,174 (32.2%)
Subtotal	23,114 (37.4%)	6,022 (42.3%)	652 (49.2%)	5,653 (53.3%)	6,336 (39.6%)	3,643 (20.4%)
Selective Noradrenaline Reuptake Inhibitors						
Desvenlafaxine	0 (0.0%)	1 (0.0%)	4 (0.3%)	28 (0.2%)	-	-
Duloxetine	3,190 (5.2%)	161 (1.1%)	57 (4.3%)	267 (2.5%)	156 (0.9%)	241 (1.3%)
Milnacipran	0 (0.0%)	-	-	2 (0.0%)	-	18 (0.1%)
Venlafaxine	3,323 (5.4%)	1,514 (10.6%)	105 (7.9%)	434 (4.0%)	144 (0.8%)	206 (1.1%)
Subtotal	6,513 (10.5%)	1,676 (11.7%)	166 (12.5%)	731 (6.9%)	290 (1.8%)	465 (2.6%)
Tricyclic Antidepressants						
Amitriptyline	10,448 (16.9%)	2,629 (18.4%)	120 (9.0%)	796 (7.5%)	7,255 (45.4%)	1,181 (6.6%)
Dosulepin	-	-	-	-	177 (1.1%)	25 (0.2%)
Imipramine	-	-	-	32 (0.3%)	54 (0.3%)	7,340 (41.2%)
Nortriptyline	3,158 (5.1%)	95 (0.6%)	18 (1.3%)	566 (5.3%)	208 (1.3%)	-
Other TCAs	1,860 (12.0%)	263 (1.8%)	24 (1.8%)	117 (1.1%)	113 (0.7%)	778 (4.4%)
Subtotal	15,466 (25.0%)	2,987 (21.0%)	162 (12.2%)	1,511 (14.2%)	7,807 (48.8%)	9,324 (52.4%)
Serotonin Antagonist & Reuptake Inhibitors						
Trazodone	12,373 (20.1%)	2,362 (16.6%)	192 (14.5%)	1,279 (12.0%)	360 (2.2%)	3,574 (20.0%)
Norepinephrine-Dopamine Reuptake Inhibitors						
Bupropion	1,406 (2.3%)	278 (1.9%)	49 (3.7%)	1,056 (9.9%)	34 (0.2%)	215 (1.2%)
Noradrenergic Serotonin Specific Antidepressants						
Mirtazapine	2,819 (4.6%)	892 (6.2%)	103 (7.7%)	354 (3.3%)	1,141 (7.1%)	535 (3.0%)
Subtotal	16,598 (26.9%)	3,532 (24.8%)	344 (26.0%)	2,689 (25.4%)	1,535 (9.6%)	4,324 (24.3%)
Other Antidepressants	5 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.0%)	2 (0.0%)	34 (0.2%)

1. Other tricyclic antidepressants include Amoxapine, Clomipramine, Desipramine, Doxepin, Lofepramine, and Trimipramine

2. Other antidepressants include Nefazodone, Maprotiline, Agomelatine, and Roboxetine

Table 4 The Prevalence of Potential Therapeutic Indications; Depression, Other Mental Health Problems, and Chronic Pain Among New Antidepressant Users, and the Proportion of Persons with Depression who had Other Concurrent Mental Health Problems or Pain by Jurisdiction

	Canada			USA	United Kingdom	Taiwan
	Ontario Sample (N=60,366 patients)	Montreal Sample (N=13,303 patients)	Quebec City & Mtl (N=1,308 patients)	Boston (N=10,131 patients)	CPRD (N=15,868 patients)	NHIRDB (N=17,580 patients)
Depression						
Prevalence, N (%)	7,484 (12.4%)	2333 (17.5%)	563 (43.0%)	2203 (21.7%)	2478 (15.6%)	1603 (9.1%)
Alcohol/Drug Abuse						
Prevalence, N (%)	1989 (3.3%)	326 (2.5%)	23 (1.8%)	290 (2.9%)	4188 (26.4%)	224 (1.3%)
Abuse in Depressed, N (%)	450 (6.0%)	97 (4.2%)	12 (2.1%)	194 (8.8%)	795 (32.1%)	25 (1.6%)
Prevalence Ratio	2.1	2.0	1.4	7.3	1.3	1.3
Anxiety						
Prevalence, N (%)	23374 (38.7%)	3641 (27.4%)	465 (35.6%)	1798 (17.7%)	1914 (12.1%)	6277 (35.7%)
Anxiety in Depressed, N (%)	3684 (49.2%)	807 (34.6%)	218 (38.7%)	905 (41.1%)	588 (23.7%)	767 (47.8%)
Prevalence Ratio	1.3	1.3	1.2	3.6	2.4	1.4
Major Mental Illness						
Prevalence, N (%)	2627 (4.4%)	692 (5.2%)	50 (3.8%)	502 (5.0%)	253 (1.6%)	570 (3.2%)
Mental Ill. In Depressed, N (%)	1473 (19.7%)	225 (9.6%)	23 (4.1%)	323 (14.7%)	79 (3.2%)	95 (5.9%)
Prevalence Ratio	9.0	2.3	1.1	6.5	2.5	2.0
Suicide Attempt						
Prevalence, N (%)	101 (0.2%)	30 (0.2%)	-	72 (0.7%)	129 (0.8%)	6 (0.0%)
Suicide Att. in Depressed, N (%)	80 (1.1%)	8 (0.3%)	-	67 (3.0%)	67 (2.7%)	2 (0.1%)
Prevalence Ratio	26.9	1.7	-	48.2	5.8	5.0
Chronic Pain						
Prevalence, N (%)	28687 (47.5%)	6379 (48.0%)	571 (43.7%)	5200 (51.3%)	6539 (41.2%)	11994 (68.2%)
Pain in Depressed, N (%)	3591 (48.0%)	1105 (47.4%)	235 (41.7%)	1365 (62.0%)	1021 (41.2%)	994 (62.0%)
Prevalence Ratio	1.0	1.0	0.9	1.3	1.0	0.9

Table 5 Starting Therapy for New Users of Antidepressants by Potential Therapeutic Indication by Therapeutic Class and Country

Therapeutic Class	Canada			United States	United Kingdom	Taiwan
	Ontario Sample (N=60,366 patients)	Montreal Sample (N=13,303 patients)	Quebec City & Mtl (N=1,308 patients)	Boston (N=10,131 patients)	CPRD (N=15,868 patients)	NHIRDB (N=17,580 patients)
	N Rx (%)	N Rx (%)	N Rx (%)	N Rx (%)	N Rx (%)	N Rx (%)
Starting Therapy for Persons with a Diagnosis of Depression						
Selective Serotonin Re. Inh.	4,357 (55.2%)	1,548 (59.5%)	386 (67.5%)	1,388 (59.0%)	1,797 (71.4%)	930 (55.8%)
Selective Noradrenaline Re. Inh.	1,039 (13.2%)	408 (15.7%)	72 (12.6%)	162 (6.9%)	67 (2.7%)	104 (6.2%)
Tricyclic Antidepressants	647 (8.2%)	129 (5.0%)	20 (3.5%)	179 (7.6%)	319 (12.7%)	138 (8.3%)
Serotonin Antagonist & Re. Inh.	940 (11.9%)	212 (8.2%)	32 (5.6%)	269 (11.4%)	56 (2.2%)	263 (15.8%)
Norepinephrine-Dopam Re. Inh.	321 (4.1%)	81 (3.1%)	30 (5.2%)	233 (9.9%)	1 (0.0%)	43 (2.6%)
Noradrenergic serotonin specific	590 (7.5%)	224 (8.6%)	32 (5.6%)	120 (5.1%)	277 (11.0%)	184 (11.0%)
Other	1 (0.0%)	-	-	1 (0.0%)	-	4 (0.2%)
Starting Therapy for Persons with a Diagnosis of Chronic Pain						
Selective Serotonin Re. Inh.	9,823 (33.5%)	2,643 (39.0%)	268 (46.4%)	2,481 (46.1%)	2,085 (31.8%)	2,291 (18.9%)
Selective Noradrenaline Re. Inh.	3,516 (12.0%)	762 (11.2%)	83 (14.4%)	395 (7.3%)	95 (1.5%)	315 (2.6%)
Tricyclic Antidepressants	8,771 (29.9%)	1,863 (27.5%)	100 (17.3%)	1,176 (21.8%)	3,963 (60.4%)	6,703 (55.2%)
Serotonin Antagonist & Re. Inh.	5,410 (18.5%)	1,020 (15.0%)	65 (11.3%)	703 (13.0%)	89 (1.4%)	2,353 (19.4%)
Norepinephrine-Dopam Re. Inh.	551 (1.9%)	108 (1.6%)	24 (4.2%)	424 (7.9%)	17 (0.3%)	126 (1.0%)
Noradrenergic serotonin specific	1,221 (4.2%)	386 (5.7%)	38 (6.6%)	211 (3.9%)	315 (4.8%)	330 (2.7%)
Other	3 (0.0%)	-	-	2 (0.0%)	1 (0.02%)	27 (0.2%)
Starting Therapy for Persons with a Diagnosis of Other Mental Health Problems						
Selective Serotonin Re. Inh.	13,018 (49.5%)	2,459 (53.3%)	309 (61.1%)	1,384 (61.4%)	2,565 (45.1%)	2,212 (32.3%)
Selective Noradrenaline Re. Inh.	3,099 (11.8%)	550 (11.9%)	61 (12.1%)	147 (6.5%)	105 (1.9%)	254 (3.7%)
Tricyclic Antidepressants	3,823 (14.5%)	563 (12.2%)	28 (5.5%)	186 (8.2%)	2,518 (44.3%)	2,250 (32.8%)
Serotonin Antagonist & Re. Inh.	4,107 (15.6%)	591 (12.8%)	53 (10.5%)	280 (12.4%)	102 (1.8%)	1,684 (24.6%)
Norepinephrine-Dopam Re. Inh.	773 (2.9%)	98 (2.1%)	18 (3.6%)	163 (7.2%)	20 (0.4%)	126 (1.8%)
Noradrenergic serotonin specific	1,480 (5.6%)	357 (7.7%)	37 (7.3%)	94 (4.2%)	374 (6.6%)	318 (4.6%)
Other	3 (0.0%)	-	-	2 (0.1%)	1 (0.0%)	15 (0.2%)

Table 6A Characteristics of the First Antidepressant Treatment Episode Among Persons with a Diagnosis of Depression

Characteristics	Canada				United States		United Kingdom		Taiwan			
	Ontario		Montreal Sample		Quebec City & Mtl		Boston		CPRD		NHIRDB	
	N	%	N	%	N	%	N	%	N	%	N	%
All patients	4,407	100%	1,221	100%	324	100%	1,259	100%	2,152	100%	835	100%
No treatment change	2,383	54%	680	56%	220	68%	757	60%	1,317	61%	566	68%
Treatment change	2,024	46%	541	44%	104	32%	502	40%	835	39%	269	32%
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
All patients												
Dose*	1.3	1.0	0.9	0.6	0.9	0.5	1.3	0.8	1.0	0.5	0.7	0.4
Duration (days)	519.5	285.1	462.5	298.9	467.7	255.0	395.6	266.2	356.2	278.7	217.0	248.0
No treatment change**												
Dose	0.9	0.7	0.7	0.4	0.8	0.4	1.0	0.9	0.8	0.4	0.6	0.4
Duration (days)	289.1	309.6	246.3	290.4	340.9	243.2	225.7	212.3	192.8	239.9	104.7	179.7
Treatment change**												
Dose	1.5	1.0	1.0	0.6	1.1	0.6	1.4	0.8	1.2	0.6	0.8	0.4
Duration (days)	616.9	209.8	569.0	240.8	574.7	213.9	507.7	239.4	469.5	247.6	312.6	260.2
	N	%	N	%	N	%	N	%	N	%	N	%
Type of changes***												
Added molecule (different class)	796	18%	139	11%	31	10%	125	10%	125	6%	72	9%
Added molecule (same class)	174	4%	22	2%	6	2%	42	3%	54	3%	26	3%
Dose decrease	921	21%	246	20%	38	12%	151	12%	407	19%	105	13%
Dose increase	1,464	33%	387	32%	64	20%	348	28%	611	28%	171	20%
Removed molecule (different class)	710	16%	132	11%	26	8%	34	3%	19	1%	75	9%
Removed molecule (same class)	178	4%	23	2%	5	2%	6	0%	6	0%	28	3%
Switch class	10	0%	48	4%	-	-	56	4%	70	3%	1	0%
Switch molecule (same class)	5	0%	11	1%	-	-	19	2%	24	1%	-	-

*Dose is the proportion of the WHO recommended daily dose (dose prescribed/recommended daily dose)

**Treatment change in the first antidepressant episode, defined as continuous therapy with gaps of no greater than 90 days

***Patients can have >1 type of change in the episode of antidepressant use.

Table 6B. Characteristics of the First Antidepressant Treatment Episode Among Persons with a Diagnosis of Chronic Pain

Characteristics	Canada				United States				United Kingdom		Taiwan	
	Ontario		Montreal Sample		Quebec City & Mtl		Boston		CPRD		NHIRDB	
	N	%	N	%	N	%	N	%	N	%	N	%
All patients, all changes	16045	100%	3276	100%	349	100%	2657	100%	5360	100%	6029	100%
No treatment change	10650	66%	2220	68%	261	75%	1793	67%	4017	75%	4761	79%
Treatment change	5395	34%	1056	32%	88	25%	864	33%	1343	25%	1268	21%
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
All patients, all changes												
Dose*	0.9	0.7	0.7	0.5	0.8	0.6	1.0	0.8	0.6	0.5	0.5	0.4
Duration (days)	416.3	312.8	407.8	313.7	437.0	263.6	384.6	261.7	257.6	270.8	168.9	227.3
No treatment change**												
Dose	0.6	0.5	0.4	0.3	0.6	0.5	0.8	0.7	0.40	0.4	0.4	0.3
Duration (days)	198.7	271.4	202.1	270.2	300.9	238.6	247.4	223.3	122.3	192	83.6	154.6
Treatment change**												
Dose	1	0.7	0.8	0.5	1.0	0.6	1.1	0.7	0.7	0.5	0.5	0.4
Duration (days)	534.6	260.5	534.7	265.1	590.0	201.5	482.2	239.6	398.0	266.9	264.4	252.8
	N	%	N	%	N	%	N	%	N	%	N	%
Type of changes***												
Added molecule (different class)	1776	11%	267	8%	30	9%	189	7%	159	3%	245	4%
Added molecule (same class)	375	2%	31	1%	5	1%	69	3%	68	1%	90	1%
Dose decrease	2291	14%	455	14%	32	9%	243	9%	629	12%	569	9%
Dose increase	3980	25%	818	25%	58	17%	611	23%	1032	19%	809	13%
Removed molecule (different class)	1547	10%	245	7%	26	7%	47	2%	14	0%	262	4%
Removed molecule (same class)	372	2%	32	1%	4	1%	6	0%	7	0%	95	2%
Switch class	30	0%	120	4%	-	-	92	3%	77	1%	15	0%
Switch molecule (same class)	22	0%	30	1%	-	-	27	1%	29	1%	4	0%

*Dose is the proportion of the WHO recommended daily dose (dose prescribed/recommended daily dose)

**Treatment change in the first antidepressant episode, defined as continuous therapy with gaps of no greater than 90 days

***Patients can have >1 type of change in the episode of antidepressant use.

APPENDIX**DEPRESSION****At least one ICD-9 in:**

- 311 Depressive disorder, not elsewhere classified
- 296.2 Major depressive disorder, single episode
- 296.3 Major depressive disorder, recurrent episode
- 309 Adjustment reaction
 - 309.0 Adjustment disorder with depressed mood
 - 309.1 Prolonged depressive reaction
 - 309.2 With predominant disturbance of other emotions
 - 309.3 Adjustment disorder with disturbance of conduct
 - 309.4 Adjustment disorder with mixed disturbance of emotions and conduct
 - 309.8 Other specified adjustment reactions
 - 309.9 Unspecified adjustment reaction

OR

At least one ICD-10 in:

- F32 Depressive episode
 - F32.0 Mild depressive episode
 - F32.1 Moderate depressive episode
 - F32.2 Severe depressive episode without psychotic symptoms
 - F32.3 Severe depressive episode with psychotic symptoms
 - F32.8 Other depressive episodes
 - F32.9 Depressive episode, unspecified
- F33 Recurrent depressive disorder
 - F33.0 Recurrent depressive disorder, current episode mild
 - F33.1 Recurrent depressive disorder, current episode moderate
 - F33.2 Recurrent depressive disorder, current episode severe without psychotic symptoms
 - F33.3 Recurrent depressive disorder, current episode severe with psychotic symptoms
 - F33.4 Recurrent depressive disorder, currently in remission
 - F33.8 Other recurrent depressive disorders
 - F33.9 Recurrent depressive disorder, unspecified
- F41.2 Mixed anxiety and depressive disorder

OR

At least one READ code in:†:

E2B..00	Depressive disorder NEC	Eu32311	[X]Single episode of major depression and psychotic symptoms
Eu32z11	[X]Depression NOS	E113400	Recurrent major depressive episodes, severe, with

1	E112.14	Endogenous depression	E113z00	psychosis
2	E200300	Anxiety with depression	E113300	Recurrent major depressive episode NOS
3				
4	E135.00	Agitated depression	E11y200	Recurrent major depressive episodes, severe, no psychosis
5	E204.00	Neurotic depression reactive type	E11y200	Atypical depressive disorder
6	E290.00	Brief depressive reaction	E001300	Presenile dementia with depression
7	2257.00	O/E - depressed	Eu02z16	[X] Senile dementia, depressed or paranoid type
8	1B17.00	Depressed	Eu32z13	[X]Prolonged single episode of reactive depression
9	E11..12	Depressive psychoses	Eu33.14	[X]Seasonal depressive disorder
10	E204.11	Postnatal depression	Eu32314	[X]Single episode of reactive depressive psychosis
11	1465.00	H/O: depression	E113100	Recurrent major depressive episodes, mild
12			Eu33100	[X]Recurrent depressive disorder, current episode moderate
13				
14	62T1.00	Puerperal depression	R007z13	[D]Postoperative depression
15	Eu32z00	[X]Depressive episode, unspecified	Eu33000	[X]Recurrent depressive disorder, current episode mild
16				
17	E2B0.00	Postviral depression	Eu33314	[X]Recurr severe episodes/psychogenic depressive psychosis
18				
19	Eu32z12	[X]Depressive disorder NOS	E112400	Single major depressive episode, severe, with psychosis
20				
21	Eu33.00	[X]Recurrent depressive disorder	Eu92000	[X]Depressive conduct disorder
22	E2B1.00	Chronic depression	Eu33313	[X]Recurr severe episodes/major depression+psychotic symptom
23				
24	Eu32.00	[X]Depressive episode	Eu33200	[X]Recurr depress disorder cur epi severe without psych sympt
25				
26	1B17.11	C/O - feeling depressed	E112000	Single major depressive episode, unspecified
27	Eu53012	[X]Postpartum depression NOS	E113000	Recurrent major depressive episodes, unspecified
28	E112.11	Agitated depression	E290z00	Brief depressive reaction NOS
29	Eu32z14	[X] Reactive depression NOS	Eu33z11	[X]Monopolar depression NOS
30	E113700	Recurrent depression	Eu33316	[X]Recurrent severe episodes/reactive depressive psychosis
31				
32	E112.12	Endogenous depression first episode	E002z00	Senile dementia with depressive or paranoid features NOS
33				
34	Eu32y00	[X]Other depressive episodes	Eu32211	[X]Single episode agitated depressn w/out psychotic symptoms
35				
36	E113.11	Endogenous depression - recurrent	E004300	Arteriosclerotic dementia with depression
37	E112.13	Endogenous depression first episode	E112500	Single major depressive episode, partial or unspec remission
38				
39	E112z00	Single major depressive episode NOS	Eu33z00	[X]Recurrent depressive disorder, unspecified
40	Eu32.13	[X]Single episode of reactive depression	E002.00	Senile dementia with depressive or paranoid features
41				
42	Eu34113	[X]Neurotic depression	E02y300	Drug-induced depressive state
43	Eu41211	[X]Mild anxiety depression	Eu33300	[X]Recurrent depress disorder cur epi severe with psych symp
44				
45	Eu34100	[X]Dysthymia	Eu33y00	[X]Other recurrent depressive disorders
46	Eu34111	[X]Depressive neurosis	Eu32312	[X]Single episode of psychogenic depressive psychosis
47				
48	Eu33.15	[X]SAD - Seasonal affective disorder	E113600	Recurrent major depressive episodes, in full remission
49				
50	Eu33.11	[X]Recurrent episodes of depressive reaction	E113500	Recurrent major depressive episodes,partial/unspec remission
51				
52	Eu33.13	[X]Recurrent episodes of reactive depression	Eu32y12	[X]Single episode of masked depression NOS
53				
54				
55				
56				
57				
58				
59				
60				

1	Eu32.11 [X]Single episode of depressive reaction	E112600 Single major depressive episode, in full remission
2	E11z200 Masked depression	Eu32213 [X]Single episode vital depression w/out psychotic symptoms
3		
4	Eu32100 [X]Moderate depressive episode	Eu33214 [X]Vital depression, recurrent without psychotic symptoms
5		
6	Eu32200 [X]Severe depressive episode without psychotic symptoms	Eu32600 [X]Major depression, moderately severe
7		
8	1B1U.00 Symptoms of depression	Eu32500 [X]Major depression, mild
9	1BT..00 Depressed mood	Eu32700 [X]Major depression, severe without psychotic symptoms
10		
11	1B1U.11 Depressive symptoms	Eu32800 [X]Major depression, severe with psychotic symptoms
12		
13	E112.00 Single major depressive episode	Eu32900 [X]Single major depr ep, severe with psych, psych in remiss
14		
15	Eu32400 [X]Mild depression	Eu32A00 [X]Recurr major depr ep, severe with psych, psych in remiss
16		
17		
18	Eu32y11 [X]Atypical depression	Eu32B00 [X]Antenatal depression
19	E118.00 Seasonal affective disorder	Eu34114 [X]Persistant anxiety depression
20	Eu33212 [X]Major depression, recurrent without psychotic symptoms	E112100 Single major depressive episode, mild
21		
22	Eu33211 [X]Endogenous depression without psychotic symptoms	E291.00 Prolonged depressive reaction
23		
24	Eu32000 [X]Mild depressive episode	Eu33315 [X]Recurrent severe episodes of psychotic depression
25		
26		
27	Eu41200 [X]Mixed anxiety and depressive disorder	Eu32.12 [X]Single episode of psychogenic depression
28		
29	Eu32300 [X]Severe depressive episode with psychotic symptoms	Eu3y111 [X]Recurrent brief depressive episodes
30		
31	Eu53011 [X]Postnatal depression NOS	Eu33.12 [X]Recurrent episodes of psychogenic depression
32	E113200 Recurrent major depressive episodes, moderate	Eu20400 [X]Post-schizophrenic depression
33		
34	E113.00 Recurrent major depressive episode	E002100 Senile dementia with depression
35	E112200 Single major depressive episode, moderate	Eu33400 [X]Recurrent depressive disorder, currently in remission
36		
37	E112300 Single major depressive episode, severe, without psychosis	Eu32212 [X]Single episode major depression w/out psychotic symptoms
38		
39	Eu32313 [X]Single episode of psychotic depression	Eu33311 [X]Endogenous depression with psychotic symptoms
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

ANXIETY**At least one ICD-9 in:**

300 Anxiety, dissociative and somatoform disorders

OR

At least one ICD-10 in:

F40 Phobic anxiety disorders
 F41 Other anxiety disorders (except F41.2)
 F42 Obsessive-compulsive disorder
 F43 Reaction to severe stress, and adjustment disorders
 F44 Dissociative and conversion disorders
 F45 Somatoform disorders
 F48 Other nonpsychotic mental disorders

OR

At least one READ code in:

1B13.00	Anxiousness	Eu42.11	[X]Anankastic neurosis
E28..00	Acute reaction to stress	Eu45213	[X]Hypochondriacal neurosis
E200111	Panic attack	Eu93100	[X]Phobic anxiety disorder of childhood
E200.00	Anxiety states	Eu45000	[X]Somatization disorder
E200300	Anxiety with depression	E201C00	Phantom pregnancy
E20z.11	Nervous breakdown	E201z12	Ataxia - hysterical
Eu41111	[X]Anxiety neurosis	E283100	Acute posttrauma stress state
E202B00	Cancer phobia	Eu41z11	[X]Anxiety NOS
E205.11	Nervous exhaustion	E28z.00	Acute stress reaction NOS
E202800	Claustrophobia	Z4I7211	Reducing anxiety
E200400	Chronic anxiety	E29y400	Adjustment reaction due to hospitalisation
E202.00	Phobic disorders	Eu44.13	[X]Hysteria
E203100	Obsessional neurosis	Eu44600	[X]Dissociative anaesthesia and sensory loss
E201.00	Hysteria	Eu40y00	[X]Other phobic anxiety disorders
E202000	Phobia unspecified	E28z.13	Stage fright
E202C00	Dental phobia	Eu46.00	[X]Other neurotic disorders
Eu40000	[X]Agoraphobia	E202600	Acrophobia
E29..00	Adjustment reaction	E28z.11	Examination fear
E264200	Cyclical vomiting - psychogenic	Eu41y11	[X]Anxiety hysteria
E202100	Agoraphobia with panic attacks	E292312	Specific work inhibition
E203.00	Obsessive-compulsive disorders	Z4I7200	Alleviating anxiety
E205.00	Neurasthenia - nervous debility	E202700	Animal phobia
1466.00	H/O: anxiety state	E201B00	Compensation neurosis
E201100	Hysterical blindness	Eu45413	[X]Psychogenic headache
E20y100	Writer's cramp neurosis	E262.00	Psychogenic cardiovascular symptoms
E264400	Psychogenic dyspepsia	E263.00	Psychogenic skin symptoms
E200100	Panic disorder	E283z00	Other acute stress reaction NOS
Eu41012	[X]Panic state	Eu93200	[X]Social anxiety disorder of childhood

1	E201z11	Aphonia - hysterical	Eu45400	[X]Persistent somatoform pain disorder
2	E201612	Globus hystericus	Eu45212	[X]Dysmorphophobia nondelusional
3	E202A0	Fear of flying	E262300	Psychogenic cardiovascular disorder
4	0			
5	Eu43100	[X]Post - traumatic stress disorder	E264.00	Psychogenic gastrointestinal tract symptoms
6	E26..00	Physiological malfunction arising from mental factors	Eu43z00	[X]Reaction to severe stress, unspecified
7				
8	E201700	Hysterical amnesia	E2D0.00	Disturbance of anxiety and fearfulness childhood/adolescent
9				
10	E200z00	Anxiety state NOS	E202900	Fear of crowds
11	E200500	Recurrent anxiety	E202400	Social phobia, fear of public speaking
12	E200200	Generalised anxiety disorder	E261000	Psychogenic air hunger
13	E201800	Hysterical fugue	Eu43111	[X]Traumatic neurosis
14	E264000	Psychogenic aerophagy	E29y100	Other post-traumatic stress disorder
15	E26z.00	Psychosomatic disorder NOS	Eu45312	[X]Da Costa's syndrome
16	E20..00	Neurotic disorders	E201511	Fit - hysterical
17	Eu42.00	[X]Obsessive - compulsive disorder	Eu40z00	[X]Phobic anxiety disorder, unspecified
18	E206.00	Depersonalisation syndrome	E261z00	Psychogenic respiratory symptom NOS
19	Eu41.00	[X]Other anxiety disorders	E201400	Hysterical paralysis
20	E203000	Compulsive neurosis	Eu45111	[X]Undifferentiated psychosomatic disorder
21	1B13.11	Anxiousness - symptom	Eu44400	[X]Dissociative motor disorders
22	E202E00	Fear of pregnancy	Eu44.11	[X]Conversion hysteria
23	E293000	Adjustment reaction with aggression	E2D0z00	Disturbance anxiety and fearfulness childhood/adolescent NOS
24				
25	E292000	Separation anxiety disorder	E2D0000	Childhood and adolescent overanxiousness disturbance
26				
27	Eu41011	[X]Panic attack	E29y200	Adjustment reaction with physical symptoms
28	E200000	Anxiety state unspecified	Eu41112	[X]Anxiety reaction
29	Eu40z11	[X]Phobia NOS	E293100	Adjustment reaction with antisocial behaviour
30	Eu45200	[X]Hypochondriacal disorder	Eu45y14	[X]Psychogenic torticollis
31	E29y300	Elective mutism due to an adjustment reaction	Eu45414	[X]Somatoform pain disorder
32				
33	Eu41211	[X]Mild anxiety depression	Eu43211	[X]Culture shock
34	Eu43015	[X]Psychic shock	Eu43011	[X]Acute crisis reaction
35	Eu41000	[X]Panic disorder [episodic paroxysmal anxiety]	E29z.00	Adjustment reaction NOS
36				
37	Eu46100	[X]Depersonalization - derealization syndrome	E264.11	Globus abdominalis
38				
39	Eu40.00	[X]Phobic anxiety disorders	E261.00	Psychogenic respiratory symptoms
40	Eu46011	[X]Fatigue syndrome	Eu45412	[X]Psychogenic backache
41	Eu40200	[X]Specific (isolated) phobias	E283.00	Other acute stress reactions
42	E202.12	Phobic anxiety	Eu42y00	[X]Other obsessive-compulsive disorders
43	Eu41100	[X]Generalized anxiety disorder	E20y200	Other occupational neurosis
44	E202D0	Fear of death	Eu44300	[X]Trance and possession disorders
45	0			
46	Eu43012	[X]Acute reaction to stress	Eu44100	[X]Dissociative fugue
47	Eu43.00	[X]Reaction to severe stress, and adjustment disorders	Eu44y12	[X]Multiple personality
48				
49	Eu40213	[X]Claustrophobia	E201z13	Ganser's syndrome - hysterical
50	Eu43200	[X]Adjustment disorders	E278.00	Psychalgia
51	Eu46y13	[X]Occupational neurosis, including writer's cramp	Eu44000	[X]Dissociative amnesia
52				
53	Eu44511	[X]Pseudoseizures	Eu45300	[X]Somatoform autonomic dysfunction
54	Eu40100	[X]Social phobias	Eu43213	[X]Hospitalism in children
55				
56				
57				
58				
59				
60				

1	Eu43000	[X]Acute stress reaction	E29y.00	Other adjustment reactions
2	146G.00	H/O: agoraphobia	E201000	Hysteria unspecified
3	1B1V.00	C/O - panic attack	E261500	Psychogenic aphonia
4	Eu41200	[X]Mixed anxiety and depressive disorder	E20y.00	Other neurotic disorders
5	E280.00	Acute panic state due to acute stress reaction	E2z..00	Neuroses or other mental disorder NOS
6				
7	Eu44411	[X]Psychogenic aphonia	E281.00	Acute fugue state due to acute stress reaction
8	Eu45500	[X]Globus pharyngeus	Eu40112	[X]Social neurosis
9	Eu40300	[X]Needle phobia	E20yz00	Other neurotic disorder NOS
10	Eu40214	[X]Simple phobia	E201900	Multiple personality
11	Eu45316	[X]Psychogenic cough	Eu45317	[X]Psychogenic diarrhoea
12	Eu45322	[X]Psychogenic hyperventilat	E28..11	Combat fatigue
13	E202200	Agoraphobia without mention of panic attacks	E260.00	Psychogenic musculoskeletal symptoms
14				
15	2258.00	O/E - anxious	Eu45311	[X]Cardiac neurosis
16	E202z00	Phobic disorder NOS	Eu41300	[X]Other mixed anxiety disorders
17	E20z.00	Neurotic disorder NOS	Eu46y00	[X]Other specified neurotic disorders
18	Eu40012	[X]Panic disorder with agoraphobia	E265200	Psychogenic dysmenorrhea
19	E262z00	Psychogenic cardiovascular symptom NOS	Eu46y16	[X]Psychogenic syncope
20	E260z00	Psychogenic musculoskeletal symptoms NOS	E201200	Hysterical deafness
21	Eu34114	[X]Persistant anxiety depression	E278200	Psychogenic backache
22	E263z00	Psychogenic skin symptoms NOS	E294.00	Adjustment reaction with disturbance emotion and conduct
23				
24	E262200	Neurocirculatory asthenia	E201611	Astasia - abasia, hysterical
25	E262000	Cardiac neurosis	Eu44y11	[X]Ganser's syndrome
26	E20y000	Somatization disorder	Eu45y11	[X]Psychogenic dysmenorrhoea
27	E264300	Psychogenic diarrhoea	E203.11	Anancastic neurosis
28	E201600	Other conversion disorder	Eu46y12	[X]Dhat syndrome
29	E261100	Psychogenic cough	Eu45320	[X]Psychogenic flatulence
30	E282.00	Acute stupor state due to acute stress reaction	E261200	Psychogenic hiccough
31				
32	E203z00	Obsessive-compulsive disorder NOS	E260000	Psychogenic paralysis
33	E292z00	Adjustment reaction with disturbance of other emotion NOS	E292y00	Adjustment reaction with mixed disturbance of emotion
34				
35	E264500	Psychogenic constipation	Eu45z00	[X]Somatoform disorder, unspecified
36	E263000	Psychogenic pruritus	Eu44z00	[X]Dissociative [conversion] disorder, unspecified
37				
38	E202300	Social phobia, fear of eating in public	Eu46z00	[X]Neurotic disorder, unspecified
39	E293.00	Adjustment reaction with predominant disturbance of conduct	E2y..00	Other specified neuroses or other mental disorders
40				
41	E201500	Hysterical seizures	Eu44611	[X]Psychogenic deafness
42	Eu45324	[X]Psychogenic IBS	Eu41113	[X]Anxiety state
43	Eu46000	[X]Neurasthenia	Eu45314	[X]Neurocirculatory asthenia
44	E202.11	Social phobic disorders	Eu44.12	[X]Conversion reaction
45	Eu45y13	[X]Psychogenic pruritis	Eu45319	[X]Psychogenic dysuria
46	Eu45318	[X]Psychogenic dyspepsia	E29y000	Concentration camp syndrome
47	Eu40011	[X]Agoraphobia without history of panic disorder	Eu45321	[X]Psychogenic hiccough
48				
49	Eu44y13	[X]Psychogenic confusion	E278000	Psychogenic pain unspecified
50	Eu45323	[X]Psychogenic freq micturit	E278z00	Psychalgia NOS
51	Eu51511	[X]Dream anxiety disorder	Eu45411	[X]Psychalgia
52	Eu93000	[X]Separation anxiety disorder of childhood	E292200	Early adult emancipation disorder
53	Eu45.00	[X]Somatoform disorders	E265300	Psychogenic dysuria
54	Eu40212	[X]Animal phobias	Eu44200	[X]Dissociative stupor
55				
56				
57				
58				
59				
60				

1	Eu42200	[X]Mixed obsessional thoughts and acts	E260100	Psychogenic torticollis
2	E202500	Social phobia, fear of public washing	E292400	Adjustment reaction with anxious mood
3	Eu44412	[X]Psychogenic dysphonia	E20y011	Briquet's disorder
4	225J.00	O/E - panic attack	Eu44500	[X]Dissociative convulsions
5	Eu45z11	[X]Psychosomatic disorder NOS	Eu45100	[X]Undifferentiated somatoform disorder
6	E29y500	Other adjustment reaction with withdrawal	E292500	Culture shock
7	E261300	Psychogenic hyperventilation	Eu45012	[X]Briquet's syndrome
8	E265100	Psychogenic vaginismus	Eu93y12	[X]Childhood overanxious disorder
9	E283000	Acute situational disturbance	Eu46y14	[X]Psychasthenia
10	Eu42000	[X]Predominantly obsessional thoughts or ruminations	Eu45y00	[X]Other somatoform disorders
11				
12	Eu05400	[X]Organic anxiety disorder	E292300	Specific academic or work inhibition
13	E28z.12	Flying phobia	E26y.00	Other psychogenic malfunction
14	Eu45y12	[X]Globus hystericus	Z4I7100	Recognising anxiety
15	Eu46z11	[X]Neurosis NOS	Eu45313	[X]Gastric neurosis
16	Eu43014	[X]Crisis state	Eu44y00	[X]Other dissociative [conversion] disorders
17	Eu43y00	[X]Other reactions to severe stress	E293200	Adjustment reaction with destructiveness
18	Eu42.12	[X]Obsessive-compulsive neurosis	Eu45215	[X]Nosophobia
19	Eu42100	[X]Predominantly compulsive acts [obsessional rituals]	E292311	Specific academic or work inhibition
20				
21	Eu44.00	[X]Dissociative [conversion] disorders	Eu40z12	[X]Phobic state NOS
22	Z4I7.00	Acknowledging anxiety	Eu40211	[X]Acrophobia
23	Eu42z00	[X]Obsessive-compulsive disorder, unspecified	Eu44y14	[X]Psychogenic twilight state
24				
25	E292100	Adolescent emancipation disorder	E265.00	Psychogenic genitourinary tract symptoms
26	E201z00	Hysteria NOS	Eu43013	[X]Combat fatigue
27	E261400	Psychogenic yawning	E264z00	Psychogenic gastrointestinal tract symptom NOS
28				
29	E29yz00	Other adjustment reactions NOS	E20y300	Psychasthenic neurosis
30	E201A0	Dissociative reaction unspecified	E265z00	Psychogenic genitourinary tract symptom NOS
31	0			
32	E201300	Hysterical tremor	Eu44700	[X]Mixed dissociative [conversion] disorders
33	Eu45011	[X]Multiple psychosomatic disorder	E267.00	Psychogenic symptom of special sense organ
34	Eu4..00	[X]Neurotic, stress - related and somoform disorders	Eu46y15	[X]Psychasthenia neurosis
35				
36	Eu41z00	[X]Anxiety disorder, unspecified	Eu45325	[X]Psychogenic pylorospasm
37	E284.00	Stress reaction causing mixed disturbance of emotion/conduct	1B13.12	Anxious
38				
39	Eu41y00	[X]Other specified anxiety disorders	E26yz00	Other psychogenic malfunction NOS
40	E292.00	Adjustment reaction, predominant disturbance other emotions	Eu45511	[X]Globus hystericus
41				
42	E293z00	Adjustment reaction with predominant disturbance conduct NOS	Eu46y11	[X]Briquet's disorder
43	Eu45013	[X]Briquet's disorder	Eu43400	[X]Chron post-traumatic stress disorder follow military comb
44			Eu43300	[X]Acute post-traumatic stress disorder follow military comb
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

MENTAL DISORDERS**At least one ICD-9 in:**

295	Schizophrenic disorders
296	Episodic mood disorders (except 296.2 & 296.3)
297	Delusional disorders
298	Other nonorganic psychoses
299	Pervasive developmental disorders
301	Personality disorders

OR

At least one ICD-10 in:

F20	Schizophrenia
F21	Schizotypal disorder
F22	Delusional disorders
F23	Brief psychotic disorder
F24	Shared psychotic disorder
F25	Schizoaffective disorders
F28	Other psychotic disorder not due to a substance or known physiological condition
F29	Unspecified psychosis not due to a substance or known physiological condition
F30	Manic episode
F31	Bipolar disorder
F34	Persistent mood [affective] disorders
F39	Unspecified mood [affective] disorder

OR

At least one READ code in:

E104.00	Acute schizophrenic episode	Eu6y100	[X]Intent product/feign of symptom/disab eith physical/psych
Eu2z.11	[X]Psychosis NOS	Eu50400	[X]Overeating associated with other psychological disturbncs
E21z.11	Psychopathic personality	Eu60711	[X]Asthenic personality disorder
E10..00	Schizophrenic disorders	E04z.00	Chronic organic psychosis NOS
E2F3z00	Speech or language developmental disorder NOS	Eu34z00	[X]Persistent mood affective disorder, unspecified
E214100	Obsessional personality	Eu6z.00	[X]Unspecified disorder of adult personality and behaviour
E21y500	Immature personality disorder	Eu10600	[X]Mental and behav dis due to use alcohol: amnesic syndrome
E103.00	Paranoid schizophrenia	E214.11	Anancastic personality
Eu31.11	[X]Manic-depressive illness	Eu60800	[X]Addictive personality
E2A1200	Change in personality	Eu53000	[X]Mild mental/behav disorder assoc with the puerperium NEC
1B1E.00	Hallucinations	Eu21.15	[X]Prodromal schizophrenia
1BH..00	Delusions	Eu53100	[X]Severe mental and behav disorder assoc wth puerperium NEC
ZV40.13	[V]Psychological problems	Eu22y11	[X]Delusional dysmorphophobia

1	E21..00	Personality disorders	Eu25112	[X]Schizophreniform psychosis, depressive type
2	Eu22011	[X]Paranoid psychosis	E141100	Residual disintegrative psychoses
3	E03y300	Unspecified puerperal psychosis	Eu13.00	[X]Mental and behavioural dis due use sedatives/hypnotics
4	E107.00	Schizo-affective schizophrenia	Eu05y00	[X]Oth sp mental disord brain damag/dysfunction/physcal disd
5			E11z.00	Other and unspecified affective psychoses
6	R001.00	[D]Hallucinations	1S04.00	C/O - illusions seen
7	E11..12	Depressive psychoses	E2z..00	Neuroses or other mental disorder NOS
8	E21y711	Neurotic personality	Eu11000	[X]Mental & behav dis due to use opioids: acute intoxication
9	Eu30000	[X]Hypomania	Eu60z00	[X]Personality disorder, unspecified
10			Eu34.00	[X]Persistent mood affective disorders
11	E00z.00	Senile or presenile psychoses NOS	E110300	Single manic episode, severe without mention of psychosis
12	Eu63300	[X]Trichotillomania	Eu15.00	[X]Mental & behav disorder due other stimulants inc caffein
13	E212.00	Schizoid personality disorder	E14..00	Psychoses with origin in childhood
14			Eu20100	[X]Hebephrenic schizophrenia
15	E11z100	Rebound mood swings	1BH0.00	Delusion of persecution
16	E2F3.00	Speech or language developmental disorder	Eu60400	[X]Histrionic personality disorder
17	E...00	Mental disorders	E107200	Chronic schizo-affective schizophrenia
18	E13z.11	Psychotic episode NOS	E215000	Unspecified histrionic personality disorder
19	E114.00	Bipolar affective disorder, currently manic	Eu10000	[X]Mental & behav dis due to use alcohol: acute intoxication
20	E215200	Emotionally unstable personality	Eu23300	[X]Other acute predominantly delusional psychotic disorders
21	E121.00	Chronic paranoid psychosis	Eu84z00	[X]Pervasive developmental disorder, unspecified
22	E100200	Chronic schizophrenic	Eu13200	[X]Mental and behav dis due to seds/hypntcs: dependence synd
23			Eu81y00	[X]Other developmental disorders of scholastic skills
24			E100400	Acute exacerbation of chronic schizophrenia
25	E12..00	Paranoid states	Eu23y00	[X]Other acute and transient psychotic disorders
26			Eu30z00	[X]Manic episode, unspecified
27	285..11	Psychotic condition, insight present	Eu8y.00	[X]Other disorders of psychological development
28	E011000	Korsakov's alcoholic psychosis	Eu31600	[X]Bipolar affective disorder, current episode mixed
29			Eu60215	[X]Sociopathic personality disorder
30	E216.00	Inadequate personality disorder	Eu19200	[X]Mental and behav dis mlti/oth psych sbs: dependence syndr
31	E115.00	Bipolar affective disorder, currently depressed	ZV40z00	[V]Unspecified mental or behavioural problem
32	Eu30z11	[X]Mania NOS	Eu0z.00	[X]Unspecified organic or symptomatic mental disorder
33	Eu31500	[X]Bipolar affect dis cur epi severe depres with psyc symp	Eu80y00	[X]Other developmental disorders of speech and language
34			E111z00	Recurrent manic episode NOS
35	E215.11	Hysterical personality disorders	E111100	Recurrent manic episodes, mild
36	Eu22015	[X]Paranoia	E114200	Bipolar affective disorder, currently manic, moderate
37	Eu10.00	[X]Mental and behavioural disorders due to use of alcohol	Eu6y200	[X]Munchausen's by proxy
38	E210.00	Paranoid personality disorder		
39			L184.00	Mental disorders in pregnancy, childbirth and the puerperium
40	Eu3..00	[X]Mood - affective disorders	Eu33300	[X]Recurrent depress disorder cur epi severe with psyc symp
41	146..00	H/O: psychiatric disorder	Eu24.12	[X] Induced paranoid disorder
42			Eu11.00	[X]Mental and behavioural disorders due to use of opioids
43	Eu80.00	[X]Specific developmental disorders of speech and language	Eu02z12	[X] Presenile psychosis NOS
44	1464.00	H/O: schizophrenia	Eu14100	[X]Mental and behav dis due to use of cocaine:
45	E213.11	Aggressive personality		
46	Eu83.00	[X]Mixed specific developmental disorders		
47	Eu80z00	[X]Developmental disorder of speech and language unspecified		
48	Eu81z00	[X]Developmental disorder of scholastic skills, unspecified		
49	Eu05y11	[X]Epileptic psychosis NOS		
50				
51	Eu31.12	[X]Manic-depressive psychosis		
52	Eu31.00	[X]Bipolar affective disorder		
53				
54	Eu84.00	[X]Pervasive developmental disorders		
55	Eu...00	Organic psychotic conditions		

1	Eu82.00	[X]Specific developmental disorder of motor function	Eu22013	harmful use [X]Paraphrenia - late
2				
3	E132.00	Reactive confusion	Eu84y00	[X]Other pervasive developmental disorders
4	Eu60300	[X]Emotionally unstable personality disorder	E101z00	Hebephrenic schizophrenia NOS
5	E10z.00	Schizophrenia NOS	Eu62000	[X]Enduring personality change after catastrophic experience
6				
7	Eu60600	[X]Anxious [avoidant] personality disorder	1S40.00	Dysphoric mood
8	E130.00	Reactive depressive psychosis	Eu06013	[X]Limbic epilepsy personality
9	E11..11	Bipolar psychoses	Eu30212	[X]Mania with mood-incongruent psychotic symptoms
10	Eu0z.12	[X]Symptomatic psychosis NOS	Eu60014	[X]Sensitive paranoid personality disorder
11	E103z00	Paranoid schizophrenia NOS	E216.11	Asthenic personality
12	Eu25.00	[X]Schizoaffective disorders	Eu66z00	[X]Psychosexual development disorder, unspecified
13	Eu30.11	[X]Bipolar disorder, single manic episode	Eu22z00	[X]Persistent delusional disorder, unspecified
14	E2...00	Neurotic, personality and other nonpsychotic disorders	Eu20y00	[X]Other schizophrenia
15				
16	Eu...00	[X]Mental and behavioural disorders	E2A..00	Nonpsychotic mental disorders following organic brain damage
17				
18	Eu34112	[X]Depressive personality disorder	Eu14500	[X]Mental & behav dis due to use cocaine: psychotic disorder
19				
20	E211200	Depressive personality disorder	Eu14000	[X]Mental & behav dis due to use cocaine: acute intoxication
21				
22	E03y000	Organic delusional syndrome	Eu60y00	[X]Other specific personality disorders
23	E107z00	Schizo-affective schizophrenia NOS	Eu60z12	[X]Pathological personality NOS
24	Eu12.00	[X]Mental and behavioural disorders due to use cannabinoids	E10yz00	Other schizophrenia NOS
25				
26	Eu19.00	[X]Men & behav disorder multiple drug use/psychoactive subst	E117000	Unspecified bipolar affective disorder, unspecified
27				
28	Ez...00	Mental disorders NOS	Eu60y13	[X]Immature personality disorder
29	Eu25100	[X]Schizoaffective disorder, depressive type	Eu21.16	[X]Pseudoneurotic schizophrenia
30	E011100	Korsakov's alcoholic psychosis with peripheral neuritis	Eu15500	[X]Mental/behav dis oth stims inc caffeine: psychotic dis
31				
32	Eu22012	[X]Paranoid state	Eu23011	[X]Bouffee delirante
33	Eu2z.00	[X]Unspecified nonorganic psychosis	Eu20011	[X]Paraphrenic schizophrenia
34	146D.00	H/O: manic depressive disorder	Eu05z00	[X]Unspec mental disorder brain damag/dysfunction/physcal dr
35				
36	E11y000	Unspecified manic-depressive psychoses	E2y..00	Other specified neuroses or other mental disorders
37	Eu10611	[X]Korsakov's psychosis, alcohol induced	Eu18000	[X]Mental & behav dis due vol solvents: acute intoxication
38				
39	Eu23200	[X]Acute schizophrenia-like psychotic disorder	Eu60.00	[X]Specific personality disorders
40	Eu24.13	[X]Induced psychotic disorder	E110400	Single manic episode, severe, with psychosis
41	R001400	[D]Visual hallucinations	Eu34y00	[X]Other persistent mood affective disorders
42	Eu32300	[X]Severe depressive episode with psychotic symptoms	Eu22y12	[X]Involuntal paranoid state
43				
44	R001000	[D]Hallucinations, auditory	Eu16.00	[X]Mental and behavioural disorders due to use hallucinogens
45				
46	Eu30.00	[X]Manic episode	Eu14200	[X]Mental and behav dis due to use cocaine: dependence syndr
47				
48	E211100	Hypomanic personality disorder	Eu52800	[X]Erotomania
49	Eu10500	[X]Mental & behav dis due to use alcohol: psychotic disorder	Eu12100	[X]Mental and behav dis due to use cannabinoids: harmful use
50				
51	225E.00	O/E - paranoid delusions	Eu60y16	[X]Psychoneurotic personality disorder
52	Eu45211	[X]Body dysmorphic disorder	E123.11	Folie a deux
53	E211300	Cyclothymic personality disorder	Eu11500	[X]Mental & behav dis due to use opioids: psychotic disorder
54				
55	E12z.00	Paranoid psychosis NOS	Eu3y000	[X]Other single mood affective disorders
56	146H.00	H/O: psychosis	Eu31y12	[X]Recurrent manic episodes
57	E115.11	Manic-depressive - now depressed	E02y.00	Other drug psychoses
58	Eu30100	[X]Mania without psychotic symptoms	Eu19300	[X]Mental and behav dis mlti/oth psychoa sbs:
59				

1	E11..00	Affective psychoses			withdrwl state
2	E110100	Single manic episode, mild		Eu24.00	[X]Induced delusional disorder
3				E103300	Acute exacerbation of subchronic paranoid schizophrenia
4	E120.00	Simple paranoid state		Eu84511	[X]Autistic psychopathy
5	E212z00	Schizoid personality disorder NOS		E00y.11	Presbyophrenic psychosis
6	E117.00	Unspecified bipolar affective disorder		E211z00	Affective personality disorder NOS
7	E13z.00	Nonorganic psychosis NOS		Eu25012	[X]Schizophreniform psychosis, manic type
8	E122.00	Paraphrenia		Eu60500	[X]Anankastic personality disorder
9	E211.00	Affective personality disorder		225F.00	O/E - delusion of persecution
10	E133.00	Acute paranoid reaction		Eu32312	[X]Single episode of psychogenic depressive psychosis
11	F481K00	Visual hallucinations		Eu18200	[X]Mental and behav dis due to vol solvents: dependence synd
12				E14z.00	Child psychosis NOS
13	E21z.00	Personality disorder NOS		Eu06y00	[X]Oth organ personality behav disorders brain dis dam dysf
14	E00y.00	Other senile and presenile organic psychoses		E22y500	Nymphomania
15				E103400	Acute exacerbation of chronic paranoid schizophrenia
16	E100000	Unspecified schizophrenia		Eu60y14	[X]Narcissistic personality disorder
17	E115000	Bipolar affective disorder, currently depressed, unspecified		Eu62013	[X]Personality change aft prolong captiv+possib/being killed
18	E1...00	Non-organic psychoses		E100z00	Simple schizophrenia NOS
19	E21yz00	Other personality disorder NOS		Ryu5300	[X]Other hallucinations
20				Eu31y00	[X]Other bipolar affective disorders
21	E211000	Unspecified affective personality disorder		Eu84314	[X]Symbiotic psychosis
22	E01..00	Alcoholic psychoses		Eu20111	[X]Disorganised schizophrenia
23	E02..00	Drug psychoses		R001100	[D]Hallucinations, gustatory
24	E13y.00	Other reactive psychoses		E116400	Mixed bipolar affective disorder, severe, with psychosis
25	E13y.00	Other reactive psychoses		Eu21.12	[X]Borderline schizophrenia
26	E114300	Bipolar affect disord, currently manic, severe, no psychosis		E11z000	Unspecified affective psychoses NOS
27	E1y..00	Other specified non-organic psychoses		Eu34012	[X]Cycloid personality
28				Eu16500	[X]Mental & behav dis due to hallucinogens: psychotic disord
29	Eu31300	[X]Bipolar affect disorder cur epi mild or moderate depressn		E116600	Mixed bipolar affective disorder, in full remission
30	Eu20000	[X]Paranoid schizophrenia		E03..00	Transient organic psychoses
31	Eu31000	[X]Bipolar affective disorder, current episode hypomanic		Eu22111	[X]Capgras syndrome
32	Eu33315	[X]Recurrent severe episodes of psychotic depression		Eu22y13	[X]Paranoia querulans
33	Eu25011	[X]Schizoaffective psychosis, manic type		1BH2.00	Ideas of reference
34	Eu2..00	[X]Schizophrenia, schizotypal and delusional disorders		ZV40y00	[V]Other specified mental or behavioural problem
35	E114.11	Manic-depressive - now manic		E114400	Bipolar affect disord, currently manic,severe with psychosis
36	Eu60513	[X]Obsessive-compulsive personality disorder		Eu60y11	[X]Eccentric personality disorder
37	Eu10514	[X]Alcoholic psychosis NOS		E141.00	Disintegrative psychosis
38	Eu53111	[X]Puerperal psychosis NOS		Eu17100	[X]Mental and behav dis due to use of tobacco: harmful use
39	E130.11	Psychotic reactive depression		Eu16300	[X]Mental and behav dis due hallucinogens: withdrawal state
40	1BH..11	Delusion		Eu62.00	[X]Enduring personality change not attrib to brain damag/dis
41	Eu20y13	[X]Schizophrenifrm psychos NOS		E107500	Schizo-affective schizophrenia in remission
42	E21y200	Borderline personality disorder		Eu60213	[X]Asocial personality disorder
43				Eu12200	[X]Mental and behav dis due to cannabinoids: dependence synd
44	E110.11	Hypomanic psychoses			
45	212T.00	Psychosis, schizophrenia + bipolar affective disord resolved			
46	1B1b.00	Transient hallucinations			
47	R001z00	[D]Hallucinations NOS			
48	E215100	Munchausen's syndrome			

1	E216.13	Labile personality	Eu19700	[X]Men/beh dis mlt drg use/oth subs: resid/late psychot dis
2	E111000	Recurrent manic episodes, unspecified	Eu8z.00	[X]Unspecified disorder of psychological development
3	E2C3200	Kleptomania	Z57C611	Schizophrenic language
4	E21yz11	Manipulative personality	Eu62011	[X]Personality change after concentration camp experiences
5			E115600	Bipolar affective disorder, now depressed, in full remission
6	E110000	Single manic episode, unspecified	Eu12700	[X]Mnt/bh dis due cannabinds: resid & late-onset psychot dis
7			E114z00	Bipolar affective disorder, currently manic, NOS
8	E13..11	Reactive psychoses	E03z.00	Transient organic psychoses NOS
9			E100300	Acute exacerbation of subchronic schizophrenia
10	E2C3300	Pyromania	Eu03.11	[X]Korsakov's psychosis, nonalcoholic
11	Eu10300	[X]Mental and behav dis due to use alcohol: withdrawal state	Eu25y00	[X]Other schizoaffective disorders
12	Eu20211	[X]Catatonic stupor	E100500	Schizophrenia in remission
13	Eu20400	[X]Post-schizophrenic depression	Eu60313	[X]Explosive personality disorder
14	Eu60311	[X]Aggressive personality disorder	E102000	Unspecified catatonic schizophrenia
15	E214.00	Compulsive personality disorders	E107000	Unspecified schizo-affective schizophrenia
16	Eu6..00	[X]Disorders of adult personality and behaviour	E111500	Recurrent manic episodes, partial or unspecified remission
17	Eu30200	[X]Mania with psychotic symptoms	E107300	Acute exacerbation subchronic schizo-affective schizophrenia
18	E21y700	Psychoneurotic personality disorder	Eu60714	[X]Self defeating personality disorder
19	Eu81.00	[X]Specific developmental disorders of scholastic skills	Eu18100	[X]Mental and behav dis due volatile solvents: harmful use
20	Eu60000	[X]Paranoid personality disorder	E114500	Bipolar affect disord,currently manic, part/unspec remission
21			Eu23211	[X]Brief schizophreniform disorder
22	Eu23012	[X]Cycloid psychosis	Eu15700	[X]Mnt/bh dis oth stm inc caffne resid/late-onset psycht dis
23	Eu34000	[X]Cyclothymia	E03yz00	Other transient organic psychoses NOS
24	Eu23100	[X]Acute polymorphic psychot disord with symp of schizophren	Eu84512	[X]Schizoid disorder of childhood
25	E216.12	Dependent personality	Eu06000	[X]Organic personality disorder
26	Eu60214	[X]Psychopathic personality disorder	Eu20300	[X]Undifferentiated schizophrenia
27	Eu10100	[X]Mental and behav dis due to use of alcohol: harmful use	E11y.00	Other and unspecified manic-depressive psychoses
28	Eu0z.11	[X]Organic psychosis NOS	E2Az.00	Nonpsychotic mental disorder post-organic brain damage NOS
29	Eu05200	[X]Organic delusional [schizophrenia-like] disorder	E215z00	Histrionic personality disorder NOS
30	Eu04.15	[X]Acute / subacute psycho-organic reaction	Eu19000	[X]Mental/behav dis multi drg use/psychoac subs: acute intox
31	ZV11112	[V]Personal history of manic-depressive psychosis	E107100	Subchronic schizo-affective schizophrenia
32	E02y400	Drug-induced personality disorder	Eu84013	[X]Infantile psychosis
33	ZV11000	[V]Personal history of schizophrenia	Eu13300	[X]Mental and behav dis due sed/s/hypntcs: withdrawal state
34	E13y000	Psychogenic stupor	Eu20200	[X]Catatonic schizophrenia
35	E1z..00	Non-organic psychosis NOS	Eu17.00	[X]Mental and behavioural disorder due to use of tobacco
36	Eu60512	[X]Obsessional personality disorder	E212200	Schizotypal personality
37	Euz..11	[X]Mental illness NOS	Eu10700	[X]Men & behav dis due alcoh: resid & late-onset psychot dis
38	1BH3.00	Paranoid ideation	E04..00	Other chronic organic psychoses
39	286..11	Poor insight into psychotic condition	Eu84312	[X]Disintegrative psychosis
40	1S42.00	Manic mood	Eu22100	[X]Delusional misidentification syndrome
41	Eu0..00	[X]Organic, including symptomatic, mental disorders	Eu21.14	[X]Prepsychotic schizophrenia
42	E13y100	Brief reactive psychosis		
43	E213.00	Explosive personality disorder		
44	E100100	Subchronic schizophrenia		
45	Eu53z00	[X]Puerperal mental disorder, unspecified		

E04y.00	Other specified chronic organic psychoses	E123.00	Shared paranoid disorder
Eu06.00	[X]Personality and behav disorder brain dis dam and dysfunct	E2Ay.00	Other specific mental disorder post-organic brain damage
Eu31400	[X]Bipol aff disord, curr epis sev depress, no psychot symp	Eu19100	[X]Mental and behav dis mlti drg/oth psychoa sbs: harmfl use
Eu33311	[X]Endogenous depression with psychotic symptoms	E116200	Mixed bipolar affective disorder, moderate
E040.11	Korsakoff's non-alcoholic psychosis	E116300	Mixed bipolar affective disorder, severe, without psychosis
Eu34013	[X]Cyclothymic personality	E107400	Acute exacerbation of chronic schizo-affective schizophrenia
ZV11111	[V]Personal history of manic-depressive psychosis	E116z00	Mixed bipolar affective disorder, NOS
E217.00	Antisocial or sociopathic personality disorder	E116500	Mixed bipolar affective disorder, partial/unspec remission
Eu05300	[X]Organic mood [affective] disorders	E117100	Unspecified bipolar affective disorder, mild
Eu84111	[X]Atypical childhood psychosis	E115400	Bipolar affect disord, now depressed, severe with psychosis
Eu20511	[X]Chronic undifferentiated schizophrenia	E114600	Bipolar affective disorder, currently manic, full remission
Eu32313	[X]Single episode of psychotic depression	ZV40200	[V]Other mental problems
Eu32311	[X]Single episode of major depression and psychotic symptoms	E2A1z00	Organic personality syndrome NOS
E113400	Recurrent major depressive episodes, severe, with psychosis	E102z00	Catatonic schizophrenia NOS
E117600	Unspecified bipolar affective disorder, in full remission	Eu06z00	[X]Unspec organ personality behav disorder brain dam dysfunc
E14y000	Atypical childhood psychoses	R001300	[D]Hallucinations, tactile
E134.00	Psychogenic paranoid psychosis	Eu13000	[X]Mental & behav dis due seds/hypntcs: acute intoxication
Eu04.13	[X]Acute / subacute infective psychosis	Eu20500	[X]Residual schizophrenia
146Z.00	H/O: psychiatric disorder NOS	Eu20212	[X]Schizophrenic catalepsy
Eu19500	[X]Ment/behav dis mlti drug use/oth psyc sbs: psychotc dis	Eu6y.00	[X]Other disorders of adult personality and behaviour
E110200	Single manic episode, moderate	Eu21.13	[X]Latent schizophrenia
E116100	Mixed bipolar affective disorder, mild	Eu22014	[X]Sensitiver Beziehungswahn
Eu53.00	[X]Mental and behav disorders assoc with the puerperium NEC	Eu12300	[X]Mental and behav dis due cannabinoids: withdrawal state
Eu23.00	[X]Acute and transient psychotic disorders	Eu62012	[X]Personality change after disasters
Eu04.00	[X]Delirium, not induced by alcohol+other psychoactive subs	E111300	Recurrent manic episodes, severe without mention psychosis
E2A1.00	Organic personality syndrome	Eu16200	[X]Mental and behav dis due to hallucinogens: dependence syn
ZV40.00	[V]Mental and behavioural problems	Eu22y00	[X]Other persistent delusional disorders
E21y.00	Other personality disorders	Eu31.13	[X]Manic-depressive reaction
Eu8..00	[X]Disorders of psychological development	Eu16000	[X]Mental & behav dis due hallucinogens: acute intoxicatn
R001200	[D]Hallucinations, olfactory	E105.00	Latent schizophrenia
E102.00	Catatonic schizophrenia	E101000	Unspecified hebephrenic schizophrenia
Eu54.00	[X]Psychological/behav factor assoc with disorder or dis EC	E0y..00	Other specified organic psychoses
E02z.00	Drug psychosis NOS	E14yz00	Other childhood psychoses NOS
E13yz00	Other reactive psychoses NOS	E12y000	Paranoia querulans
Eu23112	[X]Cycloid psychosis with symptoms of schizophrenia	E212000	Unspecified schizoid personality disorder
E11..13	Manic psychoses	Eu16100	[X]Mental and behav dis due to use hallucinogens: harmfl use
E111.00	Recurrent manic episodes	Eu14300	[X]Mental and behav dis due to use cocaine: withdrawal state

1	Eu31100	[X]Bipolar affect disorder cur epi manic wout psychotic symp	E215300	Psychoinfantile personality
2	Eu34011	[X]Affective personality disorder	E01z.00	Alcoholic psychosis NOS
3	Eu21.18	[X]Schizotypal personality disorder	E101500	Hebephrenic schizophrenia in remission
4	E215.00	Histrionic personality disorders	E217.11	Amoral personality
5	Eu31700	[X]Bipolar affective disorder, currently in remission	E133.11	Bouffe delirante
6				
7	Eu11700	[X]Men & beh dis due opioids: resid & late-onset psychot dis	E01yz00	Other alcoholic psychosis NOS
8				
9	Eu66.00	[X]Psychol and behav disorder assoc with sex dev and orienta	E03y.00	Other transient organic psychoses
10				
11	Ey...00	Other specified mental disorders	E117400	Unspecified bipolar affective disorder,severe with psychosis
12				
13	E111200	Recurrent manic episodes, moderate	E117200	Unspecified bipolar affective disorder, moderate
14	Eu02z16	[X] Senile dementia, depressed or paranoid type	Eu60013	[X]Querulant personality disorder
15				
16	Eu23312	[X]Psychogenic paranoid psychosis	Eu13500	[X]Mental & behav dis due to seds/hypntcs: psychotic disordr
17				
18	E21y400	Eccentric personality disorder	E14y100	Borderline psychosis of childhood
19	E115200	Bipolar affective disorder, currently depressed, moderate	Eu60412	[X]Psychoinfantile personality disorder
20				
21	Eu02z15	[X] Senile psychosis NOS	E110600	Single manic episode in full remission
22	Eu60411	[X]Hysterical personality disorder	E11y300	Other mixed manic-depressive psychoses
23	Eu05.00	[X]Oth mental disorder brain damag/dysfunction/physical disr	E117500	Unspecified bipolar affect disord, partial/unspec remission
24				
25	E117z00	Unspecified bipolar affective disorder, NOS	Eu23212	[X]Brief schizophrenifrm psych
26	Eu3y.00	[X]Other mood affective disorders	E21y600	Masochistic personality disorder
27	Eu44.14	[X]Hysterical psychosis	E11y100	Atypical manic disorder
28	E21..11	Neurotic personality disorder	Eu21.17	[X]Pseudopsychopathic schizophrenia
29	Eu31200	[X]Bipolar affect disorder cur epi manic with psychotic symp	Eu60y12	[X]Haltlose type personality disorder
30				
31	Eu22.00	[X]Persistent delusional disorders	E14y.00	Other childhood psychoses
32	Eu33312	[X]Manic-depress psychosis,depressed type+psychotic symptoms	E115500	Bipolar affect disord, now depressed, part/unspec remission
33				
34	E02yz00	Other drug psychoses NOS	E100.11	Schizophrenia simplex
35	Eu32314	[X]Single episode of reactive depressive psychosis	E117300	Unspecified bipolar affective disorder, severe, no psychosis
36				
37	Eu33213	[X]Manic-depress psychosis,depressd,no psychotic symptoms	ZVu6K00	[X]Personal history/other mental and behavioural disorders
38				
39	Eu3yy00	[X]Other specified mood affective disorders	Eu31y11	[X]Bipolar II disorder
40	Eu23z12	[X]Reactive psychosis	ZV11z00	[V]Personal history of unspecified mental disorder
41	Eu3y100	[X]Other recurrent mood affective disorders	212V.00	Bipolar affective disorder resolved
42	E131.00	Acute hysterical psychosis	1B1e.00	Hypnopompic hallucination
43	Eu1..00	[X]Mental and behavioural disorders due to psychoactive subs	212X.00	Psychosis resolved
44				
45	ZV11.00	[V]Personal history of mental disorder	Eu1A100	[X]Mental behav disorders due use crack cocaine: harmful use
46				
47	ZRby100	Profile of mood states, bipolar	1B1d.00	Hypnagogic hallucination
48	E214000	Anankastic personality	Eu62z00	[X]Enduring personality change, unspecified
49	Eu66y00	[X]Other psychosexual development disorders	212W.00	Schizophrenia resolved
50	Eu61.00	[X]Mixed and other personality disorders	Eu21.11	[X]Latent schizophrenic reaction
51	E101.00	Hebephrenic schizophrenia	Eu20311	[X]Atypical schizophrenia
52	Eu3y011	[X]Mixed affective episode	E10y.11	Cenesthopathic schizophrenia
53	Eu2y.00	[X]Other nonorganic psychotic disorders	Eu13100	[X]Mental and behav dis due to use seds/hypntcs: harmful use
54				
55	ZV71000	[V]Observation for mental disorder	ZV11y00	[V]Personal history of other specified mental disorder
56	Eu6y111	[X] Munchausens syndrome	Eu06011	[X]Organic pseudopsychopathic personality
57	E116.00	Mixed bipolar affective disorder	Eu20y12	[X]Schizophreniform disord NOS
58				
59				
60				

1	E103200	Chronic paranoid schizophrenia	E105200	Chronic latent schizophrenia
2	E12yz00	Other paranoid states NOS	Eu23214	[X]Schizophrenic reaction
3	Eu20214	[X]Schizophrenic flexibilatis cerea	E105500	Latent schizophrenia in remission
4	E116000	Mixed bipolar affective disorder, unspecified	Eu12600	[X]Mental and behav dis due to use cannabinoids: amnesic syn
5	E12y.00	Other paranoid states	Eu05z12	[X]Organic mental disorder NOS
6	Eu60200	[X]Dissocial personality disorder	E101400	Acute exacerbation of chronic hebephrenic schizophrenia
7			Eu32800	[X]Major depression, severe with psychotic symptoms
8	Eu3z.11	[X]Affective psychosis NOS	Eu18500	[X]Mental & behav dis due to vol solvents: psychotic disordr
9	ZV40.12	[V]Mental problems	Eu22200	[X]Cotard syndrome
10			E107.11	Cyclic schizophrenia
11	Eu23z11	[X]Brief reactive psychosis NOS	E10y100	Coenesthopathic schizophrenia
12	Eu18.00	[X]Mental & behav disorders due to use of volatile solvents	E102100	Subchronic catatonic schizophrenia
13	Eu2y.11	[X]Chronic hallucinatory psychosis	Eu94211	[X]Affectionless psychopathy
14	Eu33314	[X]Recurr severe episodes/psychogenic depressive psychosis	Eu3y200	[X]Premenstrual dysphoric disorder
15	Eu60312	[X]Borderline personality disorder	14g..00	History of developmental disorder
16	Eu62015	[X]Personality change after torture	L184400	Mental disorder in puerperium - baby previously delivered
17	Eu60700	[X]Dependent personality disorder	Eu32900	[X]Single major depr ep, severe with psych, psych in remiss
18	Eu05212	[X]Schizophrenia-like psychosis in epilepsy	Eu32A00	[X]Recurr major depr ep, severe with psych, psych in remiss
19			Eu17300	[X]Mental and behav dis due to use tobacco: withdrawal state
20	E13..00	Other nonorganic psychoses	Eu22300	[X]Paranoid state in remission
21	Eu14.00	[X]Mental and behavioural disorders due to use of cocaine	Eu1A300	[X]Mental behav disord due crack cocaine: withdrawal state
22	Eu30y00	[X]Other manic episodes	Eu26.00	[X]Nonorganic psychosis in remission
23	E112400	Single major depressive episode, severe, with psychosis	E105000	Unspecified latent schizophrenia
24	E100.00	Simple schizophrenia	E102500	Catatonic schizophrenia in remission
25	E111400	Recurrent manic episodes, severe, with psychosis	E105z00	Latent schizophrenia NOS
26	Eu1A.00	[X]Mental and behavioural disorders due use of crack cocaine	Eu1A500	[X]Mental behav disord due crack cocaine: psychotic disorder
27	Eu60212	[X]Antisocial personality disorder	Eu1A200	[X]Mental behav disorders due use crack cocaine: depend synd
28	1BH1.00	Grandiose delusions	Eu14700	[X]Men & beh dis due cocaine: resid & late-onset psychot dis
29	Eu33313	[X]Recurr severe episodes/major depression+psychotic symptom	L184200	Mental disorder in the puerperium - baby delivered
30	E10y000	Atypical schizophrenia	Eu31900	[X]Bipolar affective disorder type II
31	E103000	Unspecified paranoid schizophrenia	Eu11600	[X]Mental and behav dis due to use opioids: amnesic syndrome
32	Eu25z11	[X]Schizoaffective psychosis NOS	Eu31911	[X]Bipolar II disorder
33	E11zz00	Other affective psychosis NOS	Eu31800	[X]Bipolar affective disorder type I
34	E11yz00	Other and unspecified manic-depressive psychoses NOS	E103100	Subchronic paranoid schizophrenia
35	Eu15200	[X]Mental and behav dis oth stim inc caffein: dependnce synd	Eu25211	[X]Cyclic schizophrenia
36	E01y.00	Other alcoholic psychosis	Eu60211	[X]Amoral personality disorder
37	Eu25200	[X]Schizoaffective disorder, mixed type	Eu16700	[X]Mnt/bh dis due hallucngns: resid & late-onset psychot dis
38	E00..00	Senile and presenile organic psychotic conditions	Eu24.11	[X]Folie a deux
39	Eu60713	[X]Passive personality disorder	Eu19600	[X]Mental/behav dis multi drg use/oth psy sbs:
40	Eu31z00	[X]Bipolar affective disorder, unspecified		
41	E2Fz.00	Developmental disorder NOS		
42	Eu25000	[X]Schizoaffective disorder, manic type		

1	Eu23z00	[X]Acute and transient psychotic disorder, unspecified	amnesic syndr	E102400	Acute exacerbation of chronic catatonic schizophrenia
2					
3	Eu20.00	[X]Schizophrenia	Eu8z.11	[X]Psychological developmental disorder NOS	
4	Eu11200	[X]Mental and behav dis due to use opioids: dependence syndr	Eu17200	[X]Mental and behav dis due to use tobacco: dependence syndr	
5					
6	Eu22000	[X]Delusional disorder	E21y000	Narcissistic personality disorder	
7	E214z00	Compulsive personality disorder NOS	E115z00	Bipolar affective disorder, currently depressed, NOS	
8	Eu62y11	[X]Chronic pain personality syndrome	Eu12000	[X]Mental & behav dis due cannabinoids: acute intoxication	
9					
10	Eu6yy00	[X]Other specified disorders of adult personality/behaviour	E14z.11	Childhood schizophrenia NOS	
11					
12	Eu20z00	[X]Schizophrenia, unspecified	Eu62100	[X]Enduring personality change after psychiatric illness	
13	Eu2..00	[X]Mental disorder, not otherwise specified	Eu11100	[X]Mental and behav dis due to use of opioids: harmful use	
14					
15	Eu62y00	[X]Other enduring personality changes	Eu25212	[X]Mixed schizophrenic and affective psychosis	
16	Eu25111	[X]Schizoaffective psychosis, depressive type	Eu6y000	[X]Elaboration of physical symptoms for psychological reason	
17					
18	E115300	Bipolar affect disord, now depressed, severe, no psychosis	Eu25z00	[X]Schizoaffective disorder, unspecified	
19	E21y100	Avoidant personality disorder	Eu33316	[X]Recurrent severe episodes/reactive depressive psychosis	
20					
21	E115100	Bipolar affective disorder, currently depressed, mild	Eu60712	[X]Inadequate personality disorder	
22					
23	E114000	Bipolar affective disorder, currently manic, unspecified	E106.00	Residual schizophrenia	
24	E21y300	Passive-aggressive personality disorder	Eu60511	[X]Compulsive personality disorder	
25	Eu20600	[X]Simple schizophrenia	Eu60100	[X]Schizoid personality disorder	
26	Eu20213	[X]Schizophrenic catatonia	Eu12500	[X]Mental & behav dis due to cannabinoids: psychotic disordr	
27					
28	E213.12	Quarrelsome personality	E212100	Introverted personality	
29	E114100	Bipolar affective disorder, currently manic, mild	E10y.00	Other schizophrenia	
30					
31	E103500	Paranoid schizophrenia in remission	ZS34.00	Developmental disorder of scholastic skill	
32	Eu11300	[X]Mental and behav dis due to use opioids: withdrawal state	Eu21.00	[X]Schizotypal disorder	
33					
34	E110z00	Manic disorder, single episode NOS	Eu10200	[X]Mental and behav dis due to use alcohol: dependence syndr	
35					
36	Eu23000	[X]Acute polymorphic psychot disord without symp of schizoph	Eu3z.00	[X]Unspecified mood affective disorder	
37					
38	E0z..00	Organic psychoses NOS	Eu30211	[X]Mania with mood-congruent psychotic symptoms	
39	E110.00	Manic disorder, single episode	E111600	Recurrent manic episodes, in full remission	
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

ALCOHOL AND DRUG DEPENDENCE**At least one ICD-9 in:**

- 303 Alcohol dependance syndrome
- 305.00 Non dependent alcohol abuse
- 305.00 Alcohol abuse, unspecified
- 305.01 Alcohol abuse, continuous
- 305.03** Alcohol abuse, episodic
- 305.03 Alcohol abuse, in remission
- 304 Drug dependence
- 304.0 Opioid type dependence
- 304.1 Sedative, hypnotic or anxiolytic dependence
- 304.2 Cocaine dependence
- 304.3 Cannabis dependence
- 304.4 Amphetamine and other psychostimulant dependence
- 304.5 Hallucinogen dependence
- 304.6 Other specified drug dependence
- 304.7 Combinations of opioid type drug with any other drug dependence
- 304.8 Combinations of drug dependence excluding opioid type drug
- 304.9 Unspecified drug dependence

OR

At least one ICD-10 in:

- F10 Alcohol related disorders
- F10.0 acute intoxication
- F10.1 harmful use
- F10.2 dependence syndrome
- F10.3 withdrawal state
- F10.4 withdrawal state with delirium
- F10.5 psychotic disorder
- F10.6 amnesic syndrome
- F10.7 Residual and late-onset psychotic disorder
- F10.8 other mental and behavioural disorder
- F10.9 unspecified mental and behavioural disorder
- F11 Opioids related disorders
- F12 Cannabis related disorders
- F13 Sedative, hypnotic, or anxiolytic related disorders
- F14 Cocaine related disorders
- F15 Other stimulant related disorders
- F16 Hallucinogen related disorders
- F17 Nicotine dependence
- F18 Inhalant related disorders
- F19 Other psychoactive substance related disorders

OR

At least one READ code in:

136..00	Alcohol consumption	E245z00	Hallucinogen dependence NOS
136K.00	Alcohol intake above recommended sensible limits	E246.00	Glue sniffing dependence
136S.00	Hazardous alcohol use	E246000	Glue sniffing dependence, unspecified
136T.00	Harmful alcohol use	E246100	Glue sniffing dependence, continuous
136W.00	Alcohol misuse	E246200	Glue sniffing dependence, episodic
136Z.00	Alcohol consumption NOS	E246300	Glue sniffing dependence in remission
13c..00	Drug user	E246z00	Glue sniffing dependence NOS
13c0.00	Injecting drug user	E247.00	Other specified drug dependence
13c1.00	Intravenous drug user	E247.11	Absinthe addiction
13c2.00	Never injecting drug user	E247000	Other specified drug dependence, unspecified
13c3.00	Intramuscular drug user	E247100	Other specified drug dependence, continuous
13c4.00	Intranasal drug user	E247200	Other specified drug dependence, episodic
13c7.00	Current drug user	E247300	Other specified drug dependence in remission
13c9.00	Subcutaneous drug user	E247z00	Other specified drug dependence NOS
13cA.00	Smokes drugs	E248.00	Combined opioid with other drug dependence
13cB.00	Misuses drugs orally	E248000	Combined opioid with other drug dependence, unspecified
13cC.00	Continuous use of drugs	E248100	Combined opioid with other drug dependence, continuous
13cD.00	Episodic use of drugs	E248200	Combined opioid with other drug dependence, episodic
13cE.00	Prolonged high dose use of cannabis	E248300	Combined opioid with other drug dependence in remission
13cH.00	Persistent substance misuse	E248z00	Combined opioid with other drug dependence NOS
13cJ.00	Previously injecting drug user	E249.00	Combined drug dependence, excluding opioids
13cK.00	Current non recreational drug user	E249000	Combined drug dependence, excluding opioid, unspecified
1462.00	H/O: alcoholism	E249100	Combined drug dependence, excluding opioid, continuous
1463.00	H/O: drug dependency	E249200	Combined drug dependence, excluding opioid, episodic
146E.00	H/O: recreational drug use	E249300	Combined drug dependence, excluding opioid, in remission
146F.00	H/O: drug abuse	E249z00	Combined drug dependence, excluding opioid, NOS
1B1c.00	Alcohol induced hallucinations	E24A.00	Ecstasy type drug dependence
1P30.00	Compulsive uncontrollable drug taking	E24z.00	Drug dependence NOS
1P31.00	Compulsive drug taking	E250.11	Drunkenness NOS
1P6..00	Craving for drugs	E250.12	Hangover (alcohol)
1P62.00	Abnormal craving for drugs	E250.13	Inebriety NOS
1T...00	History of substance misuse	E250.14	Intoxication - alcohol
1T0..00	H/O heroin misuse	E254.11	Barbiturate abuse
1T00.00	H/O daily heroin misuse	E254.12	Hypnotic or anxiolytic abuse
1T01.00	H/O weekly heroin misuse	E254.13	Sedative abuse
1T02.00	Previous history of heroin misuse	E254.14	Tranquilliser abuse
1T03.00	H/O infrequent heroin misuse	E257.11	Psychostimulant abuse
1T1..00	H/O methadone misuse	E257.12	Stimulant abuse
1T10.00	H/O daily methadone misuse	E259400	Misuse of prescription only drugs
1T11.00	H/O weekly methadone misuse	E25y.11	Analgesic abuse
1T12.00	H/O infrequent methadone misuse	E25y.12	Laxative abuse
1T13.00	Previous history of methadone misuse	E25y.13	Steroid abuse

1	1T2..00	H/O ecstasy misuse	E25z.00	Misuse of drugs NOS
2	1T20.00	H/O daily ecstasy misuse	Eu1..00	[X]Mental and behavioural disorders due to psychoactive subs
3	1T21.00	H/O weekly ecstasy misuse	Eu10.00	[X]Mental and behavioural disorders due to use of alcohol
4				
5	1T22.00	H/O infrequent ecstasy misuse	Eu10000	[X]Mental & behav dis due to use alcohol: acute intoxication
6				
7	1T23.00	Previous history of ecstasy misuse	Eu10011	[X]Acute alcoholic drunkenness
8	1T3..00	H/O benzodiazepine misuse	Eu10100	[X]Mental and behav dis due to use of alcohol: harmful use
9				
10	1T30.00	H/O daily benzodiazepine misuse	Eu10200	[X]Mental and behav dis due to use alcohol: dependence syndr
11				
12	1T31.00	H/O weekly benzodiazepine misuse	Eu10211	[X]Alcohol addiction
13	1T32.00	H/O infrequent benzodiazepine misuse	Eu10212	[X]Chronic alcoholism
14	1T33.00	Previous history of benzodiazepine misuse	Eu10213	[X]Dipsomania
15	1T4..00	H/O amphetamine misuse	Eu10300	[X]Mental and behav dis due to use alcohol: withdrawal state
16				
17	1T40.00	H/O daily amphetamine misuse	Eu10400	[X]Men & behav dis due alcohol: withdrawal state with delirium
18				
19	1T41.00	H/O weekly amphetamine misuse	Eu10411	[X]Delirium tremens, alcohol induced
20	1T42.00	H/O infrequent amphetamine misuse	Eu10500	[X]Mental & behav dis due to use alcohol: psychotic disorder
21				
22	1T43.00	Previous history of amphetamine misuse	Eu10511	[X]Alcoholic hallucinosis
23	1T5..00	H/O cocaine misuse	Eu10512	[X]Alcoholic jealousy
24	1T50.00	H/O daily cocaine misuse	Eu10513	[X]Alcoholic paranoia
25	1T51.00	H/O weekly cocaine misuse	Eu10514	[X]Alcoholic psychosis NOS
26	1T52.00	H/O infrequent cocaine misuse	Eu10600	[X]Mental and behav dis due to use alcohol: amnesic syndrome
27				
28	1T53.00	Previous history of cocaine misuse	Eu10611	[X]Korsakov's psychosis, alcohol induced
29	1T6..00	H/O crack cocaine misuse	Eu10700	[X]Men & behav dis due alcohol: resid & late-onset psychot dis
30				
31	1T60.00	H/O daily crack cocaine misuse	Eu10711	[X]Alcoholic dementia NOS
32	1T61.00	H/O weekly crack cocaine misuse	Eu10712	[X]Chronic alcoholic brain syndrome
33	1T62.00	H/O infrequent crack cocaine misuse	Eu10800	[X]Alcohol withdrawal-induced seizure
34	1T63.00	Previous history of crack cocaine misuse	Eu10y00	[X]Men & behav dis due to use alcohol: oth men & behav dis
35				
36	1T7..00	H/O hallucinogen misuse	Eu10z00	[X]Ment & behav dis due use alcohol: unsp ment & behav dis
37				
38	1T73.00	Previous history of hallucinogen misuse	Eu11.00	[X]Mental and behavioural disorders due to use of opioids
39				
40	1T8..00	H/O cannabis misuse	Eu11000	[X]Mental & behav dis due to use opioids: acute intoxication
41				
42	1T80.00	H/O daily cannabis misuse	Eu11100	[X]Mental and behav dis due to use of opioids: harmful use
43				
44	1T81.00	H/O weekly cannabis misuse	Eu11200	[X]Mental and behav dis due to use opioids: dependence syndr
45				
46	1T82.00	H/O infrequent cannabis misuse	Eu11211	[X]Drug addiction - opioids
47	1T83.00	Previous history of cannabis misuse	Eu11212	[X]Heroin addiction
48	1T9..00	H/O solvent misuse	Eu11300	[X]Mental and behav dis due to use opioids: withdrawal state
49				
50	1T90.00	H/O daily solvent misuse	Eu11311	[X]Cold turkey, opiate withdrawal
51	1T91.00	H/O weekly solvent misuse	Eu11400	[X]Men & behav dis due opioid: withdrawal state with delirium
52				
53	1T93.00	Previous history of solvent misuse	Eu11500	[X]Mental & behav dis due to use opioids: psychotic disorder
54				
55	1TA..00	H/O barbiturate misuse	Eu11600	[X]Mental and behav dis due to use opioids: amnesic syndrome
56				
57	1TB..00	H/O major tranquilliser misuse	Eu11700	[X]Men & beh dis due opioids: resid & late-onset psychot dis
58				
59				

1	1TB0.00	H/O daily major tranquilliser misuse	Eu11y00	[X]Men & behav dis due to use opioids: oth men & behav dis
2	1TC..00	H/O anti-depressant misuse	Eu11z00	[X]Ment & behav dis due use opioids: unsp ment & behav dis
3				
4	1TC0.00	H/O daily anti-depressant misuse	Eu12.00	[X]Mental and behavioural disorders due to use cannabinoids
5				
6	1TC3.00	Previous history of anti-depressant misuse	Eu12000	[X]Mental & behav dis due cannabinoids: acute intoxication
7				
8	1TD..00	H/O opiate misuse	Eu12100	[X]Mental and behav dis due to use cannabinoids: harmful use
9				
10	1TD0.00	H/O daily opiate misuse	Eu12200	[X]Mental and behav dis due to cannabinoids: dependence synd
11				
12	1TD1.00	H/O weekly opiate misuse	Eu12211	[X]Drug addiction - cannabis
13	1TD2.00	H/O infrequent opiate misuse	Eu12300	[X]Mental and behav dis due cannabinoids: withdrawal state
14				
15	1TD3.00	Previous history of opiate misuse	Eu12500	[X]Mental & behav dis due to cannabinoids: psychotic disorder
16				
17	1TE..00	Uses heroin on top of substitution therapy	Eu12600	[X]Mental and behav dis due to use cannabinoids: amnesic syn
18				
19	1V...00	Drug misuse behaviour	Eu12700	[X]Mnt/bh dis due cannabinds: resid & late-onset psychot dis
20				
21	1V0..00	Misuses drugs	Eu12y00	[X]Men/behav dis due to use cannabinoids: oth men/behav disd
22				
23	1V01.00	Long-term drug misuser	Eu12z00	[X]Ment/behav dis due use cannabinoids: unsp ment/behav disd
24				
25	1V02.00	Poly-drug misuser	Eu13.00	[X]Mental and behavioural dis due use sedatives/hypnotics
26				
27	1V08.00	Smokes drugs in cigarette form	Eu13000	[X]Mental & behav dis due seds/hypntcs: acute intoxication
28				
29	1V09.00	Smokes drugs through a pipe	Eu13100	[X]Mental and behav dis due to use seds/hypntcs: harmful use
30				
31	1V0A.00	Chases the dragon	Eu13200	[X]Mental and behav dis due to seds/hypntcs: dependence synd
32				
33	1V0B.00	Sniffs drugs	Eu13211	[X]Drug addiction- sedative / hypnotics
34	1V0C.00	Drug addict	Eu13300	[X]Mental and behav dis due seds/hypntcs: withdrawal state
35				
36	1V0E.00	Health problem secondary to drug misuse	Eu13400	[X]Men & beh dis due seds/hypns: withdrwl state wth delirium
37				
38	1V26.00	Misused drugs in past	Eu13500	[X]Mental & behav dis due to seds/hypntcs: psychotic disorder
39				
40	1V3..00	Drug injection behaviour	Eu14.00	[X]Mental and behavioural disorders due to use of cocaine
41				
42	1V4..00	Priority of drug-related activities	Eu14000	[X]Mental & behav dis due to use cocaine: acute intoxication
43				
44	1V5..00	Routine of drug-related activities	Eu14100	[X]Mental and behav dis due to use of cocaine: harmful use
45				
46	1V6..00	Drug-related offending behaviour	Eu14200	[X]Mental and behav dis due to use cocaine: dependence syndr
47				
48	1V64.00	Illicit drug use	Eu14211	[X]Drug addiction - cocaine
49	1V65.00	Heroin misuse	Eu14300	[X]Mental and behav dis due to use cocaine: withdrawal state
50				
51	1V66.00	Ecstasy misuse	Eu14500	[X]Mental & behav dis due to use cocaine: psychotic disorder
52				
53	222N.00	O/E - signs of drug withdrawal	Eu14700	[X]Men & beh dis due cocaine: resid & late-onset psychot dis
54				
55	C150500	Alcohol-induced pseudo-Cushing's syndrome	Eu15.00	[X]Mental & behav disorder due other stimulants inc caffein
56				
57	E01..00	Alcoholic psychoses	Eu15000	[X]Mnt/beh dis due oth stim inc caffein: acute intoxication
58				
59	E010.00	Alcohol withdrawal delirium	Eu15100	[X]Ment/behav dis due to use oth stims inc caff: harmful use

1	E010.11	DTs - delirium tremens	Eu15200	[X]Mental and behav dis oth stim inc caffein: dependnce synd
2	E010.12	Delirium tremens	Eu15211	[X]Drug addiction-other stimul
3	E011.00	Alcohol amnestic syndrome	Eu15300	[X]Mnt/behav dis other stimInts inc caffeine: withdrwl state
4				
5	E011000	Korsakov's alcoholic psychosis	Eu15500	[X]Mental/behav dis oth stims inc caffeine: psychotic dis
6				
7	E011100	Korsakov's alcoholic psychosis with peripheral neuritis	Eu15700	[X]Mnt/bh dis oth stm inc caffne resid/late-onset psycht dis
8				
9	E011z00	Alcohol amnestic syndrome NOS	Eu15z00	[X]Ment/beh dis oth stims inc caffeine: unsp ment/behav disd
10				
11	E012.00	Other alcoholic dementia	Eu16.00	[X]Mental and behavioural disorders due to use hallucinogens
12				
13	E012.11	Alcoholic dementia NOS	Eu16000	[X]Mental & behav dis due hallucinogens: acute intoxicatn
14				
15	E012000	Chronic alcoholic brain syndrome	Eu16100	[X]Mental and behav dis due to use hallucinogens: harmfl use
16				
17	E013.00	Alcohol withdrawal hallucinosis	Eu16200	[X]Mental and behav dis due to hallucinogens: dependence syn
18				
19	E014.00	Pathological alcohol intoxication	Eu16211	[X]Drug addiction - hallucinogen
20	E015.00	Alcoholic paranoia	Eu16300	[X]Mental and behav dis due hallucinogens: withdrawal state
21				
22	E01y.00	Other alcoholic psychosis	Eu16500	[X]Mental & behav dis due to hallucinogens: psychotic disord
23				
24	E01y000	Alcohol withdrawal syndrome	Eu16700	[X]Mnt/bh dis due hallucngns: resid & late-onset psychot dis
25				
26	E01yz00	Other alcoholic psychosis NOS	Eu16711	[X]Post hallucinogen perception disorder
27	E01z.00	Alcoholic psychosis NOS	Eu16z00	[X]Ment/behav dis due use hallucinogens: unsp ment/behav dis
28				
29	E02..00	Drug psychoses	Eu18.00	[X]Mental & behav disorders due to use of volatile solvents
30				
31	E020.00	Drug withdrawal syndrome	Eu18000	[X]Mental & behav dis due vol solvents: acute intoxication
32				
33	E021.00	Drug-induced paranoia or hallucinatory states	Eu18100	[X]Mental and behav dis due volatile solvents: harmful use
34				
35	E021000	Drug-induced paranoid state	Eu18200	[X]Mental and behav dis due to vol solvents: dependence synd
36				
37	E021100	Drug-induced hallucinosis	Eu18211	[X]Drug addiction - solvent
38	E021z00	Drug-induced paranoia or hallucinatory state NOS	Eu18400	[X]Men & beh dis vol solvents: withdrawal state wth delirium
39				
40	E022.00	Pathological drug intoxication	Eu18500	[X]Mental & behav dis due to vol solvents: psychotic disordr
41				
42	E023.00	Nicotine withdrawal	Eu18z00	[X]Ment/behav dis due use vol solvents: unsp ment/behav dis
43				
44	E02y.00	Other drug psychoses	Eu19.00	[X]Men & behav disorder multiple drug use/psychoactive subst
45				
46	E02y000	Drug-induced delirium	Eu19000	[X]Mental/behav dis multi drg use/psychoac subs: acute intox
47				
48	E02y100	Drug-induced dementia	Eu19100	[X]Mental and behav dis mlti drg/oth psychoa sbs: harmfl use
49				
50	E02y300	Drug-induced depressive state	Eu19200	[X]Mental and behav dis mlti/oth psych sbs: dependence syndr
51				
52	E02y400	Drug-induced personality disorder	Eu19211	[X]Drug addiction NOS
53	E02yz00	Other drug psychoses NOS	Eu19300	[X]Mental and behav dis mlti/oth psychoa sbs: withdrwl state
54				
55	E02z.00	Drug psychosis NOS	Eu19400	[X]Mnt/bh dis mlti drg use/oth psy sbs: wthdr state + dlrium
56				
57	E040.11	Korsakoff's non-alcoholic psychosis	Eu19500	[X]Ment/behav dis mlti drug use/oth psyc sbs: psychotc dis
58				
59	E23..00	Alcohol dependence syndrome	Eu19600	[X]Mental/behav dis multi drg use/oth psy sbs:

1	E23..11	Alcoholism	Eu19700	amnesic syndr [X]Men/beh dis mlt drg use/oth subs: resid/late psychot dis
2				
3	E23..12	Alcohol problem drinking	Eu19y00	[X]Men/beh dis mlt drg use/oth psy sbs: oth men & behav dis
4				
5	E230.00	Acute alcoholic intoxication in alcoholism	Eu19z00	[X]Ment/beh dis multi drug use/oth psy sbs unsp mnt/beh dis
6				
7	E230.11	Alcohol dependence with acute alcoholic intoxication	Eu1A.00	[X]Mental and behavioural disorders due use of crack cocaine
8				
9	E230000	Acute alcoholic intoxication, unspecified, in alcoholism	Eu1A000	[X]Ment behav dis due use crack cocaine: acute intoxication
10				
11	E230100	Continuous acute alcoholic intoxication in alcoholism	Eu1A100	[X]Mental behav disorders due use crack cocaine: harmful use
12				
13	E230200	Episodic acute alcoholic intoxication in alcoholism	Eu1A200	[X]Mental behav disorders due use crack cocaine: depend synd
14				
15	E230300	Acute alcoholic intoxication in remission, in alcoholism	Eu1A300	[X]Mental behav disord due crack cocaine: withdrawal state
16				
17	E230z00	Acute alcoholic intoxication in alcoholism NOS	Eu1A500	[X]Mental behav disord due crack cocaine: psychotic disorder
18				
19	E231.00	Chronic alcoholism	Eu1Az00	[X]Ment behav dis due crack cocaine: unsp ment and behav dis
20				
21				
22	E231.11	Dipsomania	F11x000	Cerebral degeneration due to alcoholism
23	E231000	Unspecified chronic alcoholism	F11x011	Alcoholic encephalopathy
24	E231100	Continuous chronic alcoholism	F144000	Cerebellar ataxia due to alcoholism
25	E231200	Episodic chronic alcoholism	F25B.00	Alcohol-induced epilepsy
26	E231300	Chronic alcoholism in remission	F375.00	Alcoholic polyneuropathy
27	E231z00	Chronic alcoholism NOS	F394000	Drug-induced myopathy
28				
29	E23z.00	Alcohol dependence syndrome NOS	F394100	Alcoholic myopathy
30	E24..00	Drug dependence	G555.00	Alcoholic cardiomyopathy
31	E24..11	Drug addiction	G852300	Oesophageal varices in alcoholic cirrhosis of the liver
32				
33	E240.00	Opioid type drug dependence	J153.00	Alcoholic gastritis
34	E240.11	Heroin dependence	J610.00	Alcoholic fatty liver
35	E240.12	Methadone dependence	J611.00	Acute alcoholic hepatitis
36	E240.13	Morphine dependence	J612.00	Alcoholic cirrhosis of liver
37	E240.14	Opium dependence	J612000	Alcoholic fibrosis and sclerosis of liver
38	E240000	Unspecified opioid dependence	J613.00	Alcoholic liver damage unspecified
39	E240100	Continuous opioid dependence	J613000	Alcoholic hepatic failure
40	E240200	Episodic opioid dependence	J617.00	Alcoholic hepatitis
41	E240300	Opioid dependence in remission	J617000	Chronic alcoholic hepatitis
42	E240z00	Opioid drug dependence NOS	J61y.00	Other non-alcoholic chronic liver disease
43	E241.00	Hypnotic or anxiolytic dependence	J670800	Alcohol-induced acute pancreatitis
44	E241.11	Anxiolytic dependence	J671000	Alcohol-induced chronic pancreatitis
45	E241.12	Barbiturate dependence	L183.00	Drug dependence in pregnancy, childbirth and the puerperium
46				
47				
48	E241.13	Benzodiazepine dependence	L183.11	Pregnancy and drug dependence
49	E241.14	Diazepam dependence	L183100	Drug dependence during pregnancy - baby delivered
50				
51	E241.15	Librium dependence	L183300	Drug dependence during pregnancy - baby not yet delivered
52				
53	E241.16	Sedative dependence	L183z00	Drug dependence during pregnancy/childbirth/puerperium NOS
54				
55	E241.17	Valium dependence	L255300	Maternal care for (suspected) damage to fetus from alcohol
56				
57	E241000	Hypnotic or anxiolytic dependence, unspecified	SM0..00	Alcohol causing toxic effect
58				
59				
60				

1	E241100 Hypnotic or anxiolytic dependence, continuous	SM00.00 Ethyl alcohol causing toxic effect
2	E241200 Hypnotic or anxiolytic dependence, episodic	SM00000 Ethanol causing toxic effect
3		
4	E241300 Hypnotic or anxiolytic dependence in remission	SM00100 Denatured alcohol causing toxic effect
5		
6	E241z00 Hypnotic or anxiolytic dependence NOS	SM00z00 Ethyl alcohol causing toxic effect NOS
7	E242.00 Cocaine type drug dependence	SM01.00 Methyl alcohol causing toxic effect
8	E242000 Cocaine dependence, unspecified	SM01000 Methanol causing toxic effect
9	E242100 Cocaine dependence, continuous	SM01100 Wood alcohol causing toxic effect
10	E242200 Cocaine dependence, episodic	SM02.00 Isopropyl alcohol causing toxic effect
11	E242300 Cocaine dependence in remission	SM03000 Amyl alcohol causing toxic effect
12	E242z00 Cocaine drug dependence NOS	SM03100 Butyl alcohol causing toxic effect
13	E243.00 Cannabis type drug dependence	SM0y.00 Other alcohol causing toxic effect
14	E243.11 Hashish dependence	SM0z.00 Alcohol causing toxic effect NOS
15	E243.12 Hemp dependence	SyuG000 [X]Toxic effect of other alcohols
16	E243.13 Marihuana dependence	Z1Q6200 Methadone maintenance
17	E243000 Cannabis dependence, unspecified	Z1Q6214 Heroin maintenance
18	E243100 Cannabis dependence, continuous	ZV11300 [V]Personal history of alcoholism
19	E243200 Cannabis dependence, episodic	ZV11311 [V]Problems related to lifestyle alcohol use
20	E243300 Cannabis dependence in remission	ZV11400 [V]Personal history of psychoactive substance abuse
21		
22	E243z00 Cannabis drug dependence NOS	ZV11500 [V]Personal history of drug abuse by injection
23	E244.00 Amphetamine or other psychostimulant dependence	ZV4K100 [V]Drug use
24		
25	E244.11 Psychostimulant dependence	ZV4KC00 [V] Alcohol use
26	E244.12 Stimulant dependence	E245.11 LSD dependence
27	E244000 Amphetamine or psychostimulant dependence, unspecified	E245.12 Lysergic acid diethylamide dependence
28	E244100 Amphetamine or psychostimulant dependence, continuous	E245000 Hallucinogen dependence, unspecified
29	E244200 Amphetamine or psychostimulant dependence, episodic	E245100 Hallucinogen dependence, continuous
30	E244300 Amphetamine or psychostimulant dependence in remission	E245200 Hallucinogen dependence, episodic
31	E244z00 Amphetamine or psychostimulant dependence NOS	E245300 Hallucinogen dependence in remission
32	E244z11 Amphetamine or psychostimulant dependence NOS	E245.00 Hallucinogen dependence
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

ATTEMPTED SUICIDE**At least one ICD-9 in:**

- E950 Self-inflicted poisoning
- E950.0 Self-inflicted poisoning by analgesics antipyretics and antirheumatics
 - E950.1 Self-inflicted poisoning by barbiturates
 - E950.2 Self-inflicted poisoning by other sedatives and hypnotics
 - E950.3 Self-inflicted poisoning by tranquilizers and other psychotropic agents
 - E950.4 Self-inflicted poisoning by other specified drugs and medicinal substances
 - E950.5 Self-inflicted poisoning by unspecified drug or medicinal substance
 - E950.6 Self-inflicted poisoning by agricultural and horticultural chemical and pharmaceutical preparations other than plant foods and fertilizers
 - E950.7 Self-inflicted poisoning by corrosive and caustic substances
 - E950.8 Self-inflicted poisoning by arsenic and its compounds
 - E950.9 Self-inflicted poisoning by other and unspecified solid and liquid substances
- E951 Self-inflicted poisoning
- E951.0 Self-inflicted poisoning by gas distributed by pipeline
 - E951.1 Self-inflicted poisoning by liquefied petroleum gas distributed in mobile containers
 - E951.8 Self-inflicted poisoning by other utility gas
- E952 Self-inflicted poisoning
- E952.0 Self-inflicted poisoning by motor vehicle exhaust gas
 - E952.1 Self-inflicted poisoning by other carbon monoxide
 - E952.8 Self-inflicted poisoning by other specified gases and vapors
 - E952.9 Self-inflicted poisoning by un specified gases and vapors
- E953 Self-inflicted injury by hanging, strangulation and suffocation
- E953.0 Self-inflicted injury by hanging
 - E953.1 Self-inflicted injury by suffocation by plastic bag
 - E953.8 Self-inflicted injury by other specified means
 - E953.9 Self-inflicted injury by other unspecified means
- E954 Self-inflicted injury by drowning
- E955 Self-inflicted injury by firearms and explosives
- E955.0 Self-inflicted injury by handgun
 - E955.1 Self-inflicted injury by shotgun
 - E955.2 Self-inflicted injury by hunting rifle
 - E955.3 Self-inflicted injury by military firearms
 - E955.4 Self-inflicted injury by other and unspecified firearm
 - E955.5 Self-inflicted injury by explosives
 - E955.6 Self-inflicted injury by air gun
 - E955.7 Self-inflicted injury by paintball gun
 - E955.9 Self-inflicted injury by firearms and explosives unspecified
- E956 Self-inflicted injury by cutting and piercing instrument
- E957 Self-inflicted injury by jumping from high places
- E957.0 Self-inflicted injury by jumping from residential premises
 - E957.1 Self-inflicted injuries by jumping from other man-made structures
 - E957.2 Self-inflicted injuries by jumping from natural sites
 - E957.9 Self-inflicted injuries by jumping from unspecified site
- E958 Self-inflicted injury
- E958.0 Self-inflicted injury by jumping or lying before a moving object
 - E958.1-E958.2 Self-inflicted injury by smoke, fire, flames, steam, hot vapours and

hot objects

E958.3, E958.4, E958.6-E958.9 Self-inflicted injury by other and unspecified means

E958.5 Self-inflicted injury by crashing of motor vehicle

E959 Late effects of self-inflicted injury

OR

At least one ICD-10 in:

X60-84 Intentional self-harm

X60 Intentional self-poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics

X61 Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified

X62 Intentional self-poisoning by and exposure to narcotics and psychodysleptics [hallucinogens], not elsewhere classified

X63 Intentional self-poisoning by and exposure to other drugs acting on the autonomic nervous system

X64 Intentional self-poisoning by and exposure to other and unspecified drugs, medicaments and biological substances

X65 Intentional self-poisoning by and exposure to alcohol

X66 Intentional self-poisoning by and exposure to organic solvents and halogenated hydrocarbons and their vapours

X67 Intentional self-poisoning by and exposure to other gases and vapours

X68 Intentional self-poisoning by and exposure to pesticides

X69 Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances

X70 Intentional self-harm by hanging, strangulation and suffocation

X71 Intentional self-harm by drowning and submersion

X72 Intentional self-harm by handgun discharge

X73 Intentional self-harm by rifle, shotgun and larger firearm discharge

X74 Intentional self-harm by other and unspecified firearm discharge

X75 Intentional self-harm by explosive material

X76 Intentional self-harm by smoke, fire and flames

X77 Intentional self-harm by steam, hot vapours and hot objects

X78 Intentional self-harm by sharp object

X79 Intentional self-harm by blunt object

X80 Intentional self-harm by jumping from a high place

X81 Intentional self-harm by jumping or lying before moving object

X82 Intentional self-harm by crashing of motor vehicle

X83 Intentional self-harm by other specified means

X84 Intentional self-harm by unspecified means

Y87.0 Late effects of intentional self-harm

OR

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

At least one READ code in:

SL...15	Overdose of drug	U1A4.11	[X]Accidental poisoning with antidepressant
T8...00	Accidental poisoning by drugs, medicines and biologicals	T952.00	Accidental poisoning from other fish
T91z.00	Accidental poisoning by household agents NOS	ZX1C.00	Nipping self
U20...11	[X]Deliberate drug overdose / other poisoning	ZX17.00	Head-banging
T8...11	Cause of overdose - accidental	T938000	Accidental poisoning by cyanides
1BD1.00	Suicidal ideation	U20A000	[X]Intent self pois organ solvent,halogen hydrocarb, home
T803000	Accidental poisoning by aspirin	TK7z.00	Suicide+selfinflicted injury-jump from high place NOS
TK05.00	Suicide + selfinflicted poisoning by drug or medicine NOS	T964200	Accidental poisoning by cadmium and its compounds
T921300	Accidental poisoning by kerosene	ZX1B200	Jumping from bridge
TK...15	Attempted suicide	T953z00	Accidental poisoning from berries or seeds NOS
T930.00	Accidental poisoning by organochlorine insecticides	T80y.00	Accidental poisoning by oth analgesics,antipyretic,antirheum
U1A..12	[X]Accidental drug overdose / other poisoning	TKx0000	Suicide + selfinflicted injury-jumping before moving object
TK...17	Para-suicide	U209z00	[X]Intent self poison alcohol unspecif place
TK...12	Injury - self-inflicted	T930500	Accidental poisoning by toxaphene
U2...13	[X]Suicide	ZX11400	Biting own arm
1BD3.00	Suicidal plans	T954.00	Accidental poisoning from other plants
T924z00	Accidental poisoning by other solvents NOS	T820.00	Accidental poisoning by chloral hydrate
T81..00	Accidental poisoning by barbiturates	U221.00	[X]Intent self harm by drowning/submersn occ resid instit'n
T804100	Accidental poisoning by paracetamol	T935200	Accidental poisoning by chlorates
U2E..00	[X]Self mutilation	T930100	Accidental poisoning by chlordane
1BD4.00	Suicide risk	U1A0z00	[X]Accid poison/expos to nonopioid analgesic unspecif place
TK3y.00	Suicide + selfinflicted inj oth mean hang/strangle/suffocate	U204.13	[X]Overdose - SSRI
TK...11	Cause of overdose - deliberate	T951.00	Accidental poisoning from shellfish
146B.00	H/O: deliberate self harm	U2A1.00	[X]Intent self harm by blunt object occ resident instit'n
U2...15	[X]Para-suicide	T903300	Accidental poisoning by secondary propyl alcohol
1B19.11	Suicidal - symptom	TK3z.00	Suicide + selfinflicted inj by hang/strangle/suffocate NOS
TK60111	Slashed wrists self inflicted	T854.00	Accidental poisoning by anticholinergics
ZX1..13	Deliberate self-harm	TK72.00	Suicide+selfinflicted injury-jump from natural sites
U209.00	[X]Intent self poison/exposure to alcohol	U2zz.00	[X]Intent self harm by unspecif means occ at unspecif place
ZX...00	Self-harm	U1A9z00	[X]Accid poison/expos to alcohol unspecif place
T99y000	Accidental poisoning by chlorine	U409z00	[X]Pois/expos ?intent to alcohol unspecif place
TK...13	Poisoning - self-inflicted	T83yz00	Accidental poisoning by other tranquillisers NOS
U2...11	[X]Self inflicted injury	T842100	Accidental poisoning by caffeine
146A.00	H/O: attempted suicide	T806300	Accidental poisoning by ibuprofen
TK60100	Self inflicted lacerations to wrist	U408z00	[X]Pois/expos ?intent to oth/unsp drug/medic unspecif place

ZX17100	Banging own head against object	U20y200	[X]Int self poison unspecif chemical school/pub admin area
SL...14	Overdose of biological substance	U1A2.00	[X]Accident poisoning/exposure to sedative hypnotic
1BDC.00	Intent of deliberate self harm with detailed plans	TK70.00	Suicide+selfinflicted injury-jump from residential premises
ZX16211	Poking own eyes	TK2..00	Suicide + selfinflicted poisoning by other gases and vapours
ZX13.00	Cutting self	T840200	Accidental poisoning by monoamine oxidase inhibitors
1BDA.00	Thoughts of deliberate self harm	T93z.00	Accidental poisoning agricultural chemical preparations NOS
ZX14200	Pulling out sutures	T832z00	Accidental poisoning- benzodiazepine-based tranquilliser NOS
TK30.00	Suicide and selfinflicted injury by hanging	T932.00	Accidental poisoning by carbamates
14K0.00	H/O: repeated overdose	TN04.00	Injury ?accidental, poisoning by other spec drug/medicament
T967.00	Accidental poisoning by cosmetics	ZX1K.00	Self-incineration
TK00.00	Suicide + selfinflicted poisoning by analgesic/antipyretic	U40y400	[X]Pois/expos ?intent unspecif chemical in street/highway
TK60.00	Suicide and selfinflicted injury by cutting	U40B400	[X]Pois/expos ?intent other gas/vapour in street/highway
1B19.00	Suicidal	T993000	Accidental poisoning by bromobenzyl cyanide
T901.00	Accidental poisoning by other ethyl alcohol and its products	T832100	Accidental poisoning by diazepam
T9...00	Accidental poisoning by other non-drug substances	U405.00	[X]Poisoning/exposure, ? intent, to narcotic drug
TK01.00	Suicide + selfinflicted poisoning by barbiturates	U208000	[X]Int self poison/exposure to oth/unsp drug/medicam home
14K..00	H/O: poisoning	T840.00	Accidental poisoning by antidepressants
U30..11	[X]Deliberate drug poisoning	U1Ayy00	[X]Accid pois/expos to unspecif chemical other spec place
U2...00	[X]Intentional self-harm	T971.00	Accidental poisoning by coal gas NOS
U2...14	[X]Attempted suicide	T99yz00	Accidental poisoning by other gases and vapours NOS
T955.00	Accidental poisoning from mushrooms and other fungi	U2A..00	[X]Intentional self harm by blunt object
T80..00	Accidental poisoning by analgesics,antipyretic,antirheumatic	T840000	Accidental poisoning by amitriptyline
T88..00	Accidental poisoning by other drugs	T805.00	Accidental poisoning by pyrazole derivatives
T8z..00	Accidental poisoning by drugs NOS	U2C4.00	[X]Int self harm jump/lying befr mov obje occ street/highway
T840z00	Accidental poisoning by antidepressants NOS	U274.00	[X]Intent self harm by smoke fire/flame occ street/highway
U1AB.11	[X]Accidental carbon monoxide poisoning	U400.00	[X]Poisoning/exposure, ? intent, to nonopioid analgesic
T90..00	Accidental poisoning by alcohol, NEC	U1ADz00	[X]Acc poison by and exposure to amphetamine - unspec places
U200.11	[X]Overdose - paracetamol	T825.00	Accidental poisoning by mixed sedatives NEC
1BD8.00	At risk of DSH - deliberate self harm	U1A9000	[X]Accident poison/exposure to alcohol at home
ZX13100	Cutting own wrists	T832500	Accidental poisoning by nitrazepam
ZX1P.00	Swallowing substances	U1A2.13	[X]Accidental poisoning with temazepam
ZX1I.00	Self-scalding	T83y.00	Accidental poisoning by other tranquillisers
T91..00	Accidental poisoning by household agents	U4A5.00	[X]Contct wth blunt obj undet intent occ trade/service area

1	T921200	Accidental poisoning by petrol	TN0..00	Injury ?accidental, poisoning by solid/liquid substances
2	U2...12	[X]Injury - self-inflicted	T912.00	Accidental poisoning by polishes
3	U200z00	[X]Intent self poison nonopioid analgesic unspecif place	T916z00	Accidental poisoning by paint or varnish NOS
4				
5	U1A..11	[X]Accidental drug / other poisoning	U1A9400	[X]Accid poison/expos alcohol in street/highway
6				
7	TK...14	Suicide and self harm	TN07.00	Injury ?accidental, poisoning by agricultural chemicals
8				
9	TK...00	Suicide and selfinflicted injury	T980100	Accidental poisoning by butane
10	U200.00	[X]Intent self poison/exposure to nonopioid analgesic	ZX1L600	Self-mutilation of ears
11				
12	T910.00	Accidental poisoning by synthetic detergents and shampoos	ZX1L500	Enucleation of own eyes
13				
14	ZV1B200	[V]Personal history of self-harm	ZX1K.11	Setting fire to self
15	TK04.00	Suicide + selfinflicted poisoning by other drugs/medicines	T964000	Accidental poisoning by beryllium and its compounds
16				
17	ZX11.00	Biting self	ZX1E.00	Pinching self
18	U1Ay.00	[X]Accident poisoning/exposure to unspecif chemical	U20Bz00	[X]Intent self poison other gas/vapour unspecif place
19				
20	TK3..00	Suicide + selfinflicted injury by hang/strangulate/suffocate	T920z00	Accidental poisoning by petrol solvents NOS
21				
22	T935.00	Accidental poisoning by herbicides	U211.00	[X]Intent self harm by hangng strangult/suffoct resid instit
23				
24	T913z00	Accidental poisoning by other cleaning agents NOS	T965100	Accidental poisoning by fertilisers
25				
26	T884.00	Accidental poisoning by gastrointestinal system drugs	U1A3.00	[X]Accident poisoning/exposure to antiparkinson drug
27				
28	T96y.00	Accidental poisoning by other solid and liquid substances OS	T983z00	Accidental poisoning by carbon monoxide - domestic fuel NOS
29				
30	TK7..00	Suicide and selfinflicted injury by jumping from high place	TKx5.00	Suicide and selfinflicted injury by crashing motor vehicle
31				
32	U40..00	[X]Poisoning/expos to noxious substance,undetermined intent	T822000	Accidental poisoning by bromides
33				
34	U20A.11	[X]Self poisoning from glue solvent	T930300	Accidental poisoning by dieldrin
35	T970.00	Accidental poisoning by carbon monoxide from piped gas	T938.00	Accidental poisoning by fumigants
36				
37	U27..00	[X]Intentional self harm by smoke, fire and flames	U1A6.00	[X]Accident poisoning/exposure to hallucinogen
38				
39	U20B.11	[X]Self carbon monoxide poisoning	U40A300	[X]Pois/exp ?intent org solvent,halogen hydrocarb,sport area
40				
41	T95..00	Accidental poisoning from foodstuffs and poisonous plants	ZX1L811	Snapping own bones
42				
43	U1A..00	[X]Accidental poisoning by + exposure to noxious substances	TK54.00	Suicide and selfinflicted injury by other firearm
44				
45	ZX11200	Biting own fingers	T961000	Accidental poisoning by mercury, unspecified
46	ZX11500	Biting own tongue	TK6z.00	Suicide and selfinflicted injury by cutting and stabbing NOS
47				
48	TN...11	Poisoning undetermined - accidentally or purposely inflicted	U4C..00	[X]Falling lying running befor/into moving obj undet intent
49				
50	ZX19.00	Hitting self	T843100	Accidental poisoning by opiate antagonists
51	ZX1G.00	Scratches self	TN21.00	Injury ?accidental, poisoning by other carbon monoxide
52				
53	1BD7.00	Low suicide risk	T921z00	Accidental poisoning by petrol fuel or cleaner NOS
54				
55	T911.00	Accidental poisoning by soap products	U1AD000	[X]Accident poisoning by and exposure to
56				
57				
58				
59				
60				

1	U29..00	[X]Intentional self harm by sharp object	U1A5000	amphetamine - home [X]Accident poison/exposure to narcotic drug at home
2				
3	TK61.00	Suicide and selfinflicted injury by stabbing	U201.00	[X]Intent self poison/exposure to antiepileptic
4	TK03.00	Suicide + selfinflicted poisoning	TKxy.00	Suicide and selfinflicted injury by other specified means
5		tranquilliser/psychotropic		
6	T842000	Accidental poisoning by amphetamine	TK01000	Suicide and self inflicted injury by Amylobarbitone
7				
8	U20..00	[X]Intentional self poisoning/exposure to noxious substances	U201z00	[X]Intent self poison antiepileptic unspecif place
9				
10	U40y.00	[X]Poisoning/exposure, ? intent, to unspecif chemical	U204z00	[X]Intent self poison psychotropic drug unspecif place
11				
12	T953000	Accidental poisoning from berries	T936000	Accidental poisoning by organic mercurials
13	TK07.00	Suicide + selfinflicted poisoning by corrosive/caustic subst	U1A7z00	[X]Accid poison/expos to oth autonomic drug unspecif place
14				
15	T913.00	Accidental poisoning by other cleaning agents	TK0z.00	Suicide + selfinflicted poisoning by solid/liquid subst NOS
16				
17	TK51.00	Suicide and selfinflicted injury by shotgun	U207z00	[X]Intent self poison oth autonomic drug unspecif place
18				
19	U45..00	[X]Other+unspecified firearm discharge undetermined intent	T83z.00	Accidental poisoning by tranquilisers NOS
20				
21	ZX1LD00	[X]Self mutilation	U402.00	[X]Poisoning/exposure, ? intent, to sedative hypnotic
22				
23	ZX1..14	Self-abusive behaviour	T84z.00	Accidental poisoning by psychotropic agents NOS
24				
25	ZX18.00	Hanging self	T96..00	Accidental poisoning by other solid and liquid substances
26				
27	U205.11	[X]Overdose - heroin	U1AA000	[X]Accid poison/expos organ solvent,halogen hydrocarb, home
28				
29	T938200	Accidental poisoning by phosphine	U40B.00	[X]Poisoning/exposure, ? intent, to other gas/vapour
30				
31	U200.13	[X]Overdose - aspirin	U1AC.12	[X]Accidental poisoning with paraquat
32	U409.00	[X]Poisoning/exposure, ? intent, to alcohol	U1Ay600	[X]Acc pois/expos unspecif chemical indust/construct area
33				
34	T955000	Accidental poisoning from mushrooms	TK5..00	Suicide and selfinflicted injury by firearms and explosives
35				
36	U290.00	[X]Intentional self harm by sharp object occurrence at home	TN20.00	Injury ?accidental, poisoning by motor vehicle exhaust gas
37				
38	TK0..00	Suicide + selfinflicted poisoning by solid/liquid substances	T921.00	Accidental poisoning by petrol fuels and cleaners
39				
40	U21..00	[X]Intent self harm by hanging strangulation / suffocation	U4A3.00	[X]Contct wth blunt obj undet intent occ sport/athletic area
41				
42	ZX1H100	Self-strangulation	T831000	Accidental poisoning by haloperidol
43	T916200	Accidental poisoning by non-lead paints	U280.00	[X]Intent self harm by steam hot vapour/hot obj occ at home
44				
45	U1A9.00	[X]Accident poisoning/exposure to alcohol	U2y0.00	[X]Intentionl self harm by oth specif means occurrn at home
46				
47	T935500	Accidental poisoning by paraquat	T935z00	Accidental poisoning by herbicides NOS
48	TN1..00	Injury ?accidental, poisoning by gases in domestic use	T80yz00	Accidental poisoning-oth analgesic,antipyretic,antirheum NOS
49				
50	TK4..00	Suicide and selfinflicted injury by drowning	U241.00	[X]Int self harm rifl s'gun/lrg frarm disch occ resid instit
51				
52	ZX1L.00	Self-mutilation	T955z00	Accidental poisoning from mushrooms and fungi NOS
53				
54	ZX19300	Head-hitting	U406y00	[X]Pois/exp ?intent to hallucinogen other spec place
55				
56				
57				
58				
59				
60				

1	ZX1..11	Self-destructive behaviour	T935400	Accidental poisoning by mixtures herbicides+plant food etc
2	T92..00	Accidental poisoning by petrol products	U4D3.00	[X]Crash of motor vehicle undeterm intent sport/athlet area
3				
4	TK02.00	Suicide + selfinflicted poisoning by oth sedatives/hypnotics	T82y.00	Accidental poisoning by other sedatives and hypnotics OS
5				
6	T914.00	Accidental poisoning by disinfectants	U20C.12	[X]Self poisoning with paraquat
7	T88yz00	Accidental poisoning by other drugs NOS	T940.00	Accidental poisoning by corrosive aromatics
8	T961.00	Accidental poisoning by mercury and its compounds and fumes	TN05.00	Injury ?accidental, poisoning by drug or medicament NOS
9				
10				
11	T9z..00	Accidental poisoning NOS	T802.00	Accidental poisoning by other opiates
12	T85..00	Accidental poisoning by other drugs acting on nervous system	T841.00	Accidental poisoning by hallucinogens
13				
14	T883.00	Accidental poisoning by cardiovascular system drugs	U1A2.12	[X]Accidental poisoning with diazepam
15				
16	U2z..00	[X]Intentional self harm by unspecified means	U2A0.00	[X]Intentional self harm by blunt object occurrence at home
17				
18	U1AA.11	[X]Accidental poisoning from glue solvent	U208z00	[X]Intent self poison oth/unsp drug/medic unspecif place
19				
20	T886.00	Accidental poisoning by muscle + respiratory system drugs	T991.00	Accidental poisoning by sulphur dioxide
21				
22	U204.12	[X]Overdose - amitriptyline	U409000	[X]Poison/exposure ?intent, to alcohol at home
23				
24	T923000	Accidental poisoning by paraffin wax	T99..00	Accidental poisoning by other gases and vapours
25				
26	T902000	Accidental poisoning by methanol	T850.00	Accidental poisoning by anticonvulsant + anti-parkinson drug
27				
28	ZX10.00	Swallowing objects	T850.11	Accidental poisoning by anticonvulsant
29	ZX1L100	Self-mutilation of hands	U205z00	[X]Intent self poison narcotic drug unspecif place
30				
31	ZX1..00	Self-injurious behaviour	U202z00	[X]Intent self poison sedative hypnotic unspecif place
32				
33				
34	1BD5.00	High suicide risk	U207.00	[X]Intent self poison/exposure to oth autonomic drug
35				
36	ZX1LA00	Removing own nails	U20C.00	[X]Intent self poison/exposure to pesticide
37	ZX11100	Biting own hand	T964700	Accidental poisoning by thallium compounds
38	ZX11300	Biting own toes	U40y600	[X]Poison/expos ?intent unspec chemic indust/construct area
39				
40	U4D0.00	[X]Crashng of motor vehicle undetermined intent occ at home	T95y.00	Accidental poisoning by other foods
41				
42	T800.11	Accidental poisoning by diamorphine	T88y000	Accidental poisoning by central appetite depressants
43				
44	U2D4.00	[X]Intent self harm by crash motor vehicl occ street/highway	T961z00	Accidental poisoning by mercury, NOS
45				
46	U208.00	[X]Int self poison/exposure to other/unspec drug/medicament	U1A8y00	[X]Accid pois/expos to oth/unsp drug/medic other spec place
47				
48	T887000	Accidental poisoning by skin drugs	ZX1K.12	Setting self alight
49	TKx2.00	Suicide and selfinflicted injury by scald	U720.00	[X]Sequelae of intentional self-harm
50	U4B..00	[X]Falling jumping/pushed from high place undeterm intent	U2yz.00	[X]Intent self harm by oth specif means occ unspecif place
51				
52	TK6..00	Suicide and selfinflicted injury by cutting and stabbing	U202y00	[X]Int self poison sedative hypnotic other spec place
53				
54	T86..00	Accidental poisoning by antibiotics	U404300	[X]Pois/exp ?intent psychotropic drug in sport/athletic area
55				
56				
57	T98..00	Accidental poisoning by other utility gas + carbon monoxide	T802z00	Accidental poisoning by other opiates NOS
58				
59				

1	U204.00	[X]Intent self poison/exposure to psychotropic drug	U409200	[X]Pois/exp ?intent alcohol school/pub admin area
2	ZX13.11	Cuts self	U1Ayz00	[X]Accid poison/expos to unspecif chemical unspecif place
3			T950.00	Accidental poisoning from meat
4	T966000	Accidental poisoning by glues	U1A1.00	[X]Accident poisoning/exposure to antiepileptic
5	ZX14100	Reopening scars	T913000	Accidental poisoning by scouring agents
6			TK10.00	Suicide + selfinflicted poisoning by gas via pipeline
7	T901100	Accidental poisoning by methylated spirit	TN08.00	Injury ?accidental, poisoning by arsenic or its compounds
8	T935300	Accidental poisoning by diquat	T966y00	Accidental poisoning by other adhesives
9			U205y00	[X]Int self poison narcotic drug other spec place
10	T902.00	Accidental poisoning by methyl alcohol	TK1..00	Suicide + selfinflicted poisoning by gases in domestic use
11			U20A400	[X]Int self poison org solvent,halogen hydrocarb,in highway
12	1BD6.00	Moderate suicide risk	T803z00	Accidental poisoning by salicylates NOS
13	T83..00	Accidental poisoning by tranquilisers	U1A2000	[X]Accident poison/exposure to sedative hypnotic at home
14			T931300	Accidental poisoning by malathion
15	U1AB.00	[X]Accident poisoning/exposure to other gas/vapour	TKx0.00	Suicide + selfinflicted injury-jump/lie before moving object
16	T942z00	Accidental poisoning by caustic alkalis NOS	TN1z.00	Injury ?accidental, poisoning by gas in domestic use NOS
17			T85z.00	Accidental poisoning by drugs acting on nervous system NOS
18	T841000	Accidental poisoning by cannabis derivatives	TKx4.00	Suicide and selfinflicted injury by electrocution
19	ZX12.00	Burning self	T807.00	Accidental poisoning by other non-narcotic analgesics
20			TK11.00	Suicide + selfinflicted poisoning by liquified petrol gas
21	U27z.00	[X]Intent self harm by smoke fire/flames occ unspecif place	TN0z.00	Injury ?accidental, poisoning by solid or liquid subst NOS
22	T901300	Accidental poisoning by ethanol, NOS	ZX...11	Self-damage
23			TKxz.00	Suicide and selfinflicted injury by other means NOS
24	T88z.00	Accidental poisoning by unspecified drugs	T806.00	Accidental poisoning by antirheumatics
25	ZX11600	Biting sides of own cheeks	T964600	Accidental poisoning by nickel compounds
26			T813.00	Accidental poisoning by pentobarbitone
27	T88y.00	Accidental poisoning by other drugs OS	T806z00	Accidental poisoning by antirheumatics NOS
28	T937300	Accidental poisoning by warfarin	ZX19100	Punching self
29			U2B0.00	[X]Intent self harm by jumping from high place occ at home
30	U20B200	[X]Int self poison other gas/vapour school/pub admin area	U270.00	[X]Intention self harm by smoke fire/flames occurrn at home
31	U2y..00	[X]Intentional self harm by other specified means	U206400	[X]Intent self pois hallucinogen in street/highway
32			C110100	Self-induced hyperinsulinism
33	T973.00	Accidental poisoning by piped natural gas	T916000	Accidental poisoning by lacquers
34	T93..00	Accidental poisoning by agricultural chemical preparations	T850z00	Accidental poisoning by anticonvulsant/anti-
35	ZX13200	Cutting own throat		
36	T806100	Accidental poisoning by indomethacin		
37	ZX1A.00	Inserting foreign bodies into own orifices		
38	T924.00	Accidental poisoning by other solvents		
39	T97..00	Accidental poisoning by gas distributed by pipeline		
40	ZX14300	Poking fingers into wound		
41				
42	ZX11111	Hand biting		
43				
44	T802200	Accidental poisoning by morphine		
45				
46	T881.00	Accidental poisoning by primarily systemic agents		
47	U41..00	[X]Hanging strangulation + suffocation undetermined intent		
48				
49	T900.00	Accidental poisoning by alcoholic beverages		
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				

1	ZV15600	[V]Personal history of poisoning	T854000	parkin drug NOS
2	T98z.00	Accidental poisoning by carbon monoxide NOS	T830200	Accidental poisoning by atropine
3	TKz..00	Suicide and selfinflicted injury NOS	T931z00	Accidental poisoning by prochlorperazine
4				Accidental poisoning by organophosphorus insecticides NOS
5	ZX1B.00	Jumping from height	T964.00	Accidental poisoning by other metals + compounds and fumes
6			U29y.00	[X]Intention self harm by sharp object occ oth specif place
7	U22..00	[X]Intentional self harm by drowning and submersion	T81z.00	Accidental poisoning by barbiturates NOS
8	U209000	[X]Int self poison/exposure to alcohol at home	U28z.00	[X]Intent self harm by steam hot vapour/obj occ unspec place
9	U1AB600	[X]Acc pois/expos other gas/vapour indust/construct area	TK2z.00	Suicide + selfinflicted poisoning by gases and vapours NOS
10	U1ABz00	[X]Accid poison/expos to other gas/vapour unspecif place	U26..00	[X]Intentional self harm by explosive material
11	T916.00	Accidental poisoning by other paints and varnishes	U1A8100	[X]Accid poison/expos to oth/unsp drug/medicam res institut
12	U20yz00	[X]Intent self poison unspecif chemical unspecif place	T95z.00	Accidental poisoning by foodstuffs and poisonous plants NOS
13	U2C..00	[X]Intent self harm by jumping / lying before moving object	U207000	[X]Int self poison/exposure to oth autonomic drug at home
14	U2z0.00	[X]Intentional self harm by unspecif means occurrn at home	T936.00	Accidental poisoning by fungicides
15	T981z00	Accidental poisoning by utility gas NOS	U1A8z00	[X]Accid poison/expos to oth/unsp drug/medic unspecif place
16	U20A.00	[X]Intentional self poison organ solvent,halogen hydrocarb	U2Cy.00	[X]Int self harm jump/lying bef mov obje occ oth specif plice
17	TKy..00	Late effects of selfinflicted injury	T963100	Accidental poisoning by arsenic compounds
18	U21z.00	[X]Intent self harm by hangng strangul/suffoct unspecif plce	T903100	Accidental poisoning by isopropanol
19	U1AD.00	[X]Accidental poisoning by and exposure to amfetamine	T855100	Accidental poisoning by noradrenalin
20	T931.00	Accidental poisoning by organophosphorus insecticides	T932200	Accidental poisoning by propoxur
21	U1A0000	[X]Accident poison/exposure to nonopioid analgesic at home	T932100	Accidental poisoning by carbaryl
22	T98yz00	Accidental poisoning by carbon monoxide from oth source NOS	T963.00	Accidental poisoning by arsenic and its compounds and fumes
23	T92z.00	Accidental poisoning by solvent NOS	T853.00	Accidental poisoning by cholinergics
24	TK71.00	Suicide+selfinflicted injury-jump from oth manmade structure	U2y1.00	[X]Intent self harm by oth specif means occ resid instit'n
25	T84..00	Accidental poisoning by other psychotropic agents	T98y200	Accidental poisoning by CO - fuels in industrial use
26	U40C.00	[X]Poisoning/exposure, ? intent, to pesticide	ZX1Q.11	Jumping under train
27	T915.00	Accidental poisoning by lead paints	U20C.11	[X]Self poisoning with weedkiller
28	U1AC.11	[X]Accidental poisoning with weedkiller	T961200	Accidental poisoning by mercury fumes
29	U4A..00	[X]Contact with blunt object, undetermined intent	ZX1H200	Self-suffocation
30	T937z00	Accidental poisoning by rodenticides NOS	T916300	Accidental poisoning by white washes
31	U204000	[X]Int self poison/exposure to psychotropic drug at home	ZX1L900	Pulling own teeth out
32	U202000	[X]Int self poison/exposure to sedative hypnotic at home	U294.00	[X]Intention self harm by sharp object occ street/highway
33	T96z.00	Accidental poisoning by solid and liquid substances NOS		

T934.00	Accidental poisoning by other insecticides	ZX1L300	Self-mutilation of penis
T953100	Accidental poisoning from seeds	U21y.00	[X]Intent self harm by hangng strangul/suffocat oth spec plce
U47..00	[X]Exposure to smoke, fire and flames, undetermined intent	T815.00	Accidental poisoning by quinalbarbitone
T832.00	Accidental poisoning by benzodiazepine-based tranquillisers	U4D7.00	[X]Crashng of motor vehicle undetermined intent occ on farm
T82..00	Accidental poisoning by other sedatives and hypnotics	ZX1R.00	Throwing self in front of vehicle
U200.12	[X]Overdose - ibuprofen	U1Ay200	[X]Acc poison/expos unspecif chemical school/pub admin area
T920.00	Accidental poisoning by petroleum solvents	U1A3500	[X]Accid poison/expos antiparkinson drug trade/service area
ZX1B100	Jumping from building	U1A9500	[X]Accid poison/expos alcohol trade/service area
U2D0.00	[X]Intent self harm by crash of motor vehicl occurrn at home	T832400	Accidental poisoning by medazepam
ZX1F.00	Rubbing own skin	TN2..00	Injury ?accidental, poisoning by other gases
T887300	Accidental poisoning by otorhinolaryngological drugs	U410.00	[X]Hanging strangulat+suffocat undet intent occurrn at home
T880.00	Accidental poisoning by hormones and synthetic substitutes	T920200	Accidental poisoning by petroleum naphtha
U1Ay000	[X]Accident poison/exposure to unspecif chemical at home	T887z00	Accidental poisoning by skin, eye, ENT and dental drug NOS
T885.00	Accidental poisoning by water,mineral,uric acid metab drugs	U2C1.00	[X]Int self harm jump/lying befr mov obje occ resid instit'n
U25..00	[X]Intent self harm by other/unspecified firearm discharge	T921.12	Accidental poisoning by petroleum fuels
U205.00	[X]Intent self poison/exposure to narcotic drug	T940011	Accidental poisoning by phenol
U202.12	[X]Overdose - diazepam	U1AC000	[X]Accident poison/exposure to pesticide at home
U72..00	[X]Sequel intentn self-harm assault+event of undeterm intent	TN11.00	Injury ?accidental, poisoning by liquid petrol gas
ZX1LB00	Eating own flesh	U2Bz.00	[X]Int self harm by jump from high place occ unspecif place
ZX17200	Banging own head against own body parts	TK1z.00	Suicide + selfinflicted poisoning by domestic gases NOS
T983100	Accidental poisoning by CO- coke in domestic stove/fireplace	T98y000	Accidental poisoning by CO - blast furnace gas
U49..00	[X]Contact with sharp object, undetermined intent	TK01400	Suicide and self inflicted injury by Phenobarbitone
ZX15.00	Drowning self	T85y.00	Accid. poisoning by other drugs acting on nervous system OS
U204.11	[X]Overdose - antidepressant	U22y.00	[X]Intent self harm by drown/submersn occ oth specif place
T814.00	Accidental poisoning by phenobarbitone	U20Cy00	[X]Int self poison pesticide other spec place
U1A2.11	[X]Accidental poisoning with sleeping tablets	U206.00	[X]Intent self poison/exposure to hallucinogen
TKx1.00	Suicide and selfinflicted injury by burns or fire	U202.18	[X]Overdose - amobarbital
U2B..00	[X]Intentional self harm by jumping from a high place	T830000	Accidental poisoning by chlorpromazine
T470.00	Accidental poisoning by gases or fumes on ship	ZX16.00	Gouging own body parts
ZX1LC00	Stripping own skin	T807z00	Accidental poisoning by non-narcotic analgesics NOS
ZRLfC12	HoNOS item 2 - non-accidental self injury	T887400	Accidental poisoning by dental drugs
ZX1L911	Extracting own teeth	U1Ay500	[X]Accid poison/expos unspecif chemical trade/service area

1	1BDB.00	Plans for deliberate self harm without intent	T966.00	Accidental poisoning by glues and adhesives
2	ZX11.11	Bites self	ZX1B300	Jumping from cliff
3	U1A2.15	[X]Accidental poisoning with nitrazepam	U2B6.00	[X]Int self harm by jump from high place indust/constr area
4	TKx..00	Suicide and selfinflicted injury by other means	U250.00	[X]Intent self harm oth/unspecif firearm disch occ at home
5	TH02.00	Late effects of accidental poisoning	ZX1L700	Self-inducing a prolapse
6	ZX1..12	SIB - Self-injurious behaviour	T852100	Accidental poisoning by lignocaine
7	T937200	Accidental poisoning by thallium	U1A5z00	[X]Accid poison/expos to narcotic drug unspecif place
8	T981400	Accidental poisoning by cooking gas NOS	U409400	[X]Pois/expos ?intent alcohol in street/highway
9	T921100	Accidental poisoning by gas oils	U2zy.00	[X]Intent self harm by unspecif means occ oth specif place
10	T965000	Accidental poisoning by plant food	ZX1L800	Breaking own bones
11	U202.16	[X]Overdose - benzodiazepine	TKx7.00	Suicide and selfinflicted injury caustic subst, excl poison
12	ZX1N.00	Stabbing self	U200y00	[X]Int self poison nonopioid analgesic other spec place
13	T803.00	Accidental poisoning by salicylates	U204y00	[X]Int self poison psychotropic drug other spec place
14	TK20.00	Suicide + selfinflicted poisoning by motor veh exhaust gas	T852.00	Accidental poisoning by local anaesthetic
15	T99y.00	Accidental poisoning by other gases and vapours OS	U408000	[X]Poison/exposure ?intent, to oth/unsp drug/medicam home
16	U200000	[X]Int self poison/exposure to nonopioid analgesic at home	U202400	[X]Intent self pois sedative hypnotic in street/highway
17	U1A5.00	[X]Accident poisoning/exposure to narcotic drug	U1ABy00	[X]Accid pois/expos to other gas/vapour other spec place
18	TK1y.00	Suicide and selfinflicted poisoning by other utility gas	U200500	[X]Intent self pois nonopioid analgesic trade/service area
19	T953.00	Accidental poisoning from berries and seeds	U208400	[X]Intent self pois oth/unsp drug/medic in street/highway
20	U202.17	[X]Overdose - barbiturate	U200100	[X]Intent self poison nonopioid analgesic at res institut
21	U1A0.11	[X]Accidental poisoning with paracetamol	U20C000	[X]Int self poison/exposure to pesticide at home
22	T955y00	Accidental poisoning from other fungi	U402z00	[X]Pois/expos ?intent to sedative hypnotic unspecif place
23	T852000	Accidental poisoning by cocaine	U208y00	[X]Int self poison oth/unsp drug/medic other spec place
24	T942000	Accidental poisoning by sodium hydroxide	U209y00	[X]Int self poison alcohol other spec place
25	U1A0.00	[X]Accident poisoning/exposure to nonopioid analgesic	U2z2.00	[X]Intent self harm by unsp mean occ sch/ins/pub adm area
26	T941000	Accidental poisoning by hydrochloric acid	ZX16100	Gouging own flesh
27	ZX1J.00	Self-electrocution	T841z00	Accidental poisoning by hallucinogen NOS
28	T854200	Accidental poisoning by hyoscine	T982z00	Accidental poisoning by exhaust gas from motor vehicle NOS
29	TN00.00	Injury ?accidental, poisoning by analgesic or anti- pyretic	T964500	Accidental poisoning by manganese and its compounds
30	T80z.00	Accidental poisoning by analgesics,antipyretic,antirheum NOS	U404.00	[X]Poisoning/exposure, ? intent, to psychotropic drug
31	ZX19200	Slapping self	U22z.00	[X]Intent self harm by drown/submersn occ unspecified place
32	U1A7.00	[X]Accident poisoning/exposure to oth autonomic drug	T94y.00	Accidental poisoning by other corrosives and caustics

1	U1A0.12	[X]Accidental poisoning with ibuprofen	U20Az00	[X]Int self pois org solv,halogen hydrocarb, unspec place
2	U408.00	[X]Poison/exposure, ?intent, to other/unspec drug/medicament	ZV71600	[V]Observation following other inflicted injury
3	U48..00	[X]Contact with steam hot vapours+objects undetermn intent	T830z00	Accidental poisoning- phenothiazine-based tranquilisers NOS
4	T982100	Accidental poisoning by exhaust gas from gas engine	T924000	Accidental poisoning by benzene
5	ZX15.00	Throwing self onto floor	ZVu0600	[X]Examination & observat following other inflicted injury
6	U24..00	[X]Intent self harm by rifle shotgun/larger firearm disch	TKx3.00	Suicide and selfinflicted injury by extremes of cold
7	T942.00	Accidental poisoning by caustic alkalis	T964100	Accidental poisoning by brass fumes
8	U202.00	[X]Intent self poison/exposure to sedative hypnotic	T960000	Accidental poisoning by lead, unspecified
9	U20B.00	[X]Intent self poison/exposure to other gas/vapour	U40yz00	[X]Pois/expos ?intent to unspecif chemical unspecif place
10	TK21.00	Suicide and selfinflicted poisoning by other carbon monoxide	T980200	Accidental poisoning by propane
11	U1A5.11	[X]Accidental poisoning with heroin	T983.00	Accidental poisoning by carbon monoxide- other domestic fuel
12	U20y000	[X]Int self poison/exposure to unspecif chemical at home	U204100	[X]Intent self poison psychotropic drug at res institut
13	ZC15100	Repeated self-induced vomiting	T964z00	Accidental poisoning by metals + compounds and fumes NOS
14	U202.13	[X]Overdose - temazepam	U1AA100	[X]Acc poison/expos org solvent,halogen hydrocarb,res instit
15	T802000	Accidental poisoning by codeine	ZX1Q.00	Throwing self in front of train
16	T82z.00	Accidental poisoning by sedatives and hypnotics NOS	T851.00	Accidental poisoning by oth central nervous syst depressants
17	T94..00	Accidental poisoning by corrosives and caustics NEC	T806200	Accidental poisoning by naproxen
18	TK31.00	Suicide + selfinflicted injury by suffocation by plastic bag	TK01100	Suicide and self inflicted injury by Barbitone
19	U1A4.13	[X]Accidental poisoning with SSRI	T990.00	Accidental poisoning by nitrogen oxides
20	T960.00	Accidental poisoning by lead and its compounds and fumes	T963000	Accidental poisoning by arsenic, unspecified
21	U1AB700	[X]Accident poison/exposure to other gas/vapour on farm	14K1.00	Intentional overdose of prescription only medication
22	T941.00	Accidental poisoning by acids	U212.00	[X]Inten slf harm hang strang/suffc sch oth ins/pub adm area
23	TN06.00	Injury ?accidental, poisoning by corrosive/caustic substance	T802300	Accidental poisoning by opium
24	U470.00	[X]Exposure to smoke fire+flame undeterm intent occ at home	U1AD200	[X]Acc pois/expo to amphet - sch, other inst+pub admin area
25	T981.00	Accidental poisoning by other utility gas	T98y.00	Accidental poisoning by carbon monoxide from other sources
26	U4D..00	[X]Crashing of motor vehicle, undetermined intent	T802100	Accidental poisoning by pethidine
27	U49z.00	[X]Contact with sharp obj undeterm intent occ unspecif place	T983300	Accidental poisoning by CO- kerosene in domestic stove/fire
28	U42..00	[X]Drowning and submersion, undetermined intent	U4Bz.00	[X]Fall jump/push frm high plce undt intnt occ unspecif plce
29	TK06.00	Suicide + selfinflicted poisoning by agricultural chemical	T850.12	Accidental poisoning by anti-parkinsonism drug
30	U40A.00	[X]Pois/exposure,?intent,to organ	T98y100	Accidental poisoning by CO - kiln vapour

1	U205000	solvent,halogen hydrocarb [X]Int self poison/exposure to narcotic drug at home	T830.00	Accidental poisoning by phenothiazine-based tranquilisers
2				
3	U1AB000	[X]Accident poison/exposure to other gas/vapour at home	U2By.00	[X]Int self harm by jump from high place oth specif plce
4				
5	U29z.00	[X]Intentional self harm by sharp object occ unspecif place	T941z00	Accidental poisoning by acids NOS
6				
7	U1A4100	[X]Accid poison/expos to psychotropic drug at res institut	U1A2.16	[X]Accidental poisoning with benzodiazepine
8				
9	T832000	Accidental poisoning by chlordiazepoxide	T936z00	Accidental poisoning by fungicides NOS
10	U291.00	[X]Intent self harm by sharp object occ resident instit'n	TK5z.00	Suicide and selfinflicted injury by firearms/explosives NOS
11				
12	U202.15	[X]Overdose - nitrazepam	T930200	Accidental poisoning by DDT
13	U1A8000	[X]Accident poison/exposure to oth/unsp drug/medicam home	U1A1000	[X]Accident poison/exposure to antiepileptic at home
14				
15	U20B000	[X]Int self poison/exposure to other gas/vapour at home	T811.00	Accidental poisoning by barbitone
16				
17	U1AC.00	[X]Accident poisoning/exposure to pesticide	T901z00	Accidental poisoning by ethyl alcohol NOS
18	T882.00	Accidental poisoning by drugs affecting blood constituents	U200400	[X]Intent self pois nonopioid analgesic in street/highway
19				
20	T90y.00	Accidental poisoning by other alcohols	T923.00	Accidental poisoning by petroleum solids
21	U201000	[X]Int self poison/exposure to antiepileptic at home	TKx6.00	Suicide and selfinflicted injury by crashing of aircraft
22				
23	ZX14.00	Damaging own wounds	U2D6.00	[X]Intent self harm crash motor vehic occ indust/constr area
24				
25	U2A3.00	[X]Intent self harm by blunt object occ sports/athlet area	U4Az.00	[X]Contact with blunt obj undeterm intent occ unspecif place
26				
27	T941200	Accidental poisoning by sulphuric acid	U40C000	[X]Poison/exposure ?intent, to pesticide at home
28				
29	T937400	Accidental poisoning by zinc phosphide	T923z00	Accidental poisoning by petrol solids NOS
30	U1A0.13	[X]Accidental poisoning with aspirin	U4B6.00	[X]Fall jump/push frm high plce undt intrn indust/constr area
31				
32	U1AA.00	[X]Accid poison/exposure to organ solvent,halogen hydrocarb	U206000	[X]Int self poison/exposure to hallucinogen at home
33				
34	T960z00	Accidental poisoning by lead, NOS	U40y000	[X]Poison/exposure ?intent, to unspecif chemical at home
35				
36	U210.00	[X]Intent self harm by hanging strangulat/suffocat occ home	U220.00	[X]Intent self harm by drowning/submersion occurrn at home
37				
38	T800.00	Accidental poisoning by heroin	U1Ay700	[X]Accident poison/exposure to unspecif chemical on farm
39				
40	T94z.00	Accidental poisoning by corrosives and caustics NOS	U40yy00	[X]Pois/exp ?intent to unspecif chemical other spec place
41				
42	U1A8.00	[X]Accident poison/exposure to other/unspec drug/medicament	T941100	Accidental poisoning by nitric acid
43				
44	U20By00	[X]Int self poison other gas/vapour other spec place	U1A9200	[X]Acc poison/expos alcohol school/pub admin area
45				
46	T938100	Accidental poisoning by methyl bromide	ZX16300	Gouging own rectum
47	U1A4.12	[X]Accidental poisoning with amitriptyline	T830300	Accidental poisoning by promazine
48	ZX1M.00	Shooting self	U216.00	[X]Intent self harm by hang strangl/suffc indust/constr area
49				
50	U44..00	[X]Rifle shotgun+larger firearm discharge undeterm intent	T887200	Accidental poisoning by ophthalmological drugs
51				
52	T922.00	Accidental poisoning by lubricating oils	1BDE.00	Suicide risk increased from previous level
53	T964400	Accidental poisoning by iron compounds	ZX1R.11	Jumping in front of vehicle
54	T964300	Accidental poisoning by copper salts	U1A9300	[X]Accid pois/expos alcohol in sport/athletic area
55				
56				
57				
58				
59				

1	T887100	Accidental poisoning by mucous membrane drugs	U1A9y00	[X]Accid pois/expos to alcohol other spec place
2	U202.11	[X]Overdose - sleeping tabs	TN02.00	Injury ?accidental, poisoning by other
3				sedative/hypnotic
4	T90z.00	Accidental poisoning by alcohol NOS	T806000	Accidental poisoning by gold salts
5	T981300	Accidental poisoning by heating gas NOS	T937100	Accidental poisoning by squill and derivatives
6	T801.00	Accidental poisoning by methadone	T965z00	Accidental poisoning by plant foods and
7				fertilisers NOS
8	T841100	Accidental poisoning by lysergide, LSD	T823.00	Accidental poisoning by methaqualone
9				compounds
10	T840100	Accidental poisoning by imipramine	U1A8600	[X]Acc pois/expos oth/unsp drug/medic
11				indust/construct area
12	U2B4.00	[X]Intent self harm by jump from high place occ	T966z00	Accidental poisoning by glues and adhesives
13		street/h'way		NOS
14	TN2y.00	Injury ?accidental, poisoning by other spec gas or	TK2y.00	Suicide + selfinflicted poisoning by other gases
15		vapour		and vapours
16	U4A0.00	[X]Contact wth blunt object undetermined intent	T832300	Accidental poisoning by lorazepam
17		occ at home		
18	TK52.00	Suicide and selfinflicted injury by hunting rifle	T822.00	Accidental poisoning by bromine compounds
19	U242.00	[X]Int slf hrm rifl s'gun/lrg frarm dis sch/ins/pub	T804.00	Accidental poisoning by aromatic analgesics
20		adm area		NEC
21	U28..00	[X]Intentional self harm by steam hot vapours /	T80y000	Accidental poisoning by pentazocine
22		hot objects		
23	U2D..00	[X]Intentional self harm by crashing of motor	U4A6.00	[X]Contct wth blunt obj undet intent occ
24		vehicle		industr/constr area
25	ZX1H.00	Self-asphyxiation	U2y6.00	[X]Intent self harm oth specif means occ
26				industr/constr area
27	T983000	Accidental poisoning by CO- coal in domestic	U200600	[X]Int self pois nonopioid analgesic
28		stove/fireplace		indust/construct area
29	T87..00	Accidental poisoning by anti-infectives	TN01300	Injury ?accidental poisoning by Pentobarbitone
30	T77z.00	Accident/poisoning occurred in residential	U1A2z00	[X]Accid poison/expos to sedative hypnotic
31		institution NOS		unspecif place
32	U20y.00	[X]Intent self poison/exposure to unspecif	TK01z00	Suicide and self inflicted injury by barbiturates
33		chemical		
34	T937.00	Accidental poisoning by rodenticides	TKx0z00	Suicide + selfinflicted inj-jump/lie before
35				moving obj NOS
36	T934z00	Accidental poisoning by insecticides NOS	T805100	Accidental poisoning by phenylbutazone
37	U1A4.00	[X]Accident poisoning/exposure to psychotropic	U1A4200	[X]Acc poison/expos psychotropic drug
38		drug		school/pub admin area
39	U1A4000	[X]Accident poison/exposure to psychotropic	U2Dz.00	[X]Intent self harm by crash motor vehic occ
40		drug at home		unspecif place
41	ZX1L200	Self-mutilation of genitalia	T804200	Accidental poisoning by phenacetin
42	T855000	Accidental poisoning by adrenalin	1BDF.00	Suicide risk unchanged from previous level
43	T99z.00	Accidental poisoning by gases and vapours NOS	U40By00	[X]Pois/exp ?intent to other gas/vapour other
44				spec place
45	T982.00	Accidental poisoning by motor vehicle exhaust	T993.00	Accidental poisoning by tear gas
46		gas		
47	ZX16200	Gouging own eyes	U1Ay100	[X]Accid poison/expos to unspecif chemical at
48				res institut
49	T940000	Accidental poisoning by carbolic acid	U2yy.00	[X]Intent self harm oth specif means occ oth
50				specif place
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

PAIN**At least one ICD-9 in:**

Lumbar pain	724
Back disorders	721, 722, 723, 723, 737
Neck and back problems	721.0, 721.1, 721.2, 721.3, 721.4, 721.5, 721.6, 721.7, 721.8, 721.9, 722.0, 722.1, 722.2, 722.3, 722.4, 722.5, 722.6, 722.7, 722.8, 722.9, 723.0, 723.1, 723.2, 723.3, 723.4, 723.5, 723.7, 723.8, 723.9, 724.0, 724.1, 724.2, 724.3, 724.4, 724.5, 724.6, 724.8, 724.9, 737.1, 737.2, 738.2, 738.4, 738.5, 739.1, 739.2, 739.3, 739.4, 756.1, 846.0, 846.1, 846.2, 846.3, 846.8, 846.9, 847.0, 847.1, 847.2, 847.3, 847.9
Complex regional pain syndrome	337.2, 354.4, 355.7, 355.9
Fibromyalgia	729.1
Painful neuropathic disorders	250.6, 357.2, 053.1, 722.1, 722.2, 722.7, 724.0, 724.3, 724.4, 721.1, 722.0, 723.0, 723.4, 337.2, 353.2, 353.3, 353.4, 354.4, 355.7, 355.9, 729.2, 353.6, 350.1, 350.2, 352.1, 353.0, 353.1, 353.8, 353.9, 354.0, 354.1, 354.2, 354.3, 354.5, 354.8, 354.9, 355.0, 355.1, 355.2, 355.3, 355.4, 355.5, 355.6, 355.8,
Pain	338
Chronic pain	338.2
Chronic pain associated with significant psychosocial dysfunction	338.4
Pain disorders related to psychological factors	307.8
Migraine and headache	346, 784, 339
Osteoarthritis/Rheumatoid Arthritis	714, 715
Irritable bowel syndrome	564.1
Lupus	710.0

OR

At least one READ code in:

N131.00	cervicalgia - pain in neck	N05..00	osteoarthritis and allied disorders
1B1G.00	headache	N217700	calcaneal spur
1BA5.00	frontal headache	N23y400	spasm of muscle
F26..00	migraine	F260.00	classical migraine
E278100	tension headache	N224.00	ganglion and cyst of synovium, tendon and bursa
N143.00	sciatica	N081000	loose body in joint, unspecified joint
N216500	prepatellar bursitis	PG17.00	spina bifida occulta
J521.11	irritable bowel syndrome	1BA8.00	temporal headache
N090.00	effusion of joint	N140.11	spinal stenosis
N213300	olecranon bursitis	N235.00	hypermobility syndrome
N145.00	backache, unspecified	N37..00	curvature of spine
N12..00	intervertebral disc disorders	N225100	rupture of popliteal space synovial cyst
N217900	plantar fasciitis	F26y000	hemiplegic migraine
F340.00	carpal tunnel syndrome	1B1G000	sinus headache
N040.00	rheumatoid arthritis	N066.00	unspecified monoarthritis
J521.00	irritable colon - irritable bowel syndrome	7H48211	release of trigger finger
N224A00	synovial cyst of popliteal space	N01w.00	reactive arthropathy, unspecified
N371.00	acquired kyphosis	F330.00	brachial plexus lesions
N21z300	exostosis of unspecified site	N224000	synovial cyst unspecified
N221.00	bunion	N043.00	juvenile rheumatoid arthritis - still's

1	R040.00	[d]headache	SC20z12	disease
2	N220.00	synovitis and tenosynovitis	F355.00	headache - post traumatic
3	N20..00	polymyalgia rheumatica	N224200	tarsal tunnel syndrome
4	F301.00	other specified trigeminal neuralgia	N083.00	ganglion of tendon sheath
5	N142.14	lumbago	N245.00	recurrent dislocation of joint
6	1BA6.00	occipital headache	N21..00	pain in limb
7				peripheral enthesopathies and allied syndromes
8	N372.00	acquired lordosis	PG16.00	klippel-feil syndrome
9	PG12.00	congenital spondylolisthesis	N213200	lateral epicondylitis of the elbow
10	N11..00	spondylosis and allied disorders	N221000	infected bunion
11	N244.00	fasciitis unspecified	N141.00	pain in thoracic spine
12	N220300	trigger finger - acquired	1BB4.00	morning headache
13	F261.00	common migraine	F262200	abdominal migraine
14	F262000	cluster headache	N110.00	cervical spondylosis without myelopathy
15	N370.00	adolescent postural kyphosis	N384.00	acquired spondylolisthesis
16	N07..00	internal derangement of knee	7K51111	unionectomy
17	N234.00	laxity of ligament		

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	4-5
Methods			
Study design	4	Present key elements of study design early in the paper	5-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5-6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	N/A
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	N/A
		(e) Describe any sensitivity analyses	N/A

Results			Page No
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	N/A
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	N/A
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	8-9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	9-10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-11
Generalisability	21	Discuss the generalisability (external validity) of the study results	N/A
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.